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ABSTRACT
TV-protected a-amino epoxides, derived from a-amino acids were synthesised in a 
stereoselective manner. From these homochiral precursors several dipeptide 
analogues were prepared. These include the hydroxymethyl dipeptide, (2R,3S,2'S)-2- 
hydroxy-1-(O-methyl leucinyl)-3-phthaloylaminobutane, synthesised via a novel 
oxirane ring-opening reaction using the Lewis acid BF3.OEt2 and (L)-leucine-O- 
methyl ester. The hydroxymethyl dipeptide, (2S,3S,2'S)-2-hydroxy-l-(0-methyl leuc- 
inyl)-3-phthaloylaminobutane, was prepared via a TV-protected a-amino O-mono 
protected diol, which itself was derived from the corresponding a-amino alkene or a- 
amino epoxide. The chloromethyl dipeptides, (2R,3R,2'S)- and (2S,3S,2 'S)~ 1 -chloro- 
2-(0-methyl leucinyl)-3-phthaloylaminobutane, the aziridine dipeptides, (IR,2S,2'S)~ 
and (1 S,2R,2'S)~ 1 -(methyl-4'-methylpentanoate)-2-( 1 -phthaloylaminoethyl) aziridine 
and the hydroxyethylamines, (2R*,3S*,2'S) and (2S*,3S*,2'S)-2-hydroxy-l-(0-methyl 
leucinyl)-3-phthaloylaminobutane were also prepared from TV-protected a-amino 
epoxides.
Molecular modelling studies of the pseudotripeptide Ac-TV-Ala-[CH(CH2OH)NH]- 
Leu-NHMe were carried out to determine the potential for (5-tums. <]),\|/-Maps were 
generated to find the lowest energy conformations. Docking of this lowest energy 
conformer of the potential inhibitor into the active site of human fibroblast 


































































GRF Growth Hormone-Releasing factor
Gly glycine
His histidine
HIV-1 Human Immunodeficiency Virus type 1
HMPA hexamethylphosphoramide
HOBt 1 -hydroxybenzotriazole

























n.m.r. nuclear magnetic resonance

















SN1 substitution nucleophilic unimolecular
SN2 substitution nucleophilic bimolecular






TcBoc 2',2',2'-trichloro-1', 1 '-dimethylethoxycarbonyl
















h p p -[\|/] Tyr-Tic-\j/[CH2NH]-Phe-Phe
T.l.c. thin layer chromatography
TMS trimethylsilane
TMSOTf trimethylsilyl trifluoromethanesulfonate
Xaa amino acid (also Yaa)
Z see cbz
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Naturally occuring Amino Acid abbreviations
x .
, c o 2 h
H2 N ^ ^ C 0 2 H H2 n '  ' c o 2 h  \ ^ n h
alanine (Ala) glycine (Gly) proline (Pro)
arginine (Arg) histidine (His)
NH2
serine (Ser)
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aspartic acid (Asp)
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cystine (Cys)
c o 2 h
lysine (Lys)NH2
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Novel Amino Acid Abbreviations
c o 2h
cyclohexylalanine (Cal)
h2n '  'c o 2h
norleucine (Nle) statine (Sta)
yV-formyltryptophan (Ftr) naphthalanine (Nal) 1,2,3,4-tetrahydroisoquinol- 
ine-3-carboxylic acid (Tic)
H
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INTRODUCTION
1.0 Background
Over the last decade there has been an increased interest in the preparation of 
transition-state analogues and their incorporation into various sized peptides for 
conformational and biological purposes. More recently there has been an explosion in 
the number of peptidomimetic preparations for the treatment of ADDS.
The aim of the project described in this thesis was to establish a new family of 
peptidomimetics and to examine their potential as transition-state mimetics. 





Enzymes are proteins that catalyse reactions in biological systems. They vary in 
molecular weights from several thousands to several millions, but can catalyse 
transformations on molecules as small as carbon dioxide.
When enzymes interact with substrates, to form enzyme-substrate complexes, it is 
these complexes which catalyse reactions, transforming the substrate into products on 
release.
Every enzyme has a unique protein structure, defined by a characteristic amino 
sequence. This is what makes enzymes substrate specific.
There have been many rationalisations put forward to represent the mechanism for 
enzyme catalysis. Most modem theories originate from that of Haldane2 in 1930, who 
introduced the concept that enzyme-substrate complexes require additional activation 
energy prior to the reaction, which presumably arises from substrate strain on the 
transition-state geometry. Eyning3 in 1935, developed the idea of transition-state 
theory, which was the basis for Pauling's4 hypothesis that enzymes are flexible 
templates, designed by evolution to be complementary to the structure of the substrate 
at the transition-state of the reaction, rather than at the ground state. As the reaction 
proceeds towards the transition-state, the enzyme interacts more effectively (increased 
binding energy) with the transition-state geometry and electronic environment, thus 
accelerating the reaction. This was remarkably accurate considering how little there 
was known about enzymes at the time. Indeed, it is possible to make some 
generalisations concerning the methods by which enzymes catalyse reactions:-
2
i. Deforming a configuration of atoms away from their equilibrium position 
revises the energy of the system. If an enzyme can stretch a bond, the energy 
of the molecule will become closer to the transition-state and thus bond 
cleavage will be aided.
ii. Enzymes which can concentrate and orientate reactants will catalyse reactions. 
Simply bringing together the reactants can theoretically cause an acceleration, 
largely due to the change in concentration caused, and
iii. Nucleophilic attack with an electrophile can be accelerated by making the 
electrophile more electrophilic and vice-versa. This is electronic activation.
Enzymes bind substrates at a region of the enzyme termed the active site. Enzymes 
are very large with the atoms in the protein being closely packed. The entire protein 
outside the active site may be functioning to hold the active site in the proper 
geometry for catalysis. Another aspect of enzyme catalysis, may involve channelling 
the substrate into the active site. Once binding sites link to specific groups in the 
substrate, relative orientation is fixed, so that reacting functionalities are in the 
vicinity of the catalytic domain of the enzyme.
The binding specificity can be absolute i.e. essentially only one substrate forms an 
enzyme-substrate complex with a particular enzyme, thus leading to one product, or 
the binding specificity may be very broad, in which case many molecules of related 
structure can be converted to products. As enzymes are chiral (mammalian enzymes 
are made up of only L-amino acids encoded from DNA) the binding energy of the 
enzyme-substrate complex (E-S) for one enantiomer may be much higher than the 
other enantiomer, due to differential binding interactions caused by steric effects. If 
this energy difference is very large, only one E-S complex may form. Alternatively, 
both E-S complexes may form, but only one may lead to product formation. If the E-
3
S complex is formed, but not converted to the product, it is said to undergo "non 
productive binding" to the enzyme.
1.2 Enzyme Inhibition and Inactivation
Many diseases, or the symptoms of diseases, are caused by an imbalance of a 
metabolite in the body, either from an infestation by a foreign body or from abnormal 
cell function. If this imbalance can be normalised and the foreign organism and 
abnormal cells can be destroyed, then the symptoms can be remedied. Many of these 
situations can be effected by specific enzyme inhibition.
If a compound can slow down or block enzyme catalysis it is said to be an enzyme 
inhibitor. If the interaction is irreversible (in which case usually covalent bonding is 
involved), then the compound is referred to as an enzyme inactivator. Many drugs 
function as enzyme inhibitors or inactivators.
If for example, a cell has a deficiency of the substrate for an enzyme, and as a result a 
disease state develops, then inhibition of the enzyme will reduce the degradation of 
the substrate, thus returning the cell to its normal state.
An ideal enzyme inhibitor should be totally specific for the one target enzyme. Since 
this is rare, highly selective inhibition is a more realistic objective. Unfortunately, 
when treating various organisms and tumour cells the enzymes that are essential for 
their growth are also vital to human health. Although this is a problem, many 
inhibitors have been developed as the tumour cells replicate at a much faster rate than 
do most normal human cells, and foreign organisms contain many enzymes that are 
non-essential for human health or not present in humans. The use of penicillins and 
inhibition of the shikimic acid pathway are two examples which are non toxic to 
humans.
4
There are several forms of enzyme inhibition: competitive, uncompetitive, non­
competitive, as well as mixed, partial and allosteric.
Competitive reversible inhibitors often have structures similar to those of the 
substrates or products of the target enzymes, and which bind at the substrate binding 
sites, thereby blocking substrate binding. The enzyme bound inhibitor either lacks the 
appropriate reactive group or is held in an unsuitable orientation with respect to the 
catalytic site. Interaction of the inhibitor with an enzyme can occur at a site other than 
the substrate binding site and still result in the shutdown of the catalytic conversion of 
the substrate to products. This process involves an inhibitor-induced conformational 
change of the enzyme, giving a form of the enzyme that is unable to bind to the 
substrate properly, this form of inhibitor is known as a non-competitive reversible 
inhibitor.
Irreversible inhibitors, also known as active site-directed irreversible inhibitors or 
enzyme inactivators, are compounds whose structures are similar to those of the 
substrate or product of the target enzyme. Irreversible inhibitors generally bind to the 
active site forming a covalent bond, this may prevent the substrate binding or it may 
destroy some component of the catalytic site. Unlike reversible inhibitors, once the 
irreversible inhibitor binds with the target enzyme, the complex cannot dissociate and 
therefore the enzyme remains inactive. This may mean smaller and fewer doses of the 
drug are required. Although the enzyme has been inactivated, this does not mean one 
dosage will remedy the disease, because our bodies are constantly encoding more 
proteins, so as the enzyme loses activity, other copies are synthesised, but this process 
is rather slow, and can take hours to several days.
Any data discussed in the text will be associated with enzyme inhibition in vivo by 
various compounds synthesised and their activities will be represented in terms of
5
binding affinities, Kj or IC50 values, where IC50 is the concentration required to 
produce half maximal enzyme inhibition.
1.2.1 Peptide mimetics as enzyme inhibitors
A peptide mimetic is a molecule that mimics the biological activity of a peptide, but is 
no longer peptidic in chemical nature. This term is sometimes used to describe 
molecules that are no longer completely peptidic in nature, such as pseudo-peptides, 
semi-peptides and peptoids. Strictly speaking, peptide mimetics are molecules that no 
longer contain any peptide bonds (i.e. amide bonds between amino acids) and have a 
molecular weight less than 700 Da.
1.3 Design of peptide mimetics
There are essentially two ways of discovering peptide mimetics: rational design and 
random screening. Random screening has provided the majority of presently known 
peptide mimetics, however, it is costly, labour intensive and does not always give 
results. On the other hand, rational design is relatively inexpensive. Ideally a 
combination of both random screening and rational is desirable.
Moore5 has discussed the three essential steps of rational design. The first step is to 
identify pharmocophoric groups that are responsible for enzyme inhibition. Using 
peptide libraries the structure-activity relationships of a given peptide can be acquired 
to identify the crucial pharmocophoric groups, together with spectroscopic data, which 
can provide further information regarding potential pharmocophores.
Step two involves modelling, minimisation and molecular mechanics, using the 
spatial arrangement of known pharmocophores acquired from n.m.r. spectroscopy or 
X-ray crystallography. Following minimisation and molecular dynamics simulation
6
the conformational model established can be used to consider possible receptor 
mechanisms. This can be useful as the dynamics of folding of peptides in the receptor 
environment often produces a particular characteristic in the peptide which the 
receptor "reads".
The final step is the mimetic design. It is now important to probe the spatial 
relationship of the pharmocophores and then guess what may happen at the receptor 
site.
The process depends on selecting a template and then mounting the pharmocophores 
on it. The simplest design is a binary mimetic in which two pharmocophores are 
mounted, becoming more difficult the more you mount, with four being the limiting 
situation.
The amide bond is the focal point when it comes to enzymatic stability of a peptidic 
substance. It can function simply as a spacer, connecting two pharmocophoric groups, 
it can provide specific spatial orientation and can ultimately be involved in binding of 
the peptide to the enzyme through hydrogen bonding. A general strategy in drug 
development, is to establish the cleavage site for a proteolytic process, and replace this 
unit with an amide isostere. A huge number of isostere replacements have been 
developed that resist proteolytic degradation, when incorporated into peptide 
mimetics. This will be discussed later.
There are clear advantages to using peptide mimetics as opposed to the native 
peptides, which commonly exhibit poor bioavailability and short duration of action 
resulting from enzymic degradation. Peptide mimetics offer greater bioavailability as 
they are small, and have longer duration of action. Finally, peptides suffer from 
problems associated with stability, storage and immunoreactivity, whereas these 
problems may not be experienced with peptide mimetics.
7
Analogues of natural peptide substrates have been prepared in which conformational 
restraints and non-peptide linkages have been introduced, as well as by changing the 
natural amino acid sequence and making amino acid side chain substitutions.
The course of preparing these peptide mimetics have been based on solid phase and 
solvent phase synthetic chemistry. More recently, there has been a move towards 
molecular biology, which has now become the driving force behind screening and the 
establishment of macromolecular targets. However, much of the research has been 
directed at peptide and protein therapeutics which still display the disadvantages of 
peptides. Because of those limitations, there is still a lot of reliance on non-peptide 
units. Small molecules are likely to remain the most viable avenue.
1.3.1 Peptide Conformation
The geometry of the peptide 
backbone is shown in Figure 1.6
In the polypeptide backbone it is generally found that each amide bond adopts a trans 
configuration. The principle torsion angle describing the rotation about N-Ca  is 
denoted by <J>, that describing rotation about Ca -C is defined by \j/, and that describing 
rotation about C-N is denoted by co. The symbols <j>f,\|/, and co, are used to denote 
torsion of bonds within the zth residue in the case of (j) and \|/ and between the ith and 
(7+1 )th residues in the case of co; specifically, (j),- refers to the torsion angle of the
Figure 1
sequence of atoms CM, N,-, Ca ,, C,; \j/, to the sequence Nt, Ca ,, C, Nf+1; and co, to the 
sequence Ca „ C, NI+1,Ca I+1; (Figure 1)
Both p-tums and y-tums are well known secondary structures in peptides and proteins, 
and cause a reversal of a peptide chain. These turns may or may not be stabilised by 
an intra-turn hydrogen bond. In the case of the p-tum it may occur between the 
carbonyl of residue i and the NH of residue i+3, while in the y-tum it may occur 







Conformationally, a p-tum is fully defined by the ((J),\|/) torsions of the middle two 
residues: (<|>2,¥2) (<l>3>¥3); and for the y-tum only the single torsion (<|)2 ,y 2) is
necessary for definition. Table 1, shows the types I-in P-tums and their mirror 
images, and the normal and inverse y-tums.
Table 1
Turn 2^ ¥ 2 ¥ 3
P-tums type
I -60 -30 -90 0
n -60 120 80 0
m -60 -30 -60 -30
r 60 30 90 0
IT 60 120 80 0
nr 60 30 60 30
y-tums type
turn 70 to 85 60 to -70
inverse turn -75 to -85 60 to 70
(j), V|/ values in (°) at position 2 and 3
9
It is notable that type I and IH p-tums are very similar; and they occupy similar 
regions of <|),\|/ space and are not distinct types.7 However, type HI can be 
conveniently placed into a separate category, since it describes a helical turn and may 
form part of a larger repeating structure.
1.3.2 Amide Bond Modifications
Modification of the peptide backbone can increase the biological half-life of a 
compound compared to its parent compound and also introduce conformational 
restraints. The tactic of replacing the amide bond with a suitable surrogate or isostere 
is of particular importance in developing new enzyme inhibitors. Several isosteric 
amide bond mimetics have been introduced into biologically active peptides e.g. \|/ 
[CH2S], \|/[CH2NH], \|/[S02], \|/[P=0(OH)], ij/[NHCO], \|/[COCH2], \j/[CH(OH)CH2] 
and \}/[(£) or (Z) CH=CH] which have all been extensively reviewed.8*9 These 
modifications have also been used in numerous enzyme inhibitors e.g. 
matrixmetalloprotease, angiotensin converting enzyme, renin,8§ aspartic protease and 
HIV protease9 and many others.
1.3.3 Transition-State Theory
As discussed earlier, Pauling4 in 1948 developed the transition-state theory. He 
concluded that an enzyme accelerates the rate of a reaction by stabilising the 
transition-state, which lowers the free energy of activation. This rate enhancement is 
achieved by the enzyme altering its conformation, so that it can bind more tightly to 
the substrate at the transition-state of the reaction. Some enzymes can also apply 
strain to the substrate and thus distort the complex towards the transition-state of the 
reaction.
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Bernhard and Orgel10 theorised that transition-state analogues would bind more 
tightly to an enzyme than the substrate. Thus, a potent enzyme inhibitor would be a 
stable compound that resembles the substrate at the transition-state of the reaction and 
not the ground state. A compound that binds more tightly to the enzyme is called a 
transition-state analogue inhibitor.
For one-substrate reactions, the unimolecular conversion of a reactant, S. to a product, 
P, will occur via the reaction pathway with the lowest energy barrier and requires that 
the reactants have sufficient energy to overcome this barrier (dashed curve, Figure 2). 
The structure of highest energy, on the lowest energy pathway, is called the transition- 
state, S’*. This is in equilibrium with the reactants (Equation 1).
K* = [S*]/[S] Equation 1
where K5* is the equilibrium constant for the formation of the transition-state. The 
rate of reaction is proportional to the concentration of the transition-state, and the 
proportionality constant is given as (Equation 2).
d[P]/dt = kt/h*[S*] = kTK*/h*[S] = kx *[S] Equation 2
where k is the Boltzmann's constant, h is Plank's constant and T is the absolute 
temperature.
Consequently, K5* is equal to the measurable first-order rate constant for the reaction, 
kx, times the factor h/kT (Equation 2). The difference in the free energy between the 
reactant and transition-state, AF^H, is related to the equilibrium constant, K’* by the 






Reaction Pathway, Binding Components
Figure 2. (A) Schematic representation of reaction 
pathway profile for nonenzymatic (---) and enzyme 
catalyzed hydrolysis of amide bond (-).
Figure 2
Application of the transition-state theory to a single-substrate enzymatic reaction and 
to the corresponding non-enzymatic reaction is shown below.
E + S
Kn*




Where Ks is the equilibrium constant for the association of the enzyme, E, KN* and 
KE* are equilibrium constants for the formation of the transition-state of the non­
enzymatic and enzymatic reactions, S* and ES*, respectively, KT is the equilibrium 
constant for the binding of S* to E to form ES*. The expression of these equilibrium 
constants are related by Equation 3.
Kx/Ks = Ke*/Kn* = Ke/Kn Equation 3.
According to the simplest transition-state theory, KE* is related to KE, the first order 
rate constant for the conversion of ES to EP by the same factor (h/kT) that relates to 
Kn* to Kn, the first order rate constant for the corresponding non-enzymatic reaction. 
This concludes that for reactions that have been reported, that the value for enzymatic
12
catalysis, expressed by the ratios KE/KN, for a typical enzymatic reaction, will fall in 
the range 108 to 1014. Since the association constant, Ks is usually of the order 103 to 
105 M_1, then the expected values for KT are extremely large 1015 M 1. These 
relationships are shown in Figure 2, in terms of the free energy-reaction pathway 
profile for a hypothetical single-substrate enzymatic reaction (unbroken line) and the 
non-enzymatic reaction (broken line).
The action of an enzyme, when hydrolysing the amide linkage of a peptide proceeds 









As mentioned earlier, modification of the cleavage site to mimic the sp3-tetrahedral 
species has resulted in the generation of analogues with high inhibitory potency and 
has been one of the most widely used strategies in peptide mimetic design.
1.4 Reduced Peptide Isosteres
This discussion will be a review of the synthetic and biological chemistry of certain 
transition-state analogues. This review will concentrate on the reduced amide, 
hydroxyethylene and hydroxyethylamino isosteres, see Chart 1.





X= H, statone analogue 
F, difluoro statone
amino statine





norstatine hydroxymethylmethylamine ketomethyl isostere
R R '  O R O R O O
X= H, double bond isostere dehydrohydroxy ethylene retro-inverso isostere 
F, fluoroalkene isostere isostere
Chart 1
1.4.1 Reduced Amide Isosteres
Using the transition-state theory, Szelke11 and co-workers developed potent inhibitors 
of angiotensin converting enzyme (ACE) and renin which used the reduced peptide 
isostere \|/[CH2NH] at the scissle site. Although the isostere contained the tetrahedral 
geometry of the sp3-transition-state intermediate, it lacked the hydroxyl group. The 
first potent renin inhibitor was the reduced peptide analogue of the Kokubu's 
tetrapeptide (Leu-Leu-Val-Phe-OMe), reported by Szelke12 in 1972, Leu-\j/[CH2NH]-
14
Leu-Val-Phe-OMe. Although this had moderate potency, a dramatic improvement 
was achieved with a reduced peptide isostere of Shegg's octapeptide, His-Pro-Phe- 
His-Leu-\|/[CH2NH]-Leu-Val-Tyr.13 When the A-terminal sequence of the human 
substrate became known other more potent reduced peptide isosteres were made 
which incorporated the human cleavage site His-Pro-Phe-His-Leu-\|/[CH2NH]-Val- 
Val-Tyr, and the human substrate sequence His-Pro-Phe-His-Leu-\j/[CH2NH]-Val-Ile- 
His, (see review by Greenlee8^ ). Szelke14 improved the renin inhibitors further by 
synthesising the reduced peptide analogue Pro-His-Pro-Phe-His-Leu-V|/[CH2NH]-Val- 
He-His-Lys.
In 1985 Martinez et al15 prepared reduced peptide isosteres of Gastrin, a 17 amino 
acid hormone isolated from hog antral mucosa, which plays a major role in the 
stimulation of gastric acid secretion. It was recognised that only the C-terminus, Trp- 
Met-Asp-Phe-NH2 was responsible for a remarkable range of physiological effects. 
Martinez et al15 prepared reduced peptide isosteres between each amino acid in this 
tetrapeptide.16 Replacement of Trp-Met peptide bond with \j/[CH2NH] gave a 
compound which stimulated gastric secretion in vivo, however Met-Asp peptide bond 
replacement gave no such release. In 1987 they found that n.m.r. analysis of bond 
replacements of each peptide link of Boc-Trp-Leu-Asp-Phe-NH2 revealed that the 
conformational effect of each modification was localised around each of the 
\|/[CH2NH] substitutions.17
15
a. HCl.N(OMe)Me, BOP or DCC/DMAP; b. LiAlH4; c. Leu-(Bn)Asp-Phe-NH2, NaCNBH3, MeOH, 
AcOH; and d. 10% Pd/C, H2.
Scheme 1
Plattner et a/18 developed potent human renin inhibitors, of which the reduced peptide 
isostere (1) was the most active, (IC50 7.8 nM), using the established reductive 




In 1986 van der Elst et al19 prepared reduced peptide analogues of Pro-Leu-Gly-NH2 
the C.N.S. active hormone, in the same manner as Martinez et al,15 and showed that
the p-tum conformations were similar to those in the parent hormone, which had 
similar biological activity. The same group20 showed that incorporation of \|/ 
[CH2NH] moiety between positions 8 and 9 in deamino-oxytocin and deamino- 
oxypressin gave analogues with much lower biological activities. Coy et al21 
developed a solid phase method for the direct introduction of \|/[CH2NH], utilising a 
cyanoborohydride reductive amination of a resin-bound peptide amine with a Boc- 
amino aldehyde. This enabled them to synthesis a series of \j/[CH2NH] pseudopeptide 
analogues of the highly potent somatostatin octapeptide (2). They found sequential 
modifications of Cys2 and Cys7 carbonyls provided analogues with the highest 






Coy et al22 also used this methodology to develop analogues of the Growth Hormone 
Releasing-Factor (1-29) Amide. They investigated the effects of sequential peptide 
bond replacement by the isostere \i/[CH2NH] in the active region [GRF(1-29)NH2], 
and found weak agonists and one antagonist. Coy et al23 also developed Substance-P 
receptor antagonists and prepared reduced peptide bond pseudopeptide analogues of 
secretin.24
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In the same year, Martinez et al25, developed reduced amide isosteres of all the 
peptide bonds in the C-terminal heptapeptide of cholecystokinin (CCK), Z-Tyr(S03-)- 
Nle-Gly-Try-Nle-Asp-Phe-NH2. They found that the peptide bonds were not crucial 
for pancreozymin activity or for binding to CCK receptors, as all the modified 
peptides stimulated amylase secretin. Later, Rees et al25h incorporated a reduced 
peptide bond surrogate in a CCK-B receptor ligand. The synthetic pathway for the 
preparation of these surrogates are shown in Scheme 2.
2 -A d o c N P h
OH
2 -A d o c N
O
C O R
2 -A d o c N
H
P h2 -A d o c N
H
P h
a. PhCH 2 CH 2 NH2, DCC, EtOAc; b. LiBH4, TMS; and c. RCOC1, Et3 N, R=alkyl.
Scheme 2
They also prepared analogues using standard reductive amination.
Oyamada and Ueli26 prepared the modified analogue [Phe-\|/(CH2NH)-Leu4'5] 
leucine-enkaphalinin in good yield via the reduction of the amide bond by borane 
(Scheme 3).
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Y = CH 2 CH 2 OMe, Me or fBu 
a. BH 3 -THF, THF.
Scheme 3
Sawyer et al27 prepared several potent renin inhibitors incorporating the reduced 
amide vj/[CH2NH], the most potent being the analogue Ac-Ftr-Pro-Phe-(A-MeHis)- 
Phe-\|/[CH2NH]-Phe-NH2, (Ftr = A-formyl tryptophan). These were synthesised using 
solid phase reductive amination as described by Coy et al.21 This same methodology 
was used by Coy et <z/28 to prepare reduced amide analogues of Lutenising Hormone- 
Releasing Hormone (LHRH).
Coy et al29 also investigated the effect reduced amide isosteres had on bombesin a 
potent autocrine growth factor in human small cell lung carcinoma systems. 
Bombesin (p-Glu-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2) 
when modifi-ed at Val10-Glyu this gave a 30% increase in potency over the parent 
peptide. The modified (Leu13-\|/[CH2NH]-Met14) bombesin exhibited a 100-fold 
improvement in binding affinity compared to previous reported bombesin receptor 
antagonists.
Guziec and Wasmund30 and Geyer et a/48 developed a completely new method for the 
preparation of reduced amide isosteres, using Raney nickel desulfurisation, (Scheme
Phsp: PSPh
B o c NB o c N
B o c N
H
a. i. RaNi, ii. 1) Et3 0 +B P 4 , 2) NaBH 4  or iii. Ni-Boride.
Scheme 4
Gianmis and Sandhoff31 developed a novel way of preparing reduced amide isosteres, 
using metal borohydrides. They successfully prepared the reduced amide isostere (3) 







a. i. LiBH4, TMS, THF, 60% or ii. NaBH4, TMS, THF, 55%. 
Figure 3
Van Binst et al32 synthesised bradykinin analogues Arg-Pro-Hyp-Gly-Phe-Ser-Pro- 
Phe-Arg with reduced peptides between Gly4-Phe5, Phe5-Ser6 and Pro7-Phe.8 Some
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displayed high potency and prolonged activity. More recently Straub et al33 prepared 
the reduced peptide analogue RMP-7 {Arg-Pro-Hyp-Gly-Thi-Ser-Pro-(4-Me-Tyr)- 
\|/[CH2NH]-Arg-OH}, Thi = thienyl amine. The reduced amide was prepared using 
the procedure of Coy and Sasaki,34 and also Ho et al.35
Martinez et al36 prepared reduced bond analogues of C-terminal hexapeptide of 
neurotensin, Arg-Arg-Pro-Tyr-fle-Leu-OH. They sequentially replaced each peptide 
bond with the reduced bond \j/[CH2NH]. Replacement of Lys8-Lys9 with \j/[CH2NH] 
produced an analogue which had the same affinity for neurotensin receptors, but was 
10 times more potent in stimulating guinea pig ileum contraction, //-terminal 
protection (Boc group) decreased potency compared to the free amine.
Christos et at31 also prepared neurotensin C-terminal modified pentapeptides, using 
the standard reductive animation with cyanoborohydride. They found that the reduced 
amide pseudopeptide did show analgesic activity.
Both Michelot et al38 and Harbeson et al39 prepared neurokinin pseudopeptide 
analogues, with reduced amide bonds. They showed little improvement on the native 
peptide. These analogues were prepared using standard reductive alkylation 
techniques.
Van Binst et al40 prepared morphiceptin and (3-casomorphin-5 analogues which 
contained reduced peptide bonds. They prepared these analogues using a combination 
of solid phase methodology and reductive animation. They noted that there was slow 
cis/trans isomerisation between the amino acid and proline bonds in the sequences. 
All analogues showed enhanced binding affinity for the ji-receptor, and very low 
binding to the 5-receptor compared to D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2, 
(Pen = penicillamine).
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Reduced amide analogues have also been used to examine the importance of the back­
bone structure and flexibility of ligand interactions with insulin. Tager et al41 
prepared the reduced amide analogues using solid-phase, solution-phase and semi­
synthetic methods. They found that the reduced amide analogues retained the ability 
to form organised metal ion-co-ordinated complexes (Co2+) in solution, but reduction 
of the peptide bonds proximal and distal to the critical side chain of PheB25 produced 
analogues which had reduced binding potency.
Schiller et al42 developed a new class of opioid peptide derived 8-antagonists which 
contained the l,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic). The two 
prototype antagonists were the tetrapeptide Tyr-Tic-Phe-Phe (5) and the tripeptide 
Tyr-Tic-Phe (6), Figure 4. They prepared reduced amide isosteres of these two 





TIPP (5) TIP (6)
Figure 4
The analogue Tyr-Tic-\|/[CH2NH]-Phe-Phe (TIPP[vj/]) was the more potent compound 
and displayed subnanomolar 8-receptor affinity. It also turned out to be highly stable 
against enzymatic degradation, unlike other 8-antagonists.
Salvadori et al43 found that replacing the D-Ala-Phe amide bond in the dermorphin 
tetrapeptide Tyr-D-Ala-Phe-Gly-NH2 with the reduced amide isostere gave a 5-fold 
increase in p-opioid receptor selectivity.
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In the last few years, there have been many reduced peptide analogues prepared to 
inhibit HIV-1 protease. These include work by Kent et al,44 who in 1989 showed that 
the reduced amide analogue A-Ac-Thr-Ile-Nle-\|/[CH2NH]-Nle-Gln-Arg-NH2, (MVT- 
101), bound to HIV-1 protease in an extended conformer. It was shown to be a poor 
inhibitor. The reduced amide inhibitor H3N+-Ser-Gln-Asn-Phe-\|/[CH2NH]-Pro-Val- 
Val-Gln45 was also shown to have low potency. Sakurai, Nishigaki and Yake et al46 
prepared reduced peptides inhibitors of HIV-1 protease using a new methodology, 
(Scheme 5). They prepared four reduced amide analogues.













c o 2 h
R=Gln-Ile-OM e, ( 8 8 %) 
Ile-Val-OM e, (73%)
R=Gln-Ile-OMe, R'=Phe, (58%) 
Ile-Val-OMe, R’=Gln, (76%)
a. M eS0 2 Cl, pyridine, 0°C, 97%; b. Nal, acetone, reflux, 69%; c. P ro -0 ?Bu, Na2 C 0 3, DM F, 80°C, 
71%; d. 4M HC1, dioxane, RT, 85%; e. HCl.Gln-Ile-OMe or HCl.Ile-Val-OMe, DPPA, E t3 N, DMF, 
0°C; f. i. Pd/C, H2, MeOH; ii. Boc-Asn, DEPC, E t3 N, DMF, 4°C; g. i. 4M  HC1, dioxane, RT; ii. Boc- 
Phe or Boc-Gln, DEPC, Et3 N, DMF, 4°C.
Scheme 5
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HIV-1 encodes its own protease which proteolytically processes precursor gag and pol 
proteins to form the native proteins needed for production of infectious viral particles. 
There are 8 possible cleavages sites, shown in bold, of which 3 were examined. There 
were : pl7-p24 sequence Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln; p7-p6, Pro-Gly-Asn- 
Phe-Pro-Gln-He-Thr; and -PR (HIV-PR is the encoded protease responsible for 
processing gag and gag-pol gene products), Thr-Leu-Asn-Phe-Pro-Ile-Ser-Pro. They 
examined the effect of polarity on p3 and p2- sites. They found that all four were 
weaker inhibitors than pepstatin A, an inhibitor of HIV-1 protease, probably due to the 
absence of the hydroxyl group, which is crucial for the interaction with the catalytic 
aspartic acids of the active site.
Reduced amide isostere analogues have also been prepared to examine binding to 
DNA,47 and extensive conformational studies using n.m.r.48 and molecular modelling 
techniques have been used to examine H-bonding, H-donor potentials of \\f 
[CH2NH],49 (3-tums, a-helices, parallel and anti-parallel P-sheets.50
More recently, new techniques have been developed to prepare reduced amide 
isosteres. Cushman et al51 found that reduction of V-methoxy-V-methylamides to the 
corresponding aldehyde, did not always give enantiomerically pure aldehydes. Even 
at -80°C using 0.8 eq. LiAlH4, the aldehyde was produced with only 88% enantiomer 
excess (e.e.). They could not achieve higher optical purities and the racemisation was 
connected to the reductive alkylation step. As they used proline, a secondary amine, 
they postulated that the imine (7) was in equilibrium with enamine (8), Scheme 6.
They developed a new synthetic route. This involved the formation of the dipeptide 
(10) which was then reduced by diborane, to the reduced amide analogue (11), Figure 
5. The reduce amide dipeptide analogue (12) was then coupled using DCC, HOBt, 
DMF, with resin bound He and the resultant pseudotripeptide was cleaved from the
24
resin using standard solid phase methodology. Veki, Myanoto and Oyanada52 have 
reported improvements in this method.
l le -S e r(O B n )O R esin
NaCNBH3
Scheme 6







" L -  's^ ’S ^ N_ 4 ro"
P h
(11) (12)
a. Pro-OR, BOP, Et3 N, CH 3 CN; b. B2 H6, THF; c. i. 1M NaOH, MeOH; or ii. H2, Pd/C, MeOH.
Figure 5
25
Salvi et al53 also encountered problems using the reductive animation method for 
preparing reduced amide isosteres. They discovered double condensation products, 
see Figure 6 were generated when they performed reductive animation with 
cyanoborohydride.
F m o c - N F m o c
R = H or /?-(CH3 )3 COC6 H4 CH 2  
a. NaCNBH3, MeOH; AcOH (99:1), RT, Gly.
Figure 6
Newlander et al54 developed an unusual constrained reduced amide inhibitor of HIV-1 
protease from the sequential incorporation of y-tum mimetic into the substrate, Figure 
7.
R 2  r 2
HN
O— H
-HN CO- -HN CO-
y-tum mimetic constrained reduced amide
Figure 7
They prepared the inhibitors from 4-methoxyphenethyl alcohol (13) following the 
experimental procedure in Scheme 7, and an alternative route in Scheme 8.
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C 0 2 M e 
CHO -
C 0 2 M e
T B D P S O T B D P S O
P hP h
j,e,k-m n-o
C O -V al-O M e B o c-A la -N
p , 0
OP h
B o c -A la -A la -N  C O -V al-O M e
H
a. Li, NH3, rBuOH, EtOH; b. TBDPSC1, imidazole, DMF; c. 0 3, MeOH, DMS; d. HCl-Val-O 'Bu, 
Et3 N, NaCNBH3, MeOH; e. aq. NaOH, dioxane, HC1; f. DPPA, Et3 N, DMF; g. TBAF, THF; h. Jones 
oxidation; i. CH 2 N2, Et2 0 ;  j. KN(TM S)2, THF, BnBr; k. EtOCOCl, Et3 N, THF, NH 4 OH; 1. TFA, 
DCM; m. Val-OMe, DCC, HOBt, DMF, DCM; n. PhI(OCOCF3)2, H 2 0 ,  CH 3 CN; o. (Boc-Ala)2 0 ,  






S er -N  C O -P ro-V al-V al-N H z
H
a. LiN(TM S)2, THF, 0°C; b. MeMgBr, reflux; c. Li, NH3, THF, 'BuOH, EtOH; d. N- 
(ethoxycarbonyl)phthalimide, E t3 N, THF; e. 0 3, DCM, MeOH, DMS; f. TSA-Phe-OBn, Et3 N, 
NaCNBH3, MeOH; g. TFA, DCM; h. HC1, dioxane; i. DPPA, Et3 N, N aH C 03, DMF; j. HF, 0°C , 45 
mins.; k. TFA-Pro-Val-Val-NH2, Et3 N, HOBt, BOP, DMF, 0 °C , 2 days; 1. NH 2 NH 2 -H 2 0 ,  EtOH; m. 
Boc-Ser, HOBt, DCC, DMF; n. TFA, DCM.
Scheme 8
Their model of the conformationally constrained reduced amide showed an 300-fold 
improvement in the binding affinity to HIV-1 protease, over the native amide.
Shuman et al55 developed an inhibitor of thrombin which contained a reduced amide 
isostere. They found this analogue exhibited little or no ability at inhibiting serine 
proteases.
Another unusual approach to preparing reduced amide analogues (13) was reported by 
Nicolaides et al.56 They prepared the analogues using standard reductive alkylation 













A major regulatory mechanism of the maintenance of blood pressure in mammals is 
the renin-angiotensin system (RAS). This involves a sequential enzymatic 
transformation of angiotensinogen to angiotensin I by renin, angiotensin I to 
angiotensin II by angiotensin converting enzyme (ACE) and angiotensin II to 
angiotensin HI by aminopeptidase, Figure 9. The major pharmacological effects of 
All are vasoconstriction and stimulation of the adrenal cortex to release aldosterone 
(AIH shows this to a lesser extent), this in turn induces sodium retention which results 
in hypertension. Possible modes of intervention in this cascade include inhibition of 
renin release, renin, ACE and aminopeptidase inhibition; and angiotensin II receptor 
antagonism.




A ngiotensin i n
H 2 N -A sp-A rg-V al-Tyr-Ile-H is-Pro-Phe-H is-Leu-O H
I angiotensin converting enzym e
H 2N -A sp-A rg-V al-Tyr-Ile-H is-Pro-Phe-O H
t |  am inopeptidase
H 2N -A rg-V al-Tyr-Ile-H is-Pro-Phe-O H  
Figure 9
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ACE inhibition has been an effective treatment for hypertension but unfortunately 
ACE is not specific for the substrate angiotensin I, since it also cleaves kinins and 
other endogenous peptides. This lack of specificity may contribute to the 
antihypertensive effects of ACE inhibitors. Inhibition of renin is by far a better 
method for the treatment of hypertension, due to fact that angiotensinogen is the only 
known naturally occurring substrate for renin.
The naturally occurring aspartic proteinase inhibitor pepstatin A, Iva-Val-Val-Sta-Ala- 
Sta; {Iva = Me2CHCH2CO and Sta = (35,45)-4-amino-3-hydroxy-6-methylheptanoic 
acid}, is a potent inhibitor of pepsin57 and a weaker inhibitor of human renin.58 The 
central statine unit has been proposed to serve as a mimic of the transition-state for 
hydrolysis. With the hydroxyl group of statine in the 3S configuration, statine-derived 
inhibitors are 1000-fold more active than the corresponding 3R isomers.59
Pepstatin A Statine
A second transition-state analogue introduced by the Szelke group, incorporates an 
hydroxy isostere \|/[CHOH(CH2)] for the Leu-Val peptide bond. These analogues 
have proved to be potent inhibitors of renin.
As has been proposed for statine by Rich,59 the hydroxy group of the isostere may 
serve as a mimic of the hydrated carbonyl of the tetrahedral intermediate in hydrolysis, 
while the Leu and Val side chains are correctly positioned to make binding 
interactions with the active site of renin. The development of this new type of 
transition-state analogue fuelled an immense amount of research into the inhibitory 
potency and activities of such analogues. These analogues have been used to inhibit
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many proteinases such as aminopeptidase B, CCK-B, renin and HIV-1. This next 
section will be a review of all the literature on hydroxyethylenes since 1982.
In a recent review, Greenlee7 discussed the use of various transition-state analogues 
for the inhibition of human renin. As mentioned earlier Szelke60 developed a second 
class of potent transition-state inhibitors in 1982.11 Rich and Holloday61 reported the 
preparation of hydroxyethylene and ketomethylene isosteres of Leu-Ala as shown in 
Scheme 9. This synthesis involved condensation of the Grignard reagent (15) with 
leucinal (16), which furnished the alcohol (17) as a 4:1 diastereomeric mixture. The 
benzyl group (18) was converted to the carboxyl group (19) by debenzylation and 
pyridinium dichromate (PDC) oxidation. The ketomethylene (20) was prepared by 







B oc-V alB oc-V al
R= Iva-Val or Iva-Val-Val
a. i. HC1, dioxane, ii. (Boc-Val)2 0 ;  b. i. Ac2 0 ,  DMAP; ii. H C 0 2 NH4, Pd-C; iii. PDC, DMF; c. 
chromatography,. K2 CC>3 , MeOH; d. PDC, DMF.
Scheme 9
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In 1985 Evans et al62 prepared hydroxyethylene analogues from Boc-Phe-H (22), 
Scheme 10. They reacted the aldehyde (22) with dimethylsulfonium methylide which 
gave the desired epoxide (23) in good yield. This was reacted with diethyl-2- 
benzylmalonate to give the lactone (24). Aqueous base followed by aqueous acid, 
gave the open-chain acid (25) which cyclised spontaneously to give the carboxy 
lactones (26). Decarboxylation gave lactone (27). Aqueous base and aqueous acid 
wash of y-lactone (27) followed by protection afforded the protected acid (28). 
Removal of the silyl group from the carboxy late gave protected alcohol (29). 
Coupling and deprotection furnished the hydroxyethylene analogue (30).
r
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a. CH 2 =SM e2; b. C 6 H 5 CH 2 C H (C 0 2 Et)2; c. NaOH; d. H+ ; e. 120°C; f. TBDPSC1, imidazole; g. H 2 0 ,  
AcOH, THF; h. Sta-Leu-NHBn, EDC, HOBt; i. TBAF, THF.
Scheme 10
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In 1987, Stanton et al63 prepared numerous hydroxyethylene isosteres in the hope of 
finding a potent inhibitor of renin. They prepared these analogues from homochiral 
iV-protected amino epoxides (31) following the procedure detailed in Scheme 11.
I!e-His-NH2
(34) (35)
a. DiBAL-H; b. H 2 NNHCONH2; c. HCHO, HC1; d. Me2 SOCH 2 Na; e. Nal, M e3 SiCl; f. KF; g. 
(M e0 2 CM e2 )Ts0H ; h. M e2 CHC0HLiCO 2 Me; i. KOrBu, H 2 0 ;  j. chromatography; k. Ile-His-NH2, 
DCC, HOBt; and 1. deprolection.
Scheme 11
The epoxides (31) were prepared via reduction of the ester (32) to the aldehyde and 
then reaction with dimethyloxosulfonium methylide.64 This produced the epoxides 
(31) as a 5:1 mixture of diastereoisomers, with the (2R,3S) isomer predominating. 
After ring-opening with iodotrimethylsilane, generated in situ, the diastereomeric 
alcohols were separated by chromatography. Acetonide formation led to protected 
aminoalcohol (33). Alkylation with methyl isovalerate, followed by hydrolysis gave 
the acid (34). The acid was then coupled to Ile-His-NH2 using standard procedures, 
followed by deprotection to give the hydroxyethylene analogue (35). Stanton et al63 
incorporated this unit into a number of renin inhibitors, all showing IC50 values 
between 2 and 20 nM.
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Day and Haber66 reported that the N-Boc protected analogue H-261 (37) was more 
potent than the analogue prepared by Thaisrivongs et al.65 Further modifications 
produced even more active inhibitors of renin, U-71,03865 (38) with the A-methylated 
His and 2-(aminomethyl)pyridine (Amp) (39), Scheme 12.
h’ n^ A n.
(39)
d-f
Boc-lle-Amp >c lle -A m pBoc-N-M eH is(Ts)-N
OH
lle -A m pB oc-P ro-P h e-/V -M eH is
OH
(38)
a. Boc-Ile, DCC, HOBt, 8 8 %; b. TFA, DCM; Boc-Leu-\|/[CH(OTBDMS)CH 2 ]-Val, DEPC, Et3 N, 
100%; c. Et2 0 ,  HC1 (g); Boc-A-Me-His(Ts)-OH, DEPC, Et3 N, 79%; d. TFA, DCM; Boc-Phe, DEPC, 
Et3 N, 98%; e. TFA, DCM; Boc-Pro, DEPC, Et3 N, 97%; f. HOBt, MeOH, 85%.
Scheme 12
34
Thaisrivongs et al67 modified this renin inhibitor and produced the most active renin 
inhibitor in this series (40).
IC50 0.22nM
(40)
Thaisrivongs et al67 also prepared a novel dihydroxyethylene isostere (41), Scheme 
13.
This preparation, started with leucinol (42) protection, oxidation and then Grignard 
addition, which gave the allylic alcohol (43) as a nearly equal mixture of 
diastereoisomers in good yield (82%). The protecting group was changed from the 
temporary trityl, to Boc (44). The trityl group was used in the vinylmagnesium 
bromide addition step, because the N-Boc protected route gave low yields with partial 
racemisation.
Protection of the amide and hydroxyl group gave (45), which was oxidised to the 
aldehyde (46). This was equilibrated under base conditions to give mainly aldehyde 
(46). Aldol addition of aldehyde (46) to acyl oxazolidinone (47) gave adduct (48) 
only as observed from 13C n.m.r. spectroscopy. The chiral auxiliary was reductively 
removed to give the diol (49), which was protected via equilibration under acidic 
conditions to give alcohol (50). The primary alcohol was oxidised to acid (51) and 
coupled with 1 -amino-2(S)-methylbutane to give the protected dihydroxyethylene 
isostere (52). This was deprotected under acidic conditions to afford the















































a. TrCl, E t3 N, DCM; b. (COCl)2, DMSO, DCM; Et3 N; c. CH 2 =CHMgBr, THF; d. DOW EX-50, W- 
X 8 , MeOH; e. (Boc)2 0 ,  THF; f. CH 2 =C(OM e)CH3, p-TSA, DCM; g. 0 3, DCM, MeOH; Zn, AcOH; h. 
K 2 C 0 3, MeOH; i. n-Bu2 BOTf, DIPEA, DCM, H 2 0 ;  j. n-Bu2 BOTf, DIPEA, THF, LiBH4; k. 
Camphorsulfonic acid, DCM; acetone; 1. RuC13, H 2 0 ,  H5 IO 6 , CH 3 CN, CC14; m. l-amino-2-(5)- 
methylbutane, DEPC, Et3 N, DCM; and n. HC1, MeOH.
Scheme 13
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B o c -P h e -H is -I
De Laszlo et a/68 modified the (P1) site for
human renin (leucine side chain) and
produced the bulkier cyclohexylalanine
(Cal) (55) derivative. This has been
incorporated into a number of renin
(55)
inhibitors.
Stanton et al69 explored the effect of modification of the P1 site and found the most 





In 1988, Mettemich and Liidi,70 prepared a novel hydroxy-y-lactone (58) from the 
pyruvate enolate (59). Chelation control of 1,2-induced asymmetric aldol addition of 
the pyruvate (59) to Boc-Cal-H (60) gave the corresponding hydroxy-8 -lactone (58) as 
the major diastereomer (80% d.e.). This was converted to the lactone (61) (59% 
overall yield), which was then ring-opened to the hydroxyethylene analogue (62) 
using allyl bromide and then butylamine, Scheme 14.
Bocl
o




a. LDA, -78°C, THF:HMPA, (9:1), b. Boc-Cal-H (60), -78 ->  0°C ; c. H2, Pd-C; HPLC; d. 
CH 2 =CHCH 2 Br, Ag2 0 ,  Et2 0 ;  and e. n-BuNH2, RT.
Scheme 14
Bradbury et a t71 expanded the use of the novel amino acid, Cal, and prepared several 
potent renin inhibitors. They incorporated non-peptidic portions for P4-P2 linked to 







These Cal-\j/[CH(OH)CH2]-Val analogues were prepared following the experimental 
procedure of Stanton et al63. The hydroxyethylene (66) was coupled with the sodium 









a. NH 4 O 2 CH, Pd/C, EtOH, H 2 0 ;  b. HOBt, HC1. M e2 N(CH 2 )3 N=C=NEt, DMF
Scheme 15
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Shiozaki and Kobayashi72 prepared hydroxyethylene isosteres from 3,4,6-tri-O-acetyl- 
D-glucal. The use of the sugar reduced the number of diastereomers in the synthesis 
to two, whereas previous syntheses have produced at least four diastereomers.
3,4,6-Tri-O-acetyl-D-glucal was converted to the lactone (68), this was transformed to 
the aldehyde (69). Wittig reaction produced the diene (70), and treatment of (70) in 
acetone with Jones reagent gave enone (71). Hydrogenation of (71) gave the lactone 
(72) and the acid (73). Lactone (72) was alkylated, to give a mixture of hydroxy ethyl 
compounds. Mesylation and then elimination with 1,5-diazabicyclo [4,3,0] non-5-ene 
(DBN) gave an E\Z (88:5) mixture of endo-isomer (Z) (74a) and the exo-isomer (E) 
(74b). Methylation of (74) with Me2CuLi gave a 1:1 mixture of diastereomers (75a) 
and (75b). The unwanted isomer (75a) was converted to (75b) by equilibrating with 
LiN(TMS)2, separating out the desired isomer (75b) and repeating the procedure with 
(75a). Lactone (75b) was converted to y-lactone (76), which was transformed to 
tetrapeptide (77) and finally the lactone was reacted with 4-(2'-aminoethyl) 




TBDM SO TBDM SO " TBDM SO
( 7 1 ) ( 7 2 ) (73)
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TBDMSO TBDMSO
(74a) R l=M e, R2=H
(74b) R l=H , R2=M e (75b) R1=H, R 2= 'Pr
(76a) R l= 'P r, R2=H 
(76b) R l= H , R 2= 'Pr
a. cat. KOH, EtOH, RT, 16 hrs.; b. pivaloyl chloride, pyridine-DMAP, RT, 16 hrs., THF, 85%; c. 
TBDMSC1, DMAP, DCM, reflux, 3 hrs., 98%; d. LiAlH4, THF, 5°C, 15 mins., 84%; e. PCC, 3A 
molecular sieves, DCM, RT, 2 hrs., 56%, or DCC, DMSO, cat. H 3 PO 4 , RT, 16 hrs., 57%; f. Ph3 P 
(CgHiOBr, LiN(TM S)2 , THF, reflux, 45 mins., 67%; g. Jones reagent, acetone, 0-5°C , 10 mins., 57%; 
h. H2, 5% Pd/C, EtOAc, RT, 8 6 %; i. i. MeCHO, LiN(TM S)2, THF, -78°C, 15 mins.; ii M e S 0 2 Cl, 
pyridine, RT, 1 hr., iii. DBN, THF, RT, 10 mins., overall E = 78% and Z  = 4%; j. M e2 CuLi, Et2 0 ,  0- 
5°C , 15 mins., a = 49% and b = 49%; k. MeOH, HC1, reflux, 20 mins., a = 94% and b = 100%; 1. 
DEAD, Ph3 P, DPPA, THF, 24°C, 1 hr.; m. H2, 10% Pd/C, EtOAc, RT, two steps, a = 95% and b = 
87%; n. (/V-cyclohexyl-./V-methyl)glycyl-[3-(l-naphthyl)]-alanyl-[3-(4-thiazolyl)]-alanine, DEPC, E t3 N, 




De Laszlo et a f 3 used piperidine and benzazepinones in novel inhibitors of renin. 
They found the conformational constrained phenylalanine benzazepinone containing 
peptidomimetic (79) to be less active than the normal hydroxyethylene (80). The 
hydroxylethylene pseudopeptide (79) was prepared from commercially available 3- 
phenylglutaric acid (81). After several steps imide (82) was furnished. The imide 
(82) was converted to the azide (83) (90% e.e.). The acetal was hydrolysed to the 
aldehyde (84) which underwent reductive animation to give the amine (85). 
Cyclisation at 110°C in DMF and hydrolysis of the r-butyl ester with HC1 in EtOAc 
gave acid (86). This was coupled, and the azide converted to the A-acetyl 








a. KN(TM S)2, THF, Tris-N3, -78°C, 98%; b. AcOH, H 2 0 ,  THF, 90°C, 67%; c. NaCNBH3, MeOH, 
Nle-O^Bu, 3A molecular sieves, 55%; d. DMF, 110°C, 84%; e. HC1, EtOAc, 100%; f. C al-y  
[CHOHCH 2 ]-Val-NH-n-Bu, EDC, HOBt, DCM, 0°C, 50%; g. HSCH 2 CH 2 SH, Et3 N, MeOH, 57%; h. 
Boc20 ,  DCM, 80%; i. Ac2 0 ,  Et3 N, 70%.
Scheme 17
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They also prepared the hydroxyethylene isostere (80), Scheme 18, starting from N- 
phthaloyl protected dipeptide (87), which coupled with Cal-\j/[CHOHCH2]-Val-NH-«- 
Bu to give pseudotetrapeptide (88) in good yield (78%). Removal of the phthaloyl 












a. Cal-y[CHO H CH 2]-Val-NH-n-Bu, EDC, HOBt, DCM, 0°C, 78%; b. N2H4, EtOH, reflux, 94%; c. 
B oc20 ,  Et3N, DCM, 86%; or d. Ac20 ,  Et3N, DCM, 100%.
Scheme 18
De Laszlo et aP3 also prepared the conformationally restrained phenyl alanine 
hydroxyethylene (90). The ester (91) was hydrolysed and the resultant acid (87) was 
condensed with formaldehyde to give the chiral oxazolone (92). When the oxazolone 
(92) was treated with triflic acid the 3-aminobenzazephin-2-one (93) was formed in 
excellent yield (96%). The W-terminal amino group was deprotected and protected as 














a. acetone, HC1, H 2 O, 60%; b. (CH2 0 )n, TsOH, toluene, 63%; c. CF 3 SO 3 H, DCM, 96%; d. Cal-\|/ 
[CHOHCH 2 ]-Val-NH-n-Bu, EDC, HOBt, DCM, 0°C, 78%; e. N 2 H4, EtOH, reflux, 94%; f. Boc2 0 , 
E t3 N, DCM; or g. Ac2 0 ,  E t3 N, DCM.
Scheme 19
It can clearly be seen in Table 2 that in this series of peptidomimetics the smaller the 
















Atsuumi et aVA prepared hydroxyethylene isosteres following a similar synthesis to 
that of Stanton et al.63 They started from a variety of amino acids, which were 
converted to their corresponding Z-amino aldehydes (97). Reaction with vinyl 
magnesium bromide and then protection with 2,2-dimethoxypropane gave alkene (98). 
This was converted to the aldehyde (99) using NaI04-0 s0 4 followed by equilibration 
with K2C 03 and MeOH to give mainly the cis aldehyde (99). Homer-Wittig-Emmons 
reaction of the aldehyde (99) with phosphonate (100) gave the alkene (101) in the 
ratio of 1:1 (E:Z). Conversion to the amide (102), followed by hydrogenation and 


















a. BrM gCH=CH 2 , b. 2,2-dimethoxypropane, p-TSA; c. N aI04, O s0 4; d. K2 CO 3 , MeOH; e. LiCl, 




Baker and Pratt75 synthesised a hydroxyethylene analogue via a y-lactone (104), first 
introduced by Evans et al.62 They prepared the y-lactone (104) from the Cbz-Cal-H 
(105) by addition to (2-isopropylpropen-2-yl)trimethylsilane (106). This gave the 
alkene (107). Using borane-dimethylsulfide (BMS) the alkene was hydroborated, 
treatment with peroxide gave a mixture of diastereomers (108). Oxidation with RuC13 
and equilibration gave the y-lactone (104a) as the major adduct. This was converted 
to the hydroxyethylene peptidomimetic (109) using 3-(4-morphiolin-4- 
yl)propylamine, Scheme 21.
TMS+
( 1 0 6 )
( 1 0 7 a )  R l= H , R 2=O H , 69%
( 1 0 7 b )  R l= O H , R 2=H , 7%
OHCbzl
OH
( 1 0 8 )
Cbzl
OH
( 1 0 4 a )  R l= H , R 2=/Pr (1 0 9 )
( 1 0 4 b )  R l=*Pr, R2=H
a. SnCl4, DCM; b. BMS; c. NaOH, H 2 0 2; d. RuC13, N aI0 4; e. MeOH, HC1 (aq); f. 3-(4-morpholin-4- 
yl)propylamine, AcOH, 55°C.
Scheme 21
( 1 0 7 a )
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Hanessian and Raghaven76 recently reported a novel synthesis of a hydroxyethylene 
analogue (110). The synthesis started with chiral GS)-mandelic acid (111) which they 
used as a chiral template. The benzyloxymethyl (Bom) ether (112) was extended via a 
two-step process to give the a,p-unsaturated ester (113). Organocuprate addition 
methylated the double bond with high stereocontrol, in which the a«fi-orientation 
predominated. Cleavage of Bom led to the lactone (114). Hydrolysis, careful 
acidification, esterification and introduction of benzylic azido group using a 
Mitsunobu reaction, followed by reduction of the azido group with 1,3-propanedithiol, 
N-Boc protection then gave lactam (115). Treatment of lactam (115) with 
diisobutylaluminium hydride (DiBAL-H) and trapping of the iminium ion with 
methanol under acid catalysis led to amino ether (116) as a mixture of anomers and 
rotamers. Lewis acid catalysed condensation of (116) with 2-(trimethylsilyloxy)furan 
gave the desired enone diastereomer (117) as the major adduct (6:1 threo.erythro). 
Hydrogenation of the double bond gave lactone (118), which was methylated to give 
lactone (119). Treatment of lactone (119) with dimethylaluminium butylamine gave 
the pyrrolidine (120). Hydrogenolysis of (120) gave the iV-Boc derivative of (110), 




























a) Bom-Cl, DIPEA, DCM, RT, 100 hrs., 83%, b) i. DiBAL-H, toluene, -78°C, 3*4 hrs.; ii. MeOH, - 
78°C , 80 mins.; iii. methyltriphenylphosphoranylidene acetate, RT, 20 mins., 75% trans, 6 % cis; c) 
M e2 CuLi2 .3TMSCl, THF, -78°C, 2 hrs.; d) TMSBr, DCM, -23°C to RT, 16 hrs., 72% for 2 steps; e) i. 
0.5M  NaOH, MeOH, 0°C  to RT, 2 hrs.; ii. 1M HC1; iii. CH 2 N2, Et2 0 ,  EtOAc, 0°C , 98%; f) DPPA, 
DEAD, PPh3, THF, 0°C  to RT, 16 hrs., 89%; g) 1,3-propanedithiol, DIPEA, MeOH, RT, 48 hrs., 8 6 %; 
h) (Boc)20 ,  DIPEA, DMAP, DCM, RT, 24 hrs., 99%; i) i. DiBAL-H, toluene, -78°C, 4 hrs.; ii. MeOH, 
-78°C, 30 mins., 72%; j) CSA, MeOH, RT, 1 hr., 100%; k) 2-(trimethylsiloxy)furan, BF3 .OEt2, DCM, 
-78°C, 1 hr., (6:1, threo.erythro), 98%; 1) H2, 10% Pd/C, EtOAc, RT, 1 hr., 93%; m) i. LiN(TM S)2, 
THF, -78°C, 40 mins.; ii. Mel, -78°C, 90 mins., -50°C, 1 hr.; iii. AcOH, THF, 67%; n) BuNHAlM e2, 
DCM, RT, 7 hrs., 76%; o) 20% Pd(OH)2, H2  (56 psi), EtOH:EtOAc (2:3), RT, 48 hrs., 73%; p) aq. 
HC1, dioxane, 0°C, 2 hrs., 100%.
Scheme 22
Amino acids have been used as the chiral templates for a vast number of 
hydroxyethylene isostere syntheses. Kempf et al11 developed a new method for the 
preparation of these analogues. Their synthesis involved the condensation of 
homochiral phenylaninal (22) with A-allylmethanylamide dianions (121), Scheme 23,
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to give the alcohols (122a) and (122b). Lactonisation gave y-lactones (123a) and 
(123b) in the ratio 1.6:1. Treatment of these y-lactones (123a) and (123b) with the 
suitable amine yielded the corresponding hydroxyethylene isosteres.


















a) n-BuLi, THF; b) TiCl(0 'Pr)3 ; c) Boc-Phe-H (22); d) xylene, reflux, (1 2 3 a ): (123b), (1.6:1)
Scheme 23
Rich and Prasad78 also used the diastereoselective allyl metal addition to a-amino 
aldehydes. They found that tin(IV)tetrachloride (SnCl4) was the best Lewis acid for 
catalysis of the allyl trimethylsilane (121) condensation reactions. Condensation of 
Boc-Leu-H (16) with silane (124), followed by protection, gave the alcohols (125) and 
(126) in the ratio 1 :2 0 .6 , with the major isomer having the desired stereochemistry. 
Hydroboration followed by oxidation afforded the corresponding primary alcohol, 
which was oxidised to the acid (127). Treatment with methanolic hydrogen chloride 
or tetrabutylammonium fluoride (TBAF) gave the lactone (128). The lactone (128) 
was alkylated with crotyl, allyl or benzyl bromide to form the corresponding alkylated 
lactones (129), (130) and (131) in excellent diastereomeric purities. The lactones
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(129), (130) and (131) were then converted to the corresponding hydroxyethylene 
analogues (132), (133) and (134), Scheme 24.












(132) R= (£)-C H 2 CH =C H M e
(133) R= Bu
(134) R= Bn
a) SnCl4, -78°C, 4hrs; b) TBDMSCl or TBDPSC1, DMF, imidazole, RT; c) BH 3 -THF, RT, 3hrs 
followed by NaOH, H 2 0 ,  RT, 6 hrs; d) RuCl3 -hydrate, N aI0 4, CH 3 CN:CC14 :H20  (2:2:3), RT, 2hrs; e) 
3M HC1 in MeOH, RT, lhr, or TBAF, THF, RT, overnight; f) LiN(TM S)2, -78°C, 0.5hrs; g) E-crotyl 
bromide, BuBr or BnBr, -78°C, 2 hr.
Scheme 24
Rich and Prasad78 used this methodology to prepare a restrained hydroxyethylene 
isostere (135), which mimics a cyclic amino acid (e.g. proline). They prepared this 
analogue by reacting cyclopent-l-enyl-l-methylsilane (136) with Boc-Leu-H (16) as 
above. The alcohol (138) was converted to the iodide (139), which underwent clean 








a) SnCl4, -78°C, 2hrs; b) Ph3 P, I2, CH 3 CN, Et2 0 ,  78%; c) 4M HC1 in MeOH; d) N aH C 03, DMF, 90%.
Scheme 25
Hanko et al79 prepared the hydroxyethylene isostere (140), following a very similar 
method to Rich and Prasad 78
More recently, Taddei et 0 / 80 and Kiyaooka et « / 81 have used allyltrimethylsilanes to 
prepare hydroxyethylene isosteres. Taddei et afi° found that N-Boc amino aldehydes 
(141) reacted with 2-chloromethyl-3-trimethylsilyl-l-propene (142) to give the 
alcohols (143) in good yields. Protection of the hydroxyl group (143d) and 
conversion of the chloride to the iodide (144) facilitated coupling with the lithium
(140)
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enolate of tert-butyl acetate. The alkene was converted to the alcohol (145) via 












(143c) R=M e2 CHCH 2  










a) BF3 .OEt2, DCM, -60°C; b) M e2 C(OM e)2, TsOH; c) Nal, acetone; d) LDA, CH 3 C 0 2 'Bu; e) BH3- 
THF, THF, 0°C followed by NaOH, H 2 0 2; f) P t0 2, 0 2.
Scheme 26









Rich et tf/ 83 in 1987, prepared hydroxyethylene isostere utilising Grignard reagents, 
from the bromo ethers (148) and (149). These reacted with Boc-Leu-H (16) to give 
the alcohols (150) in low yield (ca. 30% for R=Bn compared to 50-65% for R=Me). 
The A-terminus was extended by deprotection and coupling with Boc-Val to give 
(151). Protection, then hydrogenation, followed by oxidation gave the acid (152). 
Coupling with Ala-Iaa, (Iaa = amino acid) followed by deprotection of the A-terminus, 
and coupling with (lva)20  gave the isostere (153). After separation by 
chromatography and removal of the acetyl protecting group, the target 




















a) Mg, E t2 0 ; b) Boc-Leu-H (16); c) HC1, dioxane; d) (Boc-Val)2 0 ; e) AC2 O, DMAP; f) H 2 , Pd/C; g) 
KMn0 4 , H 2 O, Bu4 NBr; h) Ala-Iaa, DCC, HOBt; i) (Iva)2 0 ; j)  silica gel chromatography; k)
M eOH, K 2 C 0 3.
Scheme 27
Herold et a/ 84 and Bradbury et a/ 85 both developed similar routes to hydroxyethylene 
isosteres utilising the Grignard reaction to prepare the intermediate alkene (155). 
Halogenation of the double bond yielded the corresponding lactones (156). The
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bromide groups was converted to the azide (157), which was then reduced to the 







a) i. I2, AcOH, THF, H 2 0 ,  0°C or ii. NBS, H 2 0 ,  DME, 0-20°C; b) NaN3, DM PU, 20°C; c) H2, Pd/C, 
EtOH; d) n-butylamine, 40°C.
Scheme 28
Wuts et a / 86 also utilised the Grignard reaction to assemble the backbone of the 
hydroxyethylene isostere of Leu-Val. Starting from 3-methylbutyraldehyde (160), 
addition of vinylmagnesium bromide and subsequent acylation gave the ester (161). 




the diastereomeric amides (163) and (164). Selective crystallisation afforded amide 
(163) in 98% d.e. Epoxidation of the alkene followed by acid hydrolysis yielded the 
lactones (165a) and (165b). Mesylation followed by chromatographic separation gave 
the major mesylate (166). The minor mesylate was converted to the lactone (165a) by 
treatment with NaOH to hydrolyse the lactone and form a transient epoxide, which 
lactonised in acidic conditions. This process enabled the preparation of large 
quantities of the major lactone (165a) was mesylated and then converted to the azide, 
which was hydrogenated to give the free amine. This was protected to afford the N- 
Boc protected lactone (167), Scheme 29.
+
(1 6 5 b )
MsO
(1 6 6 b )  O
BocN
(1 6 7 )
MsO'+
(1 6 6 a )
a) CH 2 =CHMgBr, -30°C; b) Iva-Cl, 8 8 %; c) LDA, THF, TMSC1, H 3 0+, 90% ; d) DEPC, 
PhCH(M e)NH2; e) m-CPBA; f) H3 0+; g) MsCl, Et3 N; h) chromatography; i) NaOH; j)  N aN 3, DMSO; 
k) H2, Pd-C, EtOAc, (Boc)20 .
Scheme 29
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Jones, Nilsson and Szelke87 reported an elegant, short stereocontrolled synthesis of 
the hydroxyethylene isostere Cal-\j/[CH(OTBDMS)CH2]-Ala (168) utilising a 
Grignard reaction. Starting from Boc-Cal-H (60), treatment with the chiral Grignard 
reagent (169) gave the alcohols (170) and (171) in the ratio 6:1. The major product 
(170) was then deprotected and reprotected with 2',2',2'-trichloro -l',l'- 
dimethylethoxycarbonyl (TcBoc) to give (172). They used TcBoc, because it had 
been observed that Ar-Boc protected 3-hydroxy-4-amino acid derivatives tended to 
lactonise during Boc removal.88 The alcohol (172) was then protected using 
TBDMS-OTf and oxidised with ruthenium tetroxide to yield the protected 









a) chromatography; b) HCl-dioxane; c) TcBoc-ONSu; d) TBDMS-OTf; e) R 11O 4 .
Scheme 30
Ryckman and Diederich89 also utilised the Grignard reaction. They started from N,N- 
dibenzyl protected phenylalanine (173). They prepared the AT-methyl-O-methylcarbo- 
xamide (174) using peptide coupling techniques. This was reacted with the Grignard 
reagent (175) to give the ketone (176). Reduction of the ketone (176) using NaBH4
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gave the alcohols (177) and (178) in good yield, alcohol (177) being the major product 
[25:1 ratio (177):(178)]. The diastereomers were separated by chromatography and the 
major isomer (177) was lactonised to (179). Oxidation gave (180), which was alkylated 
and reprotected to give the N-Boc lactone (181). The lactone was opened to give the 
desired hydroxyethylene isostere (182), Scheme 31.














(181b) R=M e 
(181c) R=Bn
(182)
a) EDC, HOBt, HCl.NHMe(OMe), DMAP, DMF, DIPEA, RT, 95%; b) THF, 0°C, 93%; c) NaBH4, 
MeOH, 0°C, 95%; d) 3M HC1:THF (1:1), 92%; e) C r0 3 -H 2 S 0 4, acetone, 0°C, 95%; f) LDA, RX; g) 










Other groups have used the Wittig reaction or modified versions to prepare 
hydroxyethylene isosteres. De Laszlo et a/90  prepared the phosphonate (184) from the 
ester (183). The ester (183) underwent Wadsworth-Emmons reactions with benzalde- 
hyde, iso-butyraldehyde and acetone to give the olefins (185), (186) and (187) 
respectively in low yield (-30%). However, reaction with ethyl-3-methyl-2-oxobutano- 
ate gave a single olefin (188) in 72-78% yield. Reduction of the olefin (188) gave 
lactones (189) and (190). Epimerisation of these lactones with DBU / DMF at 90°C 
gave a 2:1 mixture of (189):(190). Hydrogenation of lactone (189) gave the single 
lactone (191), which was epimerised to give a 3:7 mixture of lactones (192) and (191). 
Repetitive recycling of (190) and (191) provided lactone (192) in multi-gram quantities. 
Lactone (192) was then converted into the hydroxyethylenes by application of the 
Weinreb amidation reaction,91 Scheme 32.




(186) R 1= 'Pr, R 2=h
(187) R 1 =Me, R 2=Me









a) H 2 , Pt0 2 , 95%; b) n-BuLi, CH 3 P(0 )(0 Me)2 , THF, 95%; c) n-BuLi, ethyl-3-methyl-2-oxobutanoate or 
aldehyde, THF, 0°C; d) NaBH4, MeOH, -30°C, (189):(190) 3:2; e) DBU, DMF, 90°C; f) H2, 10% Pd/C.
Scheme 32
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Poss and Reid92 also used the phosphonates in their preparation. They prepared the 
protected aldehyde (193) and addition to the phosphonate (194) gave the a,(3- 
unsaturated ester (195). This was converted to the amide (196) using the Weinreb91 
amidation reaction. Hydrogenation of amide (196) gave predominantly diastereomer
(197), isolated in 70% after chromatography. The hydroxyethylene isostere (198) was 
prepared by partial hydrolysis with 10% HCl-AcOH, Scheme 33.
BocN
(193)












a) KN(TM S)2 , THF, 81%, (Z:E, 20:1), chromatography; b) M-B11NH 2 , M e3 Al, DCE, 
Rh/Al2 0 3, THF; d) 10% HCl-AcOH, THF, 83%.
; c) h 2,
Scheme 33
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Plata, Leanna and Morton93 also utilised a Wittig olefination. Their preparation used a 
novel piperidine-2,5-dione (199) as a chiral template. This template (199) was prepared 
from phenylalanine via the /V-tritylphosphonate (2 0 0 ) following a similar procedure to 
de Laszlo 90  Wadsworth-Emmons condensation gave the olefin (201) which, under 
saponification conditions, underwent double bond migration to give the 
thermodynamically more stable acrylic acid (202). Activation of the acid, followed by 
acid then base conditions, afforded the chiral template (199). Selective reduction with 
L-selectride at -78°C gave exclusively the axial alcohol (203). Hydrogenation gave 
exclusively the 8 -lactam (204), which underwent lactonisation in strong acid conditions 















a) i. NaH, 0°C, THF; ii. M e 0 2 C C 0CH M e2, RT, THF; b) LiOH, H 2 0 ,  MeOH, THF; c) N- 
hydroxysuccinimide, DCC, THF; d) i. HC1, Et2 0 ,  ii. NaHC 0 3  (aq); e) L-selectride, -78°C; f) H 2, Pd/C, 
EtOAc; g) 6 M HC1, reflux.
Scheme 34
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Dondoni and Perrone94 used the stabilised phosphorus ylide, Ph3P=CHCC>2Me, to 
prepare the a,(3-unsaturated olefin (206) from N,N-Bn-Boc protected aldehyde (207). 
After hydrogenation of the double bond, lactonisation yielded the lactone (208). 
Benzylation and A-Boc removal afforded the lactone (209), Scheme 35.
P h
B o c l







B o c N
B n
O(208)
a) Ph3 P =C H C 0 2 Me, C6 H6, RT, 3 days; b) NiCl2 .6 H 2 0 -NaBH 4 , MeOH, 0°C, lhr, RT, 18hrs; c) TBAF, 
H 2 0 ,  THF, RT, 4hrs; d) LiN(TM S)2, THF, -78°C, 30mins, then Bnl, -78°C, 30mins; e) 40% TFA, DCM, 
RT, lOmins.
Scheme 35
Boyd et al95* prepared hydroxyethylene isosteres from the A-Boc oxazolidine aldehyde 
(193). Rosenburg et a/95b utilised a Lewis acid catalysed anti-aldol reaction, Scheme
36. They converted the aldehyde to the anti-aldol product (211) as the major product, 
which was separable from the minor syw-aldol (212) (1.4%). The hydroxyl moiety was 
removed by treating intermediate (213) with tributyl tin hydride to give the thio ester 
(214). Lactonisation under acid conditions gave the lactone (205), Scheme 36.
B o c N












a) BF3 .0 Et2 , DCM, -78°C, lhr.; b) thiocarbonyldiimidazole, DMAP, DCE, 50°C, 18hrs.; c) B 113S11H, 
toluene, reflux, 20hrs.; d) 4M HC1, EtOH, RT, lhr; Na2 C 0 3.
Scheme 36
The other route Rosenburg et aP5b developed used a boronyl enolate (215), which they 
reacted with aldehyde (193) to yield the aldol adduct (216) in good yield. Removal of 
the hydroxyl moiety as before, and conversion to the acid (217) allowed for the use of 
standard peptide coupling techniques to give the protected hydroxyethylene isostere 
(197). Treatment with acetyl chloride, followed by a base wash removed the N and O 













a) n-Bu2 BOTf, DCM, -78°C; b) DIPEA, -78°C, 0°C; c) (193), -78°C to 25°C; d) H 2 0 2, MeOH, pH7, 
overall 63%; e) thiocarbonyldiimidazole, DMAP, DCE, 50°C, 18hrs, 84%; f) n-Bu3 SnH, toluene, reflux, 
91%; g) LiOH, H 2 0 2, THF, H 2 0 ;  Na2 S 0 3; N aH S 04, 90%; h) EDC, HOBt, 4-methylmorpholine, DMF, 
-10 to 0°C, 2 days; BuNH2, 0 to 25°C, 89%; i) AcCl, MeOH, 0 to 25°C; N aH C 03, 79%.
Scheme 37
Shibuya et aP6 and Decamp and Kouvaguche et aP1 prepared hydroxyethylene 
analogues by reacting a-amino aldehydes with alkoxytitanium homoenolates of the 




Bn2r A CHO +  C , 2 < / P ~
R2
(218) R2=H (220) R2=H
(219) R2=Me (221) R2=Me





These precursors could then be converted to the desired hydroxyethylene isosteres using 
the Weinreb91 amidation technique.
Further avenues of hydroxyethylene isostere synthesis were explored by Kleinman et
salt of ethyl propiolate to generate an epimeric mixture of the hydroxy acetylenic esters 
(222) in poor yield (36%). Hydrogenation, without isomerisation, gave the keto-ester. 
The intermediate hydroxy esters were not isolated, but lactonised directly in refluxing 
toluene to yield lactones (128), which were converted to the alkylated analogues 
following standard procedures, Scheme 39.
a / .98 They developed a short, stereoselective synthesis of the lactone precursor (128), 
which Prasad and Rich78 prepared later. Boc-Leu-H (16) was reacted with the lithium
BocN
(222) (1 2 8 a ) 'o (1 2 8 b ) 'o
a) LiCsCCC^Et, -78°C; b) H2 , Pd, B aSO ^ c) AcOH, toluene , reflux.
Scheme 39
Nishi et a t"  also prepared the 7 -lactones (128) and the cyclohexyl derivative (223) from 











a) i. reduction; ii. cat. AcOH, toluene, reflux.
Scheme 40
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Hoffman and Kim100 synthesised the phenylalanine y-lactone (225) using a slightly 
modified Nishi" preparation. They prepared the acetylated p-keto ester (226) by 
activating Cbz-Phe (227) using carbonyldiimidazole (CDI) and reacting this with the 
enolate (228). The p-keto ester (226) was converted uneventfully to the 7 -keto ester 
(229) via addition of the ethyl ester followed by decarboxylation. Reduction and 















a) CDI, (228); b) i. NaH; ii. BrCH 2 C 0 2 Et; iii. TFA, 76%; c) i. NaBH4; ii. AcOH, toluene, reflux.
Scheme 41
CbzN
Randuz et a/ 101 prepared the hydroxyethylene isostere (230) and the lactone (231) from 
reduction of the keto ester (232). The ester was prepared via enolisation of the ketone
(233), which was trapped with methylbromoacetate. The keto ester (232) was the only 
diastereomer isolated. The ketone (233) was prepared in large scale following the 
procedure of Rapport, 102 Scheme 42.
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a) LDA, THF, -78°C, methylbromoacetate; b) U B H 4 , 2-propanol, -50°C, 30mins.
Scheme 42
Sakuri et a/ 103 prepared many y-lactone precursors of hydroxyethylene isosteres 
following a similar procedure to that of Nishi," Figure 10.
P h





B o c N B o c N
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Lagu and Liotta104 also followed a similar synthesis to that of Nishi" and isolated the 7  






Shibuya et a/ 105 reviewed some of the previous literature in 1992, which incorporated 
the synthesis of hydroxyethylene isosteres from p-oxygenated g-amino acids and y- 
oxygenated 5-amino acids.
Kotsuki et al106 and Melovi et a / 107 prepared hydroxyethylene isosteres from D-ribose 
and D-isoascorbic acid respectively. Scheme 43 shows the chemical transformations 
used to prepare the 7 -lactone (223a).





a) i. H 2 SO4 , acetone, RT, 0.5hr.; ii. NaBH 4 , 0°C, 2hrs; iii. NaI0 4 , RT, 2hrs.; b) Ph3 P-cyclohexylylide, 
THF, -30°C; c) H 2 , Raney Ni, EtOH; d) triflic anhydride, pyridine, -15°C, 15mins.; e) LiCF^CCVBu, 
THF, DMPU, -78°C, 5mins; f) TFA, RT, lhr.; g) i. MsCl, pyridine, ii. NaN3, 18-crown-6, DM PU, 80°C, 
36hrs; iii. H 2 , 10% Pd/C, B0 C2 O, EtOAc.
Scheme 43
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Nishi et a / 108 prepared 7 -lactone precursor (240) from 5-oxotetrahydrofuran-2- 





(181a) R=Bn o 
(223a) R=cyclohexylmethyl
R








a) SOCl2, reflux; b) cyclohexyl-CH2M gBr or PhCH 2 MgCl, THF, -78°C; c) L-Selectride, THF, -78°C, d) 
i. MsCl, Et3 N, DCM, 0°C; ii. LiBr, THF, reflux; iii. NaN3, DMPU, RT; iv. H2, Pd/C, Boc2 0 ,  EtOAc, RT; 
e) LDA, THF, -78°C; Mel.
Scheme 44
1.4.2.2 HIV-1 inhibitors
Most of the HIV-1 hydroxyethylene isostere inhibitors synthesised since the start of this 
decade have involved the use of the 7 -lactones (181a) and (236). Dreyer et a l109 and 
Varney et a/ 110 both prepared their isosteres from the 7 -lactone precursor (181a). 
Dreyer utilised a Grignard condensation to prepare the y-hydroxyalkene (244) from Boc- 
Phe-H (22). Following a similar procedure to that of Prasad and Rich,78 they prepared 
the 7 -lactone precursor (181a), which was transformed to the hydroxyethylene analogue 
(245), Scheme 45.
Varney et al110 converted the 7 -lactone (181a) to the protected 7 -hydroxy acid (246), 
this was then converted to a number of HIV-1 protease inhibitors (247), Scheme 46, of 
which (247c) was the most potent inhibitor.
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a) 2M LiOH, THF; b) TBDMSC1, imidazole, DMF; c) DCC, amine, DCM; d) TFA, DCM; e) TBAF, 





Thompson et allu , Cushman et al112 and Sakurai et a/ 113 all prepared derivatives of 
the y-lactone (236). Thompson et alm  prepared this intermediate using a Wittig 
reaction to give the c/s-alkene from the N-Boc aminoaldehyde (250). Conversion to 
the iodoalkene (251) allowed the formation of the diester (252). Epoxidation gave 
mainly the threo epoxide (253a) which was lactonised to the bicyclic lactone (254). 
Decarboxylation yielded the y-lactone (255), which was finally converted to the 











(254) R =C 02Et , .
(255) R=H ’*
a) Ph3 P+(CH 2 )3 C 0 2H C l', KN(TMS)2, THF, 0°C  to 25°C, 18 hrs; b) Et3 N, EtOCOCl, THF, -10°C to 
-2°C, 45 mins., then NaBH4, MeOH, 0°C, 1 hr; c) M eS 0 2 Cl, Et3 N, 0°C; d) Nal, acetone, 56°C, 3 hrs;
e) NaH, CH 2 (C 0 2 Et)2, DMF, 80°C, 45 mins., f) m-CPBA, DCM, -10°C to 25°C, 4 hrs; g) 
LiN(TM S)2, then ZnCl2, THF, Et2 0 ,  -20°C to 25°C, 3 days; h) LiOH, dioxane, H 2 0 ,  25°C, 6  hrs; i) 
xylenes, 160°C, 10 hrs; j)  PhCH 2 NH2, n-BuLi, THF, -78°C, W2 hrs; k) 5% Ph/C, EtOH, THF, H2, 20 
hrs.
Scheme 47
Cushman et alin  showed that the y-lactone (236) could be generated from Boc-Phe-H 
(2 2 ) via an aldol condensation with cyclopentanone, giving four diastereomers. 
Treatment of the (3-hydroxyketone (257) with LiCN and DEPC gave the intermediate
70
(258) which upon reaction with samarium iodide yielded the y-lactone (236), Scheme 
48.












B o c N
(236)
a) cyclopentanone, LDA, THF, -78°C, l lA hrs.; b) LiCN, DEPC, THF, 0°C , 20 mins; c) Sm l2.
Scheme 48
Sakurai e t a l 113 also used the y-lactone (236). This was incorporated into the 
hydroxyethylene peptidomimetic (259), Scheme 49.
a,b,c
B o c N
a) 4M HC1, dioxane; b) Z-Asn-O-nitrophenyl, Et3 N; and c) n-BuNH2.
Scheme 49
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W.J. Thompson et allu , Askin et alU5 and S.K. Thompson et al116 utilised the y- 
lactone precursor (260) to prepare HIV-1 inhibitors. W.J. Thompson et alu 4 prepared 
the y-lactone (260) from the N-Boc aminoaldehyde (261) and (22). Peterson reaction, 
followed by reprotection and then epoxidation gave the threo epoxide (262) and (23) 
as the major isomer. Lactonisation gave y-lactone esters (263), followed by 
decarboxylation to the y-lactones (260). These were converted to the protected 
hydroxyethylene peptidomimetics (264).
Deprotection and amidation gave the targets (265). Finally, hydrogenation gave the 
corresponding phenol derivatives (266), Scheme 50.
a-d
Bocl COoEtBoclBocl CHO
(263a) R=H(22) R=H (23) R=H
(261) R=OBn (262) R=OBn (263b) R=OBn
BocN OH
TBDMSO










(265a) R1=H, R2=OBn 
(265b) Rl=OBn, R2=H 
(265c) Ri=R2=OBn
(266a) Rl=H, R2=OH 




a) TM SCH 2 MgCl; b) BF3 .0 Et2 , DCM; c) B 0 C2 O; d) m-CPBA, DCM or magnesium monophthalate 
hexahydrate, MeOH; e) CH 2 (C 0 2 Et)2, Na/EtOH; f) BnBr or 4 -(PhCH 2 OC6 H4 )CH 2 Cl, Na/EtOH; g) 
LiOH; h) toluene, reflux, followed by chromatography; i) LiOH; j)  TBDMSC1, imidazole, DMF, 
MeOH; k) 1 (5)-amino-2(/?)-hydroxyindane, HOBt, EDC, DMF; 1) TBAF, THF; m) H2, 10% Ph/C, 
THF, MeOH.
Askin et al115 also prepared inhibitors (268) similar to those of W.J. Thompson et 
al114 from an intermediate y-lactone (267). The inhibitors they prepared are shown in 
Figure 12.
S.K. Thompson et aln6 converted the y-lactone (267) into a variety of inhibitors (269) 
which contained the hydroxyethylene unit, Figure 13.
Scheme 50
(268a) Ph H
(268b) Ph ocHgCHgi/ \>










S.K. Thompson et aln i  used the protected hydroxyethylene analogue (29) which 
Evans et al62 had prepared in 1985, for the preparation of numerous HIV-1 inhibitors, 
the most active being the inhibitor (270), Figure 14.




Chu et a/ 118 and Chakraborty et aln 9 derived hydroxyethylene analogues from the 
naturally occurring optically active sugars, D-mannose and D-glucose, respectively.
Chu et a/ 118 converted D-mannose to the cyclic ether (271) in nine steps. The ether 
subjected to by Grieco oxidation, 120 followed by hydrogenation in the presence of di- 
tert-butyl dicarbonate (Boc20 ) to give the y-lactone (181a). Standard alkylation 
yielded the y-lactone (267) which was converted to the hydroxyethylene analogue 







a) m-CPBA, BF 3 .OEt2, DCM, 0°C, 3 hrs., b) 10%, Pd/C, H 2  EtOAc, Boc2 0 ,  6  hrs; c) LiN (TM S)2, 
THF, -78°C, 30 mins.; PhCH 2 I, -78°C, 30 mins, then M eCH 2 C 0 2 H, -78°C to 23°C , 15 mins.; d) 
M e3 Al, PhCH 2 NH2, DCM, 40°C, 3 hrs.
Scheme 51
Chakraborty et alu9 described an elegant and concise method for the preparation of 
the hydroxyethylene peptidomimetic (273) from D-glucose. The sugar was converted 
to the azido alcohol (274) in several steps. Functional group manipulations gave the 
azido alcohol (275) which was converted to the aziridine (276) before opening to give 









a) Ac2 0 ,  pyridine, 12 hrs; b) HgO, BF 3 .OEt2, 85% aq THF, RT, 20 mins; c) PDC, DMF, RT, 4 hrs,
then CH 2 N2; d) K2 C 0 3, MeOH, 1 hr; e) Ph3 P, CfiHg, 1 hr., reflux, (Boc)2 0 ,  RT; or step e. followed by
f) Ph3 P, DEAD, RT, 1 hr; g) PhMgBr, CuBr, DMS, toluene, -30°C, 1 hr; h) 1M LiOH, THF, RT, 6  hrs.
Scheme 52
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Martin, 121 Huff122 and Marshall123 have recently reviewed the preparation of 
hydroxyethylene and hydroxyethylamine isosteres for the inhibition of HIV protease.
1.4.3 Hydroxyethylamine isosteres
Gordon et al124 developed a new class of ACE inhibitors in the mid-80's. This new 
class of inhibitor contained the ketomethyl unit instead of the amide bond. Substances 
of this type were reported to be the most potent at the time with IC50 of 3nM for 
inhibitor (277),124a Figure 15.
(277) (278)
Figure 15
Modification of the backbone produced more potent inhibitors with (278)124b being 
the most active inhibitor with IC50 of 0.004 nM. In 1985, Gordon et aln4c 
incorporated the aminoalcohol unit, on the hypothesis that this modification of the 
amide bond at the scissile site may mimic the putative transition state, an idea very 
similar to that considered for the hydroxyethylene analogue. They prepared the first 
hydroxyethylamine peptidomimetic (279) and found the alcohol with the (R) 
configuration to be 300 times more active than the corresponding (S) isomer (280).
IC50  (nM) R1 R2
28 (279) OH H
10,000 (280) H OH
Gordon et all24d prepared the inhibitor (279) from the V-benzamide chloroketone 
(281). This was coupled with Ala-OCH2CH2TMS. Protection of the secondary
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amine followed by reduction of the ketone with sodium borohydride gave the alcohol 
(282). Protection of the alcohol gave (283), deprotection and coupling gave the 
protected hydroxyethylamine (284). This was deprotected to furnish the inhibitors 


















a) Ala-OC(CH 2 )2 TM S, DMF, Nal, N aH C 03; b) Cbz-Cl, C 6 H6, pyridine; c) NaBH4, THF, water; d) 2- 
methoxypropene, pyridinium para-toluene sulfonic acid; e) TBAF, DMF; f) 2- 
morpholinoethylisocyanide, HOBt, Pro-OBn, THF; g) THF, AcOH, 10%, HC1; (6:4:4), 25°C; h) H2, 
Pd/C, HC1, EtOH.
Scheme 53
Gordon et aln ^  also prepared the 3° alcohol (285) to examine the constraints on 
enzyme binding. This synthesis involved the use of the epoxide (286) which was 
ring-opened to yield the tertiary analogue (285), Scheme 54.
.Ph P^h










a. CH 3 MgBr, THF, -78°C; b. CH 3 PPh 3 Br, KN(TMS)2, C6 H6; c. TFA, DCM; d. PhCOCl, DIPEA; e. 
m-CPBA, DCM; f. Ala-Pro-O'Bu, MeOH, 65°C.
Scheme 54
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Harris et al125 also saw the potential of this new class of inhibitor and developed Leu- 
Val bond mimetics that contained the hydroxyethylamine unit. They prepared their 
analogues from the iodo ketone (287) following two routes, Scheme 55. The first 
route involved the coupling with Val-OBn followed by reduction, to give the 
dipeptide mimetic (288), this was protected and then the (R) and (S) isomers (289) and 
(290) were separated by chromatography. Hydrogenation and then coupling gave the 
inhibitor (291). Route two involved coupling of (287) with Val-Ile-Phe-OMe, then 
reduction to give the alcohol (292). The isomers were then separated and the Boc 
group removed to give both isomers (291) and (293).
BoiRoute 1 Route 2
h,b
(287)










Ile-Phe-O M eIle-Phe-O M e
OHOH
(291) <293>
a) Val-OBn, THF, 40°C; b) NaBH4, MeOH; c) TBDMSC1, DMAP, DMF, Et3 N; d) chromatography; 




Rich and Kent et al126 showed that the JG-365 (294) was an active HIV-1 inhibitor 
(K| of 0.24nM). JG-365 (294) was shown to be 3000 more potent than the reduced 
amide analogue MVT-101 (A-Ac-Thr-Ile-Nle-\|/[CH2NH]-Nle-Gln-Arg-NH2).
Ph Ile-Val-OMe
Ac-Se r-Le u-Asn-N 
H JG-365 (294)
Alewood and Kent et al127 utilised solid phase chemistry to prepare this analogue 
(294), Scheme 56. Starting from the bromo ketone (295) coupling with TFA-Pro-Ile- 
Val-OCH2-Pam-Resin (OCH2-Pam = 4-(carboxamidemethyl)benzylester), followed 
by reduction gave the alcohol (296). This was then converted to heptapeptide mimetic 
(297). Removal from the resin and deprotection gave the target inhibitor JG-365 
(294).
a) DIPEA, DMF, TFA-Pro-Ile-Val-OCH 2 -Pam-Resin; b) NaBR*, THF; AcOH; c) repeated cycles of 












Cieplak and Kollman128 studied the free energy perturbation and molecular dynamics 
to predict the consequence of replacing each of the seven peptide bonds in the JG-365 
V-methyl inhibitor. As yet, no definitive results have been published.
Krohn et al129 prepared numerous hydroxyethylamine peptidomimetics with intention 













Rich et al130 designed hydroxyethylamine dipeptidyl isosteres to mimic the transition- 
state for hydrolysis of Tyr-Pro, one of the partial substrate sequences cleaved by HIV 
protease. They also prepared the inhibitor JG-365 (294). Their route involved 
coupling chloroketone (300) with Tos-Pro-Ile-Val-OMe (301), reduction and then 
hydrogenation, giving the target inhibitor (294), Scheme 57.
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Ph







a. Nal, DMF; b. N aH C 03; c. NaBH4, MeOH; d. Pd(OH)2 /C, H2, AcOH.
Scheme 57
Rich et a/131a also prepared the (^-configuration (302) of the inhibitor JG-365 (294) 
in a similar manner. They also prepared the inhibitor Boc-Asn-Phe-V|/ 
[CH(OH)CH2N]-Pro-Ile-Val-OMe (303) from the aminoalkene (304) in two steps, via 














a) m-CPBA, DCM, 0°C , chromatographic separation; b) HCl.Pro-Ile-Val-OM e, E t3 N, MeOH, reflux.
Scheme 58
Rich et <z/131b also prepared the inhibitor (299) via an epoxide ring-opening reaction.
Many other research groups have utilised epoxide ring-opening reactions to prepare 
hydroxyethylamine isosters. These included work by Tucker et al132 who prepared 
the HIV-1 proteinase inhibitors Ro 31-8959 (306), JG-365(S) (302) and L-689,502 






Ile -V a l-O M ePh







Epoxide (23) was ring-opened to give the amino alcohols (308) and (309), these were 






















a) W-200-N alumina, Et2 0 ,  THF slurry, 72-96 hrs. 
Scheme 59
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Kempf et al133 prepared the almost symmetric dipeptide (309) via the epoxide ring- 
opening by benzylhydrazine (310), Scheme 60. This was shown to be a less potent 
inhibitor than hydrofuran analogue (311).
Ph
NBoc
(3 1 1 )
H
(3 0 9 )





Gordon et a/ 134 developed a series of C2 symmetrical inhibitors which were 
complementary to the C2 symmetry of HIV protease homo dimer. The preparation of 
these inhibitors involved the epoxide (312) ring opening of selected amino epoxides, 
with ammonia and then reaction of this amino alcohol (313) with the same epoxide 
again to give the symmetrical amino alcohol (314), Scheme 61.




Kim and Huff et al135 targeted HIV-1 protease for inhibition, and developed a new 
class of protease inhibitors of which L-735,524 (315) is a member. This placed the 
piperazine carboxamide unit at the C-terminal (316), and found that the (/?)- 
configuration was more tightly bound to the enzyme than the (5) isomer (317), Figure 
18. These analogues were prepared via epoxide ring-opening reactions.
(315) L-735,524
Figure 18
Parkes et al136 prepared the potent HTV-1 inhibitor Ro 31-8959 (318), which is 
currently in phase HI of clinical trials. This hydroxyethylamine was also prepared via 





Tourwe et al137 and Kim and Huff et a / 138 prepared hydroxyethylamine inhibitors via 
reductive animation. Since Coy et all l '3A developed the solid phase procedure for the 
preparation of reduced amide isostere (see Section 1.4), its use has increased 
enormously. Tourwe et al139 adapted this procedure to prepare hydroxyethylamines 
with ease and high stereochemical control, Scheme 62.
,Ph ^Ph
CHOX  ab X j T 3Boctr^cHO —— ► B o c r r N ^ ^ s  
H (2 2 ) H OH
.Ph .Ph
BocN/ / ^ 'sYx^ X'Pro-lle-Val-0-Merrifield-resin —- — Ac-S e r-Le u - A s n P  ro-t I e - Va I 
H OH H OH
( 2 9 4 ) +  (3 0 2 ) JG-365
a) 2-trimethylsilylthiazole, DCM, -30°C, 17 hrs; b) TBAF; c) Mel, CH 3 CN, reflux; d) NaBH4; e) 
HgCl2, CH 2 CH:H20  (4:1); f) NaCNBH3, DMF, 1% AcOH, g) repeated cycles of deprotection and 
acylation; h) HF, anisole.
Scheme 62
Tourwe et al137 also used this procedure to prepare the inhibitor (318), Figure 20.
(318)
Figure 20
Kim and Huff et a/ 138 prepared the secondary amine structure (319) similar to those of 
Tucker et al132 using a reductive animation preparation, Scheme 63.
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a) NaCNBH3, AcOH, MeOH. 
Scheme 63
However, all the secondary amine analogues were less potent than the corresponding 
hydroxyethylamine structures of Tucker et al.132
1.4.4 Other Peptide bond surrogates
Recently, Herranz et al139 reported a new class of transition-state analogues. These 
contained the amide bond replacement \j/[CH(CN)NH], cyanomethyleneamino 
isostere. In this new peptide bond surrogate, they suggested that the cyano group 
keeps some //-bonding acceptor properties, while the new asymmetric centre could 
impart higher backbone rigidity than the reduced peptide bond. They prepared these 
analogues via Lewis acid catalysed reaction of ^-protected a-amino aldehydes with a 
C-protected amino acid in the presence of TMSCN, Scheme 64.
P -X a a -H  +  Y a a -O M e  P -X a a -y [C H (C N )N H ]-Y a a -O M e
P=Z, Xaa = Phe, Yaa=Ala RiS 1:1 
P=Boc, Xaa=Phe Yaa=Pro R:S 9:1
a) E t3 N, MeOH, ZnCl2, -20°C, 1 hr, TMSCN, 0°C, 24 hrs.
Scheme 64
Hangauer140 prepared a new class of renin inhibitors, which incorporates the amide 
bond replacement \j/[CH(CH2OH)], Figure 21. However, these were rather poor renin
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inhibitors and their synthesis was not published. We hope to show that this new class 
may show some inhibitory activity with other enzymes, e.g. HIV-1, matrix 
metalloprotease and others. Our modelling studies, which will be discussed in 
Chapter 3, indicates that certain hydroxymethyl peptide analogues might be 
substrates for collagenase.







Molecular dynamics procedure is a deterministic simulation process wherein the 
positions and the velocities of atoms in a molecule are integrated forward in time, 
using Newton's laws of motion. The initial velocities are randomly ascribed to atoms 
via a Maxwellian distribution consistent with the temperature at which the simulation is 
being performed. The movement of the atoms is then governed by the kinetic energy 
input into the system and the restoring forces that act on the molecule when its 
position from a minimum energy of the system can be determined. This term consists 
of strain energies; like bond length, bond angle deformations, torsional components 
etc. and interactions like van der Waals, non-bonding interactions and electrostatic 
terms. In this thesis, the Valence Force Field (VFF) is used to compute potential 
energy and the expression is given below. The potential energy of the compound 
studied is represented by the full valence force field (VFF).
V  = E { D b [ l- e - « ( b-bo) ]2 .D b }
+ HEH6(e-e0)2 







+ Es [(r*/r)12-(r*/r)6] + Eqjqj/r
The first four terms define the energy required to distort the internal from their ideal 
values (b,0,<|> and % are the bonds, valence angles, torsion angles and out of plane 
angles, respectively; b0 and 0O are the ideal bond lengths and valence angles and the H
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NOMENCLATURE
Stereochemical Notation and Compound Numbering
Throughout this thesis, the graphical representation of stereochemistry is in accord 
with the conventions proposed by Maehr141 in 1985. Thus, solid and broken thick 
lines represent racemates and wedges denote absolute configuration where greater 





The chemical nomenclature used throughout this thesis will be represented by a 
combination of that assigned in carbohydrate and in peptide nomenclature. The 
numbering system will follow that of the standard IUPAC convention. All amino 
acids mentioned are those of the natural stereochemical configuration, except were 
stated. Any text presented in italics represents that of similar work carried out by 







2.1 Aims and objectives.
The objectives of this project were as follows:
a. The preparation of homochiral //-protected aminoepoxides (322) and (323) as
key intermediates
f steps w
H2 N ^ C 0 2 H P h t N " ^ p 0  P h
(322)
b. The diastereoselective synthesis of the hydroxymethyl dipeptide mimetics
(324) and (325)
1 H 5
P h t N ^ Y ^  OMe
S h
(325)
c. The diastereoselective synthesis of the chloromethyl dipeptide mimetics (326)









 PhtN r  OMe
'"Cl
(327)
d. Diastereoselective synthesis of the mercaptomethyl, phosphonomethyl and 
carboxymethyl dipeptide mimetics (329), (330) and(331), and
O
X = C H 2 SH, (329)
OMe PhtN' Y  Y  "OMe CH 2 P 0 3 H2, (330
X \ ___  C 0 2 H, (331)
91





X = CH 2 OH, (332) X = CH 2 P 0 3 H2, (335)
= CH 2 SH, (333) X = CH 2 C1, (336)
= C 0 2 H, (334)
i. M eNH2, MeOH; ii. H 2 NNH 2 , MeOH; iii. pyridine, Ac2 0 ;  iv. deprotection.
The strategy would employ the ring opening of epoxide (322), either to give the 
desired hydroxymethyl dipeptide (324) and (325) or the corresponding hydroxymethyl 
derivatives (337-339) which could then be activated, thus facilitating coupling with 
the required amino ester (341) (Scheme 65).







i. protection; ii. reduction; iii. oxidation; iv. olefination; v. epoxidation and separation; vi. acid 
catalysed ring opening with Leu-OMe.
P h tN
(322) (323)
P h t N '  -y  'O H  
OH
(337) (338)




P h t N '  V  'O T B D P S  
O Tf TB D PSO
/
(340) (341)




2.2 a-Amino aldehyde synthesis
2.2.1 Phthaloylamino protected route
In the area of peptide mimetics there has been an immense amount of research 
undertaken. Since the late 70’s research groups have been preparing peptidomimetics 
from chiral amino acids, using a variety of protecting groups and various synthetic 
routes. A prodigious amount of groundwork has been covered by these groups and 
nowadays the preparation of peptide-mimetics has been made somewhat easier. 
However, there are still great problems associated with the optical activity of 
intermediate compounds, due to the labile nature of the acidic a-protons. Jurczak and 
Golebiowski142 reviewed the synthesis of a-amino aldehydes in 1989. They showed 
that a variety of iV-protected amino carboxylate derivatives had been successfully 
converted to the corresponding aldehydes in moderate to excellent yield. Other 
groups had reduced the a-amino acids directly to the a-amino alcohol and then 
oxidised them to the a-amino aldehydes. We had decided to use the later route to 
prepare our a-amino aldehydes. Although a vast amount of ground work had been 
achieved for the iV-protected Boc62,63,143 and Cbz144 a-amino aldehydes, less attention 
had been paid to iV-phthaloyl a-amino aldehydes.145 We adopted this protecting group 
as it usually led to crystallinity, was stable to acid and base conditions, and potentially 
easily removed using either hydrazine,146 Na2 S147 or NaBH4.148 In the event we had to 
do extensive development work to overcome the problem of racemisation of the 
aldehyde and the following low yielding Wittig or related olefination step.
In our laboratory starting from commercially available phenylalanine (342), 
reduction to phenylalaninol (343) by use of lithium aluminium hydrideU3h gave the 
corresponding alcohol at best in a 66% yield (figure 22). Lithium aluminium hydride 
is pyrophoric and an extremely powerful reducing agent. On relatively large scale
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reactions it could prove to be potentially hazardous. In an attempt to improve the 
yield and to avoid this hazard, a milder reducing agent was sought.
Unlike powerful reducing agents such as lithium aluminium hydride, the mildness of 
borane is such that reductions of carboxylic acids can be undertaken in the presence of 
other functionality’s e.g. ester, nitro, nitrile and keto groups. It was reported by
in 1 0 0 % conversion (80% by isolation) using borane-tetrahydrofuran complex. 
Preparation of alaninol (344).
Borane-THF complex was employed to reduce alanine (345) to the corresponding 
alcohol (344). Three equivalents were used, one borane unit to reduce the acid and 
the other two to complex with the nitrogen. After a day at room temperature the 
reaction was quenched using sodium hydroxide and then stirred at room temperature 
for a day to ensure that the borane-nitrogen complex was fully cleaved (Scheme 6 6 ).
i. BH 3 -THF, THF, 4 1/ 2  hrs., RT; ii. 3M NaOH, 12 hrs., RT, 63%; iii. phthalic anhydride, 170°C, 2 hrs, 
55%.
Purification by distillation did not yield the expected alcohol (344) but rather butanol, 
which was identified by it s characteristic odour and by spectroscopic techniques. It 
was probably formed by a hydride transfer reaction at room temperature. The quality 
of the commercial borane proved to be irregular. The borane, which is complexed to 





Brown et al149 that carboxylic acids are reduced rapidly to the corresponding alcohol




has been reported previously by Brown et al,'50 when the borane-THF was heated to 
60°C for 64 hours giving a 64% conversion. This may happen slower at lower 
temperatures which ultimately results in the tributyloxy borane complex (347), which 
when reacted with water produces butanol (Scheme 67).
H O '




When the reduction of alanine (345) wuth borane was repeated and the product 
purified by flash chromatography, the yield of alaninol (344) was surprisingly low. 
This was found to be due to its volatility. The isolated alcohol (344), was protected 
by the procedure outlined by Itoh et al. 151 The phthaloylamino alcohol (346) was 
formed in 55% yield, together with some phthalic derivatives which were difficult to 
separate by chromatography from the product due to similar retention factors. The 
overall yield for the first two steps was disappointingly low (34%). Protection of the 
unpurified alcohol, in a one pot reaction, gave the phthaloylamino alcohol (346) in an 
improved overall yield of 45%.
A different approach to the synthesis of the protected alcohol (346) was detailed by 
Becker et a l 145a This involved protection first and then reduction to the alcohol (346) 
using borane-dimethylsulfide complex. (Scheme 6 8 )
X
H2 N C 0 2 H P h t N ^ C 0 2H P h tN  CH2 OH
(345) (348) (346)
i. phthalic anhydride, 120°C, 7 hrs, 99%; ii. a. BH 3 -DMS, THF, RT, 2 days, 63%; b. BH 3 -THF, THF, 
RT, 2 days, 8 8 %; c. BH 3 -THF, THF, 40°C , 2 hrs., 64%.
Scheme 68
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Preparation of the N-phthaloyI-alanine (348).
Protection required heating alanine and phthalic anhydride together for several hours. 
Table 3 shows the effect of temperature on optical activity. Fusing the two together at 
a higher temperature than suggested (170°C) speeded protection up (2 hours) but 
resulted in racemisation. The best optical activity was achieved when the reaction was 
heated to 120°C as reported by Becker et a/.145a The protection worked very well and 
the N-phthaloyl-alanine (348) was isolated in 99% yield by simply washing out the 
unreacted amino acid (345).
Table 3
Temperature °C Time (hrs) Optical rotation (in 
EtOH)
170 2 -5.6°, c 0.753
140 6 -9.0°, c 1.008
130 5 -23.3°, c 1.218
1 2 0 7 -24.7°, c 1.250
I
Bose, Greer and Price in 1958 reported the synthesis of N-phthaloy 1-alanine (348) 
using phthalic anhydride in toluene with triethylamine as a base. The conditions were 
slightly milder than those described by Becker et a/,145a the advantage being that the 
reaction temperature only reached the boiling point of toluene. When this was 
attempted the optical activity was comparable to that given by Becker. From these 
results either method was satisfactory.
Preparation of the of the N-phthaloyl-alaninol (346)
Reduction of N-phthaloyl-alanine (348) to the alcohol was achieved by using one 
equivalent of borane-tetrahydrofuran complex (a third of the amount that was used 
before). The alcohol (346) was produced in high yield (8 8 %). Purification was vastly 
simplified as there were no phthalic by-products formed. Overall yield was now 8 8 %.
96
Brown153 reported in 1979 that if the borane reduction step was employed at elevated 
temperatures, the reaction would go to completion more rapidly. When this was tried 
at 40°C all the acid had been consumed, after 2 hours and the amino alcohol (346) 
was isolated in 64% yield.
2.2.2 Oxidation of iV-protected alaninol (346) and (349)
Preparation of N-phthaloyl-alaninal (350)
The preparation of iV-phthaloyl-alaninal (350) has been achieved in three major ways; 
reduction of a-amino carboxylate derivatives,62,63’142’143,144 oxidation of a-amino 
alcohols62,63’142’143’144 and hydroformylation of a-amino alkenes. 145 Our efforts were 















R = alkyl, R' = alkyl or leaving group and P = Boc, Cbz and PhFl








It has been reported by Stanfield et all43d that pyridinium dichromate (PDC) 154 is
suspected of causing racemisation when N-protected amino alcohols are oxidised.
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However, pyridinium chlorochromate (PCC) 155 has been reported by Fuchs et al156 not 
to suffer from this problem as an oxidising agent. When this was applied to our 
system, we employed 5 equivalents of PCC, stirring at room temperature for 1 day. 
The amino aldehyde (350) was isolated after chromatography in good yield (on a 
small scale, 7mmol, 78% yield). On a larger scale the yield was considerably reduced 
(15-50% yield), Table 4.
To produce a large amount of the aldehyde (350), the alcohol (346) was reacted in 
several portions. Each portion was individually oxidised, worked up, and then 
combined ready for olefination. Using the portioning technique was tedious and time 
consuming and the problem with low yield was still associated with the work up. 
Brown et al153 suggested that reduction and oxidation in one pot via the trialkoxy 











7 none 5 78 24 2 1
25 none 5 50 24 2 1
94 none 5 15 24 2 1
15 none 2 (70) 5 40
2 0 none 2 46 2 40
97 alumina 2 .8 90 2.5 40
29 celite 2 (94) 3 40







i. BH3 -THF, THF, RT, 2 days; ii. PCC, DCM, reflux, 3 hrs, overall yield 30%.
Scheme 70
This was attempted on a relatively large scale. The yield was low, being only 30% 
again. The concept that adsorbed reagents on an inert inorganic support enhance
support and adsorbed PCC onto its surface. This had the effect of enhancing the 
oxidation of the alcohols, and the use of alumina simplified the work up to a simple 
filtration. We utilised this property to oxidise alcohol (346) on a large scale, using two 
equivalents of PCC. The reaction was refluxed in DCM and was completed in two 
hours. After work up the aldehyde (350) was isolated in 90% yield (for a 0.035 molar 
scale reaction). T.l.c. of isolated samples showed marked streaking on the plate. 
Further investigation by t.l.c. (varying eluent) showed that in most cases the aldehyde 
was contaminated by unreacted alcohol and phthalic derivative(s) which run on either 
side of the aldehyde. Chromatographic purification gave the aldehyde (350) in high
158purity. Another PCC oxidation method used celite as a support agent to prevent 
loss of material and simplify the work up. This worked very well when the reaction 
was refluxed, but again by-products formed and this made it difficult to purify the 
aldehyde. Studies of the optical activity of the PCC derived amino aldehyde (350) 
showed that all but those done at room temperature had been racemised to a certain 
degree. With respect to this problem and the difficulties encountered with purifying 
the product we turned our attention to an alternative oxidation method.
Activated dimethyl sulfoxide oxidation reactions. 159
Owing to the uncomplicated procedure, simplicity of product isolation, high yield, mild 
conditions and subsequent absence of major side reactions including racemisation and
reactivity of reagents has been employed by Cheng et al , 157 They used alumina as the
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over oxidation, the activated DMSO procedures are considered to be among the most 
useful oxidation methods available to the synthetic chemist.
Parikh-Doering oxidation.14311,160
The Parikh-Doering method is probably the best documented activated DMSO 
oxidation procedure. This has the advantage that it is inexpensive and can be carried 
out at room temperature. When we attempted this we were hoping for complete 
conversion o f the alcohol to the aldehyde (350) but unfortunately the reaction did not 
go to completion, with only 7% of the product (93% alcohol) being observed by n.m.r.
Swem oxidation161
The Swem oxidation proved to be the best method for the preparation o f the desired
aldehyde independent o f molar scale. The yields were almost quantitative (92-98%),
and after work-up the aldehyde (350) was pure enough to be used directly in the next
step. The rate o f addition o f triethylamine was important in terms o f optimising optical
activity, as was the requirement for the complete removal o f excess base during work
162up. Use o f hindered base, i.e. diisopropylethylamine (DIPEA) also helped to reduce 
the problem o f racemisation during work up. In our hands, using this base, the 
aldehyde (350) was isolated enantiomerically pure [a]jg9 -38.6 in 72% yield.
TPAP oxidation163
In 1987 Ley et a l163 introduced tetrapropylammonium perruthenate (TPAP) as a 
catalytic reagent for the oxidation o f alcohols to aldehydes and ketones under very 
mild conditions with a simple work up that should not cause any racemisation. When 
this was attempted the reaction did not go to completion (only 35% converted), but 
the optically integrity was kept.
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The physical nature o f N-phthaloy l-alaninal (350)
The aldehyde (350) was found to be oxidised quite readily when exposed to the 
atmosphere and racemisation occurred readily at room temperature. After two months 
at room temperature in benzene the optical rotation had fallen to [a ]^  
-14.3° from [a ]^  -38.6°. Under an inert atmosphere at reduced temperature 
decomposition still occurred but at a much slower rate. It could be stored at -17°C for 
several days without marked racemisation. Due to the unstable nature of the aldehyde 
(350), it was always used immediately.
2.2.3 7V,./V-Dibenzyl protection procedure
Due to the low yielding preparation of A-phthaloylamino epoxide (322) and (323) via 
the Wittig olefination,143h a new protecting group was considered. Reetz et a l164 
demonstrated that the N.Af-dibenzylamino epoxides (356) and (357) can be formed in 
high yield from the corresponding aldehyde (358), (Scheme 71), by using sulfonium 
ylides of the type Me2 S=CH2 .64
Yield 76%  
S R : SS 
87 : 13
(358) (356) (357)
i. NaH, DMSO, 55°C, 1 hr., Me3 S+r ,  -10°C, 30 mins.
Scheme 71
Preparation o f the dibenzyl protected Ala-OBn (359) and alaninol (349)
Scheme 71 shows the synthetic route employed for the preparation of the N,N- 
dibenzylamino epoxides (356) and (357). The synthetic route used to make the amino 
aldehyde (358) followed that detailed by Reetz et al.165 From commercially available 
alanine, protection with benzyl bromide gave the A^N-dibenzylamino benzyl ester (359)
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in 97% yield. Previous methods used benzyl chloride166 which gave the product in 
85% yield. Reduction with LiAlH4 gave the desired protected amino alcohol (349) in 
good yield (81%) and high enantiomeric purity. The benzyl alcohol was removed by 
distillation as the two alcohols had almost identical t.l.c. retention factors. Oxidation 
to the corresponding aldehyde (358) was achieved most conveniently by Swem 
oxidation. (Scheme 72)
X  X
N C 0 2- B n ,N  C 0 2Bn B n ,N  <
— ^  B n 2 IST
HjIST ' C ' 2 fST ' C 2 '  'C H 2OH
O
(359) (349) (358)
i. BnBr, NaOH, K 2 C 0 3, EtOH, H 2 0 ,  reflux, 97%; ii. LiAlH4, THF, reflux, 81%; iii. Swem, 89%.
Scheme 72
Preparation o f the dibenzyl protected alaninal
Using PCC for the conversion of alcohol (349) to aldehyde (358), resulted in low yield 
(9%). This was a result of a combination of benzylic oxidation (as a large amount of 
benzaldehyde was isolated) and complexation of the N, A-dibenzyl protecting group 
with PCC, thus trapping it in the residual oxidant. The alcohol (349) was also oxidised
163using Ley's perruthenate oxidising reagent TPAP. This gave the aldehyde (358) in 
72% yield after flash chromatography, with benzaldehyde again being isolated as a by­
product of benzylic oxidation. Swern oxidation was by far the superior method, with 
oxidation cleanly giving the desired aldehyde (358) in good yield (89%). The overall 
yield from alanine was 70%, an improvement on the 44% achieved by Reetz et a l 167 
Another possible way of producing the aldehyde (358) was to go straight from the 
ester (359) to the aldehyde (358) using DiBAL-H. 143a,143h’168 This was attempted on 
the benzyl ester (359) at -78°C in toluene. Unfortunately only 15% of the aldehyde
(358) was isolated, (Figure 23). This was believed to be because of the steric bulk of 
the benzyl group, and it was considered reducing the size of the ester to a methyl ester 
(360) may facilitate reduction to the aldehyde (358).
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J L  ------------ ►  B n 2 l\f
B n 2 N C 0 2Bn
O
(359) (358)
i. DiBAL-H, -78°C, toluene, 30 mins., 15%.
Figure 23
Preparation o f the dibenzyl protected alanine methyl ester (360)
It has been reported in a patent169 that the methyl ester (360) could be generated by 
employing the benzylation in methanol. This was attempted, but only the benzyl ester 
(359) was isolated and benzylmethyl ether (361). (Figure 24)
JL JL
CCV B n , N " ^ <
+ Dh/ ^ n/ Me 
H3 I\T 'C O 2 ' 2 '  ' C 0 2Bn Ph 0
(359) (361)
i. BnBr, K 2 C 0 3, NaOH, MeOH, reflux.
Figure 24
These conditions were also used on the Ala-OMe.HCl (362) which was prepared 
quantitatively by treating alanine with methanolic HC1. Again only the corresponding 
dibenzyl ester (359) was isolated, along with the benzylmethyl ether (361), (Scheme
73). Attempts to convert the benzyl ester (359) to the corresponding methyl ester
(360) in acidic methanol failed, with only the starting material being isolated.
-JL -  ^ - JL + / MeH3 I\T ' C 0 2- CI*H3 N '  " C 0 2Me B n 2 N '  " C 0 2Bn Ph
(362) (359) (361)
i. MeOH, HC1, 100%; ii. BnBr, NaOH, K 2 C 0 3, MeOH, H 2 0 ,  reflux.
Scheme 73
The methyl ester (360) was finally prepared in low yield by treating Ala-OMe.HCl 
(362) with potassium carbonate and benzyl bromide in acetone, using catalytic Nal to 
activate the alkylating agent. After two days there was no reaction, so three 
equivalents of triethylamine were added. This ended up giving only 1 1% of the desired
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product after mild acidic work up. This yield was eventually improved to 32% by 
using triethylamine as the base in THF. (Figure 25)
Cl' H3 N * ^ C 0 2Me Bn2 C02Me
(362) (360)
i. a) BnBr, K 2 C 0 3, Nal, acetone, Et3 N, 3 days, 11%; or b) BnBr, E t3 N, THF, 1 day, 33%.
Figure 25
Reduction to the aldehyde using DiBAL-H at -78°C as detailed by Luly et a /143h 
unfortunately went all the way to the alcohol (40%) and no aldehyde was isolated. 
(Figure 26)
JL -u. JLBn2N COjBn Bn2N CH2OH
(359) (349)
i. DiBAL-H, -78°C, toluene, 30 mins., 40 %.
Figure 26
Swern mediated isomerisation
During the preparation of the A^A-dibenzylaminoepoxide (356) and (357) using the 
Swem oxidation, we discovered an unusual rearrangement. When we had prepared 
the aldehyde (358) using the standard Swern conditions, on one occasion, for no 
apparent reason (i.e. the conditions were not altered), we found that two compounds 
containing carbonyls (as visualised by DNP dip) were formed. We assumed incorrectly 
that one carbonyl was benzaldehyde, as there was always a small amount of residual 
benzyl alcohol left after purification of the LiAlH4 reduction step. BnzN'
However, upon epoxidation it became clear from proton n.m.r.
(363)
that there were two different isomeric epoxides (356:357):(363) in 
the ratio of 31:69 and that there was a singlet around the chemical shift expected for an 
a-methyl of alanine. Further analysis showed that this singlet was the signal for the 
rearranged epoxide (363) (see Section 2.4.2), The isomerisation must have occurred
o
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during the oxidation and one possible mechanism that may explain its formation is via 
an aziridinium salt (364). The formation of such aziridinium salts has been reported by 
Rayner et a lxl° (see Section 2.6.1), The possible mechanism may involve the 
displacement of the sulfoxide group by the labile lone pair on the nitrogen (Scheme





O S +M e 2
(364)
Scheme 74
The aziridinium salt (364) can then react with DMSO via two possible paths, either 
Path a, which regenerates the initial complex, or Path b which produces a new complex
(365). Upon addition of triethylamine, oxidative elimination occurred giving the two 
corresponding carbonyls (358) and (366). We never isolated the methyl ketone (366), 
and the only evidence for its existence is that it reacted with Brady’s reagent, showing 
the presence of the carbonyl functionality and the fact that the A^N-dibenzyl 
methylepoxypropanes (363) were isolated together with the expected epoxides (356) 
and (357). See Section 2.4.2 for the preparation of the epoxides.
o —s /\
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2.2.4 Protection of Leu-OMe
Preparation o f the mono benzyl protected Leu-OMe (367)
Leu-OMe was converted to the mono benzylamino methyl ester (367) in modest yield 
(57%), using similar conditions to that employed for the preparation of the 
dibenzylamino benzyl ester (359) as detailed by Velluz et a l 166 This protection used 
one equivalent of BnBr and K2C 03 as the base, refluxing for 2 days in THF and 
ethanol, (Figure 27).
(367)
i. K 2 CO 3 , BnBr, THF, EtOH, reflux, 2 days, 57%. 
Figure 27
Preparation o f N-trifluoroacetyl-Leu-OMe (368)
The protected amino ester (368) was prepared because we believed that its /?Ka would 
be around 11, which is suitable for the Mitsunobu reaction. The protection involved 
using Leu-OMe.HCl with two equivalents of DIPEA and one equivalent of 
trifluoroacetic anhydride, Figure 28. The reaction went to completion in 16 hours, to 
give A-trifluoroacetyl-Leu-OMe (368) in quantitative yield. It was later discovered 










Olefination of aldehydes and ketones can be achieved using a variety of stabilised 
carbanions. Probably the most widely used are phosphorus ylides due to their 
simplicity, convenience and efficiency. There are many non-phosphorus stabilised
171 172carbanions, such as trialkylsilyl groups (Peterson), sulfoximides (Johnson 
methylation), sulfones173 (Julia olefination), boron174 (Boron-Wittig), transition metals 
(Cr, 175 Zn, 176 Ti177), and other heteroatom stabilisers (chloromethyl-lithium, 178 tosyl-
179 180hydrazones and reductive elimination of phenylthiomethylcarbinyl esters ). Figure 
29.
f  + V = 0 --------- --
— c h 2 /










181 184 62 185 186The essential principles of the Wittig ' and related reactions ’ ’ are the 
stabilisation of a carbanion by the phosphorus atom, reaction with a carbonyl 
compound, and subsequent elimination driven by the formation of the highly stable 
phosphorus-oxygen bond at the expense of the weaker phosphorus-carbon bond. 
Phosphorus ylides fall into three main categories:- "Stabilised" ylides have strong 
conjugating substituents (e.g. C02Me, CN, or S0 2Ph) and usually favour the 








products; "semi-stabilised" ylides have mildly conjugating substituents (e.g. Ph or allyl) 
and often give no great preference for E or Z isomers; and "non stabilised" ylides that 
lack any stabilising functionalities favour (Z)-alkenes via a more reactant-like, early 
transition-state.
For our synthetic route we only required the addition of methylene and thus a non­
stabilised ylide was used. It has been documented that A-protected amino aldehydes 
racemise under olefination, i.e. methyltriphenylphosphonium bromide methodology, 184 
due to the labile a-proton. Luly et a /143h demonstrated that N-phthaloyl amino 
aldehydes could be converted to the corresponding alkenes using methyltriphenyl­
phosphonium bromide, w-BuLi in THF at -78°C to 20°C, without racemisation. In our 
hands, A-phthaloyl alaninal was converted to the corresponding alkene in low yield,
1 0 -2 0 %. This was not a satisfactory result, and another method was sought. Corey et
182 • •al showed that phosphorus ylides could be generated using NaH in DMSO at 0°C,
producing the alkenes in good yield. Indeed, when this was applied to our system the
yield was improved, but not substantially, to only 26%. It was also noted that the
product had been totally racemised.
In all of the above Wittig reactions a large excess of methyltriphenylphosphonium 
bromide was used to convert the aldehyde to the corresponding alkene. In a review by
187Murphy and Brennan it was reported that amides and imides (369) can be converted 





i. P h 3 P=CH2, THF, 60°C, 60hrs.
Figure 30
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To overcome any possibility of this occurring, only one equivalent of base and 
methyltriphenylphosphonium bromide was used. Table 5 shows the marked difference 
in yield for the Wittig reactions tried.
Table 5




M-BuLi THF 2 -78 13
THF 1 -78 38
KOTJu THF 3 21 8
toluene 1 - 2 0 65*
NaHMDS THF 5 0 6
toluene 1 0 64*
* Solvent effect is more important here
As the Wittig reaction was still low-yielding and the attempted epoxidation of the 
aldehyde using sulfur ylides (as detailed in Section 2.4.2) was also low yielding, the 
olefination step was re-addressed. A modified Wittig, namely the Wadsworth-
fs!7 1 6 ^ 1Emmons ’ ’ which employs a dialkylbenzylphosphonate (371) stabilised carbanion,
was reported to convert aldehydes to alkenes (372) in good yield, (Figure 31).
O
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The conditions involved using NaH or NaOR as the base in toluene or the 
corresponding alcohol respectively. In our hands using these conditions with









diethylmethylphosphonate, no alkene was isolated. This was undoubtedly due to the 
inability to form a sufficiently stable carbanion.
183 • • •A more recent paper in 1992 by Smith et al detailed the asymmetric synthesis of 
(4S)-aminohex-5-enoic acid (373), using a similar preparative assembly to the one we 
had established in our programme. (Scheme 75)





i. DMSO, DCC, pyridine, cat. TFA, 85%; ii. Ph 3 PCH 2 Br, K O B u, THF, 77%.
Scheme 75
Smith also reported that //-BuLi in THF only gave 43% yield and NaH in DMSO at 
80°C gave only 15% of (374), but using KO'Bu in THF at RT for 10 hours gave the 
best yield of (374) in 77% yield. When this was first attempted on our system, the 
alkene was obtained in extremely low yield (8 %), when three equivalents of ylide were 
used in THF. When the solvent was changed to toluene and only one equivalent was 
used the yield was dramatically increased. With this very encouraging result we
considered the effect other bases would have on the yield. It was reported by
188Bestman in 1965 that it is important that the ylide formation should not involve 
lithium anions since the lithium salts react with the ylide to form complexes which 
strongly interfere with the reaction. This may explain why when using w-BuLi, the yield 
was always so low compared with KO'Bu and NaHMDS. A much better method they
189 190suggested was to use NaHMDS detailed by Wittig, Eggers and Duffner in 1958.
Following these optimised conditions using NaHMDS in toluene at 0°C, the 
corresponding alkene was isolated in good yield (64-98%) see Table 6. Racemisation
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did not occur when the ylide was added to the aldehyde at -78°C. It is very clear that 
the nature of the solvent had a great effect on the addition of the stabilised carbanion 
to the aldehyde. Polar solvents such as THF and DMSO must form a solvation cage 
which reduces the basicity of the carbanion, this in turn reduces the reactivity, 
disrupting the formation of the oxaphosphetane (375). Scheme 76.




When toluene was used this problem was not encountered since toluene is less polar 
and does not interfere with the oxaphosphetane (375) formation. Eventual collapse of 









rt-BuLi THF -78 12 25.4
THF -78 38 22.4
toluene -78 56 25.4
KO*Bu toluene - 2 0 65 12
THF RT 8 N/Ab
NaHMDS THF 0 6 N/A
toluene RT 98 N/A
toluene 0 64 9.4
toluene -78 92 23
NaCH2S(0)Me DMSO 0 26 N/A
a temperature at which ylide was added to aldehyde 




The most widely used epoxidising agent is w-CPBA, due to its high efficiency and its 
simplicity of use. Luly et a /143h reported, in 1987, the use of w-CPBA in the synthesis 
of chiral TV-protected amino epoxides. They reported that the epoxidation of (3S)-5- 
methyl-3-(phthaloylamino)hex-l-ene (377) provided predominantly the threo (syn 





The stereochemical outcome has been discussed in a recent review by Evans et a l 191 
They suggested that epoxidation could go via intramolecular delivery of the peracid
1Q7
(Scheme 78). Albeck and Persky have also studied the epoxidation of TV-protected 
aminoalkenes. Their argument for the high degree of stereoselectivity was also 
attributed to the directing effect of the amino group. They studied the epoxidation of 
terminal aminoalkenes and looked at the directing effects of allylic alcohols, amides 
and carbamates. This effect of reagent approach control was originally argued by 
Henbest in 1957, to be due to the hydrogen bonding between the hydroxyl proton of 
one of the oxygens of the peracid (A in Scheme 77). Sharpless later suggested a 
modified mechanism (B in Scheme 77), in which, on the basis of a detailed analysis of 
stereoelectronic effects, the hydrogen bond acceptor is the oxidising oxygen of the 
peracid. Roush et al suggested the steering effect came from the amido proton and
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one of the oxygens of the peracid (C in Scheme 77). Finally, Kocovosky and Stary 
postulated a modified Roush's mechanism following Sharpless's acceptor model (D in 
Scheme 77).
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There are many other reports in the literature which have discussed the stereochemical 
epoxidation of A-protected aminoalkenes, Kogen and Nishi193 followed the work of 
Kishi, who used /w-CPBA to epoxidise c/s-4-amino allylic alcohol (380), where the 





(380) R=Bn, (383) R=*BuO
H     Ri
(382) R= Bn, (384) R= 'BuO (381)
Figure 33
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Kogen and Nishi showed that the epoxidation of cw-4-A^-benzyloxycarbonyl-a- 
aminoalkene (380) gave exclusively the syn epoxide (382) (Figure 33). Ohfune and
194Hori showed this was also true for iV-Boc protected aminoalkenes (383) (Figure
19533). Luthman showed that the epoxidation of aminoallylic esters were highly 
selective due to the contributing co-ordination between the carbamate protecting 
group and the peracid. There was also a weak co-ordination effect between the ally lie 
ester and the peracid (Figure 34).
CO2 Me
major minor
i. m-CPBA, (19:1). 
Figure 34
Assuming that the angle between the nitrogen, alpha carbon and the alkene is 120°, 
then the conformation of the amino alkene is dictated by steric hindrance effects of the 
R group. The amino alkene may adopt two possible conformations for intramolecular 
delivery of the peracid. These are the unfavourable eclipsed conformer, where the 
angle is - 1 2 0 °, and the less sterically hindered conformer, where the alkene is away 
from the R group with the angle at +120°. When the R=Bn, the less sterically 
hindered conformer may predominate, thus the peracid can hydrogen bond to the 
carbonyl of the imide and then approach from the top face With these aspects in 
mind the selectivity should be reduced when used with R=Me and indeed in practice 
the selectivity was low with syn addition still predominant 64:36, syn:anti. An 
example of a similar epoxidation is shown in Scheme 78. In this example the 
argument is much clearer as there is a conformational lock; A 1 -3 strain is relieved by 
the methyl adopting an eclipsed conformation with the proton at the chiral centre. 
Here the peracid hydrogen bonds with the amide proton and addition is again directed 
via syn addition, the selectivity here is very high (>19:1 syn:anti).
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Rich and Romeo196 have recently discussed the effect of diastereomeric enrichment 
during the epoxidation of TV-protected aminoalkenes (see Section 2.5.4). They 
postulated that the minor isomer decomposes faster to give an oxazolidine (385) and it 
is this process that is responsible for further diastereomeric enrichment.
o
favoured if R is large eclipsed, unfavoured
0 - ,
P hN H C O N
Ar
N-C-C=C 0=120°
Transition structure for the directed epoxidation of acyclic systems
Scheme 78
In our hands, epoxidation using m-CPBA went quantitatively in the ratio 64:36 with 
isomer (2R, 3S) (322) as the major diastereoisomer.
2.4.2. Epoxidation using sulfur ylides
Preparation of 3-phthaloylaminoepoxybutane (322) and (323)
Corey et a t 4 converted aldehydes directly to the corresponding epoxides using the
sulfur ylides, dimethylsulfonium methylide (386) or dimethylsulfoxonium methylide
(387) in good yield. (Figure 35)
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The sulfur ylide (386) can be generated from trimethylsulfonium salts by treatment 
with a strong base e.g. sodium hydride, /7-BuLi or methylsulfinyl carbanion. The ylide 
is both aerobically and thermally unstable (rapid decomposition at temperatures above 
10°C) .64,197 However, below -10°C the ylide is stable and can be utilised as a 
methylene equivalent for the conversion of aldehydes to the corresponding epoxides. 
Dimethylsulfoxonium methylide (387) is more stable at room temperature, and can be 
kept for several months at 0°C, under inert atmosphere without appreciable 
decomposition. This type of ylide can be generated in the analogous manner to that of 
the ylide (386). Its stability reduces its reactivity somewhat and it has been reported 
that some keto epoxidations do not occur.64 Both ylides were used to generate the 










Sulfonium (386) THF 2 30 68:32
(386) DMSO * 30 -
(386) THF 10 30 55:45
Sulfoxonium (387) THF 27 60 55:45
(387) THF 18 1 2 0 55:45
(387) DMSO 21 60 -
* many spots by t.l.c. negligible yield
The experimental procedure given by Corey for the epoxidation of benzaldehyde was 
followed. At extended periods of heating [55°C in the case of the sulfoxonium ylide
(387)] yields were reduced. The best results achieved were for those epoxidations 
using the sulfoxonium ylide and a reaction time of one hour. Careful chromatography 
could separate the two isomers, thus they were fully characterised.
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Via Corey's method for epoxidation of aldehydes, 27%. It was noted from the 
literature that epoxidation of aldehydes using sulfur ylides generated by metal
198 199hydroxides in two-phase systems, gave very respectable yields. ’ It was considered 
that these conditions may result in the phthaloylamino group being ring opened by the 
strongly basic conditions. These conditions are reported not to result in hydrolysis of 
the sulfonium salt or cause a Cannizzaro type redox of the starting aldehyde. A model 
reaction was tried with the phase transfer catalyst /7-butylammonium iodide, used to 
assist the transfer of reagents between the two phases. The reaction was carried out at 
50°C for 48 hours. After 2 days, the starting material had reacted, but only a small 
amount of the desired epoxide had been formed. T.l.c. showed some polar compounds 
and it was apparent that these were phthalic acid derivatives 
such as (388) formed by base ring opening 
of the protecting group. The reaction was 
abandoned without purification of the
products. (388)
Preparation of the N,N-dibenzylamino epoxides (356) and (357)
When the two phase epoxidation conditions were applied to the N,N-dibenzyl 
protected alaninal (358), there was no interaction of the base with the protecting group 




R = PhCH2, (356,357) 
p-M eO-PhCH2, (389,390)
i. NaH, DMSO, M e3 SI, THF, -10°C. 
Figure 36
Reetz et a ll6A reported in 1989 that double protected amino aldehydes could be 
stereoselectively converted to the corresponding epoxides using sulfonium ylides of the 
type Me2S=CH2. The larger the protecting group the greater was the diastereomeric
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excesses. For example, the benzyl protecting groups gave (356:357), 87:13 whereas 
the 4-methoxybenzyl gave (389:390), 91:9 (Figure 36).
The major diastereoisomer turned out to be the erythreo (or anti) adduct. The stereo­
chemistry was assigned by reacting the crude epoxide mixtures with dimethyl copper 
(II) lithium, giving the corresponding amino alcohols. It was also reported that using 
arsonium ylides the diastereomeric excess was increased (Table 8 ), with these ylides 
it was not the epoxides that were isolated but rather the ylide adducts (391) and (392), 
which were then converted to the corresponding epoxides, using NaH (Scheme 79).




B n 2 f T  V  'A s ( P h ) 3
OH B F 3 0
(392) (356)
i. KN[Si(CH3)3]2, 10% citric acid, ii. NaH, THF, 45°C, 3hr.
Scheme 79
Table 8
Epoxidation of double protected alanine
protecting group yield of epoxide % threo: erythreo
PhCH2 73 87:13
4-MeOPhCH2 50 91:9
With this promising report, the dibenzyl amino aldehyde (358) was reacted with the 
sulfonium ylide Me2S=CH2 at -10°C. The corresponding epoxides were isolated as an
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inseparable mixture in good yield (356:357), (13:87) (76%, 2S,3R as the major isomer 
as detailed by Reetz et a/164).
Preparation of the (2S,3S)- and (2R,3S)-dibenzylamino-2-methylepoxypropane (363) 
The Swern oxidation did not always give exclusively the corresponding aldehyde 
(358). On one occasion (as detailed in Section 2.2.3) a rearrangement occurred giving 
the expected aldehyde (358) and the rearranged product, the methyl ketone (366). 
Figure 37
4
Bn2N Bn2N i Bnc
1 1 
(366) (358) (363) (356),(357)
i. NAH, DM SO, 55°C, 45m ins, MeSI, - IOC. 5inins; then -10°C, 30mins, RT 1 hour.
Figure 37
These two products were successfully converted to the corresponding epoxides in 
good yield (83%) using the conditions employed by Reetz. 164 Table 9 shows the 
comparison between the proton n.m.r.'s of the two epoxides prepared.
Table 9
chemical shift (ppm)
Proton Epoxides (356,357) Epoxide (363)
1 2.41 and 2.66 2.62
2 3.08 -
3 2.79 2.36 and 2.62
4 1.03 1.39
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The proton n.m.r. spectra for the epoxide (363) showed that the methyl appeared as a 
singlet at 1.39 ppm, compared to the doublet at 1.03 ppm for the expected epoxide 
(356,357), that there was no H-2 signal, and that there was a quaternary carbon 
present in the carbon-13 spectra at 56.5 ppm. The proton n.m.r. also showed that the 
CH2N and CH20  protons were ABX systems, thus confirming the structure of the 
epoxide (363).
200Preparation of the epoxides using diazomethane
The insertion of methylene groups into aldehydes and ketones to give the
corresponding epoxides and other carbonyl compounds have been well documented.
200In 1954 Gutse, reviewed this area and showed that many aldehydes had been 
successfully converted to the corresponding epoxides in good yield. This carbene 
insertion reaction was attempted on aldehyde (350). Three possible products were 
expected to be seen, end insertion giving ketone (393), alkane insertion to give 
aldehyde (394) and carbonyl insertion to give the desired epoxides (322) and (323) 
(Figure 38). When this reaction was attempted, we did not isolate the aldehyde (394), 
but we did isolate the desired epoxides (322:323), (37:63) in low yield (7%) and 
ketone (393) as the major product (40%).
y h
0




V  R>]> + l>
(350) (393) (394) (322) (323)
i. Diazomethane. R = PhtNCH(M e)-
Figure 38
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2.5 Epoxide ring opening
2.5.1 Addition of amino esters to A-protected oxiranes
Preparation of the hydroxymethyldipeptide (324) and (325) via ring-opening of 
(2R,3S)- and (2S,3S)-phthaloylamino epoxybutane (322) and (323).
Most attempts at ring opening of epoxides have involved the nucleophilic addition of 
amines to the least substituted carbon of an unsymmetrical epoxide, Path A, Figure 39. 
This requires heating the epoxide in an aprotic solvent, with excess amine. Many 
groups have established the synthesis of complex peptide mimetics utilising this
r r  s  w m , 63,114,124e,131.133.136.201-203effective synthetic method.
. o hR R
f  J>ath B R\ Path A^  ii -
y ' 0HO'
X = Halogen, nitrogen, oxygen or sulfur nucleophile 
R = alkyl, and phenyl or allyl 
Figure 39
Although this direct method is satisfactory in many cases, there are a number of 
limitations to the ring opening of epoxides with first generation amines (R2NH or 
RNH2). These include; i. the low nucleophilicity of these amines require reactions to 
be carried out at elevated temperatures; ii. the regioselectivity is not always 
controllable; and iii. the reactivity of sterically bulky amines is low. To overcome 
these problems several metal amines have been developed. These are classed as 
second generation amines (R2NM). There are many examples in the literature detailing
204 205 206the use of such second generation amine metals, e.g. Li, Mg, and Pb; Al, Cu, 
YbL07 Ti and Sn.208 All provide Path A products (Figure 39), as do A120 3 mediated 
amination,209 Ti(OR)4-mediated ring openings of 2,3-epoxy alcohols and their
121
derivatives210,211 and intramolecular cyclisations of epoxy amines and amides. 170,212
However, additions at the most substituted site, via Path B, have not been well
established. These additions require the formation of a carbocation. There have been
many reports in the literature where Lewis acids that consist of metal halides, insert a
halide at the most substituted carbon of unsymmetrical epoxides i.e. via Path B. Such
examples include FeCl3,213 TiCl4 with DBU,214 BF3.OEt2 215 Other examples of this
216type of addition include the use of organotin amine compounds e.g. Sn(Me)3NEt2 





i. B F 3 .OEt2, DCM. 
Scheme 80
It is interesting to note that Takaishi et a t 1^ reported that fluorine had been added to a 
tricyclic epoxide via transfer within a dipolar fluoroborate (Scheme 80). Other 
examples of fluoride additions using BF3.OEt2 have been reported, but all these 
examples are on carbocyclic systems. These results must be interpreted taking account 
of the factors inherent in cyclic systems, i.e. ring strain and axial-equatorial preference.
With acyclic systems these problems are not apparent and thus this Lewis acid could be
218used to furnish amino alcohols. Fujimoto et al have discussed the mechanism for 
the rearrangements of acyclic systems using BF3.OEt2 and concluded that there was a
122
carbocation formed, which was then trapped as the fluoride intermediate before the 





i. BF 3 .OEt2. DCM.
Scheme 81
Our intentions were to establish a rapid entry into the reduced hydroxymethylene 
dipeptides (324) and (325) via the ring opening addition of Leu-OMe at the most 
substituted site of the homochiral epoxides (322) and (323). Our first attempt involved 
addition of the hydrochloride amine salt of Leu-OMe to the mixture of racemic 
epoxides (322) and (323), (4:6). We hoped that the hydrochloride would catalyse 
formation of a carbocation and then nucleophilic attack would take place, followed by 
treatment with base to afford the desired dipeptides (324) and (325). (Figure 40)





OM e P h tN ' O M ePhtN '
h o
(324a)







The Leu-OMe.HCl (395) was produced by reacting hydrogen chloride gas with leucine 
in methanol. The hydrochloride amino ester (395) was formed in 96% yield. It is also 
commercially available. When formation of the dipeptides (324) and (325) was 
attempted using ester (395), no reaction occurred and only the starting materials were 
isolated. This reaction was repeated using the more basic and nucleophilic free amino 
ester (396) (prepared by treatment of Leu-OMe.HCl with aqueous ammonia in 93% 
yield) and boron trifluoride etherate to activate the epoxides (322) and (323). These 
conditions involved the addition of the boron trifluoride etherate to Leu-OMe and then 
addition of the epoxides to this complex. Unfortunately no coupling occurred. Instead 
the epoxides were converted to the corresponding diols (338:337, 1:3) (37%) and the 
BF3-Leu-OMe (397) complex was also isolated after chromatography as identified 
from mass spectroscopy and !H n.m.r. data; [5H 0.96 (6 H, Me2), 1.7-1.8 (3H, 






i. BF 3 .OEt2. DCM.
Figure 41
As these conditions resulted in the complexation of the Lewis acid and amino ester, it 
was considered that addition of the Lewis acid to the epoxide first would overcome 
this problem. This procedure produced a white precipitate which immediately 
disappeared on the addition of the free amino ester (396). T.l.c. visualisation of the 
reaction mixture showed three new spots when viewed under short wavelength light. 
Isolation of the compounds and spectroscopic analysis confirmed that the coupling had 
occurred. Also observed were the diols (337) and (338). Analysis of the first spot,
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showed it to be the diols (338) and (337) in a 39:51 ratio. The second spot was found 
to be three compounds in a ratio of 1:3:6, i.e. (338) and (337) with dipeptide (324b) 
and the third spot (Rf 0.41) to be the desired dipeptide (324a) (Figure 42). Table 1 0  
shows the *H n.m.r. data for both the dipeptide mimetics (324a) and (324b). Isomers 









8 h ppm, JH z
PhtN 7.92 7.90
PhtN 7.72 7.70
3 4.97, qd 7.1,3.9 4.87, qd 7.1,4.4
2 3.85-3.96 3.89-3.95
1 3.40-3.53 3.49, d 6.4
3.50, d 5.2
T 5.09, dd 7.3, 6.4 5.08, dd 7.9, 6.0
3’ 1.90-1.96 1.90-1.99
4’ 1.66-1.80 1.70-1.87
Me i^a 1.54, d 7.1 1.52, d 7.1
OMe 3.77 3.74
MeLeu 1.03, d 6 .6 1.03, d 6.4
MeLeu 0.91, d 6 .6 0.91, d 6.4
Analysis of the spectroscopic data confirmed the presence of the NH and OH protons 
in both the IR and the n.m.r. spectra, for both the hydroxymethyl dipeptides. IR and 
n.m.r. also showed that the leucine methyl ester was present i.e., C=0 stretch at 1734 
cm' 1 and the 6 H integral signal at 0.8-0.9 ppm for the methyl groups. Mass 
spectroscopy showed the mass ion for the dipeptide at 362 a.m.u. in the E.I. and the 
(M++ l) at 363 in the C.I. spectra. The proton n.m.r. spectra run in J-DMSO showed 
that the hydroxyl group was primary, thus eliminating the possibility that the product
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to the fact that the DMSO complexes with the hydroxyl group preventing rapid 
exchange with the solvent. This has the effect of sharpening the broad peaks thus 
showing any splitting from adjacent protons. The stereochemistry for the major 
isomer (324) was not obvious. For mechanistic considerations (see Section 2.5.4), it 
can be concluded that epoxide ring-opening reactions using BF3.OEt2 give diols with 
the major isomer of stereochemical configuration (2R,3S), independent of the 
epoxide(s) used. Indeed, in this case the major diol produced was the isomer (337) i.e. 
stereochemistry (2R,3S). It therefore may follow that the major dipeptide isolated 
should have the stereochemistry (2R,3S,2'S), via a double inversion of configuration 
at centre C-3. The first inversion involves participation of a phthaloyl carbonyl 
producing a 6,5,5 tricycle, which is then ring-opened at C-3 to give the dipeptide, with 
overall retention of configuration.
On closer inspection of the proton n.m.r. for the major isomer it was observed that the 
coupling constant between the protons on C-2 and C-3 was 4.3Hz. 2D Cosy analysis 
of the dipeptide (324) produced an inconclusive result; this suggested free rotation
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about this bond. As this was the case, a 2D nOesy experiment was performed so that 
we could build a 3D picture of this dipeptide. Assuming that the stereochemistry 
could be either (2fl,35,2’5), (25,3/?,2*5) or (25,35,2*5), (2R,3R,2'S), then studying all 
the possible interactions when the dihedral angle between these protons matches that 
derived from Karplus equation J=kcos9, where 0 =1 1 5  and 65° in this instance. And 
then comparison with the interactions seen with the 2D nOesy spectra, will allow us to 
deduce the stereochemistry of this isomer. Table 11 shows the through space 
interactions seen in the 2D nOesy spectra. Represented over are the five possible 
Newman projections for each isomer.
Table 11
Observed proton Interaction Intensity




2-H 1-H very strong
1-H Me Aia no
interaction
The only possible conformation allowed for the data collected is that for the (2R,3S, 
2’5) or (25,3/?,2’5) isomers, where the protons 2-H and 3-H, the groups ’CF^OH and 
PhtN, and M e^  and Leu-OMe all lie gauche to each other. The fact that 2-H and 3-H 
are gauche to each other is in accordance with the coupling constant. There is also a 
gauche interaction between the 2-H and 4MeAla which fits the 2D nOesy spectra 
perfectly. It is also interesting to note that for all the products isolated with the 
stereochemical configuration (2R,3S) the chemical shift for 3-H was always lower 
than the corresponding isomer (25,35'), see Table 12.
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Isomer (324) (2R,3S,2’S), (2S,3R,2'S) Isomer (325) (2S,3S,2'S), (2R,3R,2’S).
3H
2H'v ^ T V Leu'OMe




L eu -O M e
0  = 60°, J = 4Hz 
l-H-4MeA|a inter­
action therefore not 
possible
0 = 60°, J = 4Hz 





M eO -L eu^K -1CH2OH 0  = 180°, />10Hz
PhtN^^j-'^MeAia not possible, does 
2H
not fit cosy 
not possible
3H
HOH2 Ci-^y ^ ' 'X /L e u -O M e















0 =  115°, /  = 4Hz 
1-H and3-H inter­













0 =  180°,/>10Hz 
not possible, does 
not fit cosy 
not possible
0 =  115°,/=4Hz 
l-H-4MeAla, 2-H 
interactions does 
not fit, therefore 
not possible






Compound isomer (2S,3S) 
3-H (ppm)
isomer (2/?, 3S) 
3-H (ppm)
l > 4.07 3.97
P h t N ^ ^ i ^ ^ C I
OH 4.71 4.68
OH 4.53 4.42
P h t N ' ^ Y ^ ^ 07’8 DP s
OH 4.65 4.64
PhtN/ ^ Y ' ' ^ OH
Leu-OMe 4.67 4.57
As this addition worked, the effect of temperature on the reaction was investigated. 
These results are detailed in Table 13. It is interesting to note that only the isomers 
(324) were isolated, independent of the starting material used, thus suggesting that a 









diols (338 & 337) 
+ dipeptide (324b)
(324a)
2 0 MIX N/A 2 (56:44) 2  (2 :8 ) 8 12
0 (323) 2 .2 3 11 15
- 2 0  (1  hr) (322) 35 0 3 (2:8) 7 27
- 2 0  (2  hrs) (322) N/A N/A 5 8 *
* decomposed on silica
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It was found that on long, narrow chromatographic columns the dipeptides 
decomposed with only 30% isolation of the products. Short, wide columns were used 
to achieve the greatest recovery, but unfortunately some product was always lost. 
With use of neutral alumina, the dipeptides adhered to the column, and were only 
removed by methanol. All flash chromatographic attempts at separating the diols from 
the hydroxymethyl dipeptide (324b) failed. Attempts at separating these compounds 
using HPLC apparatus resulted in cleavage of the newly formed C-N bond to give 
Leu-OMe and the corresponding diol (337). This was possibly caused by the 
trifluoroacetic acid protonating the secondary amine, thus allowing for displacement of 
Leu-OMe by water.
With all the previous epoxide opening reactions, the work ups involved dilute acid 
washes. We repeated the racemic epoxide opening reaction using 2 equivalents of 
Leu-OMe and one equivalent of BF3.0 Et2 at -78°C and concentrated the crude 
mixture in vacuo ready for isolation of the products by chromatography. T.l.c. of the 
crude reaction mixture showed that some of the racemic epoxide (323) had not reacted 
and that the racemic diols (337) and (338) had been formed, due to hydrolysis by 
water. A new compound, previously not isolated before, with a lower retention factor 
than the desired dipeptide product, had also been produced. After spectroscopic 
elucidation the structure appeared to be that of the aziridine (328). There were no NH 
and OH peaks in the IR spectra, the n.m.r. spectra showed a shift upfield for the 1-H 
protons, to 2.40 and 2.77ppm, which indicates that they are deshielded to a lesser 
extent than those adjacent to an oxygen functionality. The coupling values for the 
protons 1B-H with 2-H are constituent for eclipsed protons , J  = 7.6Hz, dihedral angle 
of 0°, and 1A-H with 2-H where J  = 5.0Hz, for a dihedral angle of 120°. The rest of 
the spectra is consistent for that of the PthN-Ala-Leu-OMe dipeptide. The conditions 
must have allowed for the formation of the hydroxymethyl dipeptide (324) via ring 
opening, with the BF3 having remained bound to the oxygen to make it a much better 
leaving group. The use of excess Leu-OMe could have acted as a base allowing the
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more nucleophilic secondary amine to cyclise intramolecularly to give the aziridine 
(328). The secondary amine has essentially the same basicity as that of Leu-OMe, but 
because it lies in such a close proximity to the good leaving group its rate of attack is 
much higher (Figure 43).
Further purification of the mixture of aziridines (328) was attempted using HPLC 
apparatus. Again, the solvent system used altered the structure of the product. Mass 
spectroscopy showed the new compound that had its molecular weight increased 18 
a.m.u. (363 in FAB+) and it could be clearly seen in the proton n.m.r. and IR spectra 
that two new broad peaks corresponding to OH and NH were present. The chemical 
shifts of the CH2 unit next to the hetero atom in these dipeptides (398) and (399) were 
markedly different to those of the previously formed hydroxymethyl dipeptides (324). 
This suggested that the hetero atom was nitrogen as opposed to oxygen according to 
previous data on the chemical shifts for such systems, (Scheme 82).
As nitrogen is less electronegative than oxygen, a-protons will be deshielded to a 
comparatively lesser extent than those alpha to oxygen. Indeed, the chemical shift for 
the CHX-N are in the range 2.3-3.4 ppm and for oxygen they are at 3.4-3.8  ppm, the 
observed value was 2.85-3.4 ppm. The addition of the water to the aziridines (328) 
must have been at the most substituted site, via a SN1 mechanism. The TFA most 
probably activated the aziridine (328) producing the secondary carbocation which was 





new route for the formation of the hydroxyethylamine dipeptide mimetics, not 
previously reported.









i. acetonitrile, water, TFA, HPLC. 
Scheme 82
Another attempt to overcome this problem was to prepare the 7V-Boc protected 
dipeptide (400) derivatives, which would hopefully allow for separation of the desired 
product and by-products due to the increased lipophilicity of the dipeptide. 
A mixture of the N-phthaloylamino 
epoxides (322) and (323) were reacted 
with Boc-Leu-OMe in DCM with 
BF3 ,OEt2 as a Lewis acid (Figure 44).
B o c












i. BF 3 .0 Et2 , Boc-Leu-OMe, DCM. 
Figure 44
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Addition of the amino ester did not occur. Instead the diols (338) and (337) were 
isolated in 69% yield (91:9 2R,3S as the major isomer, the absolute stereochemistry 
was established via protection of the minor isomer, to give the TBDPS derivative, 
X-ray crystallography showed it to be of the 2S,3S configuration).
One final attempt to make the hydroxymethyl dipeptides (324) and (325) (similar to the 
use of Boc-Leu-OMe) without contamination by the diols (337) and (338), was to use 
the mono benzyl protected leucine methyl ester (367). This protected amino ester was 
prepared by refluxing Leu-OMe.HCl with one equivalent of BnBr, K2C 0 3 in 
THF:EtOH (10:1) for 1 day. The product was isolated in 57% yield. The reaction was 
tried at -20°C and the work up involved a water wash. No hydroxymethyl dipeptides 
(324) and (325) were isolated, only the diols (337) and (338) and starting material 
being found. The steric bulk of the protected amino ester may have inhibited the 
reaction. Following these results no further yV-phthaloylamino epoxide (322) and (323) 
ring opening reactions using amino esters and BF^.OEto were attempted, Figure 45.
No Reaction
(322,323)
i. B F 3 .OEt2, Boc-Leu-OMe. DCM.
Figure 45
Preparation of the N,N-dibenzyl protected hydroxymethyl dipeptide (401)
The attempted preparation of the /V,/V-dibenzyl protected hydroxymethyl dipeptides 
(401) involved conditions analogous to those employed for the N-phthaloylamino 
protected epoxide ring opening by Bn-Leu-OMe. However, the unprotected amino 
ester was used (396). The reaction when viewed by t.l.c. showed a huge number of 
compounds and we decided to abandon this protected route and go back to using the 
phthaloyl group.
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Preparation of the N,N-dibenzyl protected hydroxyethylamine dipeptides (402)
Whilst preparing homochiral 7V,./V-dibenzyl protected aminoepoxides (356) and (357) 
we found that isomerisation occurred during the Swern oxidation. This gave us the a 
mixture of the rearranged epoxides (363) and the expected epoxides (356) and (357). 
The inseparable rearranged adducts (363), were ring-opened following the procedure 
of Gordon et a l n4e This gave us the expected hydroxyethylamine dipeptides (402) as 
an inseparable mixture in low yield (20%). These analogues were considered useful 
for biological screening and have been submitted for testing, (Figure 46).
HO
(402)(363)




Preparation of the N-phthaloylamino chloroalcohols (403) and (404)
Epoxide ring-opening by nucleophilic addition of chloride has been widely explored. 
Many of the reported methods showed that the addition was not confined to the least 
hindered site, with addition also occurring at the more substituted site of the
219 220 222epoxide. ’ Gorzynski-Smith illustrated that epoxides could be converted to the 
corresponding chloroalcohols under mild conditions with regioselectively, giving 
exclusively A2. We adopted these conditions, which involved refluxing the epoxide in 
methanol and DME using tetraethylammonium chloride hydrate as the source of "Cl'". 
Unfortunately these conditions did not give exclusively the chloroalcohol (35%). In 
our study the alkene (376) 2A methyl ester (405),222 the (2R,3S)- and (2S,3S)-1-
223chloro-2-methoxy-3-phthaloylaminobutane (406) and the diols (337) and (338) 









P h tN '
(376)






,224However, it is interesting to note that recently Suh et a I had detailed the use of 
tetraethylammonium bromide with the assistance of Mg(N03) 2 as an excellent Lewis 
acid catalyst. Here, the bromoalcohols were isolated typically in 78-97% yield with the 
corresponding epoxides cleaved regio and stereoselectively under neutral conditions.
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The Mg(N03) 2 activates the epoxide so that attack only occurs at the less hindered 
carbon of the unsymmetrical epoxide.
Bajwa et a I22* reported that epoxides could efficiently be converted to the 
corresponding chloroalcohols using lithium chloride with acetic acid in THF. The 
addition goes regioselectively and in high yield, with retention of configuration 
(Scheme 83). Ring-opening of the recrystallised amino epoxide (322) using the 




►  P htl
(404)
P h tN '
(322)
i. LiCl, THF. RT; ii. AcOH.
Scheme 83
Preparation of the dibenzylaminochloroalcohol (407)
The /V,/V-dibenzyl aminoepoxide (356) and (357) were converted uneventfully to the
corresponding chloroalcohol (407) in quantitative yield as outlined by Bajwa et a l 225
•  226  Figure 48. More recently Barluenga et al have synthesised these compounds via
reduction of the corresponding chloroketone, but they did not give any spectroscopic
data.




Preparation o f the (2S,3S)- and (2R,3S)-3-N-protected amino l-(protected thiol)-2- 
hydroxybutanes
The formation of the thiolmethyl dipeptide was also considered to be an important 
target. Both the /V-protected epoxides (322,323 and 356,357) were ring-opened with 
triphenylmethyl thiol in methanol with triethylamine following a procedure reported by
227 228 229Corey et al. Dellaria et al and Luly et al also employed this methodology to 
synthesis renin inhibitors using HSR, where R=C6Hn and isopropyl.
In our study the yV,/V-dibenzyl amino alcohol (408) was isolated in 9% yield and the N- 
phthaloylamino epoxides (322) and (323) were converted in 90% yield to the alcohols 
(409). The yV,/V-dibenzyl amino epoxides (356) and (357) were converted more 
efficiently to the corresponding protected thiol alcohols using 4-methoxyphenylmethyl- 
thiol (97% yield), Figure 49.
i. a) P=B n 2  and PhtN , H SCPh3, E t3 N, MeOH; b) P=Bn2, /?-methoxyphenylmethylthiol, E t3 N, MeOH.
Figure 49
2.5.4 Diol formation
Preparation of the phthaloylamino di hydroxy butane via epoxide ring-opening 
In the course of the synthesis of the hydroxymethyldipeptides (324) and (325) from the 
epoxides (322) and (323), using the Lewis acid BF3.OEt2, we found that the diols 
(337) and (338) were generally formed in modest yield as the unwanted by-products 
(69% when Boc-Leu-OMe was used see Section 2.5.1), Figure 50.
P = PthN, R = Tr, (409) 












i. a) BF 3 .OEt2, DCM, H 2 0 ,  -23°C; b) 0.1M H 2 S 0 4, THF, RT, 3 days; c) Dowex-50X, THF, H 2 0 ,  
50°C, 11 hrs or d) 6 % HCIO4 , THF, RT, 2 days.
Figure 50
We considered using BF3.OEt2 at lowered temperatures to activate the epoxides so 
that they would be hydroxylated by water to the corresponding diols (337) and (338). 
Upon our first attempt at -78°C the diols (337) and (338) were generated in low yield 
(24%) with most of the starting material recovered. When we repeated the reaction at 
-20°C the yield was only increased to 35% in a ratio of 9:91 with the isomer of 2R,3S 
configuration being the major isomer (337). We considered using the more common 
method of converting epoxides to diols, i.e. using a dilute acid such as H2S 0 4. At our 
first attempt, we found that not only were the diols formed (19%, 337:338, 93:7), but 
the acid conditions were so strong that cleavage had occurred giving the alcohol (346), 
whose n.m.r. and mass spectra were identical to the authentic material. Another 
product was isolated, the n.m.r. spectra suggested that the isolated product was almost 
symmetrical in nature and may have been formed via addition of the alcohol (346) to 
the starting material to give (410). The proton n.m.r. showed three sets of aliphatic 
protons, in the ratio of (4:2:1). The four protons had chemical shifts expected for 
ethers, the two protons showed coupling signals to a methyl group and the remaining 
proton had the expected chemical shift, for a -C//(OH)- proton, however we did not 
known the stereochemistry for this centre, Figure 51.
230We reduced the concentration of the acid to 0.1M H2S 04, thus allowing successful 
conversion of the epoxides to the corresponding diols (337) and (338), in moderate 
yield (54%, 337:338, 91:9).
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(322) (337) (338) (346) (410)
i. 1.0M H 2 S 0 4, THF, RT, 5 hours.
Figure 51
The yield was increased slightly when we employed the ion exchange resin Dowex- 
50X8-100 (strongly acidic), giving the diols (337) and (338) in 56% yield. We 
discovered the best way to produce the diols (337) and (338), was to use 6 % 
HC104 .231 This gave the diols (337) and (338) in good yield (62-100%, 337:338, 3:1), 




Acid catalyst Yield (%) Ratio of diols 
(338:337)
43:57 BF3.OEt2 69t 9:91
43:57 BF3.OEt2 35 9:91
43:57 o.i h 2s o 4 54 9:91
0 : 1 0 0 1 .0  h 2s o 4 19 7:93
0 : 1 0 0 Dowex 56 N/A
35:65 h c io 4 62-100 1:3
Bn2N^ "  Bn2r r  Y  'OH
OH
(356) (357) (411)
i. a. BF 3 .OEt2, -20gC. DCM; or b. Dowex-50. THF, RT.
Figure 52
t  as the by-product o f the ring-opening o f the epoxides (322) and (323) by Boc-Leu-OMe
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Mechanism
Katagiri et al234 showed that the epoxide ring-opening of l,2-epoxy-3,3,3- 
trifluoropropane (414) went with retention of configuration, when they used dilute 
H2S 0 4, following the procedure detailed by McBee.235 This suggests that the opening 
went exclusively via a SN2 mechanism, Figure 55.
control over which mechanistic pathway when epoxides were opened using catalytic 
BF3.OEt2. They concluded that stabilising groups e.g. phenyl or allyl, gave 
exclusively addition at the substituted carbon i.e. an SN1 pathway, whereas alkyl 
groups cause additions at the terminal carbon because of steric reasons i.e. Sn2 
pathway, and groups which lay between those extremes gave a mixture of products, 
Scheme 84.
i. R = stabilising, e.g. phenyl or allyl; ii. R = sterically hindering, e.g. alkyl; iii. R = moderate stabilising
opening of 1,2-epoxy octane (418) with ethanol, giving various mixtures of products, 
Figure 56, (Table 15).
(414), 75 % e.e. (415), 75 % e.e.
i. H2 S 0 4, H 2 0 ,  80%.
Figure 55
17A







Schnurpfeil et al had reported that BF3.OEt2 and other acids catalysed the ring
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(418) (419) (420)
i. a) BF 3 .OEt2, EtOH; b) HC104, EtOH or c) p -TS A, EtOH. 
Figure 56
Table 15
catalyst epoxide (419) % epoxide (420) %
h c io 4 52.8 47.2





























Pocker et aT carried out isotopically labelled water experiments to determine the 
mechanisms of epoxide ring-openings. They found from the acid catalysed ring- 
opening reaction, that the reaction could be interpreted in terms of a spontaneous
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opening of the epoxide to generate a carbocation, followed by subsequent capture by 
water which leads to a vicinal diol (Scheme 85). However, the evidence for this is 
sparse and inconclusive.
They found that the rearrangement process, which was similar to the pinacolic 
rearrangement, could be facilitated by increasing the acidity of the media and by using 
polar, non-nucleophilic solvents. Table 16 shows the amount of SN1 and SN2 
observed in the acidic limb of their investigations.
Table 16
epoxide SN1 (%) Sn2 (%)
propylene 70 30
isobutylene 99 1
Long and Pritchard^39 in 1956 carried out similar work to Pocker. They explored the 
effect of HC104 at different concentrations on propylene and isobutylene, Table 17.
Table 17
epoxide HCIO4 (M) SN1 (%) SN2 (%)
propylene 0 .1 2 74 26
propylene 0.25 6 6 34
isobutylene 0 .1 2 1 0 0 0
isobutylene 0 .1 99 1
These reports did not study the stereochemical outcome of the SN1 pathway. Our
238results, Table 14, were very similar to those of Pocker et al and Long and 
Pritchard/ 39 Table 17. These results were rather inconclusive and there was always a 
mixture of SN1 and SN2 addition. With the phthaloylamino protected epoxides (322) 
and (323), we found generally that there was a excess of one diastereomer formed,
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namely diol (337). This result was independent of the diastereomeric ratio of the 
epoxides (322) and (323) used. From these results, it may follow that the addition of 
water to the epoxide goes mainly via a SN1 pathway, but it is unclear why there should 
be such an excess of the (2R,3S) stereochemistry. Thus, this suggests a more complex
240mechanism, which may involve the phthaloylamino protecting group. Roush et al 














H+BocN' | — *
H ‘ O slow
(23) o (425)
Scheme 8 6
More recently Rich and Romeo196 have reported the involvement of the Boc protecting 
group in the diastereomeric enrichment of the epoxidation reaction of (3S)-Boc-4- 
phenylbut-l-ene (423) with m-CPBA (Scheme 8 6 ). In this case the minor isomer 
(424) rearranges more rapidly to the oxazolidine (385), thus increasing the ratio for the 
major isomer (23).
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The phthaloylamino group may be participating in a similar manner2413 although the 
intermediates look rather ring-strained. The activation of the racemic epoxides under 
acidic conditions, followed by an intramolecular cyclisation via a 5-exo-trig addition, 
which will proceed faster than the 6-endo-trig cyclisation,2416 will give the 6,5,5- 
tricycle system (426) and the corresponding mirror image (Scheme 87). The 
intramolecular cyclisation will be faster than the intermolecular addition of water. 
The 6,5,5-tricycle system (426) can then undergo attack by water to give the diols 
(337) and (338), Scheme 8 8 .











The formation of the 6,5,5-tricycle system (426) may occur more rapidly for the minor 
isomer (338), as the methyl and CH2OH groups will lie trans to each other. Addition 
of water to the imine will give inversion at C-2, giving the major diol (337), Scheme 
8 8 , whereas, the major epoxide isomer may form slower, due to the methyl and 
CH2OH groups lying cis to each other. This steric factor may be sufficient enough to 
slow down the cyclisation process to allow intermolecular addition of water to 
compete. Thus the mechanism will follow SN2/SN1 pathways as detailed by Pocker et
















We did not carry out any isotopic labelled experiments which would have shown 
which mechanism may have taken place i.e. if there was any lsO present in the 
phthaloylamino group (which could be removed with hydrazine), would suggest, 
formation of the 6,5,5-tricycle inline (426) which followed attack by water.
1 fiAlternatively, if the was no O present in the phthaloylamino portion, then this would 
show that the mechanism followed a straight forward SN2/SN1 pathway and involved 
no participation of the phthaloylamino group. There is still much debate about the 
mechanism of this epoxide ring-opening reaction, and that represented here maybe a 
possible route, but there may be other plausible mechanisms.
Preparation of N-phthaloylamino dihydroxybutanes (337) and (338) via the 
hydroxylation of alkene (376)
There are several oxidative reagents which are capable of converting alkenes to their 
corresponding diols. Potassium permanganate in aqueous solution has been widely 
used as an efficient oxidant in preparative chemistry. This technique had been further
242
improved by the use of phase-transfer catalysts, e.g. KMn04-TEBAC and M n04- 
CTMA. Generally the diols were formed in good yields. However, over-oxidation
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was occasionally a problem and this made us consider using another method which is 
also commonly used, namely hydroxylation using catalytic osmium tetroxide.244' 246
Ray and Matterson244 reported that catalytic 0 s 0 4 used with NMO proved highly 
successful as a preparative method for diols. These reactions went cleanly and in high 
yield. Ray and Matterson244 also suggested that the intermediate osmate esters (428) 
could be hydrolysed quicker using pyridine to release the diols [when R=PhtNCH(Me) 
(337) and (338)], Scheme 90. When we followed their experimental details we only 
managed to produce diols (337) and (338), in moderate yield (44%), with the (2S,3S) 
isomer (338) as the major diastereomer (337:338, 27:73), Figure 58.
^ O v o  Rv. / O H
\  /ii 
Os  ►
(428)
i. OSO4 , NMO, acetone; ii. pyridine. 
Scheme 90
OH









i. OSO4 , NMO, acetone:water:* BuOH, (6:5:1ml), pyridine, 44%.
Figure 58
The fact that the major isomer produced using 0 s 0 4 is the minor isomer in the epoxide 
ring-opening step, means that both isomers can be prepared in good yield from alanine.
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2.6 C oupling reactions
2.6.1 Phosphonomethyl dipeptide (330)
The formation of a phosphonomethyl dipeptide analogue (330) was attempted using 
two possible paths (Scheme 91). The first path would involve the formation of the 
ketophosphonate (432), reduction and then activation of the alcohol followed by 
displacement with Leu-OMe to give the fully protected dipeptide (434). A second 















i. C H 3 PO(O Et)2, n-BuLi, -78°C, THF, 63-97%; ii. reduction, activation, X= toluene, CF 3  or Me; iii. 
coupling; iv. am ination; v. reduction; R=Me.
Scheme 91
Preparation of 1 -(diethyl)phosphonate-2-phenyl-2-trifluorosulfonylethane (429)
A model route was tried using benzaldehyde to see if the sulfonate could be eliminated 
under weak basic conditions. Benzaldehyde was treated with methyldiethylphosphon-
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ate and /?-BuLi at -78°C to yield the p-hydroxyphosphonate (430) in 30% yield, 
Figure 59.
O OH O OTf O o
p A h ^  ^  ph^ S'“ "=
(430) (429) (431)
i. /i-BuLi. methyldiethylphosphonate, -78°C, 30%; ii. Triflic anhydride, pyridine, DCM, -23°C, 25%.
Figure 59
Activation of the alcohol can be achieved in a manner of ways, preparation of the 
sulfonate being the simplest and most efficient method. The trifluoromethanesulfonate 
is the most reactive sulfonate,247 about 5.6xl04 times a relatively better leaving group 
than the methanesulfonate moiety. The trifluoromethanesulfonates were first prepared 
by Leroux and Perkin"48 to form halides, and then Vedejs et al249 in the following year, 
who used them to form C-S bonds. Many groups have prepared compounds
247 250 251containing C-N bonds using these sulfonates" ' ‘ ' and we sought to use them to 
prepare a new family of compounds. The trifluoromethanesulfonate can be prepared 
using either the trifluoromethanesulfonyl chloride or the trifluoromethanesulfonate 
anhydride. However, Just and Hakimelahi254 reported that trifluoromethanesulfonyl 
chloride also acts as a mild chlorinating agent and therefore to avoid this problem we 
opted to use the anhydride and followed the procedure detailed by Effenberger et al.250 
Tie alcohol was treated with triflic anhydride and pyridine at -23°C for 1 hour. The 
irujor product isolated was the (Z)-alkene (431), formed via .yy/7-elimination of the 
trifluoromethanesulfonate group. The stereochemistry was proved by 2D nOesy n.m.r. 
spectra which showed that there where spatial interactions between the phenyl group 
and the phosphonate as well as there being a cis relationship for the two olefinic 
pntons. 400 MHz proton n.m.r. spectra showed that the J value was higher than for 
ncrmal cis alkenes, i.e. 2-8Hz, here the value was Jcis 17-20Hz. Small amounts of the 
(<5%) of the desired sulfonate (429) were also observed by 400 MHz proton n.m.r.
149
Although we did not manage to isolate the sulfonate (429), we decided to take the 
alkene (431) and reflux it with Bn-Leu-OMe (367) to see if any 1,4-addition could be 
effected. Under these conditions, no addition occurred and only starting materials 
were isolated.
Although the corresponding sulfonate (429) of the p-hydroxyphosphonate (430) 
appeared to be unstable, the preparation of the /VTV-dibenzyl protected
255aminophosphonate (432) was undertaken. Dellaria and Maki in 1986 prepared 
phosphostatine derivatives by reacting trityl protected amino aldehydes (435) with the 
lithium or sodium salt of methyl dimethylphosphonate to give the corresponding p- 










i. Li or N aCH 2 PO(OM e)2. -78°C, THF, 67% , 3:1.
Figure 60
However, it was reported in 1987 by Chakravarty et al256 that the p-ketophosphonates 
(437) could be generated in almost quantitative yield, when the ester (438) was reacted 












i. L iCH 2 PO(OM e)2, -78°C, THF, 78%. 
Figure 61
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Alanine was protected by benzyl bromide as reported before, 165 in good yield. The
NTV-dibenzylaminobenzylester (359) was reacted with the lithium anion of the 
methyldiethylphosphonate in THF at -78°C to give the desired product (432) in good 
yield (60% using 1.1 equivalents, with no epimerisation a 589= -67.5°). The yield was 
increased to 96% using 6  equivalents (with no epimerisation) following the procedure 
detailed by Chakravarty.256 (Figure 62)
i. BnBr, K 2 C 0 3, NaOH, EtOH, H 2 0 ,  reflux, 97%; ii. n-BuLi, THF, methyldiethylphosphonate, -78°C,
96% .
Figure 62
The first attempted preparation of the phosphonomethyl dipeptide (330) involved
a Dean-Stark distillation apparatus. This method did not give the desired product. 
The only material isolated, apart from starting material, appeared to be that of a leucine 
trimer, only the proton n.m.r. was run as we had no interest in this product. The imine 
(433) formed, probably decomposed or polymerised rapidly, as there are no stabilising 
groups attached to the nitrogen. Unfortunately other condensation reactions which 
used drying agents such as TiCl4258 or molecular sieves with p-TSA259 also failed to 
give the desired product. See Table 18.
O O O O
(359) (432)
condensation257 of the p-ketophosphonate (359) with Leu-OMe (see Figure 63), using
table 1 





Amine Reagents Conditions Time Result
Leu-OMe.HCl Et^N, Toluene Reflux 6  hrs generated new material, 
which appeared to be 
leucine trimer
Leu-OMe.HCl p-TSA, Toluene Reflux 6  hrs no dipeptide isolated
Leu-CKBu.HCl Et*N, TiCl4 Reflux 2  days no observed reaction
Another successful method for the preparation of C-N bonds is via a reductive 
animation reaction, Figure 64. There is much literature precedent for reductive 
animations, including the use of catalytic hydrogenation.
Other possible reducing agents include
260Itsuno's reagent (439), sodium
cyanoborohydride,261 sodium triacetoxy
262borohydride and iron pentacarbonyl with 
alcoholic KOH.263
Following the unsuccessful attempts at making the imine via a condensation reaction, 
we turned our attentions to the use of sodium cyanoborohydride as reported by Borch 
et al.261 In our hands no coupling occurred and the only isolated product apart from 
starting material was the P-hydroxyphosphonate (440), Table 19. When the reductive 
animation was tried in acidic media (to activate the reduction step) again the p- 
hydroxyphosphonate (440) was isolated. This route was abandoned and efforts were 
concentrated on the route using the p-hydroxyphosphonate (440) as the precursor to 
the coupling step (see Scheme 92).
Me,HC Fh phVt
0  I tsu n o 's  reagem





































material and the P~ 
hydroxyphosphonate
The P-ketophosphonate (437) was reduced using NaBH4 to the corresponding alcohol
(440), an inseparable mixture of the (2S,3S) and (2R,3S) diastereoisomers in 95% 
yield. The p-ketophosphonyl sulfonate (441) was formed in an analogous manner to 
the other sulfonates, the product was not purified and the crude material was used in a 
model reaction, which employed the treatment of the sulfonate with Leu-OMe in THF. 
This did not afford the desired compound (434). When this reaction was repeated in 




i. NaBH 4 , EtOH, 95%; ii. Triflic anhydride, pyridine, DCM, -23°C; iii. a) Leu-OMe, THF, 0°C, 5 hrs, 
RT, 6  hrs; b) Leu-OMe, NaOAc, THF, RT, 3 days; c) Leu-OMe, THF, DMF, 0-RT, 3 days, remove 
THF, 2 hrs, no change.
Scheme 92
As the model reactions did not work, we repeated the preparation of the sulfonate
(441) and characterised it fully. Spectroscopic studies showed that a rearrangement 
had occurred, 19F n.m.r. spectra showed that there was no fluorine present. Proton and 
carbon n.m.r. spectra showed that the backbone had been modified and C.I. and E.I. 
mass spectroscopy showed the presence of chlorine. Previously, all other attempts at 
making trifluoromethanesulfonates of A-phthaloylamino alcohol derivatives had 
worked very well. We came to the conclusion that the trifluoromethanesulfonate had 
been generated, but had rearranged rapidly. One possible rearrangement could 
involve the nitrogen lone pair, displacing the trifluoromethanesulfonate to give the 
aziridinium trifluoromethanesulfonate salt (442). This intermediate could then be 





After extensive spectroscopic analysis the y-chlorophosphonate (444) was found to be 
the only compound generated, via Path (b), perhaps due to the steric hindrance of the
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bulky phosphonate blocking approach via Path (a). However, following this pathway 
four possible diastereoisomers could be formed, and therefore it is not possible to 
comment on the stereochemistry here.
Rayner et a l170 had reported the existence of such salts. These had been generated by 
treating 2,3-epoxy amines (445) with trimethylsilyl trifluoromethanesulfonate 
(TMSOTf)264 which opened the epoxide to give the protected hydroxy 
trifluoromethanesulfonate and then rapidly rearranged on warming to room 








i. TM SOTf, -78°C. DCM; ii. nucleophile, -78°C to RT; iii. deprotection.
Scheme 94
265The chemical shifts shown in Table 20 were calculated using chemical increments 
for the suspected structures (443) and (444). However, no value could be found for 
the phosphonate group and thus an approximation was used for this purpose. The 
most important chemical shift data for elucidating the structure of the rearranged 
product, was that of the C-2 and C-3 protons, and their carbon-13 values. Using the 
chemical shift increments for carbon-13, published by Brown, Floyd and Sainsbury,265 
it appears that the C-2 for (444) when corrected will have the lower value as all y  
increments for any functionality will have negative values. Whereas for (443) the 
chemical shift increments here will be positive in value as they are (3 to the centre, thus 
there will be an increase in the chemical shift for C-2, making the calculated value 
much higher than the observed value. With respect to the proton n.m.r., the effect on 
the chemical shift for CH2X systems, where X=C1 or OH, are very similar. 
Comparison of the chemical shift of the (3-hydroxyphosphonate (440) with the
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rearranged product show no correlation, thus indicating that they have distinct 
structures. Further examination of the proton n.m.r. spectra showed that MeAia 
appeared at 1.43ppm much higher that for the (3-hydroxyphosphonate (440) which 
appears at l.lOppm. C-2 proton also shows a more complex coupling than would be 
exhibited for a structure of type (443), here the proton is coupled to three other 
protons and there is also a !H-31P coupling all this shows that path (b) must have been 
followed to give the y-chlorophosphonate (444), Scheme 93. This is also reinforced 
by the cosy which shows a strong coupling between the C-4 and C-2 protons, 
however, no coupling between C-2 and C-3. This may be due to the dihedral angle 
being close to 90°, giving the coupling value, /=0, when the Karplus equation /=kcos0 











1 1.83 20.9* 1 .8 2 2 .2 f 2.3 2 2
2 4.08 60.4* 4.00 56.7* 4.4 56.7
3 3.13 56.4* 3.33 56.4* 3.2 62.4
4 0.83 2 2 .2 1.03 20.9 1.4 22.9
As the trifluoromethanesulfonate is a much more reactive species than both the 
methanesulfonate and p-toluenesulfonate, we decided to prepare the more stable p- 
toluenesulfonate derivatives. Kabalka et aT66 described the preparation p- 
toluenesulfonates from the corresponding alcohols for the use in subsequent 
nucleophilic substitution reactions. Secondary alcohols are comparatively less reactive
' n o a  increm ent for phosphonate. values will be much higher
• no P increm ent for phosphonate, values should be higher
* no y increm ent for phosphonate. values will be reduced
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than primary alcohols and require longer reaction times. When we attempted this 
reaction at room temperature no transformation occurred, even when the reaction was 
refluxed for 4 hours. Due to our inability to generate the p-toluenesulfonate we
showed that methanesulfonates can be generated quite simply and rapidly even with 
highly sterically hindered alcohols. They concluded that the mechanistic course of the 
reaction did not follow the usual nucleophilic addition of the alcohol to the sulfonyl 
group, but instead addition to a sulfene (447) derived from E2 elimination of chlorine 
from the methanesulfonyl chloride, (Figure 65).
In our hands the amino alcohol (440) was converted cleanly and rapidly to the 
corresponding methanesulfonate (448) in high yield (90%). Under these conditions no 
rearrangement occurred and a 60MHz proton n.m.r. spectra showed the characteristic 
singlet peak for the methyl of the sulfonate at 2.8 ppm. However, the mass spectrum 
did not show any of the mass ion of 483 a.m.u., but the fragment for the loss of 
S 0 2Me was observed at 406 in (+) FAB. When this was treated with Leu-OMe.HCl 
the sulfonate (448) was converted to a new compound with a higher retention factor 
by t.l.c., Scheme 95.
(436) (448) (449) (444)
267decided to use the methanesulfonate to activate the alcohol. Crossland and Servis
o o





i. M esyl-Cl, E t3N, DCM, 90%: ii. Leu-OM e.HCl, TH F, 1 hr.
Scheme 95
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Upon analysis of this new compound it was discovered that the chloro compound 
(444) had been formed again. It was interesting to note that the elimination product 
(449), the (£)-alkene Jtrans 17.4 Hz, was also detected as a by-product. As a 
consequence of these results, this route was abandoned and all efforts were directed 
towards the other targets.
2,6.2 Mercaptomethyl dipeptide (329)
The synthetic strategy for the preparation of the mercaptomethyl dipeptides (329) 
involved ring-opening of the protected amino epoxides, to give the protected 
hydroxythiols (450) (discussed in section 2.5.3), followed by activation of the hydroxyl 
moiety to the corresponding sulfonates (451), to facilitate formation of a C-N bond 
with Leu-OMe. In our hands all attempts to furnish these sulfonates (451) failed, 
Figure 6 6 .
OMe
SR
pN' ^ Y NV ^ O M ,_ NMe
SHSR
(451) (452) (329)
i. a)Triflic anhydride, DCM, -20°C; b) p-toluenesulfonyl chloride, pyridine, DCM, RT, 3 days; and c) 
NaH, p-toluenesulfonyl chloride, RT; ii. Leu.OMe.
Figure 6 6
Attempted preparation of the phthaloylamino aryl thiol triflate (453)
In an attempt to prepare the triflate (453) using standard sulfonation techniques, the 
reaction produced a variety of by-products. N.m.r. spectroscopic studies showed none 
of them to be the desired product and they were not characterised further. 
Deprotection of the thiol group was apparent due to the isolation of trityl derivatives. 
As these conditions were too acidic, and these type of protecting groups were
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susceptible to deprotection by strong acids, we opted to use p-toluenesulfonate to 
activate the hydroxyl group, Figure 67.
PhtN
O T f
S C P hPhtN'
OH
(409) (453)
i. Triflic anhydride, pyridine. DCM, -20°C.
Figure 67
Attempted preparation of the N,N-dibenzylamino p-methoxyphenylmethylthiol 
sulfonate (454)
The sulfonation of the M/V-dibenzylamino p-methoxyphenylmethylthiol alcohol (455) 
did not work using pyridine and p-toluenesulfonyl chloride after stirring at room 
temperature for 3 days. We decided to use NaH to generate the alkoxide anion in the 
hope that this would react with p-toluenesulfonyl chloride to give the desired sulfonate 
(454). When it was apparent by t.l.c. that some reaction had occurred, we added Leu- 
OMe. After purification all we isolated was the starting material and the p- 





i. NaH, /Moluenesulfonyl chloride. RT, Leu-OMe 
Figure 6 8
2.6.3 Mitsunobu reactions
The Mitsunobu reaction is an exceptionally useful and general method in organic 
synthesis, whereby a hydroxyl group can be replaced by a vast range of nucleophiles.
^68 269Extensive reviews by Mitsunobu"- and Hughes have shown an wide range of
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Edwards et al270 described the synthesis of polyamines utilising this useful reaction. 
They detailed that the success of the C-N bond formation depended on the pKa of the 
acidic component, i.e. the amide (amine). There are a number of reports in the 
literature that have used imides and sulfonamides such as 
trifluoromethanesulfonamide and p-toluenesulfonamide to displace the hydroxyl 
group, but very few detail the use of primary and secondary amines. Sammes and
271Smith showed that piperidine can be coupled with benzyl alcohol in modest yield 
(43%), (Figure 69).
i. PPh3, DEAD, HC1, THF, DMF, 43%. 
Figure 69
In the Mitsunobu reaction it is essential that the pKa of the amide (or amine) is lower
272than 11. However, more recently Tsunoda has shown using tributylphosphine 
(TBP) and l , l ’-(azodicarbonyl)dipiperidine, (ADDP), instead of the triphenylphosph- 
ine (PPh3) and DEAD, that the pY^ of the acidic component may be larger than 11 to
270facilitate C-N formation. Edwards et al showed that the pK a of /?-toluenesulfon- 
amides such as TsNHMe are around 11.7 giving poor yields, but that the pKas of 
TfNHMe type amines were much lower (pKa ~ 7.5), giving very good yields.
Preparation of the chloromethyl dipeptide (327)
Our first attempt was a model reaction to identify any possible by-products that may 
form. We used the racemic A-phthaloylamino chloroalcohol (404) and the standard
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Mitsunobu reagents, PPh3 and DEAD, coupling the activated alcohol (457) with Leu- 





E t02C— N— N— C 0 2Et (327b)(327a)
PhtN
(404)
i. DEAD, PPh3; ii. Leu-OM e.
Scheme 96
This reaction did not give the expected products. Instead we isolated the racemic (Z)- 
chloroalkene (458), the racemic carbonate (459) and the racemic DEAD N-alkylation 
product (460), Figure 70.







C 0 2 Et
(460)
i. DEAD, PPh3, Leu-OM e 
Figure 70
NOe studies confirmed the relative stereochemistry of the carbonate as (2/?*,3S*). 
The DEAD A-alkylation probably occurred because of the acidity of the hydrazine 
(reduced DEAD) was higher than that of Leu-OMe. Using Boc-Leu-OMe this 
alkylation did not occur; unfortunately nor did the C-N formation. All that were 
isolated were the starting materials, (Z)-chloroalkene (458) and the carbonate (459), 
Figure 71. HPLC of the starting material (404) and the carbonate (459) using an 
isocratic run [(CH3CN:H20 ):H20  30:70] gave the carbonate (459), recovered starting 











i. PPh 3 , DEAD, THF, Boc-Leu-OMe.
Figure 71
The nature of the solvent system, together with silica gel must have resulted in the 
elimination of the chloro atom and subsequent tautomerisation, to give the methyl 
ketone (393). An alternative and possibly more likely route could involve 
















The pK a values of the two leucine esters were both greater than 13 and thus they were 
not acidic enough to be deprotonated. As we required the Leu-OMe to have a lower 
/?Ka, it was decided to make the trifluoroacetyl protected amino ester as removal of the
273acetyl group was possible using 7% K2C 03.
The protected amino ester was prepared as detailed in Section 2.2.4. Its pKa was 
experimentally calculated at 10.4.274 This was just low enough for the Mitsunobu to 
work. In our hands we could not form the C-N bond between either the racemic
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mixtures of the chloroalcohol (404) or the protected diol (339) and TFA-Leu-OMe 
(368). All that we recovered were the starting materials. Table 21
Table 21
alcohol aminoester products





alkene + carbonate 
DEAD A-alkylation
(404) Boc-Leu-OMe alkene + carbonate
(404) TFA-Leu-OMe no reaction
P h t N ^ ^ Y ^ ^ O T B D P S  
6 h (3 3 9 )
TFA-Leu-OMe DEAD yV-alkylation
Preparation of the hydroxymethyl dipeptide (324) and (325)
When the Mitsunobu reaction was attempted on the racemic protected diol (339) no 
coupling occurred with TFA-Leu-OMe (368), Figure 73. No elimination product was 
observed, instead 63% of the starting material was recovered together with 9% of the 









i. PPh 3 , DEAD, THF, TFA-Leu-OM e.
Figure 73
2.6.4 Chloromethyl dipeptide






As there were many problems involved with the Mitsunobu we turned our attentions 
back to the formation of C-N bonds using sulfonates as detailed extensively in section 
2.6.1. The diastereomeric mixture of chloromethyl dipeptides (327) and (462) were 
prepared from a racemic mixture of the trifluoromethanesulfonate (463).247,249’250 The 
sulfonate (463) was generated at -23°C using pyridine and trifluoromethanesulfonate 




i. Trifluorom ethanesulfonate anhydride, pyridine, -23°C. lhr: ii. Leu-OM e.HCl, E t3 N.
Scheme 97
Reactions of the chlorotrifluoromethanesulfonates (463) and (464)
On numerous occasions we managed to isolate the chloromethyl trifluoromethane- 
sulfonates (463) and (464) and found them to be rather stable. This was probably due 
to the p-stabilisation effect of the electronegative chlorine group. They could be easily 
chromatographed without significant loss of material and were stable to water. Under 
acidic conditions we found that they were often converted back to the chloroalcohols 








Without purification, the racemic sulfonate (463) was reacted with Leu-OMe (396), 
generated in situ by treatment of Leu-OMe.HCl and triethylamine in DCM, Figure 75.
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The coupling reaction did not go cleanly as there was a considerable amount of the 
elimination products formed. The chloromethyl dipeptide diastereoisomers (25,35,2’5) 
(327) and (2R,3R,2'S) (462) [2:1 ratio (observed by *H n.m.r. spectra)] were isolated 
in 34% yield. Also isolated were the (Z)- and (£)-chloroalkene (458:465, 95:5) (12%
spectra showed the alkene to be predominately of the cis geometry (JcHMe-H 7.3 Hz and 
Jcis 8.0 Hz).
i. Trifluorom ethanesulfonate anhydride, pyridine, DCM, -23°C, lhr, ii. Leu-O M e.H Cl, E t3 N, 2 hrs.
Figure 75
Unfortunately we found that the diastereoisomers (327) and (462) could not be 
separated by flash chromatography.
When this reaction was repeated we used an excess of base and left the reaction 
mixture stirring for 2 weeks. None of the chloromethyl dipeptide (327) was isolated. 
Instead the chloroalcohols (403:404, ~1:1, 58%) were isolated, together with the 
chloroalkene (458) (5%) and the aziridine (328) (8 %) Rf 0.14 [EtOAc:petrol (30:70)], 
Figure 76.
These conditions must have allowed the formation of the chlorodipeptides (327) and 
(462) but due to the excess amount of base and the long reaction time, elimination to 
the chloroalkenes or intramolecularly cyclisation to aziridine (328) occurred.












PhtN ^  ' a
(465)
i. Leu-OM e.HCl, excess E t3 N, THF, 2 weeks, RT.
Figure 76
The aziridines (328) and the chloromethyl dipeptide (327) are members of two new 
families of dipeptide mimetics, which have the possibility of being either irreversible 
(Scheme 98) or reversible inhibitors. The chloromethyl dipeptide (327) has the 







i. enzyme-base; ii. enzyme-Nu. 
Scheme 98
The aziridines have been shown to be very reactive species (section 2.5.1, Scheme 82) 
and as a consequence may react with enzymes forming the complex (467).
P h tN X ,x0 S 0 2 C F 3 i P h tN
•Cl
(464) (468)






We tried to reduce the amount of elimination products by changing the base and the 
solvent. The use of K2C 0 3 in MeOH, resulted in the formation of the corresponding 
methoxychloro compound (468) (6 %) and the aziridine (469) (69%). Only a very 
small amount of the chloromethyl dipeptide was detected by n.m.r. spectroscopy 
(<1%), Figure 77. The aziridine (469) was most probably formed via the mechanism 
shown below, Figure 78.
"""OSOoCF
M e -O '
(464)
C 0 2Me
i. M eOH, K2C 0 3, DCM.
Figure 78
However, when K2C 03 in DCM was used we successfully managed to make the 
chloromethyl dipeptide (326) without elimination occurring, although isolated in low 
yield (30%). Similarly, the coupling reaction was achieved using the hindered base 
DIPEA in DCM, Figure 79.
o




i. K2C 0 3, DCM, Leu-OM e.HCl, 2 hrs. 
Figure 79
(470)
A new family of reduced dipeptides have therefore been established. These are related 
to the Szelke reduced amides described in the Introduction (Section 1.4). They are 
potentially more conformationally constrained because of the chloromethyl substituent, 
and might also act as reversible or irreversible enzyme inhibitors (the later as a 
consequence of the aziridinium intermediates, Scheme 98).
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Attempted preparation of the dibenzylamino chloro trifluoromethanesulfonate (471) 
We attempted to convert A^N-dibenzylamino chloroalcohol (407), which was made in 
an analogous way to the N-phthaloylamino chloroalcohol (404), to the chloromethyl 
dipeptide (472) using the same methodology just discussed. When we attempted to 
form the trifluoromethanesulfonate (471) using standard conditions it was discovered 
that many by-products occurred, including regeneration of the epoxides (356) and 
(357). We believe, even though we did not isolate these products, that the desired 





(356) and (357) (473)
i. Trifluorom ethanesulfonate anhydride, pyridine, DCM, -23°C, lh r.
Figure 80
With this disappointing result, we abandoned this particular approach.
2.6.5 Hydroxymethyl dipeptide
A further new family of potential enzyme inhibitors 
which were targeted had the general structure 
(332). Diastereoselective routes were therefore 
required to prepare this new pseudopeptide (332).
Due to the problems encountered with the direct formation of the hydroxymethyl 
dipeptide from the addition of Leu-OMe to the N-phthaloylamino epoxide (322) and 
the failed attempts at the coupling using triphenyl phosphine and DEAD, a different 
approach was adopted. This involved the protection of the primary alcohol of the diols
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(337:338) and then activation of the secondary alcohol, hopefully facilitating the 
formation of a C-N bond with Leu-OMe. The primary alcohol in the mixture of diols
275 276was protected by terr-butyldiphenylsilane ’ (TBDPS) to give alcohols (339) and
277(474) in 82-98% yield following a modified procedure of Corey et al. The reaction 
was complete in 30 minutes when carried out in DCM at 30°C. The diastereoisomers 






















X-ray structure of the protected diol (474) with the stereochemical configuration 2R,3R
Figure 81
The stereochemistry of all the following products were assigned from this single X-ray. 
The protected diol (474) from which the X-ray was obtained, was prepared from the 
racemic aldehyde (350). In summary, all the following material was racemic, 
olefination and then epoxidation (w-CPBA) gave the threo isomer (namely 2R,3S) as 
the major isomer (322) as described by Luly et al.l4~h Acid catalysed ring-opening 
gave the diols (337:338) as a mixture (91:9). These were inseparable, and their 
stereochemistry unknown due to the addition of water via a mixture of SnI and SN2 
mechanism. However, hydroxyl protection allowed for their separation and as they
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were crystalline, X-ray crystallography of the minor isomer showed it to be a racemic 
mixture of the isomer (2/?*,3R*) (474) in a 1:1 ratio, the X-ray was of the (2R,3R)
isomer.
A model synthesis was performed using the racemic diols (337) (2R*y3S*) and (338) 
(25*,35*) to establish the best way of producing the hydroxymethyl dipeptide (Figure 
82). The protected diols (339) (2/?*,35*) and (474) (25*,35*) were prepared, 
separated and the major isomer (339) was then successfully converted to the 
corresponding trifluoromethanesulfonate (475) following the procedure outlined by 
Effenburger et al.250




i. Leu-OM e.HCl, base, DCM or THF, RT or reflux.
Figure 82
The sulfonate (475) was typically isolated in good yield (73-89%). Degerbeck et al253 
showed that 1:)NHBoc2 when treated with /7-BuLi at lowered temperature converted a- 
trifluoromethanesulfonate ester (478) to the corresponding a-amino ester (479) in 
good yield. The additions went smoothly, with Walden inversion and no loss of 
enantiomeric purity, t Figure 83
t  We recognise the possibility that a double inversion my occur involving d isplacem ent of the triflate
group by one o f the phthaloyl carbonyl groups. Thus, producing the isom er of stereochem ical config­
uration (2/?,35,2’5) which could would correlate to the isom er produced via ring-opening o f the





i. 1 5 NHBoc2 , n-BuLi, THF, -78 to -30°C, 16 hrs, 92%.
Figure 83
In our hands, there was no coupling, instead the trifluoromethanesulfonate was 




i. THF, -78°C, 1 hr, 0°C, 2 hrs, RT, 14 hrs. 
Figure 84
As these conditions did not give us the dipeptide, we decided to displace the
250trifluoromethanesulfonate at room temperature as Effenberger et al had reported. 
At our first attempt, 40% of the trifluoromethanesulfonate (475) was coupled in 3 
days at room temperature with half the starting material recovered, Figure 85.




i. Leu-OMe.HCl, Et3 N, DCM, RT, 3 days. 
Figure 85
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IR showed the NH at 3388cm'1 and the ester at 1735cm'1 and the M++1 was at 601 
a.m.u. The proton n.m.r. was comparable with that of the hydroxymethyl dipeptide 
prepared from the epoxides (322) and (323), the MeAia was seen at 1.23ppm. We 
mistakenly decided to use MeOH as the solvent in another attempt to increase the yield 
of the coupling step. This resulted in aziridine (481) as the major product (see Figure 
86). However, small amounts of the desired product (476) and (477), the silylether 
(480) and the aziridine (481) were also observed by n.m.r. spectroscopy.
OM e PhtN O M ePhtN ‘










i. Leu-OM e.HCl. MeOH. K 2 C 0 3, RT. 1 day. 
Figure 86
Other variations in solvent, base, and temperature are shown in Table 22.
Table 22





DCM TEA 1 Oto RT 50% 40% 0%
THF DIPEA 2 reflux 2hrs 50% 31%
DCM DIPEA 2 reflux 12hrs 19% 56% 2.5%
DCM DIPEA 1 reflux 8 hrs 0% 36% 31%
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As this route proved successful for the racemic compounds, the enatiomerically pure 
dipeptide (476) was prepared in an analogous manner, Figure 87, in an overall yield of 
45% from the mixture of diols (337) and (338), (91:9).
TBDPSO'OTBDPS
(337) (338) (475) (476)
i. TBDPS-C1, DCM , 30°C, lAhr, 98% ; separate by chromatography; ii. Tf20 ,  pyridine, DCM , -23°C, 
89% ; iii. Leu-OM e, DIPEA, DCM , reflux, 12hrs, 56%.
Figure 87
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2.7 Deprotection and Amidation
2.7.1 Amidation
Genin et al had shown that esters could be clearly converted to their corresponding 
amides, using methylamine in MeOH. The mixture of the silyl protected 
hydroxymethyl dipeptide isosteres (476) and (477) were converted to the 
corresponding amides (482) and (483) using excess methylamine, in poor yield, 
typically about 20%, Figure 88. The n.m.r. spectra showed the presence of the NHMe 
a t  roughly 2.6ppm, two peaks were observed, showing that two rotamers were 
present. When this was attempted on the single isomer (476) the corresponding amide 
(482) was isolated in low yield (22%). IR of this compound showed that the NH peak 
was observed at 3407cm'1 and the methylamide at 1658cm'1, accurate mass 
spectroscopy showed that the M++l, was at 600.3254 a.m.u. for the expected 
600.3257. Proton n.m.r. showed the presence of the NMe as two rotamers at 2.62 and 
2.64ppm, the MeAia was observed at 1.33ppm all other peaks were comparable to 
those observed for the precursor (476), see Table 24.
TBDPSO' TBDPSO'TBDPSO'
i. M eNH2, MeOH, RT, 4 hrs, 22%.
Figure 88
2.7.2 Deprotection
Silyl protecting groups can be removed in a manner of ways. Tetrabutylammonium 
fluoride has been used extensively to this end. When we attempted this on the mixture 
of hydroxymethyl dipeptides (476) and (477), the corresponding alcohols (325) were 
isolated in good yield (63%). Mass spectroscopy showed that the mass ion was at 363
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a.m.u. in FAB (+) spectra. The proton n.m.r. spectra showed that the ester group was 
still intact, i.e. no lactonisation had occurred. Comparison of the proton n.m.r. data 
for the preparation of the hydroxymethyl dipeptide (325) from the protected diol 
(474), with that of the epoxide opened hydroxymethyl dipeptide (324), Table 23, 










§ h P P m
Isomer (324a) 
(2S,3R,2’S) 
$ h  P P m
3 4.67 4.89 4.97
2 4.00-4.10 3.89-3.95 4.09-4.18
1 3.60-3.70 3.49, 3.50 3.40-3.53
T 5.10 5.07 5.09
MeAja 1.41 1.52 1.54
OMe 3.78 3.74 3.77
M e L eu 1.03 1.03 1.03
MeLcu 0.91 0.91 0.91
Preparation o f the hydroxymethyl dipeptide from the corresponding protected 
precursor (482)
As has been discussed earlier, the hydroxymethyl dipeptides (324) and (325) can be 
prepared directly via ring-opening off the epoxides (322) and (323) by the protected 
amino ester (Leu-OMe). The alternative route which is discussed in this section, can 
produce both the (25’,35,2’5) and (2R,3S,2'S) configurations without contamination by 
minor impurities, such as the diols (337) and (338). The protected hydroxyl groups 
were successfully deprotected to give the desired dipeptides (322) in good yield 
(67%). IR and mass spectroscopy were consistent with the authentic product, 
however, the proton n.m.r. differed slightly as they were different diastereoisomers. 
Tables 23 and 24.
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Table 24 shows the comparative n.m.r. data for the backbone of selected dipeptides.
Table 24
Proton Isomer (322) Isomer (482) Isomer (476) Isomer (324b)
number (25,35,2'5) (25,35,2*5) (25,35,2*5) (2/? ,35,2*5)
Sh Ppm §h PPm $H PPm Sh ppm
3 4.94 5.17 5.20 4.89
2 4.14 4.17-4.26 4.01-4.17 3.89-3.95
1 3.51 3.63 3.50-3.60 3.49
3.63 3.83 3.84 3.50
2’ 4.83 5.05 5.02-5.12 5.07
3’and 4 ’ 1.58-1.95 1.65-1.83 1.68-1.98 1.70-1.99
MeAla 1.44 1.33 1.23 1.52
MeLeu 0.89 0.96 1.03 1.03




T B D PSO ' HO'
(476) (322)




The synthesis of (2/?,3S,2',S)-hydroxyrnethyl dipeptide (324b) has been described, from 
the readily available amino acid L-alanine, via the homochiral epoxides (322) and 
(323). Improved synthesis of the later has been developed, with the problem of the 
low yielding Wittig reaction being resolved and the epoxides being produced 
enantiomerically pure, suitable as precursors to a number of novel analogues (337), 
(404), and (409). The diols (337) and (338) were successfully converted to the single 
isomer hydroxymethyl dipeptide mimetic (332). Also described is the synthesis of the 
novel hydroxyethylamine (398) and the new family of transition-state analogues, 
aziridine (328). The preparation of another new family of transition-state analogues, 
the chloromethyl dipeptide mimetics of general structure (326) is also described.
The use of the /V,N-dibenzyl protecting group gave the (3-hydroxyphosphonate (440) 
and the Gordon type hydroxyethylamine (402).
PhtN'
(322) (323) (337) (404) (409)
X=OMe (324), NHMe (332) (398) (328)
CHAPTER THREE
3.0 M olecu lar  M od ellin g
3.1 Generation of the structures
The pseudotripeptide structures (485) and (486) were built using the molecular 
modelling suite INSIGHT.279 These were initially based upon the tripeptide Ac- 
Ala-Leu-NHMe (487). The carbonyl bond between Ala and Leu was replaced with 
the transition-state mimic unit CH2OH. For the purpose of human physiological 
studies the pseudotripeptides were protonated, carrying a charge of +1. The 
charges assigned by the program INSIGHT, gave an overall charge of +0.22. 
Using single point calculations the charges on each atom were amended so that the 
overall charge would be ca. +1. The program GAUSSIAN 92280 was used and the 
values around the quaternary nitrogen were derived so that the charge requirement 
could be reached. Similar values and not the exact values were used, Figure 90.
0.38 0.38 o  -0.38
0.22 NMe





As it is a popular belief that many peptides bind to enzymes in a p-tum 
conformation, we decided to calculate p-tums for these pseudotripeptides to see if 
they could be implicated here. With the results obtained from these calculations we 
wanted to find the lowest energy conformers. This was achieved by generating <j), 
\|/ maps which gave us the low energy regions corresponding to distinct confomers. 
From this data it was possible to find the lowest energy conformer suitable for 
docking into the active site of collagenase, with the view to finding a relative 
binding energy for the isomers (485) and (486).
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3.2 Calculating p-turn energies
The generated pseudotripeptides (485) and (486) had their torsion angles set to the 
required values for the specific p-tum type (see Table 25) and these conformations 
were minimised using Steepest descents for 100 iterations or until the maximum 
derivative was less the 5 Kcal/mol. Followed by a modified Newton-Raphson for 
1000 iterations or until the maximum derivative was less the 0.05 Kcal/mol., 
forcing the (j), \j/ angles. The conformations for the extended structures were 
choosen so that they corresponded to the energy minimas on the 0, \|/ maps. All 





I -60 -30 90 0
n -60 120 80 0





The minimised conformations of the three standard p-tums and the extended 
conformations of the Ac-Ala-Leu-NHMe (487) are shown in Table 26. Types I 
and HI are very similar and only differ in the (j) and \|/ of the Leu residue (by *30°) 
and are the most stable p-tum conformers. Type II is less stable since the Leu side 
chain is in close proximity to the Ala carbonyl. These results are in agreement with 






♦ CO ♦ ¥ energy rel. energy
I -58.9 -29.3 170.0 -87.1 -1.5 1.9 6.1
n -63.7 115.5 -168.5 74.7 -0.5 5.1 9.3
m -58.4 -28.7 167.0 -64.8 -28.3 1.8 6.0
extended -83.2 85.4 -173.3 -89.7 84.5 -4.2 0
Hydroxymethyl methylamine dipeptides
The p-tums and the extended conformations were all relatively less energetically 
favourable than those for the corresponding native dipeptides, due to the coulombic 
interactions with the charged nitrogen species and steric clashes between the Leu 
aliphatic side chain and the acetyl group on the N-terminal. Table 27, shows that 
the p-tum types I and HI are again the more stable, and type II was again less stable 
due to CH2OH moiety and the Leu aliphatic side chain van der Waals interactions. 
For both the isomers the p-tum type I exhibits steric interactions between the 
CH2OH moiety and the Ala and Leu aliphatic side groups. For type ID P-tums 
there is a clash between the acetyl carbonyl and the Leu residue.
These results are similar to those reported by Dauber-Osguthorpe et a/281 for the 
reduced pseudotripeptide Ac-Ala-\|/[CH2NH]-Ala-NHMe, where the p-tum type II 
conformation has the least favoured geometry and the p-tum types I and m  are of 
comparable energy. This suggests that the relative stabilities are due to the sp3 





Ala Leu Kca /mol
0 ¥ CO ♦ ¥ energy rel.
energy
isomer (2S,3S,2'S) (485)
I -60.6 -32.6 163.4 -88.9 -0.1 43.0 15.3
II -61.4 113.3 -170.9 80.2 0.7 51.1 23.4
III -59.7 -31.5 164.0 -59.7 -30.5 37.7 10.0
extended -78.2 70.4 127.1 -73.4 152.8 27.7 0
isomer (2R,3S,2'S) (486)
I -58.1 -28.3 173.7 -90.5 -0.9 42.4 15.1
II -61.9 120.5 -163.4 76.7 -0.5 53.7 26.4
III -58.5 -28.7 165.0 -63.1 -31.3 43.4 16.1
extended -84.4 61.6 -129.2 -81.7 136.5 27.3 0
I s o n a r  < 2 S ,3 S ,2 'S > I s o n a r  < 2 R ,3 S ,Z 'S >
Figure 91
Beta turn type I Beta turn type II Beta turn type III
Xus *tuL;T ?
Is o « « r < 2 S ,3 S ,2 'S >
i M M r  < 2 R ,3 S ,2 'S >
Figure 92
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3.3 <|>, \\t Maps
3.3.1 Generation of the (J), \\f maps
The pseudotripeptides (484) and (485) were minimised, to reduce any unfavourable 
clashes etc., using Steepest descents followed by a modified Newton-Raphson. The 
resultant structures was then used to generate (J), \\f maps. These give an insight into 
the conformational freedom available to the molecule. This process involves 
setting the <|> and \j/ angles to pre-set values and forcing these to remain constant 
whilst the rest of the molecule is then minimised. This follows the methodology 
described by Dauber-Osguthorpe et a/.281
3.3.2 Methodology
The strategy was to explore the complete conformational space available to the 
reduced peptide mimetic and use these to examine the free energy of binding with 
collagenase. <|>, \j/ Maps were performed upon the charged and the uncharged 
transition-state mimetic (484) and (485) in an attempt to elucidate the preferred 
conformations.
The molecule was spilt into two portions, the Ala residue (488) and the Leu residue 
(489), Figure 93.




The <|>, \|/ energy map of the Ala residue (488) indicates two main low energy 
regions. One to the bottom right of the map at <(), 30° to 80°, \|/, -50° to -80° and 
the lowest energy conformation is seen in the top left region of the map at <|), -60° 
to -100°, V|/, 30° to 80°. These are low in energy due to H-bonding between the H- 
N+ and the acetyl carbonyl (distance ~2.0A). The rotational energy barrier between 
these two conformationally favoured regions is 10-12 Kcal/mol. The lowest region 
is represented by a 1 and the next lowest a 2 etc.
The <|), \|/ energy map of the Leu residue (489) indicates two distinct low energy 
regions on the left hand side of the map at <|), -80° to -100°, \|/, -80° to -120° and the 
lowest energy conformation is seen in the top left region of the map at <|), -60° to - 
120°, \|/, 120° to 160°. The rotational energy barrier between the two 
conformationally favoured regions is 22-24 Kcal/mol. Again the lowest region is 
represented by an 1 and the next lowest a 2 etc.
Uncharged species
The <|>, \|f energy map of the Ala residue (488) uncharged unit is similar to the 
charged, but here the lowest conformation no longer exists at <J>, 60°, \j/, -70° 
instead a new lowest conformation is observed at <|>, -50° to -80°, \j/, -70° to -120°, 
this is due to the CH2OH proton H-bonding to the acetyl carbonyl. The other low 
energy conformer is still seen <|), -60° to -100°, \|/, 30° to 80° where the Ala methyl 
lies gauche to the CH2OH moiety and is anti-periplanar to the backbone. The 
rotational energy barrier between these two conformationally favoured regions is 
now 18 Kcal/mol passing through a low energy region on the map at <|>, 50° to 70°, 
\j/,-100° to -160°.
The <|>, V|/ energy map of the Leu residue (489) uncharged is almost unchanged both
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the distinct low energy regions have expanded and the lowest region now lies to the 
bottom left hand side of the map at <j), -50° to -110°, y , -30° to -100° and the other 
low energy region at the top left hand side region of the map at <j), -40° to -150°, y , 
90° to 150°. The rotational energy barrier between the two conformationally 
favoured regions is now 6 Kcal/mol.
Figure 94. <J),y map of the 
charged Ala residue (488), 
the global minima is 









Figure 95. <j),y map of the
charged Leu residue (489), 
the global minima is 
represented by 1, contours at 
2 kcal/mol.
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-1*0 -100 0 100
phi
Figure 96. <j),\|/ map of the uncharged Ala residue (488), the global minima is 
represented by 1, contours at 2 kcal/mol.
psi
Figure 97. <j),\}/ map of the uncharged Leu residue (489), the global minima is 
represented by 1, contours at 2 kcal/mol.
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3.4 Generation of a Model for Ligand binding with Collagenase
Collagenase is a zinc-dependent endoproteinase and is a member of the matrix 
metalloproteinase (MMP)282*283’284 family of enzymes. The MMPs are responsible 
for cleaving extracellular matrix components during normal connective tissue 
remodelling and are regulated by a wide range of factors, such as growth factors, 
hormones and the tissue inhibitor of the metalloproteinase (TIMP) family of 
proteins.282’283
The MMPs contain three regions: i. the NH2 terminal propeptide (-80  residues) 
that contains a free cysteine thought to maintain enzyme latency by ligating to the 
catalytic zinc in the active site; ii. the catalytic domain which contains a zinc- and 
calcium-binding catalytic domain (-180 residues); and iii. a C 02H terminal 
domain (-200 residues) that may be involved in matrix binding282 and alignment 
of the catalytic domain at the site of enzymatic cleavage.283 Catalytic domains of 
the MMPs share a high degree of sequence homology. Early models of MMP's 
catalytic domains were based on the bacterial endoproteinase, thermolysin.285
Lovejoy et a/286*287 have discussed in detail the sequence homology of the active 
sites of collagenase and thermolysin. Both share three ligating ligands and a 
catalytic Glu. For collagenase there are three zinc-ligating residues (His 218, His 
222 and His 228) and a catalytic zinc which share distinct homologyJ with 
thermolysin (His 142, His 146 and Glu 166). Lovejoy et a/286,287 concluded that 
the Glu 143 (thermolysin) and Glu 219 (collagenase) act as a general base that 
together with the catalytic zinc, co-ordinates water molecules near the carbonyl of 
the scissile bond. Also, since collagenase is ligated by three neutral histidines 
rather than two His and a negatively charged Glu (as in thermolysin), collagenase 
catalytic zinc is predicted to have a higher net positive charge and a greater ability 
to stabilise the negative charge present in the transition-state than thermolysin in 
the catalytic zinc.
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There are several crystal structures for 
thermolysin available on the Brookhaven 
Protein Database. These include bound 
phosporamidates, e.g. Leucinyl phospor- 
amidate (490), which are believed to 
behave as transition-state analogues of 
the natural substrate, Figure 98.
Due to the high degree of homology between the two active sites, we were able to 
use the phosporamidate binding positions as a template for the binding position of 
the reduced peptide mimetic (484) to collagenase.
The co-ordinates for collagenase protein were supplied by Glaxo Group Research. 
We were given the data for a 10A zone around the catalytic zinc.
3.4.1 Docking of the reduced peptide analogue (484) into Collagenase
The active sites of thermolysin and collagenase structures were superimposed using 
the metal centres, two histidines and the catalytic Glu. The natural peptide Ac-Ala- 
Leu-NHMe (487) was then manually docked into the active site and the 
conformation altered to fit that occupied by the phosporamidate in thermolysin. 
The natural peptide was minimised whilst inside the active site of collagenase 
which was kept fixed. The resultant natural peptide backbone was used for the 
conformation of the reduced peptide mimetic (484). The torsion angles for the 
minimised structure were (j)^ -161°, i}/^ -82°, <|)leu -39° and \|/leu -85°. This 
conformation lies inside a low energy region on both the Ala residue (488) and Leu 
residue (489) (j), \j/ energy maps, which are 8 Kcal/mol above the global minimum 
for the charged species. However, for the uncharged species, the Ala residue lies in 
the second lowest energy region, and the Leu residue conformation lies at the 











3.4.2 AG of Binding
The vibrational frequencies of a molecule are the dynamic properties. It is possible 
to calculate the harmonic vibrational frequencies of a molecule by considering 
infinitesimal displacements about a harmonic minimum. These may then be used 
to derive the vibrational free energy. It is possible to obtain information about the 
entropy and related thermodynamic properties of a conformation of a molecule 
from the vibrational frequencies. Using the vibrational and thermodynamic 
equations detailed by Dauber-Osguthorpe et a/288 the free energy, AG, of the 
isolated inhibitor and the bound, to the enzyme can be calculated. The reduced 
peptide mimetic (484) was minimised whilst in the active site. The active site was 
kept fixed, hence interactions between the mimetic (484) and the protein were 
included in the calculations, but the protein itself did not move.
The inhibitor was then removed and minimised again as the isolated molecule. 
The vibrational and thermodynamic data were calculated for the inhibitors both 
bound and isolated. From the resultant information, AS, AH, the AG for each was 





Sffans = 2.303 ( I log10W + \  log10T - 0.5058)
Srot = 2.303 [ \  log10(1037ABC) + * log10T - log10o  -1.5072]
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where y  = 47 if the moment of inertia are evaluated in S.I. or M.K.S. units 
ABC = the principle moments of inertia of non-linear molecules 
a  = symmetry value (in this case a  = 1 and therefore there is no contrabution)
Free Energy
AG = AH - TAS
3.4.3 Results
When the charged inhibitor was used, the coulombic interactions were so great that 
the inhibitor was pushed out of the active site, resulting in the acetyl carbonyl 
binding to the catalytic zinc. When the uncharged inhibitor was used, this did not 
occur and the following results are shown in Table 28.
The energetics of binding are summarised in Table 28. A detailed summary of the 
procedure is given in the paper by Dauber-Osguthorpe et a/.281 The total 
intramolecular energy (valence and nonbond) of the pseudotripeptide is 8.5 
kcal/mol, while the corresponding energy for the bound inhibitor is 31.6 kcal/mol. 
The total strain energy of binding is therefore 23.5 kcal/mol, reflecting the 
conformational constraints imposed by the enzyme on the inhibitor. However, this 
is more than compensated by the binding energy of -83.4 kcal/mol. A comparison 
of the energies and entropies are also shown in Table 28. The total change in free 
energy is »16kcal/mol which is due to the restriction of the inhibitor motion by the 
enzyme.
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Table 28. Energy and entropy of pseudotripeptide (485), isolated and bound in the 
active site of human Fibroblast collagenase collagenase. (Energies are in kcal/mol)





Out of plane 0.0 0.9
Cross terms 1.1 1.3




Total nonbond -4.6 0.7
Total intramolecular 8.1 31.6
Vibrational
Enthalpy 261.7 263.2
T x entropy 26.4 20.3
Free energy 235.3 242.9
Rotational
Enthalpy 0.9 -
T x entropy 3.9 -
Free energy -3.0 _
Translational
Enthalpy 0.9 -
T x entropy 6.3 -
Free energy -5.4 _
Total
Enthalpy 263.5 263.2
T x entropy 36.6 20.3
Free energy 226.9 242.9
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EXPERIMENTAL
4.1 Instrumentation and Experimental Techniques
4.1.1 Solvents and Reagents
All solvents were dried and distilled before use. Petrol refers to petroleum ether 
that boils in the range 60-80°C. Tetrahydrofuran and ether (refers to diethyl ether) 
were pre-dried over sodium wire and then refluxed over sodium benzophenone 
ketyl under a nitrogen atmosphere until anhydrous. These were redistilled 
immediately prior to use. Dichloromethane, dimethyl sulfoxide and triethylamine 
were distilled from calcium hydride. EtOAc was distilled from potassium 
carbonate. Methanol was distilled using the Lund and Bjerrum method.289 All 
other solvents and reagents were purified using the procedures described in 
Purification o f Laboratory Chemicals.29°
4.1.2 Chromatography
Thin layer chromatography (t.l.c.) was used extensively as a qualitative guide during 
reactions and for assessing the purity o f compounds. Whatman silica gel F254 
(0.25mm) sheets containing fluorescent indicator were used for this purpose. 
Components were visualised by illumination under sort wavelength (254nm) and 
ultraviolet light where possible. Plates were developed by treatment with 0.5% 
(w/v) aqueous solution o f potassium permanganate, 7% (w/v) methanolic solution 
of phosphonmolybdic acid, 0.3% (w/v) ethanolic solution o f ninhydrin, 4% (w/v) 
ethanolic solution o f 2,4-dinitrophenylhydrazine and 3% (v/v) ethanolic solution of  
anisaldehyde, followed by warming o f the t.l.c. plate.
Medium pressure flash chromatography was routinely employed using Amicon 
Matrex 60A silica gel or alumina oxide, activated, neutral. Columns were packed 
as a slurry in the eluting solvent and the material to be chromatographed was
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introduced directly as a solution in the eluting solvent or pre-absorbed onto the 
column support and then applied as a thin layer to the top o f the column.
4.1.3 General
Glassware used for moisture sensitive reactions was heated in an oven at ca. 80°C 
and then allowed to cool in a desiccator over CaCl2 and blue silca. Flasks and 
stirrer bars were additionally flame dried either under vacuum or a stream o f dry 
nitrogen prior to use. Solvents were evaporated with a Buchi rotary evaporator 
using a water aspirator or vacuum pump as required, with the water bath 
temperature <35°C to avoid unnecessary heating.
4.1.4 Analysis and Spectroscopy
Melting points (m.p.) were determined using commercially available apparatus 
(Electrothermal Mk HI, Gallenkamp and liquid thermalconducting melting point 
apparatus buchi 510) and were uncorrected. Elemental analysis was performed 
using a Carlo Erba 1106 Elemental analyser. Optical rotations were measured using 
a Perkin-Elmer 141 polarimeter with concentrations (c) expressed in g/100cm3.
Infra-red spectra were recorded on a Perkin-Elmer 1600 series FT and 1310 infra­
red spectrophotometer and peaks are reported (vmax) in wavenumbers cm’1. 
Samples were prepared as liquid films, nujol mulls or CHC13 solutions.
Proton magnetic resonance spectra were recorded on a Joel JNM GX FT 270 
(270MHz) spectrometer or on a Joel JNM GX FT 400 (400MHz) spectrometer 
where indicated . Carbon-13 magnetic resonance spectra were recorded on a Joel 
JNM GX FT 270 spectrometer operating at 67.8 MHz and using 90 and 135 DEPT 
pulse sequences to aid multiplicity determination. Chemical shifts (8) are expressed 
in parts per million downfield o f tetramethylsilane. The multiplicities o f the 
resonances are denoted by s (singlet), d (doublet), t (triplet), q (quartet) and m
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(multiplet) and the coupling constant values are expressed in Hz. The abbreviation 
br (broadened) is used to indicate significant broadening, whether due to rapid 
exchange or unresolved fine coupling. 2D homonuclear shift correlated 
spectroscopy (COSY) and nuclear Overhatiser effect spectroscopy (nOesy) were 
used to confirm proton assignments and conformational orientation when required.
Mass spectra were recorded using a VG Analytical 7070E instrument with a VG 
2000 data system. Electron (E.I.) spectra were produced using an ionising potential 
o f 70 eV. Chemical ionisation (C.I.) was employed using isobutane as the reagent 
gas, although ammonia was also used where indicated. Accurate mass experiments 
were run on HP-engine/Autospec Q at Glaxo Group Research, Greenford.
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4.2 Experimental Procedure
4.2.1 Phthaloyl protected compounds 
2(iS)-Aminopropan-l-oI (344)
To a stirred and cooled 0°C suspension of alanine (0.3g, 3.37mmol) in THF (5ml) 
under N2, was added 1M BH3-THF (10.1ml, 10. Immol). The reaction mixture was 
allowed to attain room temperature and stirred for 6 hours. After cooling to 0°C, 
3M NaOH (2.02ml, 6.06mmol) was added dropwise to control the effervescence. 
The suspension was allowed to warm to room temperature and stirred for a further 
7 hours. The pH was then increased to 11 by addition of NaOH pellets and the 
solution was saturated with K2C 03 until two phases were observed. The aqueous 
phase was extracted with ether (2 x 10ml), the organics were combined, dried 
(Na2S04) and then concentrated in vacuo to give a crude colourless oil. This was 
flash chromatographed on silica, eluting with petrol :EtOAc (25:75) to yield 
aminoalcohol (344) (0.16g, 63%) as a colourless oil, Rf [petrol:EtOAc (25:75)] 
0.62; b.p. 75°C (11 mm Hg); v ^ /c n r 1 3250s (OH and NH), 1600s (C-O), 1450s 
as (Me), 1395 and 1170; 5h(270 MHz, CDC13) 1.24 (3H, d, J  6.6, Me), 2.80 (1H, 
br s, OH), 3.01 (1H, m, CH), 3.51 (1H, dd, J  11.4 and 7.2, CH2OH), 3.89 (1H, dd, 
J 11.6 and 3.3, CH2OH) and 4.38 (1H, br s, NH2) and 4.55 (1H, br s, NH2).
. . XH2 N C02' \(H2B)2N ch2o /3 b h2n ch2o h
(345) (344)
(2*S)-PhthaIoylaminopropan-l-ol (346)
Phthalic anhydride (1.99g, 13.45mmol) was added to 2-aminopropan-l-ol (344) 
(l.Olg, 13.45mmol) under N2. The mixture was refluxed at 140-150°C for 2.5
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hours. After cooling the reaction mixture was dissolved in DCM (50ml), washed 
with water (2 x 25ml), dried (Na2S04) and concentrated in vacuo to give a 
colourless crystalline solid (2.45g). This was flash chromatographed on silica, 
eluting with petrol:EtOAc (80:20), gradient up to petrol:EtOAc (50:50) to yield 
(346) (1.53g, 55%) as colourless crystals, Rf{petrol:EtOAc (50:50)] 0.29; m.p. 87° 
C (lit.,145a 86-87°C from acetone : hexane); v ^ /c n r 1 3485s (OH) and 1687s 
(C=0); 8h(270 MHz, CDC13) 1.41 (3H, d, J  7.2, Me), 2.80 (1H, br s, OH), 3.87




Phthalic anhydride (32.91g, 220mmol) was added to alanine (20.lg, 226mmol). 
The mixture was heated to 120°C and stirred for 7 hours. After cooling the 
colourless solid was dissolved in EtOAc (500ml), washed with water (3 x 500ml) to 
remove any remaining alanine. The organics were dried (MgS04) and concentrated 
in vacuo to yield the protected amino acid (348) in quantitative yield as a colourless
solid (46.38g), Rf [DCM:MeOH (90:10)] 0.65; m.p. 148-150°C (lit.,145a 150-151° 
C from water); [oc]& -24.7 (c 1.25 in EtOH) [lit.,145a -25.12 (c 8.12 in EtOH)];
(1H, dd, J1 .9  and 3.9, Ctf2OH), 4.03 (1H, dd, J 7 .9  and 3.9, Ctf2OH), 4.51 (1H,
ch2oh
(344) (346)
5h(270 MHz, CDC13) 1.72 (3H, d, J7.2 , Me), 5.05 (1H, q, J7 .2 , CH), 7.74 (2H, 
m, phthaloyl), 7.86 (2H, m, phthaloyl), 11.35 (1H, br s, C 02H).
(345) (348)
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The reaction was also carried out at 170°C for 2 hours and worked up as before to 
yield the protected amino acid in quantitative yield as a colourless solid, Rf 
[DCM:MeOH (90:10)] 0.65; m.p. 147-149°C (lit,145a 150-151°C from water); 
[a ]^  -5.6 (c 0.753 in EtOH) [lit.,145a -25.12 (c 8.12 in EtOH)].
The reaction was also carried out at 140°C for 6 hours and worked up as before to 
yield the protected amino acid in quantitative yield as a colourless solid, Rf 
[DCM:MeOH (90:10)] 0.65; m.p. 148-149°C (lit.,145a 150-151°C from water); 
[ o ®  -9 (c 1.008 in EtOH) [lit.,145a -25.12 (c 8.12 in EtOH)].
The reaction was also carried out at 130°C for 5 hours and worked up as before to 
yield the protected amino acid in quantitative yield as a colourless solid, Rf 
[DCM:MeOH (90:10)] 0.65; m.p. 148-149°C (lit.,145a 150-151°C from water); 
[a]& -23.3 («c 1.218 in EtOH) [lit.,145a -25.12 (c 8.12 in EtOH)].
Method B
To a solution o f alanine (30.55g, 343mmol) and phthalic anhydride (50.36g, 
340mmol) in toluene was added triethylamine (4.8ml, 34mmol). The reaction 
mixture was refluxed for 3 hours removing the water with a Dean-Stark apparatus 
(ca. 6ml). Water (500ml) was poured into the reaction mixture and the product 
was allowed to crystallise. The crude product was filtered and dissolved in EtOAc 
(1000ml), washed with water (3 x 700ml), dried (M gS04) and concentrated in 
vacuo to yield the protected amino acid (348) (70.2g, 93%) as colourless crystals; 
Rf [DCM:MeOH (90:10)] 0.65; m.p. 142-145°C (lit.,152 150-151°C from water); 
[0 ®  -24.3 (c 2.63 in EtOH) [lit.,152 -24.2 (c 2.6 in EtOH)].
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Preparation of (2*S)-phthaloylaminopropan-l-oI (346) by reduction of (348) 
Method A
To a cooled (0°C) solution of the protected amino acid (348) (19.73g, 90mmol) in 
THF (200ml) was added 1M BH3-THF (100ml, lOOmmol). The reaction mixture 
was allowed to stir at room temperature for 2 days before quenching with water 
(300ml), extracted with EtOAc (2 x 300ml), the organics were washed with 
saturated NaHC03 (2 x 200ml), brine (200ml), dried (MgS04) and concentrated in 
vacuo. The crude product was flash chromatographed on silica, eluting with 
petrohEtOAc (40:60) to yield the alcohol (346) (16.6g, 88%) as colourless crystals; 
Rf [petrol:EtOAc (75:25)] 0.75; m.p. 87°C (EtOAc) (lit.,145a 86-87°C from acetone 
: hexane); [a]& +12.5 (c 4.1 in CHC13) [lit.,145a +13.7 (c 4.2 in CHC13)].
Method B
To the protected amino acid (348) (19.73g, 90mmol) in THF (200ml) was added 
1M BH3-THF (100ml, lOOmmol). The reaction mixture was stirred at 40°C for 2 
hours before quenching with water (300ml) and extracted with EtOAc (200ml). 
The organics were washed with saturated NaHC03 (2 x 200ml), brine (200ml), 
dried (MgS04) and concentrated in vacuo to give 17.6g of the crude product. This 
was flash chromatographed on silica, eluting with petrohEtOAc (75:25) to yield the 
alcohol (346) (14.4g, 78%) as colourless crystals; Rf [petrohEtOAc (50:50)] 0.29; 





To a cooled (0°C) solution o f the protected amino acid (348) (23.9g, llOmmol) in 
THF (150ml) was added 2M BMS (60ml, 120mmol). The reaction mixture was 
allowed to stir at room temperature for 2  days before quenching with water (300ml) 
and extracting with EtOAc (200ml). The organics were washed with saturated 
NaHC03 (2 x 200ml), brine (200ml), dried (MgS04) and concentrated in vacuo. 
The crude product was flash chromatographed on silica, eluting with petrohEtOAc 
(40:60) to yield the alcohol (346) (14.2g, 63%) as colourless crystals; Rf 
[petrohEtOAc (75:25)] 0.75; m.p. 87°C (EtOAc) (lit.,145a 86-87°C from acetone : 
hexane).
(2*S)-Phthaloylaminopropan-l-al (350)
Method A :- General procedure
To a solution o f alcohol (346) (1.5g, 7.3mmol) in DCM (80ml) under N2  was added 
PCC (3.2g, 14.6mmol). The reaction mixture was refluxed for 3% hours. After 
cooling, the reaction mixture was diluted with ether (55ml) and filtered through 
activated charcoal and celite. The filtrate was concentrated in vacuo and flash 
chromatographed through a short column eluting with EtOAc to afford aldehyde 
(350) (1.15g, 78%) as a colourless solid, m.p. 112°C (lit.,145a 112-113°C from 
acetone : hexane): Rf [petrohEtOAc (70:30)] 0.39-0.25; [a]Jjj9 0 (c 2.74 in CgHg)
[lit.,145a -29.9 (c 2.16 in C^Hg)]; (Found: C, 64.10; H, 4.15; N, 6.74, calc, for 
Cn H9N 0 3 : C, 65.02; H, 4.46; N, 6.89%); v ^ /c n r 1 1600, 1450, 1395, 1170; 
6h (270 MHz, CDC13) 1.62 (3H, d, J 7 .3 , Me), 4.76 (1H, q, J  7.3, CH), 7.77 (2H, 
m, phthaloyl), 7.89 (2H, m, phthaloyl), 9.70 (1H, s, CHO); 8 C (67.8 MHz, CDC13) 
12.90 (Me), 54.05 (CHMe), 123.61 (tw-C), 131.83 (CC=0), 134.40 (o-C), 167.58 









10-12M BMS (7.9ml, 79mmol) was added dropwise to a solution of the amino acid
(346) (16.8g, 79mmol) in THF. After 4ml had been added the reaction mixture was 
heated to 40°C and the addition continued. The reaction was allowed to stir for 1 
hour before cooling and concentrating in vacuo to give the crude trialkoxyboroxine 
(355). This was dissolved in DCM (30ml), added to a vigorously stirred suspension 
of PCC (18.75g, 87mmol) in DCM (150ml) and refluxed for 4 hours. After 
cooling, the reaction mixture was diluted with ether (300ml) and filtered through 
activated charcoal and celite. The filtrate was concentrated in vacuo and flash 
chromatographed through a short column, eluting with EtOAc, afforded aldehyde 
(350) (7.0g, 48%) as a colourless solid, m.p. 112°C (lit.,145a 112-113°C from 
acetone : hexane): Rf [petrohEtOAc (70:30)] 0.39-0.25.
Method C
To a solution of alcohol (346) (2.83g, 13.8mmol) in DCM (60ml) under N2 was 
added celite (7.5g) and PCC (7.43g, 34.5mmol). After refluxing for 3 hours the 
reaction mixture was allowed to cooled before being diluted with ether (300ml). 
This was then filtered through Florisil (300g) and the residue washed with ether (4 
x 200ml). The combined organics were concentrated in vacuo and recrystallised 
from EtOAc : hexane to afford aldehyde (350) (0.733g, 25%) as a colourless solid,




m.p. 110°C (lit.,145a 112-113°C acetone:hexane): Rf [petrohEtOAc (70:30)] 0.39- 
0.25; [a]^  0 (c 2.74 in C ^ )  [lit.,145a -29.9 (c 2.16 in C ^ ) ] .
Method D
To a solution of alcohol (346) (7.03g, 34.3mmol) in DCM (200ml) under N2 was 
added alumina (45g) and PCC (21g, 97mmol). After stirring vigorously at 60°C for 
30 minutes the reaction mixture was allowed to cool before being diluted with ether 
(300ml). This was then filtered through alumina (300g) and the residue was washed 
with ether (4 x 200ml), the combined organics were concentrated in vacuo and flash 
chromatographed, eluting with petrohEtOAc (35:65) to afford aldehyde (350) 
(6.2g, 90%) as a colourless solid, m.p. 112°C (lit.,145a 112-113°C from 











7 none 5 78 24 21
25 none 5 50 24 21
94 none 5 15 24 21
15 none 2 (70 ) 5 60
20 none 2 46 2 60
97 alumina 2.8 90 2Vi 60
29 celite 2 (94) 3 60
39 celite 2 75 3 60
Method E
A solution of oxalyl chloride (3.4ml, 37mmol) in DCM (75ml) was cooled to -78°C. 
To this was added DMSO (5.72ml, 74mmol) in DCM (20ml) at such a rate as to
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maintain the temperature between -60 to -50°C. The reaction was then stirred for 2 
minutes before the addition o f the alcohol (346) (7.0g, 34mmol) in DCM (35ml). 
The reaction mixture was then stirred for 20 minutes at -78°C before the addition of 
triethylamine (23.8ml, 170mmol). After 5 minutes the reaction mixture was 
allowed to attain room temperature and then quenched with water (2 0 ml), washed 
with 1% HC1 (100ml), water (100ml), 5% Na2 C 0 3  (100ml), water (100ml) and 
concentrated in vacuo to afford aldehyde (350) (6.2g, 90%) as a colourless solid, 
m.p. 111-112°C (lit.,145a 112-113°C from acetone:hexane); Rf [petrohEtOAc 
(70:30)] 0.39-0.25.
Method F
To a solution o f alcohol (346) (0.265g, 1.29mmol) in DCM (2.6ml) under N 2  was 
added NMO (0.227g, 1.94mmol), powdered 4A molecular sieves and TPAP (25mg, 
0.07mmol). After stirring at room temperature for 2 hours, starting material still 
remained and by-products were also beginning to form. The reaction mixture was 
flash chromatographed, eluting with petrohether (65:35) to afford the aldehyde 
(350) (0.93g, 35%) as a colourless solid, m.p. 112°C (lit.?145a 112-113°C from 
acetone:hexane): Rf [petrohEtOAc (70:30)] 0.39-0.25. Alcohol (346) was also 
recovered (0.138g, 52%).
Method G
To a solution o f alcohol (346) (1.3 l lg , 6.4mmol) in DMSO (20ml) under N 2  was 
added pyridine-S03 (3.06g, 19.2mmol) in DMSO (2 0 ml) and diisopropylethylamine 
(DIPEA) (7.25ml, 41.6mmol). After stirring at room temperature for 2 hours a 
negligible amount o f the aldehyde was formed. The reaction mixture was diluted 
with ether ( 1 0 0 ml) was with 1 % HC1 (80ml), water ( 1 0 0 ml), the aqueous phase was 
back extracted with ether (150ml). The organics were combined, washed with sat. 
NaHC03  (80ml), water (2 x 80ml), brine (80ml), dried (M gS04) and concentrated
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in vacuo to give alcohol (346) and aldehyde (350) (95:5) (1.22g, 93%) as a 
colourless solid.
Method H
To a cooled to -63°C solution of oxalyl chloride (1.43ml, 17.0mmol) in DCM 
(15ml) was added DMSO (1.76ml, 22.8mmol) in DCM (10ml) over a 15 minute 
period. To this was added the alcohol (346) (2.34g, 11.4mmol) in DCM (80ml) 
over 15 minutes. The reaction mixture was then stirred for 10 minutes at -63°C 
before the addition of DIPEA (7.94ml, 45.56mmol) over 15 minutes. The reaction 
mixture was allowed to stir for 15 minutes before being quenched with water 
(1.5ml/mmol). The reaction mixture was then added to pentane (150ml) and 
washed with 1% HC1 (80ml), water (100ml) and the aqueous phase back extracted 
with ether (150ml). The organics were combined, washed with sat. NaHC03 
(80ml), water (2 x 80ml), brine (80ml), dried (MgS04) and concentrated in vacuo 
to afford aldehyde (350) (1.66g, 72%) as a colourless solid, m.p. 111°C (lit.,145a 
112-113°C from acetone:hexane); Rf [petrohEtOAc (70:30)] 0.39-0.25; [a]JJ9 -
38.6 (c 2.778 in C ^ )  [lit.,145a -29.9 (c 2.16 in C ^ ) ] .




To a stirred suspension of methyltriphenylphosphonium bromide (0.854g, 
2.39mmol) in THF (10ml) at -78°C, was added 1.6M w-BuLi (0.91ml, 2.28mmol) 
dropwise over the course of 5 minutes, upon which a bright yellow colour of the 
ylide was observed. The reaction mixture was then allowed to warm to room
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temperature before stirring for 30 minutes. After this time the reaction mixture was 
cooled to -78°C before it was added to a cooled solution of the aldehyde (350) 
(0.442g, 2.17mmol) in THF (10ml) over the course of 30 minutes. A dark red- 
brown solution formed immediately on addition. The reaction mixture was allowed 
to warm to room temperature and stirred for 30 minutes. Over this period the dark 
colour slowly turned pale orange-yellow. Water (30ml) was added to the reaction, 
and the aqueous phase extracted with EtOAc (2 x 30ml). The organics were dried 
(MgS04) and concentrated in vacuo to give 0.44g of the crude product. This was 
flash chromatographed on silica, eluting with petrohEtOAc (90:10) to give the 
alkene (376) (0.17g, 38%); Rf [petrohEtOAc (95:5)] 0.31; m.p. 84°C (recrystallised 
from cyclohexane); [<x]g9 +25.4 (c 3.2 in CHC13); (Found: C, 71.40; H, 5.77; N,
6.63, calc, for C12Hn N 0 2 : C, 71.63; H, 5.51; N, 6.96%); v ^ c n r 1 1772s (C=0), 
1752s (C=0), 1722s (C=0), 1461s (C=C) and 1377; 5^270 MHz, CDC13) 1.58 
(3H, d, J  7.1, Me), 4.94 (1H, qd, J  7.3 and 6.3, C//Me), 5.17 (1H, dt, J  10.3 and 
1.4, C/m ), 5.22 (1H, dt, J  17.2 and 1.4, CH#), 6.20 (1H, ddd, J  16.9, 10.3 and
6.6, C//=CH2), 7.70 (2H, m, phthaloyl) and 7.82 (2H, m, phthaloyl); 8C (67.8 
MHz, CDC13) 18.16 (Me), 48.85 (CHMe), 116.31 (CH=CH2), 123.06 (m-C), 
131.95 (CC=0), 133.83 (o-C), 136.75 (CH=CH2) and 167.9 (NC=0); m/z (70 eV) 





To 60% NaH in mineral oil (1.084g, 21.7mmol) was added DMSO (5ml, 
21.7mmol) the solution was heated to 75-80°C for 45 minutes. The resulting 
solution of methylsulfinyl carbanion was cooled to 0°C and 
methyltriphenylphosphonium bromide (10.77g, 29.6mmol) in DMSO (30ml) was
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added. The resulting ylide was stirred for 10 minutes before being added to 
aldehyde (350) (4.0g, 19.7mmol) in THF (20ml). This was stirred at room 
temperature for 3 hours before quenching with water (200ml) and extracting with 
ether (5 x 100ml). The organics were combined and washed with brine (100ml), 
dried (Na2S04) and concentrated in vacuo. The crude product was flash 
chromatographed on silica, eluting with petrohEtOAc (90:10) to give alkene (376) 
( l.lg , 26%) as a colourless solid, Rf [petrohEtOAc (95:5)] 0.31; m.p. 84°C 
(recrystallised from cyclohexane); [a]§9 0 (c 2.2 in CHC13).
Method C
The alkene (376) was prepared in an analogous manner to method B using DMSO 
instead of THF. This gave alkene (376) (27%) as a colourless solid, Rf 
[petrohEtOAc (95:5)] 0.31; m.p. 84°C (recrystallised from cyclohexane); [oc]§9 0
(c 2.2 in CHC13).
Method D
To a stirred and cooled suspension (-20°C) of methyldiethylphosphonate (0.143ml, 
0.98mmol) and 80% NaH (0.03g, 0.98mmol) in toluene (5ml) under N2 was added 
a solution of the aldehyde (350) (0.2g, 0.98mmol) in toluene (5ml). The reaction 
was stirred for 30 minutes before being refluxed for 1 hour. After this time no 
desired product was observed by t.l.c. but many by-products were formed. The 






To a stirred and cooled (0°C) suspension o f methyltriphenylphosphonium bromide 
(9.9g, 27.7mmol) in THF (80ml), was added 1.0M NaHMDS (27.5ml, 27.5mmol) 
dropwise over 5 minutes upon which a bright yellow colour o f the ylide was 
observed. The reaction mixture was then allowed to warm to room temperature 
and stirred for 15 minutes. The ylide was added to a cooled solution (0°C) o f the 
aldehyde (350) (1.126g, 5.54mmol) in THF (20ml) over 30 minutes. The reaction 
mixture was then allowed to warm to room temperature and stirred for 2  hours. 
Water (100ml) was added to the reaction, and the aqueous phase extracted with 
EtOAc (2 x 80ml). The organics were dried (M gS04) and concentrated in vacuo to 
give the crude product which was flash chromatographed on silica, eluting with 
petrohEtOAc (90:10) to give the alkene (376) (0.061g, 5%); Rf [petrohEtOAc 
(95:5)] 0.31; m.p. 84°C (recrystallised from cyclohexane).
Method F
To a stirred and cooled (-78°C) suspension o f methyltriphenylphosphonium 
bromide (0.936g, 2.6mmol) in toluene (20ml), was added 1.6M w-BuLi (1.64ml, 
2.6mmol) over 5 minutes upon which a bright yellow colour o f the ylide was 
observed. The reaction mixture was then allowed to warm to room temperature 
before stirring for 15 minutes. After this time the reaction mixture was cooled to - 
78°C before it was added to a cooled solution o f the aldehyde (350) (0.442g, 
2.17mmol) in THF (10ml) over 30 minutes. A dark red-brown solution formed 
immediately on addition. The reaction mixture was allowed to warm to room 
temperature and stirred for 30 minutes. Over this period the dark colour slowly 
turned pale orange-yellow. Water (30ml) was added to the reaction, and the 
aqueous phase extracted with EtOAc (2 x 30ml). The organics were dried 
(M gS04) and concentrated in vacuo to give 0.75 lg  o f crude product which was 
flash chromatographed on silica, eluting with petrohEtOAc (90:10) to give the
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alkene (376) (0.268g, 56%); Rf [petrol:EtOAc (95:5)] 0.31; m.p. 84°C 
(recrystallised from cyclohexane); [ a ] ^  +25.4 (c 1.318 in CHC13).
Method G
To a stirred suspension o f methyltriphenylphosphonium bromide (2.32g, 6.5mmol) 
in toluene (20ml) at room temperature, was added KO'Bu (0.717g, 6.2mmol) and 
stirred for 15 minutes. After this time the reaction mixture was cooled (-20°C) 
before addition to a cooled (-20°C) solution o f aldehyde (350) (1.2g, 5.9mmol) in 
toluene (20ml) over 30 minutes. An orange solution formed immediately on 
addition. The reaction mixture was allowed to warm to room temperature and 
stirred for 1 0  hours. Over this period the orange colour slowly turned to a pale 
yellow solution. Water (50ml) was added to the reaction, and the aqueous phase 
extracted with EtOAc (80ml), dried (M gS04) and concentrated in vacuo to give 
2.28g o f crude product which was flash chromatographed on silica, eluting with 
petrohEtOAc (90:10) to give the alkene (376) (0.75g, 63%); Rf [petrohEtOAc 
(95:5)] 0.31; m.p. 84°C (recrystallised from cyclohexane); [oc]^ +12.0 (c 1.332 in
CHC13).
Method H
To a cooled (0°C) suspension o f methyltriphenylphosphonium bromide (7.5g, 
21 mmol) in toluene (40ml), was added 1.0M NaHMDS (20ml, 20mmol) over 5 
minutes upon which a bright yellow colour o f the ylide was observed. The reaction 
mixture was warmed to room temperature, stirred for 2 0  minutes and then cooled 
to -78°C. This was added to a cooled solution (-78°C) o f aldehyde (350) (4.35g, 
20mmol) in toluene (40ml) over 30 minutes. A dark red-brown solution formed 
immediately on addition. The reaction mixture was stirred at -78°C for 1 0  minutes 
and then stirred for 4 hours at room temperature. Over this period the dark colour 
slowly turned pale orange-yellow. Water (100ml) was added to the reaction, and 
the aqueous phase extracted with ether ( 1 0 0 ml), washed with brine, dried (M gS04)
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and concentrated in vacuo to give 6.4g of crude product which was flash 
chromatographed on silica, eluting with petrohEtOAc (90:10) to give the alkene 
(376) (4.1g, 98%); Rf [petrohEtOAc (95:5)] 0.31; m.p. 84°C (recrystallised from 
cyclohexane); [a]^9 +22.6 (c 1.386 in CHC13).
(2R) and (2S)-[l(S)-Phthaloylaminoethyl] oxirane (322) and (323).
To a stirred solution of alkene (376) (0.428g, 21.3mmol) in DCM (200ml) was 
added m-CPBA (33.4g, 106.4mmol). The reaction mixture was left stirring for 2 
days under N2. The resulting mixture was then diluted with ether (300ml), washed 
with cooled (0°C) solution of 10% Na2S 0 3 (4 x 200ml), saturated NaHC03 (4 x 
200ml) brine (200ml), dried (MgS04) and concentrated in vacuo to give 5.32g of 
the crude epoxide. This was flash chromatographed on silica, eluting with 







Epoxide (322) (2.9 lg) was obtained as a colourless solid, Rf[petrol:EtOAc(70:30)] 
0.45; m.p. 96°C (from EtOAc); [a]^  +24.5 (c 1.108 in CHC13); (Found C, 66.37;
H, 5.1; N, 6.45. calc, for C12Hn N 0 3 : C, 66.35; H, 5.1; N, 6.45%); v ^ /c m -1 
1768s (C=0), 1715s (C=0), 1606 and 1254s (C-0 epoxide); 6H(270 MHz, CDC13)
I.64 (3H, d, J 7.0, Me), 2.61 (1H, dd, 7 2.6 and 4.8, C//HO), 2.76 (1H, dd, J 3.9 
and 1.1, CH/70), 3.54 (1H, ddd, 7 7.3, 3.9 and 2.6, CHO), 3.97 (1H, dq, 7 7.2 and
7.0, C//Me), 7.74 (2H, m, phthaloyl) and 7.85 (2H, m, phthaloyl); 8C (67.8 MHz, 
CDC13) 14.63 (Me), 46.58 (CH20), 49.63 (CHMe), 51.93 (CHO), 123.03 (m-C),
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CDC13) 14.63 (Me), 46.58 (CH2 0), 49.63 (CHMe), 51.93 (CHO), 123.03 (m-C),
131.69 (CC=0), 133.83 (o-C) and 167.85 (C=0); m/z (70eV) 217 (M+, 0.5%), 174 
(100, M-CHCH2 0 ), (C.I.) 218 (M++1, 100).
(2S)-[l(S)-Phthaloylaminoethyl] oxirane (323)
Epoxide (323) (1.67g) was obtained as a colourless solid, Rf[petrol:EtOAc(70:30)] 
0.55; m.p. 127-128°C (from EtOAc); [a]l% +10.7 (c 0.814 in CHC13) ; (Found C, 
66.37; H, 5.1; N, 6.45. calc, for C12Hn N 0 3 : C, 66.35; H, 5.1; N, 6.45%); v ^ /c n r
1 1771s (C=0), 1715s (C=0), 1606 and 1254s (C-0 epoxide); 5h (270 MHz, 
CDC13) 1.52 (3H, d, J 7.2, Me), 2.75 (1H, dd, J 2.6 and 4.8, CtfHO), 2.92 (1H, dd, 
J  3.8 and 0.9, CH/ZO), 3.62 (1H, ddd, J 7.3, 3.8 and 2.6, CHO), 4.07 (1H, dq, J 1.3 
and 7.2, CtfMe), 7.73 (2H, m, phthaloyl) and 7.84 (2H, m, phthaloyl); 8 C (67.8 
MHz, CDC13) 15.86 (Me), 46.58 (CH2 0), 49.69 (CHMe), 52.58 (CHO), 123.29 
(m-C), 131.82 (CC=0), 134.09 (o-C) and 167.98 (C=0); m/z (70eV) 217 (M+, 
0.5%), 174 (100, M-CHCH2 0), (C.I.) 218 (M++1, 100).
General preparation o f  (2R)- and (2S)-[l(S)-phthaloylaminoethyl]oxirane (322) 
and  (323) from  aldehyde (350) using trimethylsulfur ylides (386, 387).
Method A
To a stirred and cooled (0°C) suspension of trimethylsulfonium iodide (0.315g, 
1.54mmol) in THF (5ml) was added 1.6M /i-BuLi (0.88ml, 1.41mmol) dropwise. 
After addition the reaction mixture was stirred for 5 minutes at 0°C before 
aldehyde (350) (0.26g, 1.28mmol) in THF (5ml) was added dropwise. The 
colourless solution turned orange upon addition and was left to stir for 30 minutes 
before being allowed to attain room temperature (orange colour gradually faded). 
The reaction mixture was quenched with water (20ml) and concentrated in vacuo. 
The resulting solution was extracted with EtOAc (2 x 20ml), dried (M gS04) and
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concentrated in vacuo. The crude material was flash chromatographed on silica, 
eluting with petrohEtOAc (30:70) to give (322) and (323) (68:32) (5.4mg, 2%).
Method B
Trimethylsulfoxonium chloride (3.7g, 28.77mmol) in THF (50ml) was added to 
60% NaH (1.107g, 27.67mmol). The reaction mixture was heated at 65°C for VA 
hours and then cooled to 55°C. Aldehyde (350) (4.5g, 22.1mmol) in THF (50ml) 
was added dropwise to this solution over an hour. The reaction mixture was stirred 
for a further hour at 55°C. After cooling, the reaction mixture was quenched with 
water (50ml) and extracted with EtOAc (5 x 100ml). The organics were combined, 
dried (M gS04) and concentrated in vacuo to give 3.5g o f crude material. This was 
flash chromatographed on silica, eluting with petrohEtOAc (85:15) to yield (322) 
and (323) (55.4:44.6) (1.29g, 27%).
Method C
Trimethylsulfoxonium chloride (2.47g, 18.8mmol) in DMSO (10ml) was added to 
60% NaH (0.752g, 18.8mmol) under N2. This was stirred for 15 minutes at room 
temperature before the addition of the aldehyde (350) (3.2g, 15.7mmol) in DMSO 
(10ml). The reaction mixture was stirred for 30 minutes at room temperature 
before heating to 55°C for 5 hours. After cooling, the reaction mixture was 
quenched with water (50ml) and extracted with EtOAc (5 x 1 0 0 ml). The organics 
were combined, dried (MgS04) and concentrated in vacuo. The crude material was 
flash chromatographed on silica, eluting with petrohEtOAc (85:15) to yield (322) 
and (323) (55.4:44.6) (0.92g, 27%).
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Method D
P reparation  o f  d iazom ethane
Using the Aldrich diazald kit an ethereal diazomethane solution was prepared as 
follows:
Into a 250ml round bottom flask, fitted with a distillation head, water condensor, 
receiver adapter and collecting round bottom flask, was placed potassium hydroxide 
(6.2g, O.llmol), water (10.5ml), ether (10.5ml) and ethanol (37ml). The distilling 
flask was heated in a water bath at 70-75°C with stirring ('Teflon'* coated stirrer 
bar) and a solution of A-nitroso-A'-rnethyl-p-rnethyltoluene sulfonamide in ether 
(200ml) added at a rate approximately equivalent to the rate of the condensing 
distillate. Once all the nitrosamide solution had been added, additional ether was 
placed in the dropping funnel and added at the same rate until the distillate was 
colourless. The distillate contained 2.8-3.0g (64-69%) of diazomethane. For safety 
details see De Boer and Backer.291
Freshly distilled diazomethane (70mmol) was added to the aldehyde (350) (7g, 
35mmol) in EtOAc (100ml). The reaction mixture was stirred at room temperature 
for 2 days before quenching with excess methanol (10ml). The reaction mixture 
was concentrated in vacuo and flash chromatographed on silica, eluting with 
petrohEtOAc (70:30) to yield (322) and (323) (62:38) (0.582g, 8%). Also isolated 
was the corresponding methyl ketone (393) (3g, 40%):
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(3S*)-Phthaloylaminobut-2-one (393)
(3S*)-Phthaloylaminobut-2-one (393) was isolated as a colourless solid, 
Rf{petrol:EtOAc (60:40)] 0.61; m.p. 78°C; (Found C, 66.02; H, 5.13; N, 6.49. calc, 
for C1 2H 11N 0 3  : C, 66.35; H, 5.10; N, 6.45%); v ^ /c n r 1 1775s (C=0), 1697s 
(C=0), 1465§ ^  (Me), 1378 and 714; 8^270  MHz, CDC13) 1.67 (3H, d, J  7.3, 
Me), 2.22 (3H, s, COMe), 4.82 (1H, q, J 7 .3 , CH), 7.74-7.78 (2H, m, phthaloyl), 
7.86-7.9 (2H, m, phthaloyl); 8 C (67.8 MHz, CDC13) 13.50 (Me), 26.40 (CH3 0 ), 
54.85 (CHMe), 123.60 (m-C), 131.90 (C-CO), 134.30 (o-C), 168.00 (NC=0) and 
203.00 (MeC=0); m/z (70 eV) 217 (M+, 3%), 174 (100, M-COCH3), (C.I) 218 
(M++ l, 100).
Method E
To a solution o f aldehyde (350) (3.0g, 14.8mmol) and TBAI (0.055g, 0.15mmol) in 
DCM (30ml) was added 50% aqueous NaOH and trimethylsulfonium iodide (3.02g, 
14.8mmol). The reaction mixture was stirred at 50°C for several hours. T.l.c. 
showed many spots and the reaction was abandoned.
Attempted preparation o f  (2R*,3S*,2'S) and (2S*,3S*,2fS)-l-hydroxy-2-(0- 
methyl leucinyl)-3-phthaloylaminobutane (324) and (325)
Method A
To a solution o f the epoxides (322) and (323) (0.122g, 0.56mmol) in anhydrous 
DCM (5ml) was added Leu-OMe.HCl (0.112g, 0.62mmol). The reaction mixture 
was stirred at room temperature overnight, after which time no reaction had 
occurred. Triethylamine (0.086ml, 0.62mmol) was added to the reaction mixture 
and after stirring for 5 hours, no addition to the epoxide was observed. BF3 .OEt2  
(0.069ml, 0.56mmol) was also added and after 1 hour no change was observed, 
with only starting materials being visible by t.l.c.
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Method B
To a solution o f Leu-OMe (0.097g, 0.672mmol) in anhydrous DCM (10ml) was 
added BF3 .OEt2  (0.083ml, 0.67mmol) followed by epoxide (322) (O.lg, 0.46mmol) 
after 20 seconds. The reaction mixture was stirred at room temperature for 5 
hours, after which time two new compounds were seen by t.l.c. The reaction was 
diluted with EtOAc (15ml), washed with water ( 1 0 ml), back extracted with EtOAc 
(4 x 15ml), dried (Na2 S04) and concentrated in vacuo. The crude material was 
flash chromatographed on silica, eluting with petrohEtOAc (50:50) with gradient to 
EtOAc, to give the epoxide (322) (0.012g, 12%), diols (338:337, 1:3) (0.04g, 
37%) and a uv and ninhydrin visible compound which decomposed before 
characterisation.
Method C
To a solution o f Leu-OMe (0.131g, 1.4mmol) in anhydrous DCM (5ml) was added 
BF3 .OEt2  (0.109ml, 1.38mmol) followed by epoxides (322) and (323) (0.193g, 
0.89mmol) after 2 0  seconds. The reaction mixture was stirred at room temperature 
for Vi hour, after which time a new compound was observed by t.l.c. The reaction 
was concentrated in vacuo to give 0.433g o f crude material which was flash 
chromatographed on silica, eluting with petrohEtOAc (50:50) with gradient to 
EtOAc, to give epoxides (337) and (338) (0.16g, 83%) and BF3 -Leu-OMe (397) 
(0.092g, 31%).
BFr Leu-OMe (397)
BF3 -Leu-OMe (397) was isolated as a colourless oil; 5^270 MHz, CDC13) 0.96 
(6 H, br s, CHM?2), 1.70-1.80 (3H, m, CH2CH), 3.80 (3H, s, OMe), 4.10 (1H, m, 









To a solution of epoxides (322) and (323) (0.16g, 0.74mmol) in anhydrous DCM 
(5ml) at room temperature was added BF3.OEt2 (0.092ml, 0.75mmol). A creamy 
white precipitate formed immediately, but disappeared on the addition of Leu-OMe 
(0.215g, 1.48mmol). The reaction mixture was stirred at room temperature for XA 
hour, after which time new compounds were seen by t.l.c. The reaction was 
washed with 0.1M HC1 (7.4ml), back extracted with DCM (5ml), dried (MgS04) 
and concentrated in vacuo. The crude material was flash chromatographed on 
silica, eluting with petrol:acetone (30:70) to give a mixture of diols (337) and (338) 
and hydroxyl dipeptides (324a) and (324b). These were recombined and flash 
chromatographed, eluting with petrol:EtOAc (80:20) to give the diols (338:337, 
56:44) (0.004g, 2%), a mix of the diols (338:337, 20:80) and the hydroxymethyl 
dipeptide (324b) (0.04g) and the hydroxymethyl dipeptide (324a) (0.03g, 12%).
(322) (337) (338)
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(2R,3S,2 'S)-2-Hydroxy-l-(0-methyl leucinyl)-3-phlhaloylaminobutane (324a) 
(2R,3S, 2\S)-2-Hydroxy- 1 -(O-methyl leucinyl)-3-phthaloylaminobutane (324a) was 
isolated as a colourless gum; Rf [petrol:EtOAc (25:75)]; 0.41; vmiix/cnr' 3400„ (OH 
and NH), 1750s (C=0), 1670s (C=0), 1480 and 1390; 8^400 MHz, CDC13) 0.91 
(3H, d, 7  6.4, CHjMe), 1.03 (3H, d, J  6.4, CHjMe), 1.52 (3H, d, 7  7.1, CHMe), 
1.70-1.87 (1H, m, CHjCtfMej), 1.90-1.99 (2H, m, CtfjCHMej), 2.60 ( 1 H, brs, 
OH), 3.49 (1H, d, 7  6.4, C/7HOH), 3.52 (1H, d, 7  5.2, CHHOH), 3.74 (3H, s, 
OMe), 3.89-3.95 ( 1 H, m, CHN), 4.87 (1H, qd, J 7 . 1  and 4.4, CHMe), 5.08 ( 1 H, 
dd, J  7.9 and 6.0, C //C 0 2 Me), 7.67-7.72 (2H, m, phthaloyl), 7.87-7.90 (1H, m, 
phthaloyl) and 7.90-7.94 (1H, m, phthaloyl); 8 C (67.8 MHz, CDC13) 15.47 (Me), 
21.70 and 22.93 (CBMe2), 25.10 (CHMe2), 43.72 (CH^HM ej), 49.24 (NCHMe), 
52.51 (OMe), 59.97 (NCHC02), 64.93 (CH2 OH), 73.78 (CHN), 124.23 (m-C), 
125.23 (m-C), 129.16 (CC=0), 132.63 (o-C), 133.57 (o-C), 167.66 (C =0) and 
172.56 (C 0 2 Me); m/z (70eV) 362 (M+, 5%), 347 (5, M-CH3), 331 (5, M-CH2 OH); 
(C.I.) 363 (M++ l, 100).
(2S,3R,2'S)-1-Hydroxy-2-(O-methyl !eucinyl)-3-phthaloylaminobutane (324b) 
(2.S’,3i^ ,2'.ST)-l-Hydroxy-2 -(O-methyl leucinyl)-3-phthaloylaminobutane (324b) was 
isolated as a colourless gum; Rf [petrohEtOAc (25:75)]; 0.51; vnliIX/crrr1 3400s (OH 
and NH), 1730s (C=0), 1650s (C=0), 14608 as (Me) and 1380; 8h (270 MHz, 
CDC13) 0.91 (3H, d, J  6 .6 , CH^Me), 1.03 (3H, d, J  6 .6 , CHjAfe), 1.54 (3H, d, J  
7.1, CBMe), 1.66-1.80 (1H, m, CHjCT/Mej), 1.90-1.96 (2H, m, CZ/jCHMej), 
3.40-3.53 (2H, m, Ctf2 OH), 3.77 (3H, s, OMe), 3.85-3.96 (1H, m, CHN), 4.53 
(1H, brs, OH), 4.97 (1H, qd, J7.1  and 3.9, CtfMe), 4.81 (1H, d ,76 .41 , NH), 5.09 
(1H, dd, 7 7 .3  and 6.4, CtfC02 Me), 7.68-7.74 (2H, m, phthaloyl), 7.82-7.85 (1H, 
m, phthaloyl) and 7.90-7.95 (1H, m, phthaloyl); m/z (70eV) 362 (M+, 5%), 347 (5, 
M-CH3), 331 (M-CH2 OH); (C.I.) 363 (M++1 , 100).
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Method E
This reaction was performed using the same procedure as method D, but at 0°C. 
From the epoxides (322) and (323) (0.094g, 0.43mmol) flash chromatography o f  
the crude material, eluting with petrol:EtOAc (65:35) gave the diols (337) and 
(338) (0.003g, %), a mixture o f diols (337) and (338) and hydroxymethyldipeptide 
(324b) (0.081g) and pure hydroxymethyldipeptide (324a) (0.023g, 15%).
Method F
This reaction was performed using the same procedure as method D, but at -20°C. 
From epoxide (322) (0.215g, 0.99mmol) flash chromatography o f the crude 
material, eluting with petrol:EtOAc (60:40) gave recovered epoxide (322) (0.074g, 
21%), a mix o f diols (338:337, 20:80) and hydroxymethyldipeptide (325) (0.07g) 
and pure hydroxymethyl dipeptide (324) (O.lg, 27%).
Method G
This reaction was performed using the same procedure as method F. From epoxide 
(323) (0.74g, 3.41mmol) flash chromatography o f the crude material ( l . lg )  on 
neutral, activated, aluminium oxide, eluting with petrol:EtOAc (60:40) gave the 
reaction mixture unseparated. Flash chromatography o f this material (0.8g) on 
silica, eluting with petrol:EtOAc (60:40) gave a mix o f diols (338:337, 19:81) and 
hydroxymethyldipeptide (325) (0.27g) and pure hydroxymethyldipeptide (324) 
(0.04g, 3%). HPLC o f the mixture o f the diols (337) and (338) and 
hydroxymethyldipeptide (325) (0.05g), eluting with acetonitrile:water:TFA 
(20:80:1) gradient to 50:50:1 and back to 20:80:1 gave only the diols (337) and 
(338) and Leu-OMe. When the hydroxymethyldipeptide (325) was passed down 
the HPLC column only Leu-OMe and diol (337) were isolated.
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To a solution of the epoxides (323:322, 43:57) (0.278g, 1.28mmol) in anhydrous 
DCM (5ml) at -78°C was added BF3.OEt2 (0.173ml, 1.408mmol). A creamy white 
precipitate formed immediately, but this disappeared on the addition of Boc-Leu- 
OMe (0.345g, 1.408mmol). The reaction mixture was stirred at -78°C for Vi hour, 
after which time the reaction was allowed to attain room temperature and stirred for 
a further 20 minutes. After this time all the epoxides (322) and (323) had been 
consumed, as observed by t.l.c. The reaction was quenched with sat. ammonium 
chloride (1ml), washed with water (10ml), back extracted with EtOAc (10ml) and 
the combined organics dried (MgS04) and concentrated in vacuo to give 0.316g of 
crude material. This was flash chromatographed on silica, eluting with 
petrol:EtOAc (20:80) gradient to EtOAc to give Boc-Leu-OMe and a mixture of 
the diols (338:337, 9:91) (0.208g, 69%).
To a solution of epoxide (323) (0.095g, 0.44mmol) in anhydrous DCM (10ml) at 
-78°C was added BF3.OEt2 (0.057ml, 0.46mmol). A creamy white precipitate 
formed immediately and the reaction mixture was stirred at -78°C for 30 minutes 
before the addition of Leu-OMe (0.076g, O.53mmol). The reaction mixture was 
stirred at -78°C for 5 hours, after which time another equivalent of Leu-OMe 
(0.076g, O.53mmol) was added. The reaction was concentrated in vacuo and flash 
chromatographed on silica, eluting with petrol:EtOAc (20:80) to give recovered
Method I
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epoxide (323) (0.033g, 35%) and a new compound believed to be the aziridine 




(1R,2S,2 ’S)- and (1S,2R,2 'S)-l-(Methyl-4'-methylpentanoate)-2-(l-phthaloyl- 
aminoethyl)aziridine (328)
( \R,2S,2'S)- and (1 S,2R,2'S)~ 1 -(Methyl-4'-methylpentanoate)-2-( 1 -phthaloylamino- 
ethyl) aziridines (328) were isolated as a colourless gum; Rf [petrohEtOAc 
(70:30)]; 0.12; v ^ /c n r 1 1763s (C=0), 1734s (C=0), 1706s (C=0), 1646, 14655as 
(Me), 1387s (C-N), 1200 and 1172; 8H(270 MHz, CDC13) 0.85-0.95 (6H, m, 
CHMe2), 1.57 (3H, d, J 7.2, CHMe), 1.42-1.50 (1H, m, CHMe2), 1.60-1.80 (2H, m, 
CH2CHMe2), 2.40 (1H, dd, J 16.7 and 7.6, CHHN), 2.77 (1H, dd, J 16.7 and 5, 
CHHN), 3.24 (1H, ddd, J 7.6, 5 and 5, CHN), 3.60 and 3.66 (3H, s, OMe), 4.00- 
4.12 (1H, m, C //C 02Me), 4.31-4.35 (1H, qd, J 6.9 and 6, CtfMe), 7.70-7.78 (2H, 
m, phthaloyl) and 7.80-7.88 (2H, m, phthaloyl); 8C (67.8 MHz, CDC13) 14.35 and
14.39 (Me), 22.03, 22.08, 22.76 and 22.80 (CHM<?2), 24.86 (CHMe2), 42.44 and 
42.55 (CH2CHMe2), 49.87 and 50.09 (NCHMe), 50.24 and 50.70 (CH2N), 51.68 
and 51.80 (OMe), 59.86 and 60.07 (NCHC02), 70.29 and 70.74 (CHN), 123.35 
(m-C), 131.87 (CC=0), 134.13 (o-C), 168.61 (C=0) and 175.91 (C 02Me).
and
8h(270 MHz, CDC13) 0.85-0.95 (6H, m, CHMe2), 1.57 (3H, d, J 7.2, CHMe), 1.42-
1.50 (1H, m, CHMe2), 1.60-1.80 (2H, m, CH2CHMe2), 2.46 (1H, dd, J 14.1 
and 5, CH2N), 2.69 (1H, dd, /  13 and 6.9, CH2N), 3.24 (1H, dd, J 7.6, and 5,
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CHN), 3.60 and 3.66 (3H, s, OMe), 4.00-4.12 (1H, m, C //C02Me), 4.31-4.35 (1H, 
qd, J  6.9 and 6, CZ/Me), 7.70-7.78 (2H, m, phthaloyl) and 7.80-7.88 (2H, m, 
phthaloyl);
Purification of (328a:328b, -1:1) by HPLC eluting with acetonitrile:water:TFA 
resulted in the isolation of a different compound believed to be the 
hydroxyethylamino dipeptides (398:399, -1:1):
(2R*,3S*2'S) and (2S*,3S*,2'S)-2-Hydroxy-l-(0-methyl leucinyl)-3-phthaloyl 
aminobutane (398) and (399)
Were isolated as a colourless oil; v ^ /c n r 1 3468s (OH), 1760s (C=0), 1734s 
(C=0), 1706s (C=0), 1646, 1465§ as (Me), 1387s (C-N), 1200, and 1172; 5h(270 
MHz, CDC13) 0.85-1.10 (6H, m, CHM?2), 1.53 (3H, d, J  7.0, CHM?), 1.60-1.95 
(3H, m, CH2CHMe2), 2.85-3.40 (2H, m, CH2N), 3.80 and 3.85 (3H, s, OMe), 
3.85-4.05 (1H, m, GtfC02Me), 4.25-4.45 (1H, m, CtfMe), 4.50-4.70 (1H, m, 
C//OH), 5.30-6.40 (2H, br s, NH and OH), 7.70-7.78 (2H, m, phthaloyl) and 7.80-
7.88 (2H, m, phthaloyl); 8C (67.8 MHz, CDC13) 14.16 and 14.25 (CHMe), 21.27, 
21.35, 22.70 and 22.75 (CHM?2), 24.77 and 24.81 (CHMe^, 37.93 and 38.96 
(CH2CHMe2), 49.56 (CH2N), 49.67 and 49.83 (CHMe), 50.38 (CH2N), 53.31 and
53.39 (OMe), 59.00 and 59.14 (CHC02), 67.68 and 68.21 (CHOH), 123.53 (m-C), 
131.58 (CC=0), 134.35 (o-C), 168.49 and 169.26 (CON), 172.00 (C02Me); m/z 
(FAB+) 363 (M++l); [Found : (M++ l) 363.1945. C19H26N20 5 requires 363.1920],
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Method J
To a cooled solution (-20°C) of the epoxides (322) and (323) (0.203g, 0.935mmol) 
in DCM (5ml) was added BF3 .OEt2  (0.115ml, 0.935mmol). A creamy white 
precipitate formed immediately and the reaction mixture was stirred at -20°C for 1 
minute before the addition of Bn-Leu-OMe (367) (0.264g, 1.12mmol). The 
reaction mixture was stirred at -20°C for 1 hour, after which time the reaction was 
quenched with water (0.25ml). The reaction was concentrated in vacuo and flash 
chromatographed on silica, eluting with petrol :EtOAc (20:80) to give recovered 
epoxides (322) and (323) (0.06g, 31%), Bn-Leu-OMe (367) and diols (338:337, 
17:83) (0.06g, 28%).
(2S,3S,2 'S)-l-Hydroxy-2-(0-methyl leucinyl)-3-phthaloylamino-butane (325a)
To a cooled solution (0°C) of the protected alcohol (476) (0.04g, 0.07mmol) in 
THF (1ml) was added TBAF (0.13ml, 0.13mmol). The reaction mixture was 
stirred for 2 hours, diluted with DCM (3 x 3ml), washed with brine (20ml), dried 
(M gS04) and concentrated in vacuo to give the crude alcohol (325a). These were 
flash chromatographed, eluting with petrol:EtOAc (40:60) to give the desired 
alcohol (325a) as a gum (0.015g, 67%); Rf [CHCl3:MeOH (90:10)] 0.13; v ^ /c m ' 1 
3400s (OH and NH), 1750s (C=0), 1670s (C=0), 1480 and 1390; 6H(270 MHz, 
CDC13) 0.91 (3H, d, 76.4, CH2M e\ 1.03 (3H, d, 7 6.4, CH2M e\ 1.41 (3H, d, 77.1 , 
CHA/e), 1.50-1.70 (1H, m, CH2 C//Me2), 1.74-1.90 (2H, m, Ctf2 CHMe2), 2.30- 
2.40 (1H, brs, OH), 3.60-3.70 (2H, m, CJ72 OH), 3.78 (3H, s, OMe), 4.00-4.10 (1H, 
m, CHN), 4.67 (1H, qd, 7 7.2 and 2.2, C#Me), 5.10 (1H, dd, 7 7.5 and 6.4, 
CHC0 2Me), 7.67-7.72 (2H, m, phthaloyl), 7.87-7.90 (1H, m, phthaloyl) and 7.90- 
7.94 (1H, m, phthaloyl); 5C (67.8 MHz, CDC13) 13.03 (Me), 22.19 and 22.23 
(CHAfe2), 24.92 (CHMe2), 43.41 (CH2 CHMe2), 49.17 (NCHMe), 52.28 (OMe),
60.03 (NCHC02), 63.89 (CH2 OH), 72.67 (CHN), 124.04 (m-C), 125.21 (m-C), 
129.18 (CC=0), 132.49 and 132.71 (o-C), 133.42 and 134.26 (o-C), 167.66 and
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168.82 (C=0) and 172.76 (C02Me); m/z (70eV) 362 (M+, 5%), 347 (5, M-CH3), 
331 (5, M-CH2OH); FAB + 363 (M++1, 60); FAB (-) 361 (M+-1, 100).
Preparation o f the diols (337) and (338) using osmium tetraoxide
To a cooled solution (0°C) of the alkene (376) (0.624g, 3.1mmol) in 
acetone:water:*BuOH (6:5:1ml) was added NM0.2H20  (0.375g, 3.2mmoi) and 
osmium tetraoxide (12.6mg, 0.03mmol). The reaction mixture was left to stir at 
room temperature for 16 hours. To this was added a slurry of sodium hydrosulfite 
(O.lg), magnesium silicate (1.2g) and water (8ml). This was filtered and the filtrate 
was neutralised with 1M H2S 0 4 and concentrated in vacuo. This was flash 
chromatographed on silica, eluting with petrol:EtOAc (20:80) to yield an 
inseparable mix of (337) and (338) (27:73) (0.324g, 44%):
(25.35)-l,2-Dihydroxy-3-phthaloylaminobutane (337)
(25.35)-l,2-Dihydroxy-3-phthaloylaminobutane (337) was a colourless solid; Rf 
[petrol:EtOAc (1:1)]; 0.26; (Found C, 61.14; H, 5.65; N, 5.87. calc, for C12H13N 0 4 
: C, 61.27; H, 5.57; N, 5.95%); v ^ /c n r 1 3439s (OH), 1682s (C=0) and 1062s (C- 
O); 6h(270 MHz, CDC13) 1.47 (3H, d, /  7.1, CHMe), 2.40 (1H, br s, OH), 3.50 
(1H, br s, OH), 3.56 (1H, m, C//HO), 3.68 (1H, m, CHHO), 4.10 (1H, m, CHO), 
4.42 (1H, dq, J 7.1 and 4.8, C/TMe), 7.75 (2H, m, phthaloyl) and 7.86 (2H, m, 
phthaloyl); 5C (67.8 MHz, CDC13) 13.82 (Me), 48.78 (NCHMe), 63.86 (CH2OH),
72.88 (CHOH), 123.45 (m-C), 131.72 (CC=0), 134.28 (o-C) and 168.83 (C=0);
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m/z (70eV) 204 (28%, M-CH2 OH), 174 [100, M-CH(OH)CH2 OH]; (C.I.) 236 
(M++1, 100).
(2R,3S)-l,2-Dihydroxy-3-phthaloylaminobutane (338)
(2R,3S)~ 1,2-Dihydroxy-3-phthaloylaminobutane (338) was a colourless solid; Rf 
[petrol:EtOAc (1:1)]; 0.26; (Found C, 61.14; H, 5.65; N, 5.87. calc, for C1 2 H 1 3N 0 4  
: C, 61.27; H, 5.57; N, 5.95%); v ^ /c n r 1 3447s (OH), 1687s (C=0) 1389 and 
1064s (C-O); 6h(270 MHz, CDC13) 1.48 (3H, d, J 7.1, CHMe), 2.40 (br s, OH),
3.50 (br s, OH), 3.56 (1H, dd, J 11.5 and 6.9, CHHO), 3.68 (1H, dd, J  12.5 and 4.0, 
CHHO), 4.12 (1H, ddd, /  7.1, 6.9 and 4.0, CHO), 4.56 (1H, dq, J 7.1 and 7.0, 
CHMe), 7.73 (2H, m, phthaloyl) and 7.83 (2H, m, phthaloyl); 8 C (67.8 MHz, 
CDC13) 15.37 (Me), 48.91 (NCHMe), 64.18 (CH2 OH), 72.75 (CHOH), 123.45 (m- 
C), 131.72 (CC=0), 134.12 (o-C) and 169.18 (C=0); m/z (70eV) 204 (28%, M- 
CH2 OH), 174 [100, M-CH(OH)CH2 OH]; (C.I.) 236 (M++1, 100).
Ring opening o f the oxiranes (322) and (323) to give the corresponding diols 
(337) and (338)
Method A
To a solution of the epoxide (322) (0.239g, 1.1 mmol) in THF (1ml) and water 
(lm l) was added 1M H2 S 0 4  (0.2ml). The reaction was allowed to stir at room 
temperature and monitored by t.l.c. After 3 hours the epoxide still remained and 
by-products began to form. After 5 hours the reaction was stopped as more by­
products were observed. The reaction mixture was diluted with a sat. solution of 
K2 CO3 . The aqueous phase was extracted with EtOAc (3 x 15ml), the organics 
combined, washed with brine (30ml), dried (Na2 S 04) and concentrated in vacuo to 
give 0.19g of crude material. This was flash chromatographed on silica, eluting 
with petrol:EtOAc (50:50) to yield epoxides (322) and (323) (0.003g, 1%), alcohol
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(346) (0.042g, 19%), and what appeared to be 2-phthaloylpropyloxy-(3-phthaloyl)- 
2-hydroxybutane (410) (0.023g, 5%) and diols [(338:337), 7:93] (0.071g, 43%).
Pht P h . r A v '*  +
^ O H  ^ O H  OH
(322) (337) (338) (346) (410)
Method B
To a cooled solution (-20°C) of the epoxides (323:322, 43:57) (0.394g, 1.81mmol) 
in DCM (2ml) was added BF3.OEt2 (0.245ml, 2.0mmol). After 1 minute water 
(lml) was added. The reaction was stirred at -20°C for 10 minutes before being 
warmed to room temperature and stirred for a further 2 hours. After this time no 
change occurred so the reaction was quenched with ammonium chloride (5ml) and 
extracted with CHC13 (3 x 10ml). The organics were dried (Na2S 04) and 
concentrated in vacuo to afford 0.395g crude material. This was flash 
chromatographed on silica, eluting with petrol:EtOAc (50:50) to give diols 
(338:337, 9:91) (0.136g, 35%) and recovered epoxides (0.104g, 26%).
Method C
To a stirred solution of the epoxides (322) and (323) (0.506g, 2.33mmol) in THF 
(3ml) was added 0.1M H2S04 (3ml). The reaction mixture was stirred at 50°C for 
3 days, cooled, diluted with EtOAc (5ml), washed with sat. NaHC03, dried 
(Na2S 04) and concentrated in vacuo to afford 0.452g of crude material. This was
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flash chromatographed on silica, eluting with petrol:EtOAc (40:60) to give diols 
(338:337, 9:91) (0.297g, 54%) and recovered epoxides (0.05g, 10%).
Method D
To a stirred solution of epoxide (322) (1.224g, 5.63mmol) in THF:water 
(10ml :10ml) was added Dowex-50X8-100 ion-exchange resin (strongly acidic). 
The reaction mixture was stirred at 50°C for 11 hours, cooled and filtered. The 
resin was washed with CHC13 (50ml), concentrated in vacuo and crystallised from 
hexane:EtOAc to afford diols (337) and (338) (0.73g, 56%).
Method E
To a solution of the epoxides (323:322, 35:65) (4.0g, 18.4mmol) in THF (100ml) 
was added 6% HC104 (100ml) and the reaction mixture stirred for 2 days. The 
reaction was diluted with DCM (200ml), washed with sat. NaHC03 until the pH 
was 8 and the aqueous phase back extracted with DCM (150ml). The organics 
were combined, dried (Na2S04) and concentrated in vacuo. The crude material 
was flash chromatographed on silica, eluting with petrol:EtOAc (30:70) to give 







(322) (323) (337) (338)
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Trifliioroacetyl-N-Leu-OMe (368)
To a stirred suspension o f Leu-OMe.HCl (0.58g, 3.2mmol) in THF (10ml) was 
added DIPEA (1.23ml, 7.04mmol) and TFAA (0.48ml, 3.36mmol). The reaction 
mixture was left to stir for 16 hours. The reaction mixture was filtered, diluted with 
EtOAc (20ml), washed with water (2 x 20ml), dried (M gS04) and concentrated in 
vacuo to give the protected product (368) (0.774g, 100%) as a yellow-orange oil; 
Rf [petrol:EtOAc (80:20)] 0.2; (Found C, 44.27; H, 5.48; N, 5.67. calc, for 
C9H14NF302  : C, 44.28; H, 5.74; N, 5.66%); v ^ /c n r 1 3326s (NH), 1751s (C=0), 
1717s (C=0), 1564s (NCO), 1440 and 1203; 8^270 MHz, CDC13) 0.95 (6H, s, J
6.6, CHMe2), 1.60-1.74 (2H, m, CH2), 2.16 (2H, br s, CtfMej), 3.79 (1H, s, OMe), 
4.61-4.70 (1H, m, NCH) and 6.77 (1H, br s, NH); 5C (67.8 MHz, CDC13) 21.95 
(CHM?2), 22.65 (CHMe2), 24.86 (CT/Me^, 41.41 (CH2), 51.23 (CHN), 52.83 
(OMe), 113 and 118 (CF3), 156 and 157 (CON) and 171.93 (COMe); m/z (C.I.) 
259 (MNH4+).
(2S*,3S*) and (2R*f3S*)-l-Chloro-2-hydroxy-3-phthaloylaminobutane (403) 
and  (404)
Method A
To a stirred solution o f racemic epoxide (322) (0.219g, l.Olmmol) in 1,2- 
dimethoxyethane (4ml) and MeOH (1ml) was added tetraethylammonium chloride 
hydrate (0.9g, 5.1 mmol). The mixture was refluxed for 3 days. After cooling the 
mixture was diluted with EtOAc (10ml), washed with 2M HC1 (10ml), brine (10ml), 
dried (Na2S 0 4) and concentrated in vacuo to afford 0.135g crude material. This 
was flash chromatographed on silica, eluting with petrol :EtOAc (90:10) to give 
chloroalcohol (403) (0.052g, 20%), chloroalcohol (404) (0.039g, 15%) and the 
racemic diols (337:338, 91:9) (0.05g, 16%);
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(2S*,3S*)-l-Chloro-2-hydroxy-3-phthaloylaminobutane (403) 
(2S*,3£*)-l-Chloro-2-hydroxy-3-phthaloylaminobutane (403) was isolated as a 
colourless solid; Rf [petrol:EtOAc(70:30)] 0.63; m.p. 87°C; (Found C, 56.66; H, 
4.69; N, 5.40. calc, for C12H12N 0 3C1 : C, 56.82; H, 4.77; N, 5.52%); v ^ /c n r 1 
3477s (OH), 1688s (C=0), 13765 s (Me), 1133 and 1084; 8^270 MHz, CDC13) 
1.48 (3H, d, J  7.1, Me), 3.57 (1H, dd, J  11.4 and 5.0, C77HC1), 3.61 (1H, br s, 
OH), 3.68 (1H, dd, J  11.4 and 5.0, CHtfCl), 4.30-4.38 (1H, m, CHO), 4.68 (1H, 
dq, J  5.0 and 7.3, CHMe), 7.75-7.78 (2H, m, phthaloyl) and 7.87-7.90 (2H, m, 
phthaloyl); 8C (67.8 MHz, CDC13) 13.52 (Me), 46.42 (CH2C1), 48.87 (CHMe), 
72.68 (CHOH), 123.5 (w-C), 131.65 (CC=0), 134.33 (o-C) and 168.51 (C=0); 
m/z (70eV) 204 (7%,M-CH2C1), 174 (100, M-HOCHCH2Cl); (C.I.) 254 (M++l, 
100%).
(2R*,3S*)-l-Chloro-2-hydroxy-3-phtha1oy1aminobutane (404) 
(2/?*,35'*)-l-Chloro-2-hydroxy-3-phthaloylaminobutane (404) was isolated as a 
colourless solid; Rf[petrol:EtOAc (70:30)] 0.55; m.p. 119°C; (Found C, 56.50; H, 
4.59; N, 5.32. calc, for C12H12N 0 3C1 : C, 56.82; H, 4.77; N, 5.52%); v ^ /c n r 1 
3477s (OH), 1688s (C=0), 1462§ as (Me), 1376g s (Me), 1133 and 1084; 8^270  
MHz, CDC13) 1.52 (3H, d, 77.1, Me), 3.56 (1H, dd, J11.5 and 5.0, C//HC1), 3.59 
(1H, br s, OH), 3.66 (1H, dd, J  11.5 and 5.0, CH//C1), 4.21-4.29 (1H, m, CHO),
4.69 (1H, dq, J  7.2 and 7.0, CHMe), 7.72-7.78 (2H, m, phthaloyl) and 7.82-7.88 
(2H, m, phthaloyl); 8C (67.8 MHz, CDC13) 15.37 (Me), 46.42 (CH2C1), 49.07 
(CHMe), 72.06 (CHOH), 123.50 (/w-C), 131.72 (CC=0), 134.26 (o-C) and 168.97 
(C=0); m/z (C.I) 254 (M++1), 271 (M+NH4+).
Method B
(2S*,3S*)-l-Chloro-2-hydroxy-3-phthaloylaminobutane (403)
To a stirred solution of epoxide (323) (0.386g, 1.78mmol) in THF (10ml) was 
added lithium chloride (0.45g, 10.66mmol) and acetic acid (0.31ml, 5.33mmol). 
After stirring the mixture at room temperature for 1 day, the reaction mixture was 
diluted with EtOAc (20ml), washed with water (3 x 20ml), dried (Na2S04) and 
concentrated in vacuo to afford a quantitative yield of chloroalcohol (403) (0.453g) 
as a colourless solid; Rf [petrol:EtOAc (70:30)] 0.55; m.p. 87°C.
(2R*,3S*)-l-Chloro-2-hydroxy-3-phthaloyIaminobutane (404)
To a stirred solution of epoxide (322) (0.514g, 2.37mmol) in THF (10 ml) was 
added lithium chloride (2.406g, 56.8mmol) and acetic acid (0.38ml, 6.7mmol). 
After stirring at room temperature for 3 hours, water (30ml) was added and the 
reaction mixture was then extracted with ether (2 x 30ml), dried (Na2S04) and 
concentrated in vacuo to afford the chloroalcohol (404) (0.55g, 92%) as a 




(2S,3S) and (2R,3S)-2-Hydroxy-3-phthaloylamino-l-triphenylmethylthiobutane 
(409a) and (409b)
To a stirred solution of the racemic epoxides (322) and (323) (0.143g, 0.66mmol) 
in anhydrous methanol (6ml) was added triphenylmethylthiol (0.365g, 1.32mmol) 
and triethylamine (0.275ml, 1.97mmol). The reaction was then stirred for 4 hours 
at room temperature. After concentrating in vacuo, the resulting solid was 
dissolved in EtOAc (30ml), washed with water (20ml), brine (20ml), dried 
(MgS04) and concentrated in vacuo to give 0.3g of crude material. This was flash 
chromatographed, eluting with petrol:EtOAc (75:25) to give epoxides (322:323, 




(322) (323) (409a) (409b)
(25.35)-2-Hydroxy-3-phthaloylamino-l-triphenylmethylthiobutane (409a)
(25.35)-2-Hydroxy-3-phthaloylamino- 1-triphenylmethylthiobutane (409a) was 
isolated as a colourless solid; Rf[petrol:EtOAc (80:20)] 0.28; v ^ /c m '1 3444s 
(OH), 1774s (C=0), 1707s (C=0), 1594 and 1026; 6H(270 MHz, CDC13) 1.22 (3H, 
d, J 7.2, Me), 2.20 (1H, dd, J 12.7 and 5.7, CHHS), 2.54 (1H, dd, J 12.7 and 7.3, 
CHHS), 3.57 (1H, br s, OH), 3.57-3.63 (1H, m, C//OH), 4.27 (1H, qd, J 7.0 and
4.0, C//Me), 7.00-7.20 (15H, m, CPh3) and 7.70-7.90 (4H, m, phthaloyl); 8C (67.8 
MHz, CDC13) 15.22 (Me), 36.24 (CH2S), 50.81 (NCHMe), 71.84 (CHOH), 123.34 
(m-C), 131.66 (CC=O), 134.1 (o-C), 144.52 (CPh3) and 168.53 (C=0); m/z (C.I)
516.3 [5%, (MNa+)], 475 [3%, (M++1)-H20)], 218 [100, (M++l)-SCPh3].
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(2R,3S)-2-Hydroxy-3-phthaloylamino-l-triphenylmethylthiobutane (409b)
(2/?,35')-2-Hydroxy-3-phthaloylamino-1 -triphenylmethylthiobutane (409b) was
isolated as a colourless solid; Rf[petrol:EtOAc (80:20)] 0.28; v ^ /c m ’1 3444s 
(OH), 1774s (C=0), 1707s (C=0), 1594 and 1026; 5H(270 MHz, CDC13) 1.24 (3H, 
d, J 7.0, Me), 2.23 (1H, dd, J 12.7 and 5.7, CHHS), 2.45 (1H, dd, J 12.5 and 6 .8 , 
CHHS), 3.57 (1H, d, J 8 .8 , OH), 3.38-3.70 (1H, m, CHOH), 4.33 (1H, qd, J 6 .8  
and 6.7, CHMe), 7.00-7.20 (15H, m, CPh3) and 7.70-7.90 (4H, m, phthaloyl); 8 C 
(67.8 MHz, CDC13) 15.44 (Me), 36.53 (CH2S), 50.74 (NCHMe), 71.24 (CHOH),
123.4 (m-C), 131.77 (CC=0), 134.06 (o-C), 144.45 (CPh3) and 169.20 (C=0); m/z 
(C.I) 516.3 [5%, (MNa+)], 475 [3%, (M++1)-H20)], 218 [100, (M++l)-SCPh3].
(2R*,3S*)-l-Chloro-3-phthaloylamino-2-(trifluoromethanesulfonyloxy)butane
(463)
To a cooled solution (-20°C) of the racemic chloroalcohol (404) (0.283g, 
1.12mmol) in DCM (10ml) was added pyridine (0.09ml, 1.12mmol). The reaction 
was stirred for 5 minutes before the addition of triflic anhydride (0.226ml, 
1.34mmol). It was then allowed to stir at -20°C for 5 minutes before being warmed 
to room temperature and stirred for a further 1 hour. The reaction mixture was 
diluted with DCM (10ml), washed with 1M HC1 (20ml), brine (20ml), dried 
(MgS04) and concentrated in vacuo. The crude material was used immediately in 






To a cooled solution (-20°C) of the racemic chloroalcohol (403) (0.143g, 
0.56mmol) in DCM (3ml) was added pyridine (0.091ml, 1.13mmol). The reaction 
was stirred for 5 minutes before the addition of triflic anhydride (0.143ml, 
0.85mmol). It was then allowed to stir at -20°C for 5 minutes before being warmed 
to room temperature and stirred for a further 1 hour. The reaction mixture was 
diluted with DCM (5ml), washed with 1M HC1 (5ml), brine (5ml), dried (MgS04) 
and concentrated in vacuo. The crude material was flash chromatographed, eluting 
with petrol:EtOAc (70:30) to give the desired product (464) (0.156g, 72%) as a 
colourless solid; m.p. 108-109°C (from ether); (Found C, 40.50; H, 2.82; N, 3.50. 
calc, for C13Hn NClF30 5S : C, 40.48; H, 2.87; N, 3.50%); v ^ /c n r 1 1772s (C=0), 
1708s (C=0) 1607, 1462§ as (Me), 1377§ s (Me) and 1143; 5h(270 MHz, CDC13) 
1.61 (3H, d, J  7.0, Me), 3.64 ( 1H, dd, J  13.6 and 3.7, CtfHCl), 3.95 (1H, dd, J
13.6 and 3.3, CH//C1), 4.88 (1H, dq, J  8 .6  and 7.1, CHMe), 5.71 (1H, ddd, J  8 .6 ,
3.7 and 3.3, CHO), 7.76-7.80 (2H, m, phthaloyl) and 7.86-7.91 (2H, m, phthaloyl); 
8 C (67.8 MHz, CDC13) 14.84 (Me), 42.7 (CH2C1), 4 6  4 6  (CHMe), 86.24 (CHO), 
118 (q, C-F/309, CF3), 123.67 (m-C), 131.44 (CC=O), 134.56 (o-C) and 167.45 










Preparation o f  the chloromethyl dipeptides (326) and (327).
Method A
To a stirred solution of the crude racemic chlorotriflate (463) (0.426g, 1.12mmol) 
in THF (20ml) at room temperature was added Leu-OMe.HCl (0.204g, 1.12mmol) 
and triethylamine (0.167ml, 1.2mmol). The reaction was stirred for one day, after 
which time the t.l.c. showed no further reaction. The reaction mixture was diluted 
with EtOAc (10ml), washed with 1M HC1 (20ml), brine (2 0 ml), dried (MgS04) and 
concentrated in vacuo. The crude material was flash chromatographed, eluting with 
petrol:EtOAc:Et3N (80:20:1) to give an inseparable mixture of the (Z) and (£)- 
chloroalkenes (458:465, 87:13) (0.03lg, 12%). Also isolated was the starting 
material (463) (0.029g, 17%) and an inseparable mix of the chloromethyl dipeptides 
(327:470) (0.145g, 34%).







puttr ^  ci 
(465)
(Z)-l-Chloro-3(S*)-phthaloylaminobut-l-ene (458)
(Z)-l-Chloro-3(S*)-phthaloylaminobut-l-ene (458) was isolated as a pale yellow 
solid; Rf [petrol: EtOAc (80:20)] 0.9; (Found C, 61.01; H, 4.32; N, 5.8. calc, for 
C12H10NO2Cl : C, 61.16; H, 4.28; N, 5.94%); v ^ /c n r 1 1766s (C=0), 1719s 
(C=0), 1705s (C=C), 1464§ as (Me), 13776 s (Me), 750s (C-Cl) and 718; 8^270  
MHz, CDC13) 1.55 (3H, d, J  7.0, Me), 5.44 (1H, dqd, J7.5 , 7.0 and 1.2, C//Me),
231
6.16 (1H, dd, J  1.5 and 1.2, HCOZZCI), 6.42 (1H, dd, J  7.5 and 7.0, Z/COHC1) 
and 7.72-7.88 (4H, m, phthaloyl); 8 C (67.8 MHz, CDCI3) 18.70 (Me), 43.30 
(CHMe), 120.20 (HC=CHC1), 123.20 (m-C), 130.10 (HC=CHC1), 131.90 (CC=0), 
134.00 (o-C) and 167.60 (C=0); m/z (70eV) 220 (15%, M-CH3), 200 (100, M-Cl); 
(C.I.) 236 (M++1, 100), 253 (100, M+NH4+).
(E )-l-C h lo ro -3 (S * )-p h th a lo y la m in o b u t-l-e n e  (465)
(£)-l-Ch!oro-3(.S'*)-phthaloylaminobut-l-ene (465) was isolated as a pale yellow 
solid, Rf [petrol: EtOAc (80:20)] 0.9; (Found C, 61.01; H, 4.32; N, 5 .8 . calc, for 
C1 2H 1 0NO2Cl : C, 61.16; H, 4.28; N, 5.94%); v ^ c m - i  1766s (C=0), 1719s 
(C=0), 1705s (C=C), 1464s as (Me). 13778 s (Me), 750s (C-Cl) and 718; Sh(270 
MHz, CDC13) 1.68 (3H, d, J 7 .0 , Me), 5.44 (1H, dqd, J 8.0, 7.0 and 1.2, CZ/Me),
6.16 ( 1 H, dd, J  8.0 and 1.2, HCOZZC1), 6.34 (1H, dd, J  14 and 8.0, ZZCOHC1) 
and 7.72-7.88 (4H, m, phthaloyl); 8 C (67.8 MHz, CDC13) 19.0 (Me), 44.0 (CHMe),
120.5 (HC=CHC1), 123.5 (m-C), 130.1 (HC=CHC1), 131.9 (CC=0), 134.3 (o-C) 
and 167.6 (C=0); m/z (70eV) 220 (15%, M-CH3), 202 (M-Cl, 30), 200 (M-Cl, 
100); (C.I.) 236 (100, M++l), 253 (100, M+NH4+).
(2 R * ,3 S * )-l-C h lo ro -3 -p h th a lo y la m in o -2 -(tr iflu o ro m eth a n esu lfo n y lo xy)b u ta n e
(463)
(2R*,3S*)-l-Chloro-3-phthaloylamino-2-(trifluoromethanesulfonyloxy)butane (463) 
was isolated as a colourless solid; m.p. 132°C; (Found C, 40.50; H, 2.82; N, 3.50. 
calc, for C1 3Hn NClF3 0 5S : C, 40.48; H, 2.87; N, 3.50%); vmax/cm-> 1772s (C O ), 
1708s (C O ), 1607, 1462s as (Me), 1377S s (Me) and 1143; 8^ 270  MHz, CDC13)
1.60 (3H, d, J  7.2, Me), 3.88 (1H, dd, J  13.7 and 2.9, C//HC1), 4.06 (1H, dd, J
13.7 and 2.8, CH//C1), 4.92 (1H, dq, J 9 . 2  and 7.2, CZ/Me), 5.78 ( 1 H, ddd, J 9 .2 ,
2.9 and 2.8, CHO), 7.76 (2H, m, phthaloyl) and 7.88 (2H, m, phthaloyl); 8 C (67.8 
MHz, CDC13) 14.30 (Me), 43.46 (CH2 C1), 47.06 (CHMe), 84.95 (CHO), 121.9 (q, 
C-FJ  309, CFj), 123.55 (m-C), 131.43 (C C O ), 134.41 (o-C) and 167.72 (C O );
232
m/z (70eV) 281 (3%, M-CH2 C1), 174 (M-F3 C S0 3 CHCH2 C1, 23); (C.I.) 386 
(M++ l, 90).
(28,33,2*8) and (2R,3R,2*S)-l-Chloro-2-(0-methyl leucinyl)-3-phthalqylamino- 
butane (327) and (462)
(2S,3S,2 'S)-l-Chloro-2-(O-methyl leucinyl)-3-phthaloylaminobutane (327)
{IS, 3S,2 'S)~ 1 -Chloro-2-(0-methyl leucinyl)-3-phthaloylaminobutane (327) as the 
major isomer, was a colourless gum, v^x/cnr1 3400s (NH), 1736s (C=0), 1713s 
(C=0), 1656, 14598as (Me) and 13705 s (Me); 8h(270 M H z , CDC13) 0.92 (3H, d, J  
6.4, C H ^ e), 1.05 (3H, d, J  6.3, C H ^ e), 1.41 (3H, d, J  7.0, CHMe), 1.66-1.80 
(1H, m, CH2 C m ie2), 1.80-2.20 (2H, m, C/^CHMe^, 3.54 (1H, dd, J  11.2 and 
7.3, CHtfCl), 3.65 (1H, dd, J  11.2 and 5.7, C i/H d), 3.77 (3H, s, OMe), 4.15 (1H, 
ddd, J  7.3, 5.7 and 2.0, CHN), 4.90-5.00 (1H, m, CtfMe), 5.04-5.12 (1H, m, 
CHC0 2 Me), 6.00 (1H, br s, NH), 7.29-7.78 (2H, m, phthaloyl), 7.85-8.10 (1H, m, 
phthaloyl) and 7.90-7.94 (1H, m, phthaloyl); 8 C (67.8 MHz, CDC13) 14.3 (Me), 
21.3 and 22.2 (CHMe2), 25.1 (CHMej), 43.4 (O ^CH M eJ, 45.8 (CH2 C1), 49.5 
(NCHMe), 52.4 (OMe), 59.0 (NCHC02), 73.6 (CHN), 123.4 (m-C), 131.7 
(CC=O), 134.3 (o-C), 166.9 (C=0), 168.3 (C=0) and 172.4 (C 0 2 Me); m/z (C.I.) 
381 (M++ l, 10%), 345 (5, M+-C1); [Found : (M +l)+ 381.1587. C19H2 6 N2 0 4 C1 
requires 381.1581].
(2R,3R,2 *S)-l-Chloro-2‘(0-methyl leucinyl)-3-phthaloylaminobutane (462)
(2R, 3R, 2  'S)~ 1 -Chloro-2-(0-methyl leucinyl)-3-phthaloylaminobutane (462) as the 
minor isomer, was a colourless gum, Vn^/cnr1 3400s (NH), 1736s (C=0), 1713s 
(C=0), 1656, 14598as (Me) and 13705 s (Me); 8h(270 M H z , CDC13) the same as ( 
) except 0.91 (3H, d, J 6 .4 , C H ^ e), 1.03 (3H, d, J 6 .3 , C H ^ e), 1.38 (3H, d, J
7.0, CHMe) the other peaks were obscured; 8 C (67.8 MHz, CDC13) 14.5 (Me), 
21.1 and 21.9 (CHMe2), 24.8 (CHMe2 X 43.7 (CH2 CHMe2 ), 45.8 (CH2 C1), 49.7
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(NCHMe), 53.1 (OMe), 60.2 (NCHC02), 72.5 (CHN), 124.1 (m-C), 131.7 
(CC=0), 133.7 (o-C), 166.9 (C=0), 168.3 (C=0) and 172.4 (C02Me); m/z (C.I.) 
381 (M++1, 10%), 345 (5, M+-C1); [Found : (M+l)+ 381.1587. C19H26N20 4 C1 
requires 381.1581].
Method B
Analogous to method A, the triflate was generated from the racemic chloroalcohol
(403) (0.108g, 0.43mmol) in DCM (5ml), concentrated in vacuo and then reacted 
immediately with Leu-OMe (1 eq.) and triethylamine (1 eq.). After 3 days more 
triethylamine (1 eq.) was added and the reaction left for a further 10 days. After 
chromatography (Z) (458) and (£)-alkene (465) (0.005g, 5%), racemic 
chloroalcohols (403:404, -1:1) (0.063g, 58%) and aziridines (328) (0.012g, 8 %) 
were isolated.
Method C
To a stirred solution of the racemic chlorotriflate (464) (164mg, 0.43mmol) in 
MeOH (5ml) at room temperature was added Leu-OMe.HCl (8 6 mg, 0.47mmol) 




time a t.l.c. showed starting material. So the reaction was heated to 50°C for 3 
hours, no further reaction occurred, the reaction mixture was diluted with CHC13 
(10ml), washed with 0.5M HC1 (20ml) and the acidic phase back extracted with 
CHCI3 (10ml). The organics were combined, dried (MgS04) and concentrated in 
vacuo to give 0.155g of crude material, which was flash chromatographed, eluting 
with petrol:EtOAc (70:30) gradient to (50:50) to give racemic chloromethyl ether 
(472) (7mg, 6 %), chloromethyl dipeptide (326) and (470) (0.2mg, 0.1%) and 
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(2JR*,3.S*)-l-Chloro-2-methoxy-3-phthaloylaminobutane (468) was isolated as a 
colourless oil; Rf [petrol:EtOAc (70:30)] 0.44; vmax/cm_1 1724s (C=0), 1606, 
14645as (Me), 13568s (Me), 1318, 1085 and 764; 8^270 MHz, CDC13) 1.54 (3H, 
d, 7  6 .6 , CHMe), 3.17 (3H, s, OMe), 3.51 (1H, dd, J  11.7 and 5.9, CH//C1), 3.60 
(1H, dd, J  11.5 and 4.6, C77HC1), 4.16 (1H, qd, J  6.7 and 5.5, C//Me), 4.68 ( 1H, 
dd, J  10.1 and 5.7, CtfOMe), 7.55-7.68 (3H, m, phthaloyl) and 7.77-7.82 (1H, m, 
phthaloyl); 8 C (67.8 MHz, CDC13) 20.63 (Me), 44.18 (CH2C1), 51.93 (CHMe), 
53.48 (OMe), 89.73 (CHOMe), 124.24 (m-C), 132.58 (CC=0), 133.50 (o-C) and 
170.77 (C=0); m/z (70eV) 236 (100%, M-OMe), 218 (M-CH2C1, 5), 200 (M-HC1
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and OMe, 5), 174 (M-MeOCHCH2 Cl, 67); (C.I.) 268 (100, M++1); [Found : 
(M+l)+ 268.0717. C13H 15N 0 3 C1 requires 268.0740].
2-Methylcarboxylate-[l f(R*)-chloromethyl-2 f(S*)-methylaziridine] benzamide
(469)
2-Methylcarboxylate-[ 1 ,(^*)-chloromethyl-2'(<S,*)-methylaziridine] benzamide (469) 
was isolated as a colourless oil; Rf [petrol:EtOAc (50:50)] 0.44; (Found C, 58.00; 
H, 5.31; N, 5.23. calc, for C13H14N 0 3 C1: C, 58.33; H, 5.27; N, 5.23%); v ^ c n r 1 
173l s (C=0), 1661s (C=0), 1295 and 1272; 5h(270 MHz, CDC13) 1.40 (3H, d, J  
6 .8 , Me), 3.65 (1H, dd, J  11.4 and 10.3, C//HC1), 3.72 (1H, dd, J  11.4 and 9.5, 
CHtfCl), 3.89 (3H, s, OMe), 4.17 ( 1 H, dq, J  6.4 and 5.7, CtfMe), 4.40 ( 1 H, dd, J
11.7 and 6.1, C//NCO), 7.50-7.60 (2H, m, phthaloyl) and 7.70-7.80 (2H, m, 
phthaloyl); 5C (67.8 MHz, CDC13) 21.40 (Me), 44.47 (CH2 C1), 52.35 (C O ^ e), 
66.18 (CHMe), 85.30 (CHCH2 C1), 127.88 (CC02 Me), 128.95 (o-CCON), 129.74 
(o-CC02 Me), 130.45 (m-CCON), 130.99 (m-CC0 2 Me), 131.88 (CCON), 162.27 
(CON) and 167.64 (C 0 2 Me); m/z (70eV) 267 (10%, M+), 252 (M-Me, 10), 236 
(M-OMe), 232 (M-Cl, 25), 208 (M-C02 Me, 8 ); (C.I) 268 (100, M++1).
Method D
To a stirred solution o f the racemic chlorotriflate (464) (0.22g, 0.57mmol) in DCM 
(7ml) at room temperature was added Leu-OMe.HCl (0.16g, 0.86mmol) and 
K2 C 0 3  (0.16g, 1.14mmol). The reaction was stirred for four days, after which time 
a t.l.c. showed no starting material. The reaction mixture was diluted with CHC13  
(10ml), washed with 0.5M HC1 (20ml) and the acidic phase back extracted with 
CHC13 (10ml). The organics were combined, dried (M gS04) and concentrated in 
vacuo to give 0.33g o f a crude material. This was flash chromatographed, eluting 
with petrol:EtOAc (70:30) gradient to (50:50) to give racemic chlorotriflate (464) 
(0.05g, 23%); Rf [petrol: EtOAc (80:20)] 0.33; and the chloroalcohols; Rf [petrol: 
EtOAc (80:20)] 0.19-0.16 (403) and (404) and the chloromethyl dipeptides (326)
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and (470), Rf [petrol:EtOAc (80:20)] 0.14. The mixture was chromatographed 
several times, eluting with petrol:EtOAc (80:20) until a sample was pure enough for 
characterisation, chloromethyl dipeptides (326) and (470) (0.04g, 20%):
(2R,3S,2'S) and (2S,3R,2'S)-1-Chloro-2-(O-methyl leucinyl)-3-phthaloylaimno- 
butane (326) and  (470)
were isolated as a colourless gum, vmax/cm_1 3400s (NH), 1736s (C=0), 1713s 
(C=0), 1656s (C=0), 1459g as (Me) and 13705 s (Me); 8^270 MHz, CDC13) major 
isomer (2R, 3S, 2'S) (326) 0.85 (3H, d, J6 .4 , CBjMe), 0.97 (3H, d, J6 .3 , C U ^ e ), 
1.40 (3H, d, J  7.3, CHMe), 1.60-1.66 (1H, m, O ^C tfM e^, 1.68-2.00 (2H, m, 
Ctf2 CHMe2), 3.40-3.60 (2H, m, CH2 C1), 3.70 (3H, s, OMe), 4.14-4.22 (1H, m, 
CHN), 4.94-5.10 (2H, m, CHMq and CtfC02 Me), 6.00 (1H, br s, NH), 7.60-7.70 
(2H, m, phthaloyl) and 7.78-7.90 (1H, m, phthaloyl) and minor isomer (2<S', 3Rt 2'S)
(470) the same as the major except 0.86 (3H, d, J  6.4, C H ^ e), 0.96 (3H, d, J6 .3 , 
C H ^ e), 1.42 (3H, d, J  7.3, CHMe) all other peaks obscured; 8 C (67.8 MHz, 
CDC13) 14.08 (Me), 21.01 and 22.10 (CHMe2), 25.15 (CHMe2 ), 43.37 (CH2 C1), 
45.52 (CH2 CHMe2 ), 49.17 (NCHMe), 52.48 (OMe), 60.36 (NCHC02), 73.19 
(CHN), 123.51 (m-C), 125.23 (m-C), 129.16 (CC=0), 132.69 (o-C), 133.62 (o-C), 
168 (C=0) and 172 (C 0 2 Me); m/z (C.I.) 381 (M++ l, 10%), 345 (5, M+-C1); 
[Found : (M +l)+ 381.1587. C19H2 6N 2 0 4 C1 requires 381.1581].
Method E
To a stirred solution o f the racemic chlorotriflate (464) (0.223g, 0.58mmol) in 
DCM (2ml) at room temperature was added Leu-OMe.HCl (0.136g, 0.75mmol) 
and DIPEA (O.lOlg, O.58mmol). The reaction was stirred for 16 hours, after which 
time the reaction mixture was refluxed for 2 hours using THF as a co-solvent. 
After this time a t.l.c. showed no starting material and the reaction mixture was 
diluted with ether (30ml), washed with 0.5M HC1 (50ml), dried (M gS04) and 
concentrated in  vacuo  to give 0.265g crude material. This was flash
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chromatographed, eluting with petrol:EtOAc (70:30) to give chlorotriflate (464) 
(0.05g, 23%); Rf [petrol:EtOAc (80:20)] 0.33, and the chloroalcohols (403) and 
(404); Rf [petrol:EtOAc (80:20)] 0.19-016 and the chloromethyl dipeptides (326) 
and (470) (0.182g, 24%); Rf [petrol:EtOAc (80:20)] 0.14. The mixture was 
rechromatographed, eluting with petrol:EtOAc (80:20).
Attempted preparation o f the chloromethyl dipeptide (327) using the Mitsunohu 
reaction
Method A
To a solution of the racemic chloroalcohol (404) (0.0875g, 0.345mmol), triphenyl 
phosphine (0.136g, 0.863mmol) and Leu-OMe (0.06g, 0.41mmol) in THF (5ml) 
was added dropwise DEAD (0.136ml, 0.863mmol). The reaction was stirred at 
room temperature for 2 days. After this time no new products were observed. The 
reaction was concentrated in vacuo to give 0.53g of crude material which was flash 
chromatographed on silica, eluting with petrol:EtOAc (90:10 with a gradient to 
50:50) to give racemic (Z)- (458) and (£)-alkenes (465) (0.046g, 57%), racemic 
ethyl-carbonate (459) (0.009g, 8%) and racemic chloroalcohol (404) (0.023g, 
26%).
~ V  -
k c  cl °
(404) (465) (458) (459)
(2R*,3S*)-l-Chloro-2-ethylcarbonate-3-phthaloy1aminobutane (459) 
(2/?*,3S*)-l-Chloro-2-ethylcarbonate-3-phthaloylaminobutane (459) was isolated 
as a colourless oil; v ^ /c n r 1 2924, 2853, 1774s (C=0), 1747s (C=0), 1713s 
(C=0), 1612, 14675 as (Me), 13815 s (Me), 1255 and 722s (C-Cl); 5^270 MHz, 
CDC13) 1.13 (3H, \y J  6.9, CH2C//3), 1.56 (3H, d, J  7.2, CHMe), 3.76 (lH,dd, J
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12.5 and 4.1, C//HC1), 3.99 (1H, dd, J  12.5 and 3.1, CHtfCl), 4.01-4.11 (2H, m, 
OC//2CH3), 4.78 (1H, qd, J9.1 and 7.2, C//Me), 5.54-5.62 (1H, m, CHO), 7.67- 
7.73 (2H, m, phthaloyl) and 7.81-7.89 (2H, m, phthaloyl); m/z (FAB +ve) 326 
(M++l).
Method B
To a solution of the racemic chloroalcohol (463) (0.126g, 0.5mmol), triphenyl 
phosphine (0.197g, 0.75mmol) and Boc-Leu-OMe (0.123g, 0.75mmol) in THF 
(3ml) was added dropwise DEAD (0.086ml, 0.75mmol). The reaction was stirred 
at room temperature for 2 days. After this time no new products were observed. 
The reaction was concentrated in vacuo to give 0.56g of a crude material which 
was flash chromatographed on silica, eluting with petrol:EtOAc (80:20 with a 
gradient to 60:40) to give Boc-Leu-OMe and racemic (Z) (458) and (£)-alkenes
(465) (0.104g), racemic carbonate (459) (0.002g, 2%) and racemic chloroalcohol 
(463) (0.072g, 57%). A sample (0.02g) of the chloroalcohol (463) and 
ethylcarbonate (459) were further purified by HPLC using an isocratic eluent 
(acetonitrile:water):water:TFA (30:70:1) then after 15 mins gradient to 80:20:1. 




Area (%) Compound Yield, (mg)
14.3 39.3 chloroalcohol (463) 5
15.3 26.5 (463) + (393) 6
16.4 21.6 (463) + (393) 1









To a solution of the racemic chloroalcohol (404) (0.042g, 0.165mmol), triphenyl 
phosphine (0.043g, 0.165mmol) and TFA-Leu-OMe (0.04g, 0.165mmol) in THF 
(5ml) was added dropwise DEAD (0.026ml, 0.165mmol). The reaction was stirred 
at room temperature for 2 days, after which time no new products were observed. 
The reaction was concentrated in vacuo to give 0.56g of crude material which was 
flash chromatographed on silica, eluting with petrol:EtOAc (80:20 with a gradient 
to 60:40) to give recovered TFA-Leu-OMe (0.03 lg, 77%) and racemic 
chloroalcohol (404) (0.037g, 88%).
(2S,3S) and (2R,3S)-l-(tert-ButyUliphenylsiloxy)-2-hydroxy-3-phthaloylamina- 
butane (339) and (474)
To a solution of the diols (337) and (338) (0.562g, 2.4mmol) in anhydrous DCM 
(25ml) was added imidazole (0.409g, 6.0mmol) and /-butylchlorodiphenylsilane 
(0.657g, 2.45mmol). The reaction was stirred under N2 at room temperature for 30 
minutes. The reaction was diluted with ether (50ml) and washed with 0.5M HC1 
(50ml), brine (50ml), dried (Na2S04) and concentrated in vacuo to give 1.21g of 
crude material. This was flash chromatographed on silica, eluting with 












(2R,3S)-1 -(/er/-Butyldiphenylsiloxy)-2-hydroxy-3-phthaloylaminobutane (339) was 
isolated as a colourless solid, Rf [petrol:EtOAc (85:15)]; 0.24; m.p. 97°C (hexane); 
M 5890-9 (c 0.424 in CHC13); (Found C, 70.97; H, 6.64; N, 2.69. calc, for
C12H13N 0 4 : C, 71.0; H, 6.60; N, 2.96%); v ^ /c n r 1 3453s (OH), 1781, (C=0), 
1705s (C=0), 1393, 1108s (Si-C or C-O) and 699; 5^270 MHz, CDC13) 1.05 (9H, 
s, /-Bu), 1.36 (3H, d, J  1.2, Me), 3.20 (1H, br d, J 7.9, CHO//), 3.69 (2H, d, J  4.5, 
CH20), 4.10 (1H, m, CHO), 4.64 (1H, dq, J1 .2  and 7.2, CHMe), 7.2-7.48 (5H, m, 
ph), 7.58-7.66 (5H, m, ph), 7.70-7.74 (2H, m, phthaloyl) and 7.81-7.85 (2H, m, 
phthaloyl); 8C (67.8 MHz, CDC13) 15.15 (Me), 19.12 (CMe3), 26.76 (CMe3), 48.78 
(NCHMe), 64.78 (CH20), 72.28 (CHOH), 123.21 (m-C), 127.67 (Si-Ph), 127.74 
(Si-Ph), 129.77 (Si-Ph), 129.83 (Si-Ph), 131.94 (CC=0), 132.78 (Si-Ph), 133.91 
(o-C), 135.47 (Si-Ph), 135.56 (Si-Ph) and 168.95 (C=0); m/z (C.I.) 474 (M++1, 
100%).
(25.35)-l-(tert-Butyldiphenylsiloxy)-2-hydroxy-3-phtha1oylaminobutane (474)
(25.35)- l-(/er/-Butyldiphenylsiloxy)-2-hydroxy-3-phthaloylaminobutane (474) was 
isolated as a colourless solid; Rf [petrol:EtOAc (85:15)]; 0.29; m.p. 90-91°C 
(hexane); [a]“ 9-8.3 (c 0.65 in CHC13); (Found C, 70.97; H, 6.64; N, 2.69. calc, for
C12H13N 0 4 : C, 71.00; H, 6.60; N, 2.96%); v ^ /c n r 1 3453s (OH), 1781s (C=0), 
1705s (C=0), 1393, 1108s (Si-C or C-O) and 699; 5^270 MHz, CDC13) 1.07 (9H, 
s, /-Bu), 1.37 (3H, d, 7  7.0, Me), 3.59 (1H, dd, J  10.5 and 6.4, C//HO), 3.64 (1H, 
br s, CHO//), 3.69 (1H, dd, J  10.4 and 5.0, CH//0), 4.17 (1H, m, CHO), 4.65 (1H, 
qd, J7.0  and 5.0, CHMe), 7.25-7.40 (5H, m, ph), 7.59-7.69 (5H, m, ph), 7.70-7.73
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(2H, m, phthaloyl) and 7.81-7.84 (2H, m, phthaloyl); 6 C (67.8 MHz, CDC13) 13.05 
(Me), 19.12 (CMe3), 26.75 (C M e3), 48.38 (NCHMe), 64.25 (CH2 0 ) , 72.96 
(CHOH), 123.38 (m-C), 127.62 (Si-Ph), 127.77 (Si-Ph), 129.69 (Si-Ph), 129.83 
(Si-Ph), 131.79 (CC=0), 132.91 (Si-Ph), 134.04 (o-C), 135.47 (Si-Ph), 135.56 (Si- 
Ph) and 168.66 (C=0); m/z (C.I.) 474 (M++1 , 100%).
(2 R ,3 S )-l-(te rt-B u ty ld ip h en y lsilo xy)-3 -p h th a Io y la m in o -2 -(tr ifIu o ro m eth a n e- 
su lfo n y lo x y )b u ta n e  (340)
To a cooled solution (-20°C) o f the protected diol (339) (0.063g, 0.132mmol) in 
DCM (3ml) was added pyridine (0.012ml, 0.152mmol). The reaction was stirred 
for 5 minutes before the addition o f triflic anhydride (0.024ml, 0.145mmol). The 
reaction was then stirred at -20°C for 5 minutes before being allowed to attain room 
temperature at which it was stirred for a further 1 hour. The reaction mixture was 
diluted with ether (5ml), washed with water (5ml), brine (5ml), dried (M gS04) and 
concentrated in  vacuo. The crude material was flash chromatographed, eluting with 
petrol:EtOAc (90:10) to give the desired product (340) (0.071g, 89%); as a pale 
pink solid, m.p. 93°C; (Found C, 57.60; H, 4.91; N, 2.28. calc, for 
C2 9 H3 0NO6F3SiS : C, 57.50; H, 4.99; N, 2.31%); [o ] ” 9  17.5 (c 1.4 in CHC13);
vmax/cm-! 1770s (C=0), 1716S(C=0), 1612, 1590, 14708 a s (Me), 1411 and 1388; 
5h(270 MHz, CDC13) 1.13 (9H, s, r-Bu), 1.51 (3H, d, J  7.2, Me), 3.96 ( 1 H, dd, J  
13 and 3.1, C//HO), 4.06 (1H, dd, J 13 and 2, CHflO), 5.02 (1H, dq, 7 9 .7  and 7.2, 
Cf/Me), 5.53 (1H, ddd, J  9 .7 , 3.1 and 2, CHO) 7.40-7.50 (5H, m, ph), 7.67-7.72 
(5H, m, ph), 7.72-7.76 (2H, m, phthaloyl) and 7.85-7.9 (2H, m, phthaloyl); 5C (67.8 
MHz, CDC13) 14.58 (Me), 19.27 (CMe3), 26.67 (CM e3), 46.39 (NCHMe), 63.01 
(CHjO), 88.72 (CHOH), 123.38 (/n-C), 127.71 (Si-Ph), 127.77 (Si-Ph), 127.99 
(Si-Ph), 129.80 (Si-Ph), 129.93 (Si-Ph), 130.13 (Si-Ph), 131.66 (CC=0), 131.79 
(Si-Ph), 134.22 (o-C), 135.52 (Si-Ph), 135.61 (Si-Ph) and 167.86 (C=0); m/z (C.I.) 











To a cooled solution (-20°C) of the protected diol (474) (0.822g, 1.74mmol) in 
DCM (20ml) was added pyridine (0.16ml, 1.91mmol). The reaction was stirred for 
5 minutes before the addition of triflic anhydride (0.35ml, 2.08mmol). The reaction 
was then stirred at -20°C for 5 minutes before being allowed to attain room 
temperature at which it was stirred for a further 1 hour. The reaction mixture was 
diluted with ether (30ml), washed with water (30ml), brine (30ml), dried (MgS04) 
and concentrated in vacuo. The crude material was flash chromatographed, eluting 
with petrol:EtOAc (90:10) to give the desired product (475) (0.378g, 36%) as a 
syrup, Rf [petrol:EtOAc (75:25)]; 0.38; [a]$g90.0 (c 0.976 in CHC13); Vj^/cm-1
1777s (C=0), 1716s (C=0), 1597, 1464as (Me) and 1388; 5H(270 MHz, CDC13) 
0.96 (9H, s, t-Bu), 1.49 (3H, d, 77.2, Me), 3.64 (1H, dd, J  12.8 and 3.9, C//HO),
3.80 (1H, dd, J  12.8 and 2.9, CH//0), 4.84 (1H, dq, J  9.0 and 7.2, C//Me), 5.50 
(1H, ddd, J  9.0, 3.9 and 2.9, CHO) 7.23-7.50 (10H, m, ph) and 7.60-7.80 (4H, m, 
phthaloyl); 8C (67.8 MHz, CDC13) 15.1 (Me), 19.0 (CMe3), 26.5 (CMe3), 45.6 
(NCHMe), 62.6 (CH20), 88.9 (CHOH), 123.4 (m-C), 127.6 (Si-Ph), 127.7 (Si-Ph),
127.9 (Si-Ph), 129.7 (Si-Ph), 129.9 (Si-Ph), 130.1 (Si-Ph), 131.6 (CC=O), 131.8 





Attempted preparation o f  the tert-butyldiphenylsiloxymethyl dipeptide (476) 
using the Mitsunobu reaction
To a solution of the protected diol (339) (0.159g, 0.336mmol), triphenyl phosphine 
(0.097g, 0.37mmol) and TFA-Leu-OMe (368) (0.085g, 0.336) in THF (3ml) was 
added dropwise DEAD (0.058ml, 0.37mmol). The reaction was stirred at room 
temperature for 4 days after which time no new products were observed. The 
reaction was concentrated in vacuo and flash chromatographed, eluting with 
cyclohexane:EtOAc (70:30) to give starting materials.
Preparation o f (2S}3S,2'S)-l-(tert-butyldipheny1siloxy)-2-(0-methyl leucinyl)-3- 
phthaloylaminobutane (476) by displacement o f  the TBDPS protected triflate 
(340).
Method A
To a stirred a solution of racemic triflate (340) (0.08g, 0.132 mmol) in anhydrous 
DCM (2 ml) was added Leu-OMe.HCl (0.03g, 0.16mmol) and triethylamine 
(0.017ml, 0.16mmol). The reaction was stirred at room temperature for 3 days 
before being diluted with ether (20 ml). The organics were washed with water (30 
ml), dried (Na2S 04) and concentrated in vacuo. The crude material was flash 
chromatographed on silica, eluting with petrol:EtOAc (85:15) gradient 
petrol:EtOAc (80:20). This gave the starting material (340) (0.041g, 51%) and an 




(2S,3S,2 'S)-l-(tert-Butyldiphenylsiloxy)-2-(O-methyl leucinyl)-3-phthaloylamino 
butane (476).
(2S,3S,2'S)-l-(terr-Butyldiphenylsiloxy)-2-(0-methyl leucinyl)-3-phthaloylamino- 
butane (476) was isolated as a colourless oil; Rf [petrol:ether(60:40)] 0.27; (Found 
C, 70.5; H, 7.39; N, 4.22. calc, for C3 5 H4 4 N 2 0 5 S i : C, 69.97; H, 7.38; N, 4.66%); 
v ^ /c m - 1 3388s (NH), 1735s (C=0), 1713s (C=0), 1656, 14706as (Me), 1430 and 
1387; 8H(400 MHz, CDC13) 0.91 (3H, d, J 6.4, CHMe2), 1.03 (3H, d, J 6.4, 
CHMe2), 1.11 (9H, s, 'Bu), 1.23 (3H, d, J 7.0, CHMe), 1.68-1.76 (1H, m, 
CH2C//Me2), 1.86-1.98 (2H, m, CH2CHMq2), 3.50-3.60 (1H, m, CH/70) 3.72 
(3H, s, OMe), 3.84 (1H, ddd, J 10.3, 4.8 and 2.4, CHN), 4.01-4.17 (1H, m, 
C/7HO), 5.02-5.12 (1H, m, CT7C02Me), 5.20 (1H, brq, J 7.3, CHMe), 5.80-6.00 
(1H, brs, NH), 7.22-7.34 (5H, m, phenyl); 7.58-7.65 (7H, m, phenyl and phthaloyl) 
and 7.82-7.88 (2H, m, phthaloyl); 8 C (67.8 MHz, CDC13) 11.02 (CHMe), 19.17 
(CMe3), 21.92 (CHMe2), 22.85 (CHMe2), 25.06 (CHMe2), 26.67 (CMe3), 26.78 
(CMe3), 26.84 (CMe3), 43.75 (CH2), 48.82 (CHMe), 52.44 (OMe), 60.41 
(CHC02), 64.72 (CH2 0 ), 73.73 (CHN), 123.25 (SiPh), 124.03 (SiPh), 125.32 (m- 
C), 127.6 (SiPh), 129.4 (CC=O), 129.56 (SiPh), 129.76 (SiPh), 132.38 (SiPh), 
132.91 (SiPh), 133.29 (SiPh), 133.95 (o-C), 135.59 (SiPh), 167.50 (CON), 168.00 
(CON) and 172.00 (C 0 2Me); m/z (C.I.) 601 (M++1, 100%).
(2R,3R,2 'S)-l-(tert-Butyldiphenylsiloxy)-2-(O-methyl leucinyl)-3-phthaloyl- 
amino butane (477).
(2R,3R,2'S)~ 1 -(terf-Butyldiphenylsiloxy)-2-(0-methyl leucinyl)-3-phthaloylamino 
butane (477) was isolated as a colourless gum; Rf [petrol:ether(60:40)] 0.27; 
(Found C, 70.5; H, 7.39; N, 4.22. calc, for C3 5 H4 4 N2 0 5Si : C, 69.97; H, 7.38; N, 
4.66%); v ^ /c n r 1 3388s (NH), 1735s (C=0), 1713s (C=0), 1656, 14705 ^  (Me), 
1430 and 1387; 8^270 MHz, CDC13) 0.85-1.06 (6 H, m, CHMe2), 1.10 (9H, s, 
'Bu), 1.22 (3H, m, CHMe), 1.68-1.76 (1H, m, CH2CHMc2), 1.86-1.98 (2H, m, 
CH2CHMq2), 3.71 and 3.73 (3H, s, OMe), 3.79-3.98 (1H, m, CHN), 4.01-4.17
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(2H, m, CH2 0 ), 4.96-5.05 (1H, m, C //C 0 2 Me), 5.20 (1H, m, CHMe), 7.22-7.34 
(5H, m, phenyl); 7.58-7.65 (7H, m, phenyl and phthaloyl) and 7.82-7.88 (2H, m, 
phthaloyl); 5C (67.8 MHz, CDC13) 10.78 (CHMe), 19.17 (CMe3), 21.12 (CHMe2), 
22.78 (CHMe2), 25.06 (CHMe2), 26.67 (CMe3), 26.78 (CMe3), 26.84 (CMe3), 
43.46 (CH2), 48.73 (CHMe), 52.37 (OMe), 60.27 (CHC02), 64.72 (CH2 0), 73.53 
(CHN), 123.32 (SiPh), 124.07 (SiPh), 125.32 (m-C), 127.68 (SiPh), 129.40 
(CC=0), 129.65 (SiPh), 129.87 (SiPh), 132.38 (SiPh), 132.91 (SiPh), 133.29 
(SiPh), 134.08 (o-C), 135.7 (SiPh), 167.50 (CON), 168.00 (CON) and 172.00 
(C 0 2Me); m/z (C.I.) 601 (M++1,100%).
Method B
To a stirred a solution of racemic triflate (340) (0.89g, 1.47mmol) in anhydrous 
MeOH (15 ml) was added Leu-OMe.HCl (0.294g, 1.62mmol) and K2 C 0 3 (0.406g, 
2.94mmol). The reaction was stirred at room temperature for 1 day before being 
diluted with CHC13 (50ml). The organics were washed with 0.5M HC1 (30 ml), 
back extracted with CHC13 (60ml), dried (Na2 S 0 4) and concentrated in vacuo to 
give 0.812g of crude material. This was flash chromatographed on silica, eluting 
with petrol:EtOAc (85:15) to give the enol ether (480) (O.Olg, 1.5%), 
hydroxymethyl dipeptides (476) and (477) (0.134g, 15%) and the aziridine (481) 
(0.468g, 65%):
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(Z)- l-(rm-Butyldiphenylsilyloxy)-3(S*)-phthaloylaminobut- 1-ene (480) was 
isolated as a colourless oil; Rf [petrol:ether (60:40)] 0.35; (Found C, 73.5; H, 6.99; 
N, 2.61. calc, for C28H29N 0 3Si : C, 73.8; H, 6.42; N, 3.07%); v ^ /c n r 1 1774s 
(C=0), 1712s (C=0), 1654s (C=C), 14685 ^  (Me), and 1116s (Si-C); 6H(270 MHz, 
CDC13) 1.06 (9H, s, t-Bu), 1.55 (3H, d, J 7.2, Me), 5.11 (1H, dd, J 8.4 and 5.7, 
C=C//CHMe), 5.70 (1H, dq, J 8.3 and 7.2, CHMe), 6.17 (1H, dd, J 5.7 and 1.1, 
HCOTBDPSi), 7.20-7.50 (6 H, m, SiPh), 7.55-7.6 (2H, m, SiPh), 7.64-7.74 (4H, m, 
phthaloyl and SiPh) and 7.80-7.84 (2H, m, phthaloyl); Sc (67.8 MHz, CDC13)
14.10 (Me), 26.50 (CMe3), 26.60 (CMe3), 41.24 (NCHMe), 109.16 (C=CHCHMe), 
122.96 (m-C), 127.63 (Si-Ph), 127.68 (Si-Ph), 127.73 (Si-Ph), 127.84 (Si-Ph),
129.60 (Si-Ph), 129.93 (Si-Ph), 130.05 (Si-Ph), 132.32 (CC=0), 133.62 (Si-Ph),
134.80 (o-C), 135.32 (Si-Ph), 135.42 (Si-Ph), 140.50 (C=CHCHMe) and 167.93 




aziridine] benzamide (481) was isolated as a colourless solid; m.p. 57°C; Rf 
[petrohether (60:40)] 0.3; v ^ /c n r 1 1730s (C=Q), 1646s (C=Q), 1591, 1292s (C-O-
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C), 1256 and 1109s (Si-O); 6H(270 MHz, CDC13) 1.06 (9H, s, f-Bu), 1.30 (3H, d, J
7.0, Me), 3.77 (3H, s, OMe), 3.90 (2H, dd, J 6.2 and 1.6, Ctf2 OTBDPSi), 4.45 (1H, 
dq, J 9.0 and 7.0, CtfMe), 4.75 (1H, d, /  9.0 and 6.2, NCH), 7.35-7.44 (6 H, m, 
SiPh), 7.46-7.52 (2H, m, phthaloyl), 7.64-7.74 (6 H, m, phthaloyl and SiPh) and 
7.80-7.84 (6 H, m, SiPh and phthaloyl); 8 C (67.8 MHz, CDC13) 15.32 (Me), 26.69 
(CMe3), 26.73 (CMe3), 52.32 (CO2M e\ 61.97 (CH2 0 ), 63.22 (NCHMe), 82.56 
(CHCH2 0 ), 127.68 (Si-Ph), 127.76 (Si-Ph), 128.02 (CC02Me), 128.75 (o-CCON), 
129.68 (Si-Ph), 129.74 (o-CC0 2Me), 130.32 (m-CCON), 132.29 (m-CC02Me), 
133.08 (Si-Ph), 133.14 (CCON), 135.51 (Si-Ph), 162.30 (NC=0) and 167.70 
(C 0 2 Me); m/z (70eV) 430 (5%, M-tBu), 269 (8 , CH2 OSiTBDP+); (C.I.) 488 
(M ++1,100%); [Found : (M+l)+ 488.2254. C2 9 H3 4 N0 4Si requires 488.2257].
Method C
To a stirred a solution of racemic triflate (340) (0.56g, 0.925mmol) in anhydrous 
DCM (5 ml) was added Leu-OMe.HCl (0.202g, l.llm m ol), triethylamine (0.36ml, 
2.6mmol) and catalytic amount of DMAP (0.005g, 0.05mmol). The reaction was 
allowed to stir at room temperature for 2 days before refluxing for 3 hours. The 
reaction mixture was then diluted with ether ( 1 0 ml), the organics washed with 
0.5M HC1 (20 ml), dried (Na2 S 0 4) and concentrated in vacuo to give 0.83g of 
crude material. This was flash chromatographed on silica, eluting with 
petrol:EtOAc (85:15) to give the racemic enol ether (480) (0.06g, 12%) and the 
hydroxymethyl dipeptides (476) and (477) (0.11 lg, 20%).
Method D
To a stirred a solution of the racemic triflate (340) (0.23g, O.38mmol) in anhydrous 
THF (4ml) was added Leu-OMe.HCl (0.083g, 0.46mmol) and DIPEA (0.146ml, 
0.84mmol). The reaction was allowed to stir at room temperature for 2 days before 
refluxing for 3 hours. The reaction mixture was then diluted with ether (10ml), the 
organics were washed with 0.5M HC1 (20 ml), dried (Na2 S 0 4) and concentrated in
^48
vacuo.. The crude material was flash chromatographed on silica, eluting with 
petrol:EtOAc (85:15) to give starting material (0.12g, 52%) and the hydroxymethyl 
dipeptides (476) and (477) (0.07g, 31%).
Method E
To a stirred a solution of racemic triflate (340) (0.523g, 0.86mmol) in anhydrous 
DCM (2 ml) was added Leu-OMe.HCl (0.164g, 0.9mmol) and DIPEA (0.301ml, 
1.73mmol). The reaction was allowed to stir at room temperature for 1 day before 
refluxing for 12 hours. The reaction mixture was then diluted with ether (10ml), 
the organics were washed with 0.5M HC1 (20 ml), dried (Na2 S 0 4) and 
concentrated in vacuo. The crude material was flash chromatographed on silica, 
eluting with gradient petrol:EtOAc (90:10) to (85:15) to give starting material 
(340) (0.015g, 3%), racemic enol ether (480) (0.08g, 20%) and the hydroxymethyl 
dipeptides (476) and (477) (0.278g, 56%).
(2S,3S)-l-(tert-Butyldiphenylsilyloxy)-2-(0-methyl leucinyl)-3-phthaloylamino- 
butane (476).
To a stirred a solution of the triflate (340) (2.39g, 3.95mmol) in anhydrous THF 
(10ml) was added Leu-OMe.HCl (0.79g, 4.3mmol) and DIPEA (0.75ml, 4.3mmol). 
The reaction was allowed to stir at room temperature for 3 days before refluxing 
for 6  hours. The reaction mixture was then diluted with ether (40ml), the organics 
were washed with 0.5M HC1 (60 ml), dried (Na2 S 0 4) and concentrated in vacuo. 
The crude material was flash chromatographed on silica, eluting with petrol:EtOAc 






butane (476) was isolated as a gum; [a ]^  -18.2 (c 1.35 in CHC13).
(3S)-(Z)-l-(tert-Butyldiphenylsilyloxy)-3-phthaloylaminobut-l-ene (480)
(3S)-(Z)-1 -(tert-butyldiphenylsilyloxy)-3-phthaloylaminobut-1 -ene (480) was
isolated as an oil; [a]Jg9 8.33 (c 1.668 in CHC13).
(2S*,3S*,2'S)-l-(tert-Butyldiphenylsilyloxy)-2-leucinylmethylamide-3-phthaloyl- 
aminobutane (482) and (483).
To a cooled solution (0°C) of protected esters (476) and (477) (1.55g, 2.58mmol) 
in anhydrous methanol (10ml) was bubbled methylamine gas. After 30 mins., the 
methylamine gas flow was stopped and the reaction mixture was left to stir for 16 
hours. After this time the reaction mixture was acidified with 1M HC1 (pH~5), 
neutralised (saturated NaHC03), concentrated in vacuo, extracted with CHC13 (2 x 
80ml), the organics dried (MgS04) and concentrated in vacuo to give a crude 
material that flash chromatographed, eluting with petrol:EtOAc gradient from 
(50:50) to EtOAc. Four compounds were isolated of which the desired amides 
(482) and (483) was isolated (0.2g, 13%) as a colourless gum; Rf 
[petrol:ether(50:50)] 0.33; v ^ /c n r 1 3407s (NH), 1720s (C=0), 1713s (C=0), 
1660s (NC=0), 14705 m (Me), 1384s s (Me) and 1111; 8^270 MHz, CDC13) 0.87 
(3H, d, /6 .4 , CHMe2), 0.96 (3H, d, 76.4, CHMe2), 1.10 (9H, s, ®u), 1.33 (3H, d, J
7.1, CHMe), 1.65-1.83 (3H, m, CH2 CHMe2), 2.62 and 2.64 (3H, s, rotamers, 
NHA/e), 3.63 (1H, dd, J 10.1 and 8.3, CHHOSi), 3.83 (1H, dd, J  10.2 and 5.3, 
CHHOSi), 4.17-4.26 (1H, m, CHN), 5.00 (1H, dd, J  10.2 and 5.3, CHC02Me),
5.05 (1H, brs, NH), 5.17 (1H, dq, J 1 3  and 3.0, CHMe), 6.20 (1H, s, rotamers, 
NHMe), 7.34-7.50 (5H, m, phenyl), 7.64-7.74 (5H, m, phenyl), 7.90-7.94 (2H, m, 
phthaloyl) and 8.03-8.08 (2H, m, phthaloyl); 5C (67.8 MHz, CDC13) 11.72 
(CHMe), 19.14 (CMe3), 21.94 (CHMe2), 22.56 (CHMe2), 23.18 (CHMe2), 24.95 
(NHMe), 25.90 (NHMe), 26.78 (CMe3), 44.43 [minor isomer (2R,3R,2'S) CH2],
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44.76 [major isomer (2S,3S,2'S) CH2], 48.78 (CHMe), 62.04 (CHC02), 64.33 
[major isomer (2S,3S,2'S) CH20], 64.44 [minor isomer (2R,3R,2'S) CH20], 73.49 
(CHN), 123.03 (SiPh), 123.74 (SiPh), 125.85 (m-C), 127.64 (SiPh), 127.69 (SiPh), 
129.14 (CC=O), 129.69 (SiPh), 129.76 (SiPh), 132.32 (SiPh), 132.41 (SiPh), 
133.88 (SiPh), 133.07 (o-C), 135.60 (SiPh), 133.75 (SiPh), 135.28 (SiPh), 135.40 
(SiPh), 152.84 (CONMe), 168.20 (CON) and 173.20 (C02Me); m/z (C.I.) 600 









(476) and (477) (482) (483)
(2S,3S,2'S)-l-(tert-Butyldiphenylsilyloxy)-2-leucinylmethylamide-3-phthaloyl- 
aminobutane (482).
To the protected ester (476) (0.462g, 0.77mmol) was added a diluted solution (5ml) 
of (33%) methylamine in methylated spirits in anhydrous methanol (2ml:98ml) . 
The reaction mixture was left to stir for 2 days. After this time the reaction mixture 
was concentrated in vacuo to give a crude material that flash chromatographed, 
eluting with petrol:EtOAc gradient from (50:50). Four compounds were isolated 
of which the starting materials (476) (0.19g, 41%) and the desired amide (482) was 
isolated (O.lg, 22%) as a colourless gum; Rf [petrohether (50:50)] 0.33; [a]5g9-6 .4
(c 0.92 in CHC13).
(2S,3S,2 ’S) and (2R,3R,2 ’S)-l-Hydroxy-2-leucinylmethylamide-3-phthaloyl- 
aminobutane (484a) and (484b).
To a cooled solution (0°C) of the protected alcohols (482) and (483) (O.lg, 
0.167mmol) in THF (3ml) was added TBAF (0.33ml, O.33mmol). The reaction 
mixture was stirred for 2 hours, diluted with EtOAc (15ml), washed with brine
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(20ml), dried (MgS04) and concentrated in vacuo to give the crude alcohols (484). 
This was flash chromatographed, eluting with CHCl3:MeOH (90:10) to give the 
desired alcohol (484a) and (484b) (0.04g, 67%); Rf [CHCl3:MeOH (90:10)] 0.23; 
vmax/cm_1 3332s (NH), 1725s (C=0), 1660s (NC=0), 1539, 14656 M (Me), 1377 
and 1056; 8H(270 MHz, CDC13) 0.81 (3H, d, J 6 .6 , CHMe2), 0.89 (3H, d, J 6 .6 , 
CHMe2), 1.36 [minor isomer (2R,3R,2'S) 3H, d, J 7.0, CHMe], 1.44 (3H, d, J 7.0, 
CHMe), 1.58-1.70 (1H, m, CH2CHMe2), 1.72-1.95 (1H, m, CH2CHMe2), 2.70 and 
2.72 (3H, s, rotamers, NHMe), 3.51 (1H, dd, J 11.7 and 4.0, CHHO), 3.61 (1H, s, 
OH), 3.63 (1H, dd, J 11.4 and 4.4, CHHO), 4.14 (1H, dd, J 5.9 and 4.2, CHN), 
4.83 (1H, dq, J 7.0 and 6.2, C//Me), 4.94 (1H, dd, J 7.9 and 4.7, CHC02Me), 6 .8 8  
(1H, brs, NH), 7.30 (1H, 2 x s, rotamers, NHMe), 7.58-7.67 (2H, m, phthaloyl), 
7.78-7.84 (1H, m, phthaloyl) and 7.92-7.98 (2H, m, phthaloyl); 8 C (67.8 MHz, 
CDC13) major isomer (25,35,25) 13.56 (CHMe), 22.32 (CHMe2), 23.31 (CHMe2),
25.10 (CHMe2), 26.31 and 26.52 (NHMe), 44.56 (CH2), 48.07 (CHMe), 61.71 
(CHC02), 63.43 (CH2OH), 73.68 (CHN), 123.74 (m-C), 129.16 (CC=0), 132.32 
(o-C), 151.36 (CONMe) and 168.20 (CON); m/z (C.I.) 362 (M++1, 40%), 331 (5, 







(482) and (483) (484a) (484b)
(25,35,2 '5)-l-Hydroxy-2-leucinylmethylamide-3-phthaloylaminobutane (484a)
To a cooled solution (0°C) of the protected alcohol (482) (0.097g, 0.16mmol) in 
THF (3ml) was added TBAF (0.33ml, O.33mmol). The reaction mixture was 
stirred for 2 hours, diluted with EtOAc (15ml), washed with brine (20ml), dried 
(MgS04) and concentrated in vacuo to give the crude alcohol (484a). This was 
flash chromatographed, eluting with CHCl3:MeOH (90:10) to give the desired
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alcohol () (0.045g, 77%); Rf [CHCl3:MeOH(90:10)] 0.23; [a]“ , -1.3 (c 0.896 in 
CHC13).
4.2.2 A,Af-Dibenzylamino protected compounds 
iV,iV-Dibenzyl-Ala-OBn (359)
Method A
To a solution of Ala (lO.Og, 112mmol) in EtOH (60ml) and water (60ml) was 
added BnBr (44ml, 370mmol), K2C 03 (23.22g, 168mmol) and NaOH (6.72g, 
168mmol). The reaction mixture was refluxed for 7 hours or until all the Ala had 
been consumed. The reaction mixture was diluted with EtOAc (200ml), washed 
with 1M HC1 (100ml), brine (100ml), water (100ml), dried (MgS04) and 
concentrated in vacuo. Any remaining BnBr or BnOH were distilled off under 
vacuum to give the desired protected benzyl ester (360) in excellent yield (39.15g, 
97%).
Method B
To a solution of alanine (lO.Og, 112mmol) in 95% EtOH (200ml) was added BnBr 
(29.38ml, 247mmol), K2C 03 (16.30g, 118mmol) and NaOH (4.72g, 118mmol). 
The reaction mixture was refluxed for 7 hours or until all the alanine had been 
consumed. The reaction mixture was diluted with EtOAc (200ml), washed with 
1M HC1 (100ml), brine (100ml), water (100ml), dried (MgS04) and concentrated 




eluting with petrohEtOAc (90:10) to give the protected benzyl ester (359) (10. lg,
25%).
Attempted preparation of N,A-dibenzyl-Ala-OMe (360) 
Method A
To a solution of Ala-OMe.HCl (362) (15.8g, 113mmol) in MeOH (200ml) was 
added BnBr (38.7ml, 226mmol), K2C 0 3 (23.2g, 170mmol) and NaOH (23.0ml, 
170mmol). The reaction mixture was refluxed for 7 hours or until all the alanine 
had been consumed. The reaction mixture was diluted with EtOAc (200ml), 
washed with 1M HC1 (100ml), brine (100ml), water (100ml), dried (MgS04) and 
concentrated in vacuo to give the crude product (30.3g). This material was flash 
chromatographed, eluting with petrohEtOAc (90:10) to give the protected benzyl 
ester (-) (30.lg, 73%) and the methylphenylmethyl ether (360) (6.9g).
Method B
To a stirred suspension of K2C 03 (5.43g, 39.3mmol) in acetone (30ml) was added 
Ala-OMe.HCl (362) (1.71g, 12.3mmol), Nal (0.02g, 0.12mmol) and BnBr (4.67ml, 
39.3mmol). The reaction mixture was stirred for 2 days, triethylamine (1.7ml, 
12.3mmol) was added and the reaction was stirred for 4 hours. The reaction 
mixture was diluted with 0.1M HC1 (30ml), concentrated in vacuo until water 
remained, this was extracted with EtOAc (2 x 50ml), dried (MgS04) and 
concentrated in vacuo to give the crude product (1.25g). This was flash 
chromatographed, eluting with petrol:EtOAc (95:5) to give the protected 
methylester (360) (0.383g, 11%) as a colourless oil; Rf [petrol:EtOAc (90:10)] 0.4;





(Found C, 76.62; H, 7.23; N, 4.34. calc, for C18H21N 0 2 : C, 76.60; H, 7.47; N, 
4.94%); v ^ /c n r 1 1734s (CO), 1495, 14545as (Me), 1202 and 1147; 6H(270 MHz, 
CDC13) 1.33 (3H, d, 7 7.0, CHMe), 3.51 (1H, q, 7 7.0, CHMe), 3.62 (2H, d, J 14.0, 
PhCH2), 3.74 (2H, s, OMe), 3.83 (2H, d, J 14.0, PhCH2) and 7.20-7.40 (10H, m, 
phenyl); m/z (C.I.) 284 (100%, M++1) and 224 (M+-C02Me, 50).
CIH3N





To a stirred suspension of Ala-OMe.HCl (362) (7.57lg, 54.2mmol) in THF 
(120ml) was added triethylamine (24.2ml, 173.6mmol) and BnBr (21.3ml, 
179mmol). The reaction mixture was stirred for 1 day. The reaction mixture was 
diluted with 0.1M HC1 (100ml), extracted with EtOAc (3 x 150ml), the organics 
were combined, washed with brine (150ml), dried (MgS04) and concentrated in 
vacuo. The crude material was flash chromatographed, eluting with petrohEtOAc 
(95:5) to give the protected methyl ester (360) (4.89g, 32%) as a colourless oil.
Method D
To a stirred solution of Bn2-Ala-OBn (359) (2.21g, 6.15mmol) in methanol (20ml) 
was bubbled freshly generated HC1 gas (from a Kepp's apparatus). The reaction 
mixture was stirred for 4 hours whilst HC1 gas was passed into the methanol, then a 
further 4 hours. No benzyl alcohol was observed by t.l.c. The reaction mixture 
was neutralised with NaHC03, concentrated in vacuo, the residue was diluted with 
water (100ml), extracted with EtOAc (100ml), dried (MgS04) and concentrated in 
vacuo, to give recovered starting material (2.1g, 95%).
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mono protected Leu-OMe (367)
To a stirred suspension of Leu-OMe.HCl (395) (1.19g, 6.57mmol) in THF (30ml) 
and EtOH (3ml) was added K2C 0 3 (2.72g, 19.7mmol) and BnBr (0.87ml, 
7.3mmol). The reaction mixture was refluxed for 2 days. After cooling, the 
reaction mixture was diluted with EtOAc (30ml), washed with water (50ml), dried 
(M gS04) and concentrated in vacuo to give 1.34g of a crude oil. This was flash 
chromatographed, eluting with petrohEtOAc (90:10) to give the product (367) 
(0.885g, 57%); Rf [petrohEtOAc (1:1)] 0.92; (Found C, 71.56; H, 9.08; N, 5.80. 
calc, for C14H21N 0 2 : C, 71.46; H, 9.00; N, 5.95%); V ^ /cn r 1 3333s (NH), 1737s 
(C=0), 1466 and 1195; 6H(270 MHz, CDC13) 0.84 (3H, d, J 6 .6 , CHMe2), 0.91 
(3H, d, J 6 .6 , CHA/e2), 1.44-1.50 (2H, m, CH2), 1.71-1.82 (2H, m, NH and 
C//Me2), 3.31 (1H, t, /  7, NCH), 3.61 (1H, d, J 13, CH2N), 3.77 (1H, d, J 13, 





To a stirred solution of LiAlH4 (4.85g, 121.2mmol) in THF (80ml) was added Bn2- 
Ala-OMe (360) (29.05g, 80.8mmol) in THF (80ml) at such a rate to maintain 
reflux. The reaction mixture was refluxed for 6  hours. Cooled to 0°C, quenched 
with sat. NH4C1 (3ml), diluted with ether (100ml) and filtered through celite. The 
residual salts were washed with ether (3 x 150ml), the organics combined, dried 
(MgS04) and concentrated in vacuo to give crude oil. This was distilled under 
vacuum (to remove BnOH) to give the product (349) (16.7g, 81%); Rf 
[petrohEtOAc (1:1)] 0.5; [a]*J9 86.5 (c 0.614 in CHC13); v ^ /c n r 1 3447s (OH),
1494, 1452g as (Me) and 1043; 8H(270 MHz, CDC13) 0.97 (3H, d, J 6 .6 , CHMe2),
256
2.94-3.05 (1H, m, CHMe), 3.20 (1H, br s, OH), 3.30-3.50 (4H, m, CH2N, 








To a solution of alcohol (349) (4.82g, 19mmol) in DCM (150ml) under N2 was 
added celite (8 g) and PCC (8.13g, 38mmol). After refluxing for 1 hour the 
reaction mixture was allowed to cool before being diluted with ether (400ml). This 
was then filtered through Florisil (300g) and the residue washed with ether (4 x 
400ml). The combined organics were concentrated in vacuo to give 0.6g of crude 
material. T.l.c. showed three compounds when visualised by short wavelength 
light, these were benzaldehyde, starting material and the desired aldehyde (358) 
(0.433g, 9%) as a colourless oil; Rf [petrohEtOAc (85:15)] 0.5; vmax/cm ' 1 1727s 
(CO), 1495 and 14535 as (Me); 6H(270 MHz, CDC13) 1.00 (3H, d, J 7.0, CHMe), 
3.50-4.00 [5H, m, (PhC//2)2N, CHMe], 7.21-7.35 (10H, m, phenyl) and 9.7 (1H, s,
Method B
To a solution of alcohol (349) (1.41g, 5.52mmol) in DCM (20ml) under N2 was 
added NMO (0.97g, 8.28mmol), powdered 4A molecular sieves and TPAP 
(0.098g, 0.28mmol). After stirring at room temperature for 2 hours the reaction





mixture was flash chromatographed, eluting with petrol:ether (10:90) to afford the 
aldehyde (358) (l.Og, 72%) as a colourless oil.
Method C
A solution of oxalyl chloride (3.18ml, 34.6mmol) in DCM (60ml) was cooled to 
-78°C. To this was added DMSO (4.92ml, 63.6mmol) in DCM (15ml) at such a 
rate as to maintain the temperature between -60 to -50°C. The reaction was then 
stirred for 2 minutes before the addition of the alcohol (349) (8.12g, 31.8mmol) in 
DCM (25ml). The reaction mixture was then stirred for 20 minutes at -78°C 
before the addition of triethylamine (22.3ml, 159mmol). After 5 minutes the 
reaction mixture was allowed to attain room temperature and then quenched with 
water (20ml), washed with 1% HC1 (100ml), water (100ml), 5% Na2C 0 3 (100ml), 
water (100ml) and concentrated in vacuo to afford aldehyde (358) (7.18g, 89%) as 
a colourless oil.
DiBAL-H reduction of A,A-dibenzyl-Ala-OBn (359)
To cooled (-78°C) solution of A,A-dibenzyl-Ala-OBn (359) (4.02g, 11.2mmol) in 
toluene (30ml) was added 1.0M DiBAL-H (13.5ml, 13.5mmol) over 30 minutes. 
The reaction mixture was stirred for 2 hours. The reaction was quenched with 
MeOH (3ml), diluted with Rochelle salts (33ml of sat. in 200ml) and stirred at 
room temperature for 1 hour. The reaction mixture was diluted with ether (100ml) 
and filtered through celite. The residual salts were washed with ether (3 x 150ml), 
the organics combined, dried (MgS04) and concentrated in vacuo to give a crude 
oil. This was flash chromatographed, eluting with petrohEtOAc (95:5) to give the 





DiBAL-H reduction of iV,iV-dibenzyl-Ala-OMe (360)
To cooled (-78°C) solution of N,N-dibenzyl-Ala-OMe (360) (5.21g, 18.4mmol) in 
toluene (30ml) was added 1.0M DiBAL-H (38.6ml, 38.6mmol) over 30 minutes. 
The reaction mixture was stirred for 1 hour. The reaction was quenched with 
MeOH (1.5ml) and poured onto Rochelle salts (15ml of sat. in 100ml of water) and 
stirred at 0°C for 1 hour. The reaction mixture was diluted with ether (50ml) and 
filtered through celite. The residual salts were washed with ether (5 x 50ml), the 
organics combined, dried (MgS04) and concentrated in vacuo to give only alcohol 
(349) (1.91g, 40%).
(2R) and (2S)-[lS-A,iV-Dibenzylaminoethyl]-oxirane (356) and (357)
Method A
To a solution of aldehyde (358) (0.33g, 1.3mmol) and TBAI (0.005g, 0.015mmol) 
in DCM (10ml) was added 50% aqueous NaOH (0.3ml) and trimethylsulfonium 
iodide (0.27g, 1.3mmol). The reaction mixture was stirred at 50°C for 1 hour. 
T.l.c. showed that all the starting material had been consumed, the reaction was 
poured onto ice, the organic phase was separated, washed with water ( 1 0 ml), dried 
(MgS04) and concentrated in vacuo. The crude material was flash 
chromatographed, eluting with EtOAc:petrol (15:85) to give an inseparable 
mixture of the epoxides (356) and (357) (0.04g, 12%), Rf [petrohEtOAc (85:15)] 
0.38; as a colourless oil; (Found C, 80.61; H, 8.00; N, 4.78. calc, for C18H2 iNO : 
C, 80.86; H, 7.92; N, 5.24%); v ^ /c n r 1 1493, 14536 as (Me), 13695s (Me), 1260s 
(C-O-C) and 850s (C-O-C); 8H(270 MHz, CDC13) for major isomer (356), 1.03 
(3H, d, J 6 .6 , CHMe), 2.41 (1H, dd, J 4.8 and 2.9, CHHO), and minor isomer 




J 6 .6  and 4.4, CHMe), 3.08 (1H, ddd, J 7.3, 4.4 and 2.9, CHO), 3.60 (2H, J  14.3, 
Ctf2N), 3.80 (2H, d, J 14.3, CH2N) and 7.17-7.40 (10H, m, phenyl); m/z (C.I.) 268 
(M++1, 50%).
B n 2 N
H
B n 2 N !0




To NaH (0.39g, 13mmol) was added DMSO (20ml) the solution was heated to 75- 
80°C for 45 minutes. The reaction mixture was allowed to attain room 
temperature, THF (40ml) was added and the reaction mixture was cooled (-10°C). 
To the rapidly stirred mixture, a solution of trimethylsulfonium iodide (2.6g, 
12.5mmol) in DMSO (20ml) was added. After 5 minutes the aldehyde (358) (3.0g, 
12mmol) in THF (10ml) was added and stirred at -10°C for 30 mins and a further 1 
hour at room temperature. The reaction mixture was quenched with water (250ml), 
extracted with ether (3 x 250ml), the organics were combined, dried (MgS04) and 
concentrated in vacuo. The crude material was flash chromatographed on silica, 
eluting with petrohEtOAc (90:10) to give (356) and (357) (87:13) (2.4g, 76%).
Preparation o f (2R) and (2S)-methyl-[(lS)-N,N-dibenzylamino-l-methyl]- 
oxirane (363).
To NaH (0.147g, 4.9mmol) was added DMSO (10ml) the solution was heated to 
75-80°C for 45 minutes. The reaction mixture was allowed to attain room 
temperature, THF (20ml) was added and the reaction mixture was cooled (-10°C). 
To the rapidly stirred mixture, a solution of trimethylsulfonium iodide (0.96g, 
4.7mmol) in DMSO (10ml). After 5 minutes aldehydes (358) and (363) (1.13g, 
4.5mmol) in THF (5ml) were added and stirred at -10°C for 30 mins and a further 1 
hour at room temperature. The reaction mixture was quenched with water (100ml),
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extracted with ether (3 x 150ml), the organics were combined, dried (MgS04) and 
concentrated in vacuo to give 1.99g of crude material. The crude material was 
flash chromatographed on silica, eluting with petrohEtOAc (95:5) to give an 
inseparable mixture of the epoxides (356) and (357) and the epoxides (363); 
(356,357:363, 31:69) (0.73g, 61%); Rf [petrohEtOAc (85:15)] 0.38:
(2R) and (2S)-methyl-[(lS)-N,N-dibenzylamino-l-methyl]-oxirane (363).
(2 R) and (2S)-methyl-[(lS)-N,N-dibenzylamino-l-methyl]-oxirane (363) was 
isolated as a colourless oil; (Found C, 80.80; H, 8.29; N, 5.14. calc, for C]8H21NO 
: C, 80.86; H, 7.92; N, 5.24%); v ^ /c n r 1 1682, 1493, 14536 as (Me), 13695 s (Me), 
1260s (C-O-C) and 850s (C-O-C); 5H(270 MHz, CDC13) 1.39 (3H, s, CHMe), 2.36 
(1H, d, J 13.4, C//HN), 2.52-2.57 (2H, m, CH20), 2.62 (1H, d, J 13.2, CHUN), 
3.46 (2H, d, J 13.5, PhC//2N), 3.73 (2H, d, J 13.5, PhC//2N) and 7.20-7.40 (10H, 
m, phenyl); 5C (67.8 MHz, CDC13) 19.0 (Me), 52.0 (CH20), 56.5 (CHMe), 59.0 
(PhCH2N), 59.5 (CH2N), 127 (p-phenyl), 128.5 (phenyl), 129.0 (phenyl) and 139.0 
(phenyl-CH2); m/z (E.I 70eV) 267 (M+, 5%) and 210 (50, M+-CH3C2H20); (C.I.) 
268 (M++ l, 70%) and 210 (50, M+-CH3C2H20).
Bn2N Bn2NBn2N
(356) and (357)
Attempted preparation of (2S,3S,2’S)- and (2R,3S,2'S)-3-N,N-dibenzylamino-l- 
hydroxy-2-(0-methyl leucinyl)butane (401).
To a cooled solution (-78°C) of epoxides (356) and (357) (0.44lg, 1.65mmol) in 
anhydrous DCM (7ml) was added BF3.OEt2 (0.193ml, 1.57mmol) and Leu-OMe 
generated by reacting Leu-OMe.HCl (0.60g, 3.3mmol) with triethylamine (0.46ml, 
3.3mmol) in THF, and then filtered before addition. By t.l.c. there were a vast 
number of spots, so we abandoned the reaction.
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(2S,3S,2 ’S)- and (2R,3S,2 'S)-3-N,N-dibenzylamino-2-hydroxy-2-methyl-l-( O- 
tert-butyl leucinyl) propane (402).
To a solution of /V,A-dibenzylamino epoxide (363) (0.32g, 1.2mmol) in MeOH 
(10ml), was added Leu-O^Bu.HCl (0.35g, 1.56mmol) and triethylamine (0.217ml, 
1.56mmol). The reaction mixture was refluxed for 1 day, cooled, concentrated in 
vacuo and diluted with EtOAc (20ml). The organics were washed with water 
(20ml), dried (MgS04) and concentrated in vacuo to give 0.39g of crude material. 
This was flash chromatographed, eluting with petrohEtOAc (90:10), to yield 
starting materials (363) (0.16g, 50%) and the amino alcohol (402) (0.1 lg, 20%) as 
a colourless oil Rf [petrohEtOAc (80:20) ] 0.35; v ^ /c m -1 3442s (OH), 1726s 
(C=0), 1455Sas (Me), 13685s (Me), 1250s (C-N) and 1151; 8H(270 MHz, CDC13) 
0.80-0.90 (6 H, m, CUMe2), 0.99 (3H, s, Me), 1.30-1.70 (3H, m, CH2CHMe2), 1.38 
(9H, s, *Bu), 1.97-2.09 (2H, m, CHr Leu), 2.35-2.47 (2H, m, CH2NBn2), 3.60 [4H, 
d, J 12.1, (PhCH2)2N], 3.70-3.80 (1H, m, NCHCO) and 7.18-7.30 (10H, m, 
phenyl); 8 C (67.8 MHz, CDC13) 22.17 (CHM<?2), 22.64 (CMe3), 22.77 (CHM<?2), 
24.81 (CHMe2), 25.25 (Me), 42.75 (CH2CHMe2), 56.24 (Bn2NCH2), 60.26 (CH2- 
Leu) 61.48 (NCHCO), 80.75 [C(Me)OH], 126.90 (p-phenyl), 128.28 (phenyl), 
128.45 (phenyl), 128.51 (phenyl), 128.99 (phenyl), 139.57 (phenyl-CH2N) and
175.07 (C02*Bu); m/z (C.I.) 455 (M++1, 100%); [Found : (M++1) 455.3277. 






(2S,3S) and (2R,3S)-3-N,N-Dibenzylamino-l-chloro-2-hydroxybutane (407).
To a stirred solution of epoxides (356:357, 87:13) (2.3g, 8 .6 mmol) in THF (80ml) 
was added lithium chloride (1.75g, 42.0mmol) and acetic acid (1.5ml, 25.8mmol).
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After stirring the mixture at room temperature for 1 day the reaction mixture was 
diluted with EtOAc (80ml), washed with water (3 x 100ml), dried (Na2S 0 4) and 
concentrated in vacuo to afford a quantitative yield of chloroalcohols (407a:407b, 
87:13) (2.6g) as a colourless oil; Rf [petrohEtOAc (70:30)] 0.5; 8H(270 MHz, 
CDC13) 1.25 (3H, d, J 6 .8 , Me), 3.44 (2H, d, J 13.5, PhC//2N), 3.50-3.70 (2H, m, 
CH2C1), 4.01 (1H, br s, OH), 4.27 (1H, dq, J 6.9 and 6 .8 , CHMe), 4.50-4.58 (1H, 
m, CHO), 3.73 (2H, d, J 13.5, PhC//2N) and 7.22-7.40 (10H, m, phenyl).
B n 2 + B n 2 N 'X^ | .....q
(356) (357)
->» B n 2 N + B n 2 N
Cl Cl
(407a) (407b)
Attempted preparation o f (2S,3S)- and (2R,3S)-3-N,N-dibenzylamino-l-chloro-2- 
(trifluoromethanesulfonyloxy)butane (471)
To a cooled solution (-20°C) of the chloroalcohol (407) (2.6g, 8 .6 mmol) in DCM 
(100ml) was added pyridine (0.87ml, 10.8mmol). The reaction was stirred for 5 
minutes before the addition of triflic anhydride (1.97ml, 11.7mmol). It was then 
allowed to stir at -20°C for 5 minutes before being warmed to room temperature 
and stirred for a further 1 hour. The reaction mixture was diluted with DCM 
(50ml), washed with 1M HC1 (150ml), brine (150ml), dried (MgS04) and 
concentrated in vacuo to give 2.7g of a crude red oil. T.l.c. showed a huge number 




+  B n 2 N Bn2 N
(407) (471) (356) and (357) (473)
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(2R,3S)- and (2S,3S)-3-N,N-Dibenzylamino-2-hydroxy-l-triphenylmethylthio- 
butane (408).
To a stirred solution of the epoxides (0.112g, 0.42mmol) in anhydrous methanol 
(5ml) was added triphenylmethylthiol (0.348g, 1.26mmol) and triethylamine 
(0.23ml, 1.68mmol). The reaction was then stirred for 3 hours at room 
temperature. The reaction mixture was filtered to remove the excess 
triphenylmethylthiol and concentrated in vacuo. The resulting solid was dissolved 
in EtOAc (20ml), washed with water (20ml), brine (20ml), dried (MgS04) and 
concentrated in vacuo. The crude material was flash chromatographed, eluting 
with cyclohexane:EtOAc (95:5) to give epoxides (356) and (357) (0.03g, 27%) and 
an inseparable mix of the desired products (408a:408b, 38:62) (0.02g, 9%); as a 
colourless oil; Rf[petrol:EtOAc (90:10)] 0.16; v ^ /c m - 1 3444s (OH) and 1494s as 
(Me); 8h(270 MHz, CDC13) 0.99 (3H, d, J 6 .8 , Me), 1.60 (1H, br s, OH), 2.24 (1H, 
dd, J 13.0 and 10.0, CtfOH), 2.44 (1H, dd, J 7.3 and 6.7, C/TMe), 2.90 (1H, dd, J
13.0 and 2.5, CHHS), 3.10-3.30 (1H, m, CHHS), 3.26 (2H, d, J 13.8, NCH2Ph), 
3.51 (2H, d, J 13.8, NCH2Ph) and 7.10-7.50 (25H, m, phenyl); 5C (67.8 MHz, 
CDC13) 8.51 (Me), 38.63 (CH2S), 54.22 (CH2Ph), 57.53 (NCHMe), 71.47 




Attempted preparation of the (2S,3S)- and (2R,3S)-3-N,N-dibenzylamino-2- 
dihydroxybutane (411).
Method A
To a cooled solution (0°C) of the epoxides (356:357, 87:13) (0.20g, l.Ommol) in 
DCM (2ml) was added BF3.OEt2 (0.11ml, l.lmmol). After 1 minute, water
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(O.lml) was added. The reaction was stirred at 0°C for 10 minutes before being 
warmed to room temperature and stirred for a further 2 hours. After this time the 
starting material had been consumed and the reaction was quenched with 2M HC1 
(5ml) and extracted with DCM (2 x 10ml). The organics were dried (Na2S 0 4) and 
concentrated in vacuo to afford 0.207g crude material. This was flash 
chromatographed on silica, eluting with petrokEtOAc (50:50) to give an unknown 
material which was highly deliquescent, we did not determine the structure of this 
compound.




To a stirred solution of epoxides (356:357, 87:13) (0.055g, 2.06mmol) in 
THF:water (20ml:5ml) was added Dowex-50X8-100 ion-exchange resin (strongly 
acidic). The reaction mixture was stirred at 50°C for 11 hours, cooled and filtered. 
The resin was washed with CHC13 (50ml), concentrated in vacuo and crystallised 
from hexane:EtOAc to afford 0.03g of unknown material which we could not 
identify.
(2R,3S)- and (2S,3S)-3-N,N-Dibenzylamino-2-hydroxy-2-methylpropoxymethyl- 
phenyl (413).
Method A
A suspension of 80% NaH in mineral oil (0.032g, 1.06mmol) was washed with 
pentane. To this was added DMF (15ml) and the reaction mixture was cooled (0° 
C). To this solution was added benzyl alcohol (0.11ml, 1.06mmol) dropwise and
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epoxides (363) (0.95g, 0.355mmol) in DMF (5ml). The reaction mixture was 
heated to 100°C for 10 hour, cooled, and partitioned between water (20ml) and 
ether (20ml). The aqueous layer was extracted with ether (2 x 15ml), the organics 
combined, washed with water (15ml), dried (MgS04) and concentrated in vacuo. 
The crude material was flash chromatographed on silica, eluting with petrol :EtOAc 
(80:20) to give a racemic mixture of the ethers (413) (0.05g, 38%); Rf 
[petrohEtOAc (80:20)] 0.51; as a colourless oil; v ^ / c m 1 3464s (OH), 1494, 
14535 as (M e ) ’ 1 3 6 9 8 s (Me) and 1094; 8H(270 MHz, CDC13) 1.09 (3H, s, CHMe), 
2.53 (1H, d, J 13.9, CtfHN), 2.73 (1H, d, /  13.9, CHHN), 2.84 (lH,br s, OH), 3.24 
(2H, dd, J 22.0 and 9.0, CH2OBn), 3.60 (2H, d, J 13.6, PhC//2N), 3.70 (2H, J 13.6, 
PhC//2N), 4.42 (2H, s, OCH2Ph) and 7.22-7.30 (15H, m, phenyl); 8 C (67.8 MHz, 
CDCI3) 23.92 (Me), 59.91 (CH2N), 60.04 (PhCH2N), 71.86 (CH20), 73.29 
(OCH2Ph), 76.00 [C(Me)OH], 127.03 (p-phenyl), 127.52 (phenyl), 127.58 
(phenyl), 128.26 (phenyl), 129.03 (phenyl), 138 (phenyl-CH20 ) and 139.39 
(phenyl-CH2N); m/z (C.I.) 376 (M++1, 70%); [Found : (M++1) 376.2276. 
C25H3oN0 2 requires 376.2276].
Method B
To a stirred suspension of A120 3 (0.5g) in toluene (20ml) was added benzyl alcohol 
(1.05ml, lO.lmmol) and the epoxide () (0.54g, 2.02mmol). The reaction mixture 
was stirred for 1 day before refluxing for 4 hours. The reaction mixture was 
concentrated in vacuo and flash chromatographed, eluting with petrohEtOAc 
(80:20) to give the starting material and the desired ethers (413) (0.014g, 2%).
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l-(diethylphosphonate)-2-phenylethan-2-ol (430).
To a solution of diethyl methylphosphonate (0.37ml, 2.46mmol) in THF (20ml) at 
-78°C was added 1.6M n-BuLi (1.44ml, 2.3mmol) dropwise. The reaction mixture 
was stirred under an inert atmosphere of nitrogen for 30 minutes before the 
addition of benzaldehyde (0.52g, 4.9mmol). The reaction mixture was stirred at - 
78°C for 30 minutes, no reaction occurred, so the reaction mixture was allowed to 
stir overnight. The reaction mixture was then quenched with water (20ml), diluted 
with EtOAc (20ml), extracted, washed with brine (30mi), the organics were 
combined, dried (MgS04) and concentrated in vacuo to give 0.9g of crude yellow 
oil. This was flash chromatographed, eluting with EtOAc to give the p- 
hydroxyphosphonate (430) (0.68g, 54%) as a colourless oil; Rf [EtOAc] 0.36; 
(Found C, 55.50; H, 7.42. calc, for C12H19N 04P : C, 55.80; H, 7.40%); v ^ /c n r 1 
3288s (OH), 122 l s (C-O), 1028s (P-O) and 960; 6H(270 MHz, CDC13) 1.29 (3H, t,
77.0, CH2C//3), 1.62 (3H, t, 77.0, CH2C//3), 2.26-2.4 (2H, m, CH2P=0), 3.95 (1H, 
d, 72.6, OH), 4.09 (4H, qm, 77, CH2CH3), 5.12 (1H, tm, 7 11.2, C//OH) and 7.24-
7.42 (5H, m, phenyl); 6p(109.25MHz, CDC13) 29.84; 8 C (67.8 MHz, CDC13) 16.4 
(CH2CH3), 34.9 and 36.9 (CH2P), 61.9 and 62.0 (d, 7 7.5, CH2CH3), 68.7 and 6 8 .8  
(CHOH), 125.5 (p-phenyl), 127.7 (o-phenyl), 128.5 (m-phenyl) and 143.4 and 
143.6 (phenyl); m/z (70eV) 258 (M+, 23%), (C.I.) 259 (M++1, 80) and 241 (100, 
M+-OH).
Attempted preparation o f the l-(diethylphosphonate)-2-phenyl-2- 
(trifluoromethane sulfonyloxy)ethane (429).
To a cooled solution (-23°C) of p-hydroxyphosphonate (429) (0.276ml, 1.07mmol) 




minutes triflic anhydride was added, the solution immediately turned pink and then 
yellow. The reaction mixture was left for 5 minutes before allowing to warm to 
room temperature. After 10 minutes the reaction mixture was diluted with DCM 
(15ml), washed with 0.5M HC1 (20ml), the acid phase was extracted with DCM 
(10ml), the organics were combined, dried (MgS04) and filtered through a plug of 
flash silica and concentrated in vacuo to give mostly the (£)-alkene (431) (0.23g, 
90%);
(E)-l-diethylphosphonate-2-phenylethene (431).
(E)-1 -diethylphosphonate-2-phenylethene (431) was isolated as a brown oil; Rf 
[EtOAc] 0.6; (Found C, 56.7; H, 7.13. calc, for C12H17N 0 3P : C, 56.67; H, 
6.74%); vmax/crn-i 2919, 1649s (C=C), 1496, 1455g as (Me), 1249s (P=0) and 
1027s (P-O); 6h(270 MHz, CDC13) 1.36 (6 H, t, J 6.7, CH2CH3), 4.14 (4H, qdd, J 
7, 1.1 and 1.0, C//2CH3), 6.26 (1H, t, J 17.7, PhHC=C//P), 7.4-7.51 (5H, m, 
phenyl) and 7.51 (1H, t, J 20, Ph//C=CHP); 8 C (67.8 MHz, CDC13) 16.3 and 16.4 
(CH2CH3), 61.85 and 61.93 (d, J 7, CH2CH3), 112.4 and 115.3 (CHP), 127.7 (p- 
phenyl), 128.8 (o-phenyl), 130.3 (m-phenyl), 134.67 and 135.03 (phenyl) and 
148.84 and 148.75 (CHPh); m/z (70eV) 240 (M+, 20%), (C.I.) 241 (M++1, 100) 
and 241 (10, M+-OEt).
(429) (431)
Preparation o f 3(S)-N,N-dibenzylamino-l-(diethylphosphonate)butan-2-one 
(432).
To a solution of diethyl methylphosphonate (5.66ml, 38.76mmol) in THF (150ml) 
at -78°C was added 1.6M n-BuLi (24.23ml, 38.76mmol) dropwise. The reaction 
mixture was stirred under an inert atmosphere of N2 for 30 minutes before the
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addition of the protected amino benzyl ester (359) (2.32g, 6.46mmol) in THF 
(15ml). The reaction mixture was stirred at -78°C for 2 hours, and then at -30°C 
for 1 hour before the addition of acetic acid (1.8ml). The reaction mixture was 
then poured onto sat. solution of NaHC03 (100ml), extracted with EtOAc (2 x 
150ml), the organics were combined, dried (MgS04) and concentrated in vacuo to 
give 4.38g of crude yellow oil. This was flash chromatographed, eluting with 
petrohEtOAc (1:1) to give the (3-ketophosphonate (432) (2.5lg, 96%) as a 
colourless oil; Rf [petrohEtOAc] 0.5; [a]5g9-67.5 (c 0.237 in CH3CI); vmax/crn' 1
3288, 2979, 1718s (0=0), 1494, 14545as (Me), 13708s (Me), 1256s (P=0), 1058s 
(P-O) and 1024; 6H(270 MHz, CDC13) 1.14 (3H, t, 7 7.0, CH2CH3), 1.18 (3H, d, 7 
6 .6 , CHMe), 1.25 (3H, t, 7 7.0, CH2C//3), 2.97 (1H, dd, 7 22.9 and 14.5, CH2P=0),
3.43 (2H, d, 7 13.5, CH2N), 3.55 (1H, q, 7 6 .6 , CT/Me), 3.68 (2H, d, 7 13.5, CH2N), 
3.72 (1H, dd, 7 20.7 and 14.1, CH2P), 3.8-4.0 (2H, m, POCH2), 4.02 (2H, dq, 7 8.2 
and 7.1, POCH2) and 7.22-7.36 (10H, m, phenyl); 5p(109.25MHz, CDC13) 20.75; 
5C (67.8 MHz, CDC13) 6.5 (CHMe), 16.1 and 16.2 (CH2CH3), 36.7 and 38.6 
(CH2P), 57.6 (CH2N), 62.1 and 62.2 (CH2CH3), 62.3 and 62.7 (CHMe), 127.3 (p- 
phenyl), 128.5 (o-phenyl), 128.9 (m-phenyl), 138.87 (phenyl) and 203.2 and 203.3 




Attempted preparation o f the imine (433).
(432)




To the p-ketophosphonate (432) (l.lg , 2.73mmol) in toluene (50ml) was added 
Leu-OMe.HCl (0.59g, 3.27mmol) and triethylamine (0.45ml, 3.27mmol). The 
reaction was refluxed under an inert atmosphere of nitrogen for 6  hours, a new spot 
was observed by t.l.c. The reaction mixture was concentrated in vacuo and then 
flash chromatographed, eluting with petrohEtOAc (70:30) to give recovered 
starting material and a Leucine trimer.
Method B
To the p-ketophosphonate (432) (0.89g, 2.2mmol) in toluene (50ml) was added 
Leu-OMe.HCl (0.48g, 2.6mmol) and p-toluenesulfonic acid mono hydrate (0.038g,
0.2mmol). The reaction was refluxed under an inert atmosphere of nitrogen for 6  
hours, a plethora of spots were observed by t.l.c. and the reaction was abandoned.
Attempted preparation o f (2R,3S,2'S) and (2S,3S,2'S)-3-N,N-dibenzylamino-l- 
diethylphosphonate-2-(0-methyl leucinyl)butane (434) from the ketone (432).
Method A
To a stirred solution of the p-ketophosphonate (432) (1.85g, 4.59mmol) in 
methanol (50ml) was added Leu-OMe.HCl (1.67g, 9.17mmol), NaCNBH3 (0.304g, 
4.6mmol) and NaOAc (0.384g, 4.59mmol). The reaction was stirred at room 




reaction had occurred, the reaction was left for 2  weeks, after which time all the 
starting material had been consumed. The reaction mixture was acidified to pH ~2 
using 2M HC1, basified to pH~9 with a saturated solution of NaHC03, extracted 
with EtOAc (2 x 50ml), the organics were combined, dried (MgS04) and 
concentrated in vacuo to give 1.44g of crude colourless oil. This was flash 
chromatographed, eluting with petrohEtOAc (40:60) to give the p- 
hydroxyphosphonate (436) (1.4g, 80%) as a colourless oil:
(2R,3S)- and (2S,3S)-3-N,N-Dibenzylamino-l-(diethylphosphonate)-2-hydroxy- 
butane (436).
(2R, 35)- and (2S,3S)-3-Af,A-Dibenzylamino-l-(diethylphosphonate)-2- 
hydroxybutane (436) were isolated as a colourless oil; Rf [DCM:MeOH (95:5)] 0.3; 
(Found C, 65.0; H, 7.98; N, 3.6. calc, for C22H32N0 4P : C, 65.15; H, 7.95; N, 
3.45%); v^ /cm -i 3370s (OH), 2980, 1603, 1494, 14545 as (Me), 13885 s (Me), 
1250s (P=0), 1227 and 1160; 5H(270 MHz, CDC13) 1.06 (3H, d, J 6 .8 , CHMe), 
1.28 (3H, t, J 7.0, CH2CH3), 1.29 (3H, t, J 7.0, CH2CH3), 1.77 (1H, dd, J 15.2 and
9.3, CH2P), 1.86 (1H, dd, J 15.2 and 2.5, CH2P), 2.56-2.68 (1H, m, CHOU), 3.31 
(2H, d, J 13.5, CH2N), 3.85 (2H, d, J 13.5, CH2N), 3.86 (1H, m, CHMe), 4.05 and 
4.12 (2H, dq, J 7.1 and 7.1, POCH2), 4.4 (1H, br s, OH) and 7.22-7.8 (10H, m, 
phenyl); Sc (67.8 MHz, CDC13) 8.1 (CHMe), 16.3 and 16.4 (CH2CH3), 29.97 and
32.0 (CH2P), 53.5 (CH2N), 58.7 and 59.0 (CHMe), 61.4 and 61.8 (CH2CH3), 67.01 
and 67.09 (CHOH), 127.2 (p-phenyl), 128.4 (o-phenyl), 129.0 (w-phenyl) and





To a stirred solution of the P-ketophosphonate (432) (2.63g, 6.51mmol) in DCE 
(25ml) was added Leu-OMe.HCl (1.3g, 7.16mmol), Na(OAc)3BH (2.07g, 
9.8mmol) and triethylamine (1.0ml, 7.16mmol). The reaction was stirred at room 
temperature under an inert atmosphere of N2 for 10 minutes, no reaction occurred 
so acetic acid (0.373ml) was added and the reaction mixture was heated to 50°C for 
5 hours. The starting material was slowly converted to new compound with very 
similar Rf to that of the p-hydroxyphosphonate (432), (Md ammonium dip also 
showed the presence of phosphorus). The reaction was left for two weeks at room 
temperature. The reaction mixture was basified to pH~9 with a saturated solution 
of NaHC03, acidified with 1M HC1, neutralised with 1M NaOH, extracted with 
CH3C1 (2 x 50ml), the organics were combined, dried (MgS04) and concentrated 
in vacuo  to give 3.62g of crude yellow/brown oil. This was flash 
chromatographed, eluting with petrohEtOAc (1:1) to give recovered starting 
material (1.88g, 72%) and the p-hydroxyphosphonate (436) (0.04g, 2%) as a 
colourless oil.
A tte m p te d  p rep a ra tio n  o f  3 (S )-N ,N -d ibenzy lam ino -l-(d ie thy lphosphona te)-  
2 (R ,S )-(0 -m e th y lle u c in y l)b u ta n e  (434) f r o m  the  y-ch lorophosphonate (444).
Method A
To a suspension of Leu-OMe.HCl (0.48g, 2.64mmol) in THF (4ml) was added 
triethylamine (0.334ml, 2.4mmol), the reaction was stirred for 30 minutes before 
being filtered and added to the y-chlorophosphonate (444) (0.646g, 1.53mmol) in 
THF (4ml) at 0°C. After 5 hours no reaction occurred, the reaction was allowed to 




To a freshly prepared solution of Leu-OMe (0.047g, 0.32mmol) in THF (1ml) was 
added NaOAc (0.013g, 0.16mmol) and the y-chlorophosphonate (444) (0.086g,
0.2mmol) in THF (1ml). The reaction was stirred at room temperature for 3 days 
no reaction had occurred. The reaction was abandoned.
Method C
To a freshly prepared solution of Leu-OMe (0.047g, 0.32mmoi) in THF (1ml) was 
added the y-chlorophosphonate (444) (0.086g, 0.2mmol) in DMF (1ml). The 
reaction was stirred for 3 days no reaction had occurred. It was then refluxed for 2 
hours, no change occurred so the reaction was abandoned.
Attempted preparation of (2R,3S,2'S) and (2S,3S,2'S)-3-N,N-dibenzylamino-l- 
diethylphosphonate-2-(0-methyl leucinyl)butane (434) from the 
methanesulfonate (448).
To a solution of the methanesulfonate (448) (0.078g, 0.16mmol) in THF (20ml) 
was added Leu-OMe.HCl (0.035g, 0.19mmol). The reaction was stirred at room 
temperature for 1 hour. T.l.c. showed that all the starting material had been 
consumed. The reaction mixture was washed with brine (20ml), dried (MgS04) 
and concentrated in vacuo to give the y-chlorophosphonate (444) (0.033g, 50%).
OMs o Bn2N O
(448) (444)
(2S,3S)- and (2R,3S)-3-N,N-Dibenzylamino-l-(diethylphosphonate)-2-hydroxy- 
butane (436).
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To a cooled solution (0°C) of the p-ketophosphonate (432) (2.43g, 6.0mmol) in 
EtOH (30ml) was added NaBH4 (0.062g, 1.65mmol). The reaction was stirred for 
10 minutes before being allowed to attain room temperature. After 6  hours some 
starting material still remained, some more NaBH4 (0.0 lg) was added and the 
reaction was left to stir overnight after which time all the starting material had been 
consumed. The reaction mixture was diluted with EtOAc (100ml), washed with 
water (100ml), brine (100ml), dried (MgS04) and concentrated in vacuo to give the 
p-hydroxyphosphonate (436) (2.3g, 95%) as a colourless oil.
Attempted preparation o f (2S,3S)- and (2R,3S)-3-N,N-dibenzylamino-l- 
(diethylphosphonate)-2-(trifluoromethanesulfonyloxy)butane (441).
To a cooled solution (-20°C) of the p-hydroxyphosphonate (441) (0.83g, 
2.052mmol) in DCM (20ml) was added pyridine (0.191ml, 2.36mmol), the reaction 
was stirred for 5 minutes before the addition of triflic anhydride (0.38ml, 
2.26mmol). The reaction was then allowed to stir at -20°C for 5 minutes before 
being allowed to attain room temperature and stirred for 1 hour. The reaction 
mixture was diluted with ether (30ml), washed with water (30ml), brine (30ml), 
dried (MgS04) and concentrated in vacuo to give 1.02g of a deep red viscous oil. 
This was flash chromatographed, eluting with petrohEtOAc (1:1) to give the 
rearranged y-chlorophosphonate (444) (0.7g, 64%):
(2S,3R)- and (2R>3R)-2-N,N-Dibenzylamino-3-chloro-1 -(diethylphosphonate) 
butane (444).
(2R,3R)- and (2S,3/?)-2-A, N-Dibenzylamino-3-chloro- l-(diethylphosphonate) 
butane (444) were isolated as a colourless oil, Rf [petrohEtOAc (1:1)]; 0.38;
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vmax/crn-i 2980, 1737, 1603, 1494, 14538 *  (Me), 13705 s (Me), 1244s (P=0), 
1027s (P-O); 6h(270 MHz, CDC13) 1.32 (3H, t, J 6.9, CH2Ctf3), 1.33 (3H, t, J 6.9, 
CH2C//3), 1.43 (3H, d, J 6.9, CHMe), 2.17-2.41 (2H, m, CH2P), 3.21 (1H, dddd, J
12.7, 9.8, 2.9 and 2.9, CtfNBn2), 3.29 (2H, d, J 13.5, CH2N), 4.10 (2H, d, J 13.5, 
CH2N), 4.00-4.20 (4H, dq, J 7.1 and 7.1, POCH2), 4.33-4.40 (1H, m, CHC1) and 
7.22-7.8 (10H, m, phenyl); 5C (67.8 MHz, CDC13) 16.3 and 16.4 (CH2CH3), 22.9 
(CHMe), 21.1 and 23.1 (CH2P), 55.5 (CH2N), 56.6 (CHN), 61.6 and 61.7 
(CH2CH3), 62.4 (CHC1), 127.1 (p-phenyl), 128.1 (o-phenyl), 129.3 (m-phenyl) and
139.3 (phenyl); m/z (C.I.) 424 (M++1, 1 0 0 %), 388 (45, M+-C1); [Found : (M++1) 







Attempted preparation o f (2S,3S)- and (2R,3S)-3-N,N-dibenzylamino-l- 
(diethylphosphonate)-2-(methanesulfonyloxy)butane (448).
To a cooled solution (0°C) of the p-hydroxyphosphonate (436) (0.094g, 0.23mmol) 
in DCM (2ml) was added triethylamine (0.125ml, 1.54mmol) and methanesulfonyl 
chloride (0.319g, 1.67mmol) over 5 minutes. The reaction was stirred for 30 
minutes at 0°C. The reaction mixture was diluted with DCM (10ml), washed with 
iced water (10ml), 0.5M HC1 (30ml), sat. solution of NaHC03 (10ml), brine 
(10ml), dried (MgS04) and concentrated in vacuo to give methanesulfonate as a 
colourless oil (448) (0.088g, 80%), this was used without purification; crude 5H(60 
MHz, CDC13) 1.1-1.5 [9H, m, Me and P(OCH2C//3)2], 2.0-2.4 (2H, m, CH2PO), 
2.9 (3H, s, S 0 2CH3), 3.0-3.5 (2H, m, CHMe and CHO), 3.6-4.2 [6 H, m, 




methoxyphenylmethyl-thio) butane (455a) and (455b).
To a stirred solution of the epoxides (1.15g, 4.3mmol) in anhydrous methanol 
(20ml) was added triphenylmethylthiol (0.6ml, 4.3mmol) and triethylamine (0.6ml, 
4.3mmol). The reaction was then refluxed for 3 hours. The reaction mixture was 
filtered to remove the excess triphenylmethylthiol. The reaction mixture was 
concentrated in vacuo to give 2.05g of crude material, which was flash 
chromatographed, eluting with cyclohexane:EtOAc (92:8) to give the desired 




(2R,3S)-3-N,A-dibenzylamino-2-hydroxy-1 -(4'-methoxyphenylmethylthio) butane 
(455a) was isolated as a colourless oil; Rf[petrol:EtOAc (90:10)] 0.21; (Found C, 
73.50; H, 7.60; N, 3.30. calc, for C26H31N 0 2S: C, 74.07; H, 7.41; N, 3.32%); 
v ^ /c m - 1 3348s (OH), 1608, 1511, 14555as (Me), 1248s (C-O), 1033s (SCH2) and 
700s (C-S); 6h(270 MHz, CDC13) 1.14 (3H, d, J 6 .8 , Me), 2.18 (1H, dd, J 14.1 and
10.1, SC//2CHO), 2.60 (1H, qd, J 7.0 and 4.0, CHMe), 3.03 (1H, dd, J 10.1 and
2.4, SC//2CHO), 3.38 (2H, d, J 13.7, CH2N), 3.61 (2H, s, SCH2Ar), 3.62 (2H, d, /
13.7, CH2N), 3.73 (3H, s, OMe), 3.60-3.75 (2H, m, CHOH), 6.70-6.80 (2H, m, 
ArOMe), 7.10-7.20 (2H, m, ArOMe) and 7.20-7.30 (10H, m, phenyl); 8 C (67.8 
MHz, CDC13) 14.1 (Me), 35.1 (CH2SCH2Ar), 37.5 (CH2S), 54.3 (CH2N), 54.8 
(OMe), 57.3 (NCHMe), 70.5 (CHOH), 113.9 (o-ArOMe), 126.0-130.0 (phenyl and
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ArOMe), 139.8 (phenyl) and 158.7 (ArOMe); m/z (E.I. 70 eV) 224 (5%, 
Bn2NCHMe+); (C.I) 422 (M++1, 80), 224 (100, Bn2NCHMe+).
(25.35)-3-N,N-Dibenzylamino-2-hydroxy-l-(4'-methoxyphenylmethylthio ) 
butane (455b).
(25.35)-3-N,Af-Dibenzylamino-2-hydroxy-1 -(4'-methoxyphenylmethylthio) butane 
(455b) was isolated as a colourless oil; Rf[petrol:EtOAc (90:10)] 0.13; (Found C, 
73.50; H, 7.60; N, 3.30. calc, for C26H31N 0 2S: C, 74.07; H, 7.41; N, 3.32%); 
vmax/cm-i 3348s (OH), 1608, 1511, 14555as (Me), 1248s (C-O), 1033s (SCH2) and 
700s (C-S); 6h(270 MHz, CDC13) 1.18 (3H, d, J 6 .8 , Me), 2.65-2.74 (1H, m, 
SC//2CHO), 2.75-2.98 (2H, m, CHMe and SC//2CHO), 3.26 (2H, d, J 13.7, 
CH2N), 3.61 (2H, s, SCH2Ar), 3.70-3.82 (2H, m, CHOH), 3.70 (2H, d, J 13.7, 
CH2N), 3.78 (3H, s, OMe), 6.80-6.88 (2H, m, ArOMe), 7.10-7.20 (2H, m, ArOMe) 
and 7.20-7.35 (10H, m, phenyl); 8 C (67.8 MHz, CDC13) 14.2 (Me), 34.7 
(CH2SCH2Ar), 36.6 (CH2S), 54.1 (CH2N), 55.3 (OMe), 56.9 (NCHMe), 71.4 
(CHOH), 113.9 (o-ArOMe), 114.0 (o-ArOMe), 127.1 (p-phenyl), 127.4 (phenyl),
128.3 (phenyl), 128.5 (phenyl), 129.0 (phenyl), 129.2 (ArOMe), 129.9 (ArOMe),
130.0 (ArOMe), 130.1 (ArOMe), 138 (phenyl-CH20 ) and 139.39 (phenyl-CH2N),
139.4 (phenyl) and 159.0 (ArOMe); m/z (E.I. 70 eV) 224 (5%, Bn2NCHMe+); (C.I) 
422 (M++1, 80), 224 (100, Bn2NCHMe+).
(356) and (357) (455a) (455b)
Attempted preparation of (2R,3S) and (2S,3S)-3-N,N-dibenzylamino-l-(4'- 
methoxyphenylmethylthio)-2-(trifluoromethanesulfonyloxy)butane (45la) and 
(451b).
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To a cooled solution (-20°C) of the protected thiolalcohol (450) (0.47g, 1.15mmol) 
in DCM (6ml) was added pyridine (0.103ml, 1.27mmol). The reaction was stirred 
for 5 minutes before the addition of triflic anhydride (0.213ml, 1.27mmol). It was 
then allowed to stir at -20°C for 5 minutes before being warmed to room 
temperature and stirred for a further 1 hour. The reaction mixture was diluted with 
DCM (5ml), washed with 1% HC1 (10ml), brine (10ml), dried (MgS04) and 
concentrated in vacuo to give 0.62g of a crude red oil. T.l.c. showed a huge 
number of spots and the crude mixture was not purified.
Attempted preparation o f (2R,3S) and (2S,3S)-3-N,N-dibenzylamino-l-(4'- 
methoxyphenylmethylthio)-2-(p-toluenesulfonyloxy)butane (454a) and (454b).
Method A
To a cooled solution (0°C) of the alcohol (450) (0.4g, 0.95mmol) in DCM (10ml) 
was added pyridine (0.076ml, 0.94mmol) and p-toluenesulfonyl chloride (0.181g,
l.Ommol) in small portions with constant stirring. The reaction was stirred at 0°C 
for 6 hours, no change was observed by t.l.c., so the reaction was allowed to attain 
room temperature and stirred for a further 3 days. No change was observed, the 
reaction mixture was washed with 2M HC1 (10ml), the acid phase back extracted 
with DCM (2 x 10ml), the organics combined, dried (MgS04) and concentrated in 
vacuo. The crude material was flash chromatographed, eluting with petrohEtOAc 
(87.5:12.5) to give the recovered starting material (0.306g, 78%).
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Method B
To a cooled solution (-20°C) of the alcohol (450) (0.306g, 0.73mmol) in THF 
(20ml) was added NaH (0.024g, 0.80mmol). After 10 minutes /?-toluenesulfonyl 
chloride (0.166g, 0.87mmol) was added, after 10 minutes t.l.c. showed that some of 
the starting material had been converted to a new compound. After 2 hours Leu- 
OMe.HCl (0.20g, l.lOmmol) and the reaction mixture was left to stir for 3 hours. 
The reaction mixture was washed with 2M HC1 (20ml), the acid phase back 
extracted with EtOAc (2 x 20ml), the organics combined, dried (MgS04) and 
concentrated in vacuo to give 0.42g of crude material. This was flash 
chromatographed, eluting with petrohEtOAc (90:10) to give the recovered starting 
material (O.lg, 33%) and Tos-Leu-OMe (456) as a colourless oil (0.069g, 32%); 
Rf[petrol:EtOAc (90:10)] 0.61.
N-Toluenesulfonate-Leu-OMe (456).
A-Toluenesulfonate-Leu-OMe (456) was isolated as a colourless oil; (Found C, 
56.50; H, 7.17; N, 4.38. calc, for C19H21N 0 4S: C, 56.17; H, 7.07; N, 4.68%); 
vmax/crn-i 3273s (NH), 1741s (C=0), 1337s (0=S-N) and 1163; 8H(270 MHz, 
CDC13) 0.87 (3H, d, J 6.4, Me), 0.90 (3H, d, J 6.4, Me), 1.45-1.50 (2H, m, 
CH2C HMe2), 1.74-1.81 (1H, m, CHMe2), 2.42 (3H, s, phenyl -Me) 3.43 (3H, s, 
OMe), 5.11-5.15 (1H, m, N //-S02), 7.29 (2H, d, J 8.3, phthaloyl) and 7.72 (2H, d, 
J 8.3, phthaloyl); m/z (E.I. 70 eV) 240 (100%, M+-C02Me); (C.I) 300 (M++1, 






Failed preparation of (2R,3S)- and (2S,3S)-3-N,N-dibenzylamino-2- 
hydroxybutyl-oxymethyl ether (491).
To a solution of NaOMe (0.045g, O.83mmol) in DMF (2ml) was added epoxides 
(356,357:366, 1:1) (0.074g, 0.28mmol). The reaction mixture was heated to 100°C 
for 10 hour, cooled, and partitioned between water (5ml) and ether (5ml). The 
aqueous layer was extracted with ether (2 x 5ml), the organics combined, washed 
with water (5ml), dried (MgS04) and concentrated in vacuo. The crude material 
was flash chromatographed on silica, eluting with petrohEtOAc (80:20) to give 
only the starting material (491) (0.05g, 68%).
Attempted preparation o f the imine (492) using Leu-OtBu
To the P-ketophosphonate (432) (0.613g, 1.52mmol) in toluene (50ml) was added 
Leu-O'Bu.HCl (1.04g, 4.64mmol) and TiCl4 (0.144g, 0.76mmol). The reaction 
was refluxed under an inert atmosphere of nitrogen for 2 days. After this time no 









Attempted preparation of (2S,3S)- and (2R,3S)-3-N,N-dibenzylamino-l- 
(diethylphosphonate)-2-(toluenesulfonyloxy)butane (493).
To a cooled solution (0°C) of the p-hydroxyphosphonate (436) (0.52g, 1.28mmol) 
in DCM (20ml) was added pyridine (0.125ml, 1.54mmol), p-toluenesulfonyl 
chloride (0.319g, 1.67mmol) in small portions with constant stirring. The reaction 
was stirred at 0°C for 1 day, no change was observed by t.l.c., so the reaction was 
allowed to attain room temperature and stirred for a further 3 days. The reaction 
mixture was then refluxed for 4 hours after which time no reaction had occurred. 
The reaction mixture was washed with 2M HC1 (30ml), the acid phase back 
extracted with DCM (2 x 100ml), the organics combined, dried (MgS04) and 
concentrated in vacuo to give 0.6g of crude material. This was flash 
chromatographed, eluting with petrohEtOAc (1:1) to give the recovered starting 
material.
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APPENDIX ONE
X-ray Crystallographic Data for (474)




Crystal data'. C28H31N 0 4Si, M  = 947.3, monoclinic, a  = 32.219(9), b = 8.887(1), c = 
18.816(5)A, J3 = 1 1 0 .6 6 (2 )°, £7= 5041.1 A3, space group C2/c, Z = 8, Dc = 1.25gcnr3, 
p(Mo-ATa) = 1.20cm-1, .F(000) = 2016. Data were measured at room temperature on a 
CAD4 automatic four-circle diffractometer in the range 2<3<24°. 3409 reflections
were collected of which 1460 were unique with 7>2a(7). Data were corrected for 
Lorentz and polarization but not for absorption. The structure was solved by Direct 
methods and refined using the SHELX292*293 suite of programs. In the final least 
squares cycles all atoms were allowed to vibrate anisotropically. Hydrogen atoms were 
included at calculated positions except in the instance of the H3 (attached to 03). This 
proton was located in an advanced Difference Fourier and refined at a distance of 0.92 
A from the parent atom.
Final residuals after 12  cycles of least squares were R = 0.0512, Rw = 0.0453, for a 
weighting scheme of w = 2.6106/[g2(F) + 0.000482(F)2]. Max. final shift/esd was 
0.018. The max. and min. residual densities were 0 .1 0  and -0.08 eA-3 respectively. 
Final fractional atomic coordinates and isotropic thermal parameters, bond distances 
and angles are given in Tables 33, 34 and 35 respectively. Tables of anisotropic 
temperature factors are available as supplementary data. The asymmetric unit is shown 
in Figure 1 0 1 , along with the labelling scheme used.
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Table 31
Fractional atomic co-ordinates (xl04) for (474)
x y z
Si(i) 3679(1) 2224(2) 3554(1)
0 ( 1 ) 4306(2) 2492(5) 6309(3)
0 (2 ) 3029(2) -216(5) 5347(3)
0(3) 2907(2) 4807(5) 5080(2)
0(4) 3560(1) 2359(4) 4336(2)
N (l) 3608(2) 1473(6) 5831(3)
C(l) 4062(3) 1402(8) 6117(4)
C(2) 4187(2) -193(7) 6118(3)
C(3) 4592(2) -893(9) 6355(4)
C(4) 4602(3) -2440(9) 6284(4)
0(5) 4215(3) -3261(8) 5993(4)
C(6 ) 3804(2) -2566(7) 5747(3)
C(7) 3802(2) -1028(7) 5819(3)
C(8 ) 3422(2) 61(8) 5625(4)
C(9) 3355(2) 2861(8) 5800(3)
C(1 0 ) 3121(2) 3417(8) 5048(4)
C (ll) 3320(2) 3615(7) 4459(4)
C(1 2 ) 3146(2) 2889(8) 6390(3)
C(13) 3974(2) 394(6) 3625(3)
C(14) 4077(2) 121(7) 2893(3)
C(15) 4413(2) 400(7) 4306(4)
C(16) 3688(2) -918(7) 3715(4)
C(17) 4059(2) 3807(7) 3528(4)
C(18) 4284(2) 4602(8) 4188(4)
0(19) 4585(3) 5729(8) 4210(5)
C(20) 4672(3) 6084(8) 3570(6)
0 (2 1 ) 4459(3) 5330(9) 2917(5)
C(22) 4157(2) 4213(7) 2894(4)
C(23) 3148(2) 2226(7) 2731(3)
0(24) 2780(2) 1490(8) 2799(4)
0(25) 2379(2) 1394(8) 2197(5)
0(26) 2330(2) 2040(8) 1513(4)
C(27) 2684(2) 2793(8) 1435(4)
C(28) 3083(2) 2883(7) 2031(3)
Table 32
A nisotrop ic temperature factors (A x !0 3 )  for (474)
U l l U22 U33 U23 U13 U12
Si(l) 47(1) 48(1) 42(1) 1 ( 1 ) 24(1) - 1 ( 1 )
0 ( 1 ) 72(3) 59(3) 92(4) -13(3) 32(3) -6(3)
0 (2 ) 57(3) 70(3) 87(4) -1(3) 21(3) 4(3)
0(3) 91(4) 64(3) 60(3) -4(2) 41(3) 30(3)
0(4) 58(3) 45(2) 49(2) 2 (2 ) 31(2) 1 2 (2 )
N (l) 55(4) 44(4) 48(3) 4(3) 25(3) 9(3)
C (l) 52(5) 58(5) 46(4) -4(4) 22(4) -2(4)
C(2) 49(4) 45(4) 42(4) 2(3) 21(3) 8(4)
C(3) 60(5) 69(6) 75(5) 9(4) 32(4) 8(4)
C(4) 76(6) 73(6) 83(5) 16(4) 46(5) 28(5)
C(5) 89(6) 54(5) 71(5) 9(4) 40(5) 20(5)
C(6 ) 75(5) 50(5) 60(4) 4(4) 30(4) 5(4)
C(7) 52(5) 43(4) 42(4) 6(3) 20(4) 16(4)
C(8 ) 42(5) 67(5) 45(4) 7(4) 15(4) -5(4)
C(9) 93(5) 59(5) 57(4) 13(4) 40(4) 33(4)
C(1 0 ) 1 1 0 (6 ) 60(5) 71(5) 12(4) 56(5) 41(5)
C (ll) 84(6) 62(5) 70(5) 4(4) 44(4) 20(4)
C(12) 97(6) 89(5) 65(4) 11(4) 52(4) 25(5)
C(13) 46(4) 51(4) 40(4) 2(3) 26(4) 3(3)
C(14) 82(6) 72(5) 58(5) -5(4) 39(4) 9(4)
C(15) 70(5) 74(5) 62(5) 5(4) 29(4) 16(4)
C(16) 74(5) 56(4) 93(6) 8(4) 47(5) 9(4)
C(17) 44(4) 45(4) 55(4) 5(4) 24(4) 3(3)
C(18) 73(6) 61(5) 75(6) -3(4) 33(5) -6(4)
C(19) 80(6) 59(5) 108(7) -19(5) 34(5) -24(5)
C(20) 56(5) 56(5) 138(8) 18(6) 38(6) -2(4)
C(21) 62(6) 8 6 (6 ) 92(6) 33(5) 32(5) -2(5)
C(22) 49(5) 72(5) 65(5) 14(4) 26(4) -6(4)
C(23) 52(4) 48(4) 47(4) 2(3) 32(3) -1(3)
0(24) 60(5) 91(5) 48(4) 12(4) 22(4) -8(4)
C(25) 57(5) 95(6) 72(5) -3(5) 25(5) -19(4)
0(26) 59(5) 62(5) 63(5) -13(4) 15(4) 6(4)
C(27) 72(5) 79(5) 53(4) 13(4) 23(4) 0(5)
C(28) 53(5) 79(5) 48(4) 7(4) 14(4) -7(4)
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Table 33
Hydrogen fractional atomic co-ordinates (xl04) and isotropic temperature 
factors (A2 x!03) for (474)
X y z U
H(3) 3017(21) 5231(69) 5556(16) 102(5)
H(31) 4862(2) -325(9) 6564(4) 102(5)
H(41) 4883(3) -2951(9) 6440(4) 102(5)
H(51) 4231(3) -4336(8) 5959(4) 102(5)
H(61) 3534(2) -3131(7) 5537(3) 102(5)
H(91) 3556(2) 3694(8) 5963(3) 102(5)
H(101) 2942(2) 2537(8) 4869(4) 102(5)
H ( l l l ) 3519(2) 4455(7) 4603(4) 102(5)
H(112) 3084(2) 3835(7) 3989(4) 102(5)
H(121) 2984(2) 3811(8) 6351(3) 102(5)
H(122) 3372(2) 2823(8) 6885(3) 102(5)
H(123) 2947(2) 2052(8) 6316(3) 102(5)
H(141) 4257(2) 930(7) 2823(3) 102(5)
H(142) 3805(2) 74(7) 2465(3) 102(5)
H(143) 4235(2) -812(7) 2937(3) 102(5)
H(151) 4594(2) 1220(7) 4255(4) 102(5)
H(152) 4566(2) -533(7) 4320(4) 102(5)
H(153) 4352(2) 517(7) 4767(4) 102(5)
H(161) 3619(2) -775(7) 4166(4) 102(5)
H(162) 3848(2) -1843(7) 3753(4) 102(5)
H(163) 3419(2) -958(7) 3281(4) 102(5)
H(181) 4230(2) 4361(8) 4644(4) 102(5)
H(191) 4732(3) 6262(8) 4675(5) 102(5)
H(201) 4881(3) 6860(8) 3584(6) 102(5)
H(211) 4519(3) 5574(9) 2466(5) 102(5)
H(221) 4010(2) 3701(7) 2423(4) 102(5)
H(241) 2805(2) 1039(8) 3276(4) 102(5)
H(251) 2135(2) 8 6 8 (8 ) 2261(5) 102(5)
H(261) 2053(2) 1970(8) 1095(4) 102(5)
H(271) 2653(2) 3263(8) 960(4) 102(5)
H(281) 3324(2) 3419(7) 1959(3) 102(5)
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C (ll)-0 (4 )-S i(l) 120.9(4)
C (9)-N (l)-C (l) 123.8(7)
N (l)-C (l)-0 (1 ) 124.6(7)
















C(21 )-C(20)-C( 19) 119.3(9)












H (l ll) -C (l l) -0 (4 )  107.9(4)
H (112)-C (ll)-0(4) 107.9(4)
H(112)-C(11)-H(111) 109.5
H( 122)-C( 12)-C(9) 109.5(5)
H( 123)-C( 12)-C(9) 109.5(5)
H(123)-C(12)-H(122) 109.5












































H(101)-O(4) 2.531 H (lll) -0 (4 ) 1.945
H (112)-0(4) 1.945 C(13)-0(4) 2.806
C(17)-0(4) 2.877 H(181)-0(4) 2.697
C(23)-0(4) 2.840 C(2)-N(l) 2.291
C(7)-N(l) 2.312 H(91)-N(l) 2.003
C(10)-N(l) 2.447 H(101)-N(l) 2.457
C (ll)-N (l) 3.075 C(12)-N(l) 2.452
H (122)-N(l) 2.647 H(123)-N(l) 2.647
C(3)-C(l) 2.597 C(7)-C(l) 2.312
C(8)-C(l) 2.274 C(9)-C(l) 2.503
H(91)-C(l) 2.560 H(31)-C(2) 2.038
C(4)-C(2) 2.362 C(5)-C(2) 2.741
C(6)-C(2) 2.419 C(8)-C(2) 2.317
H(41)-C(3) 2.035 C(5)-C(3) 2.406
C(6)-C(3) 2.815 C(7)-C(3) 2.387
C(4)-H(31) 2.049 H(41)-H(31) 2.349
H(51)-C(4) 2.032 C(6)-C(4) 2.411
C(7)-C(4) 2.718 C(5)-H(41) 2.034
H(51)-H(41) 2.324 H(61)-C(5) 2.058
C(7)-C(5) 2.346 C(6)-H(51) 2.035
H(61)-H(51) 2.359 C(8)-C(6) 2.611
C(7)-H(61) 2.048 C(9)-C(8) 2.530
H(101)-C(8) 2.777 C(12)-C(8) 3.176
H(101)-C(9) 1.810 C (ll)-C(9) 2.573
H(121)-C(9) 2.022 H(122)-C(9) 2.022
H(123)-C(9) 2.022 C(10)-H(91) 1.813
C (ll)-H (91) 2.659 C(12)-H(91) 1.911
H(121)-H(91) 2.211 H(122)-H(91) 2.163
H (lll)-C (10) 1.988 H(112)-C(10) 1.988
C(12)-C(10) 2.543 H(121)-C(10) 2.664
C(ll)-H (101) 1.912 H(112)-H(101) 2.196
C(12)-H(101) 2.719 H (112)-H (lll) 1.568
H (181)-H (lll) 2.264 H(122)-H(121) 1.567
H(123)-H(121) 1.567 H(123)-H(122) 1.568
H(141)-C(13) 2.075 H(142)-C(13) 2.075
H(143)-C(13) 2.075 H(151)-C(13) 2.066
H(152)-C(13) 2.066 H(153)-C(13) 2.066
H(161)-C(13) 2.060 H(162)-C(13) 2.060
H(163)-C(13) 2.060 C(17)-C(13) 3.056
C(23)-C(13) 3.066 C(15)-C(14) 2.504
H(151)-C(14) 2.698 H(152)-C(14) 2.654
C(16)-C(14) 2.487 H(162)-C(14) 2.656
H(163)-C(14) 2.656 H(142)-H(141) 1.567
H(143)-H(141) 1.567 C(15)-H(141) 2.695
H(143)-H(142) 1.568 C(16)-H(142) 2.660





































































Key to symmetry operations relating 
designated atoms to reference atoms 
at (x,y,z):
(a) 1.0-x,1.0-y,1.0-z
(b) x,1.0-y,-0.5+z
(c) 0.5-x,0.5-y,1.0-z
(d) x,-1.0+y,z
310

